<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:738.6pt;left:485.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#ffffff">Vol.:(0123456789)</span></p>
<p style="top:733.2pt;left:503.7pt;line-height:15.0pt"><span style="font-family:Springnew,serif;font-size:15.0pt">1 3</span></p>
<p style="top:44.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">https://doi.org/10.1007/s00213-021-05960-2</span></p>
<p style="top:65.8pt;left:56.8pt;line-height:9.5pt"><b><span style="font-family:MyriadPro,serif;font-size:9.5pt">REVIEW</span></b></p>
<p style="top:105.8pt;left:51.0pt;line-height:16.0pt"><b><span style="font-family:MyriadPro,serif;font-size:16.0pt">Co&#x2011;exposure of&#xa0;cannabinoids with&#xa0;amphetamines and&#xa0;biological, </span></b></p>
<p style="top:123.8pt;left:51.0pt;line-height:16.0pt"><b><span style="font-family:MyriadPro,serif;font-size:16.0pt">behavioural and&#xa0;health outcomes: a&#xa0;scoping review of&#xa0;animal </span></b></p>
<p style="top:141.8pt;left:51.0pt;line-height:16.0pt"><b><span style="font-family:MyriadPro,serif;font-size:16.0pt">and&#xa0;human studies</span></b></p>
<p style="top:176.4pt;left:51.0pt;line-height:10.0pt"><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">Dimitri&#xa0;Daldegan&#x2011;Bueno</span></b><sup><b><span style="font-family:MyriadPro,serif;font-size:7.0pt">1</span></b></sup><b><span style="font-family:MyriadPro,serif;font-size:10.0pt"> &#xa0;&#xb7; Lucas&#xa0;O.&#xa0;Maia</span></b><sup><b><span style="font-family:MyriadPro,serif;font-size:7.0pt">2</span></b></sup><b><span style="font-family:MyriadPro,serif;font-size:10.0pt"> &#xa0;&#xb7; Michelle&#xa0;Glass</span></b><sup><b><span style="font-family:MyriadPro,serif;font-size:7.0pt">3</span></b></sup><b><span style="font-family:MyriadPro,serif;font-size:10.0pt"> &#xa0;&#xb7; Didier&#xa0;Jutras&#x2011;Aswad</span></b><sup><b><span style="font-family:MyriadPro,serif;font-size:7.0pt">4,5</span></b></sup><b><span style="font-family:MyriadPro,serif;font-size:10.0pt"> &#xa0;&#xb7; Benedikt&#xa0;Fischer</span></b><sup><b><span style="font-family:MyriadPro,serif;font-size:7.0pt">1,2,6,7</span></b></sup><b><span style="font-family:MyriadPro,serif;font-size:10.0pt"> </span></b></p>
<p style="top:206.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">Received: 1 March 2021 / Accepted: 2 August 2021 </span></p>
<p style="top:216.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">&#xa9; The Author(s) 2021</span></p>
<p style="top:244.2pt;left:51.0pt;line-height:10.0pt"><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">Abstract</span></b></p>
<p style="top:256.7pt;left:51.0pt;line-height:10.0pt"><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">Rationale</span></b><span style="font-family:STIX,serif;font-size:10.0pt"> The growing prevalence of psychostimulant (including amphetamine) use and associated health harms, with </span></p>
<p style="top:269.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">limited treatment options, present a global challenge. There is an increasing availability and medical applications of can-</span></p>
<p style="top:281.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">nabinoids, and growing interest in their therapeutic potential for addictive disorders.</span></p>
<p style="top:294.2pt;left:51.0pt;line-height:10.0pt"><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">Objectives</span></b><span style="font-family:STIX,serif;font-size:10.0pt"> The objective of this study is to review available data regarding cannabis/cannabinoid co-use or exposure on </span></p>
<p style="top:306.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amphetamine-related outcomes.</span></p>
<p style="top:319.2pt;left:51.0pt;line-height:10.0pt"><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">Methods</span></b><span style="font-family:STIX,serif;font-size:10.0pt"> Towards the present scoping review, we systematically searched four databases (Medline, Web-of-Science, </span></p>
<p style="top:331.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">CINAHL Plus and PsycInfo) using cannabis/cannabinoid and amphetamine text-terms identifying peer-reviewed, English-</span></p>
<p style="top:344.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">language studies published in 2000&#x2013;2020 involving multiple methods approaches among both human and animal study sam-</span></p>
<p style="top:356.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ples, assessing the association of co-use/administration of cannabis/cannabinoids products with non-medical amphetamines </span></p>
<p style="top:369.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">on biological, behavioural or health outcomes.</span></p>
<p style="top:381.7pt;left:51.0pt;line-height:10.0pt"><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">Results</span></b><span style="font-family:STIX,serif;font-size:10.0pt"> Twenty-five articles were included. Pre-clinical studies (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 15) found mostly protective effects of single or repeated </span></p>
<p style="top:394.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cannabinoids administration on rodents in amphetamine addiction models, amphetamine-induced models of human mental </span></p>
<p style="top:406.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">disorders (e.g. schizophrenia) and amphetamine-induced neurotoxicity. Human studies (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 10) were more heterogeneously </span></p>
<p style="top:419.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">designed (e.g. cross-sectional, case&#x2013;control, longitudinal) and assessed natural ongoing cannabis and methamphetamine use or </span></p>
<p style="top:431.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">dependence, showing mostly enhanced harms in a diversity of outcomes (e.g. mental health, methamphetamine use, cognition).</span></p>
<p style="top:444.2pt;left:51.0pt;line-height:10.0pt"><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">Conclusions</span></b><span style="font-family:STIX,serif;font-size:10.0pt"> While human studies suggest cannabis use as an adverse risk factor among non-medical amphetamine users, </span></p>
<p style="top:456.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">pre-clinical studies suggest therapeutic potential of cannabinoids, especially cannabidiol, to alleviate amphetamine addic-</span></p>
<p style="top:469.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tion and harms, including treatment outcomes. Given increasing psychostimulant harms but lack of care options, rigorous, </span></p>
<p style="top:481.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">high-quality design studies should aim to translate and investigate pre-clinical study results for potential therapeutic benefits </span></p>
<p style="top:494.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">of cannabinoids for amphetamine use/abuse in human subjects.</span></p>
<p style="top:519.2pt;left:51.0pt;line-height:10.0pt"><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">Keywords</span></b><span style="font-family:STIX,serif;font-size:10.0pt"> Amphetamines&#xa0;&#xb7; Cannabis&#xa0;&#xb7; Cannabinoids&#xa0;&#xb7; Cannabidiol&#xa0;&#xb7; Co-use&#xa0;&#xb7; Exposure&#xa0;&#xb7; Tetrahydrocannabinol&#xa0;&#xb7; </span></p>
<p style="top:531.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Translational research&#xa0;&#xb7; Addictive behaviour&#xa0;&#xb7; Review</span></p>
<p style="top:567.6pt;left:51.0pt;line-height:12.0pt"><b><span style="font-family:MyriadPro,serif;font-size:12.0pt">Introduction</span></b></p>
<p style="top:594.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">A 0.5% (approximately 27 million people) of the world&#x2019;s </span></p>
<p style="top:606.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">adult population use amphetamines, a central nervous sys-</span></p>
<p style="top:619.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tem stimulant. Of these users, approximately 6.6 million </span></p>
<p style="top:569.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(86/100,000 population) are estimated to be dependent, </span></p>
<p style="top:581.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">rendering amphetamine substances to be among the most </span></p>
<p style="top:594.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">used illicit drugs globally (Degenhardt et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2013</span><span style="font-family:STIX,serif;font-size:10.0pt">; Peacock </span></p>
<p style="top:606.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2018</span><span style="font-family:STIX,serif;font-size:10.0pt">; UNODC </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">). Extra-medical amphetamine </span></p>
<p style="top:619.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">use, especially methamphetamine (a more potent structural </span></p>
<p style="top:631.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">form (Lake and Quirk </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">1984</span><span style="font-family:STIX,serif;font-size:10.0pt">)), is associated with elevated </span></p>
<p style="top:644.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">risks for both mortality and morbidity outcomes, including </span></p>
<p style="top:656.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">acute poisoning, mental health (e.g. depression, psychosis, </span></p>
<p style="top:669.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">suicidal behaviours) and neurocognitive impairments, car-</span></p>
<p style="top:681.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">diovascular problems, injury and violence (Cumming et&#xa0;al. </span></p>
<p style="top:694.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">; Marshall and Werb </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2010</span><span style="font-family:STIX,serif;font-size:10.0pt">; Marshall et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2011</span><span style="font-family:STIX,serif;font-size:10.0pt">; McKe-</span></p>
<p style="top:706.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tin et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2019</span><span style="font-family:STIX,serif;font-size:10.0pt">; Wood et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2006</span><span style="font-family:STIX,serif;font-size:10.0pt">). Amphetamine dependence </span></p>
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,691.6667,93.333339)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAB4AAAAdCAYAAAC9pNwMAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAkklEQVR4nMXDgQpDAABF0fv/X7eZjI0xY5OIRBJ5+4x36iATzvOU
I8dxyJF93+XItm1yZF1XObIsixyZ51mOTNMkR8ZxlCPDMMiRvu/lSNd1cqRtWznS
NI0c+f5+cqSuaznyqSo58i5LOVIUhRx55bkcybJMjjzTVI4kyUOO3ONYjkRRJEdu
YShHguAmRy7Xqxz/9cejFeCVYgAAAAAASUVORK5CYII=">
<p style="top:653.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">This article belongs to a Special Issue on Cannabis and </span></p>
<p style="top:663.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cannabinoids</span></p>
<p style="top:693.8pt;left:50.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> </span><sup><span style="font-family:STIX,serif;font-size:8.5pt"> </span></sup><sup><span style="font-family:Wingdings,serif;font-size:8.5pt">*</span></sup><sup><span style="font-family:STIX,serif;font-size:8.5pt"> Benedikt Fischer </span></sup></p>
<p style="top:693.8pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">bfischer@sfu.ca</span></p>
<p style="top:708.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Extended author information available on the last page of the article</span></p>
<p style="top:206.4pt;left:216.4pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">/ Published online: 6 October 2021</span></p>
<p style="top:33.4pt;left:50.4pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">Psychopharmacology (2022) 239:1211&#x2013;1230</span></p>


<p style="top:733.2pt;left:52.5pt;line-height:15.0pt"><span style="font-family:Springnew,serif;font-size:15.0pt">1 3</span></p>
<p style="top:57.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">was responsible for about 0.6% (approximately 326,000 </span></p>
<p style="top:69.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">deaths) of global all-cause mortality in 2017, entailing a </span></p>
<p style="top:82.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">mortality risk among people with amphetamine dependence </span></p>
<p style="top:94.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">up to six times higher than the general population (Farrell </span></p>
<p style="top:107.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2019</span><span style="font-family:STIX,serif;font-size:10.0pt">). Changes in illegal drug production patterns sug-</span></p>
<p style="top:119.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">gest that amphetamines supply and use have been globally </span></p>
<p style="top:132.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">increasing. Global methamphetamine seizures increased by </span></p>
<p style="top:144.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">16% in 2015/16; despite seizures occurring mainly in North </span></p>
<p style="top:157.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">America and Asia, a 50% increase of countries reporting </span></p>
<p style="top:169.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">seizures has been observed in the last decade. The major-</span></p>
<p style="top:182.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ity (90%) of dismantled methamphetamine laboratories are </span></p>
<p style="top:194.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">located in North America, with the USA harbouring most </span></p>
<p style="top:207.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">of these (3,036 or 82%) worldwide in 2017 &#x2014; mostly sup-</span></p>
<p style="top:219.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">plying the local market (i.e. &#x201c;kitchen lab&#x201d;) in contrast with </span></p>
<p style="top:232.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">large-scale, export-oriented laboratories in Mexico and East/</span></p>
<p style="top:244.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">South-East Asia (Farrell et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2019</span><span style="font-family:STIX,serif;font-size:10.0pt">; UNODC </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">).</span></p>
<p style="top:257.3pt;left:62.4pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Currently, there are no pharmacotherapeutic </span></p>
<p style="top:269.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">options&#xa0;approved for the treatment of stimulant use disor-</span></p>
<p style="top:282.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">der, including amphetamines, at any of the main stages of </span></p>
<p style="top:294.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">treatment (e.g. withdrawal, relapse prevention) (Brandt et&#xa0;al. </span></p>
<p style="top:307.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">; Castells et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2016</span><span style="font-family:STIX,serif;font-size:10.0pt">; Morley et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2017</span><span style="font-family:STIX,serif;font-size:10.0pt">; P&#xe9;rez-Ma&#xf1;&#xe1; </span></p>
<p style="top:319.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2013</span><span style="font-family:STIX,serif;font-size:10.0pt">; Ronsley et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">; Siefried et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">; Tar-</span></p>
<p style="top:332.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">delli et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">). The range of evidence-based, non-phar-</span></p>
<p style="top:344.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">macotherapeutic treatment or targeted prevention measures </span></p>
<p style="top:357.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">is overall highly limited, although select cognitive-behav-</span></p>
<p style="top:369.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ioural interventions, including contingency management </span></p>
<p style="top:382.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">approaches, have shown some promise (Cumming et&#xa0;al. </span></p>
<p style="top:394.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2016</span><span style="font-family:STIX,serif;font-size:10.0pt">; Fischer et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015a</span><span style="font-family:STIX,serif;font-size:10.0pt">; Knapp et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2007</span><span style="font-family:STIX,serif;font-size:10.0pt">; Lee and Raw-</span></p>
<p style="top:407.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">son </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2008</span><span style="font-family:STIX,serif;font-size:10.0pt">; Minozzi et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2016</span><span style="font-family:STIX,serif;font-size:10.0pt">; Shearer </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2007</span><span style="font-family:STIX,serif;font-size:10.0pt">). This situa-</span></p>
<p style="top:419.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tion underscores a need for the examination of potentially </span></p>
<p style="top:432.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">effective therapeutic strategies or interventions for psycho-</span></p>
<p style="top:444.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">stimulant and specifically problematic amphetamine use </span></p>
<p style="top:457.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">or use disorders (Fischer et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015b</span><span style="font-family:STIX,serif;font-size:10.0pt">; Kogan and Mech-</span></p>
<p style="top:469.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">oulam </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2007</span><span style="font-family:STIX,serif;font-size:10.0pt">; Shorter et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015</span><span style="font-family:STIX,serif;font-size:10.0pt">). Recently, there has been </span></p>
<p style="top:482.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">increased focus on the endocannabinoid system as a possible </span></p>
<p style="top:494.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">target for treating drug dependence, craving or withdrawal </span></p>
<p style="top:507.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(Chye et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2019</span><span style="font-family:STIX,serif;font-size:10.0pt">; Manzanares et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2018</span><span style="font-family:STIX,serif;font-size:10.0pt">; Parsons and Hurd </span></p>
<p style="top:519.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015</span><span style="font-family:STIX,serif;font-size:10.0pt">; Spanagel </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">), with a growing number of studies </span></p>
<p style="top:532.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">examining the therapeutic effects of cannabinoid agents for </span></p>
<p style="top:544.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">addictive disorders (Batalla et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2019</span><span style="font-family:STIX,serif;font-size:10.0pt">; Calpe-L&#xf3;pez et&#xa0;al. </span></p>
<p style="top:557.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2019</span><span style="font-family:STIX,serif;font-size:10.0pt">; Prud&apos;homme et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015</span><span style="font-family:STIX,serif;font-size:10.0pt">; Turna et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2019</span><span style="font-family:STIX,serif;font-size:10.0pt">).</span></p>
<p style="top:569.8pt;left:62.4pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">The endocannabinoid system (ECS) is a central bio-</span></p>
<p style="top:582.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">logical system composed of at least two endocannabinoids </span></p>
<p style="top:594.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(neurotransmitters; anandamide and 2-arachidoyl glycerol) </span></p>
<p style="top:607.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">that bind to cannabinoid receptors expressed throughout the </span></p>
<p style="top:619.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">mammalian vertebrate central and peripheral nervous sys-</span></p>
<p style="top:632.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tems. The ECS is centrally involved in regulating essential </span></p>
<p style="top:644.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">neural, physiological and cognitive processes, including </span></p>
<p style="top:657.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">movement control and motor coordination, learning and </span></p>
<p style="top:669.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">memory, mood, stress response and motivation, the immune </span></p>
<p style="top:682.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">system, appetite, addictive behaviours and pain modulation, </span></p>
<p style="top:694.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">among others (Cabral et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015</span><span style="font-family:STIX,serif;font-size:10.0pt">; Kruk-Slomka et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2017</span><span style="font-family:STIX,serif;font-size:10.0pt">; </span></p>
<p style="top:707.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Lu and Mackie </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2021</span><span style="font-family:STIX,serif;font-size:10.0pt">; Mechoulam and Parker </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2013</span><span style="font-family:STIX,serif;font-size:10.0pt">). The </span></p>
<p style="top:57.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ECS is also involved in key brain structures (e.g. prefrontal, </span></p>
<p style="top:69.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">limbic, striatal) and neurotransmitter systems (e.g. sero-</span></p>
<p style="top:82.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tonin, dopamine) essential in the reward system and drug </span></p>
<p style="top:94.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">addiction. Of special interest is the role of CB1 receptors, </span></p>
<p style="top:107.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">expressed in brain regions involved in decision-making, </span></p>
<p style="top:119.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">withdrawal and relapse, and therefore, essential for modu-</span></p>
<p style="top:132.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">lating the rewarding effects of drugs (Chye et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2019</span><span style="font-family:STIX,serif;font-size:10.0pt">; Mal-</span></p>
<p style="top:144.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">donado et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2006</span><span style="font-family:STIX,serif;font-size:10.0pt">; Manzanares et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2018</span><span style="font-family:STIX,serif;font-size:10.0pt">; Parsons and </span></p>
<p style="top:157.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Hurd </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015</span><span style="font-family:STIX,serif;font-size:10.0pt">; Spanagel </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">). Moreover, there is increasing </span></p>
<p style="top:169.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">evidence and practice of medical usage for some indications </span></p>
<p style="top:182.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(e.g. neuropathic pain, chemotherapy-induced nausea &#x2014; for </span></p>
<p style="top:194.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">reviews see (Abrams </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2018</span><span style="font-family:STIX,serif;font-size:10.0pt">; Crippa et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2018</span><span style="font-family:STIX,serif;font-size:10.0pt">; NASEM </span></p>
<p style="top:207.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2017</span><span style="font-family:STIX,serif;font-size:10.0pt">)) and legal availability of cannabinoids products in </span></p>
<p style="top:219.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">many countries. Related, a purified cannabis-derived pre-</span></p>
<p style="top:232.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">scription form of cannabinoid has been recently approved in </span></p>
<p style="top:244.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Europe and the USA for selected medical usage indications </span></p>
<p style="top:257.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(GlobeNewswire </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2021</span><span style="font-family:STIX,serif;font-size:10.0pt">; Marcu </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">). Possibly benefi-</span></p>
<p style="top:269.8pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cial effects or properties from cannabinoids agents specifi-</span></p>
<p style="top:282.3pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cally for addictive behaviours related to various substance </span></p>
<p style="top:294.8pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">groups (e.g. opioids, alcohol, nicotine, other stimulants) </span></p>
<p style="top:307.3pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">have been suggested, but no conclusive (e.g. clinical trial-</span></p>
<p style="top:319.8pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">based) evidence or reviews for amphetamine use and related </span></p>
<p style="top:332.3pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">problems presently exist (Abrams </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2018</span><span style="font-family:STIX,serif;font-size:10.0pt">; Prud&apos;homme et&#xa0;al. </span></p>
<p style="top:344.8pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015</span><span style="font-family:STIX,serif;font-size:10.0pt">). On this basis, we sought to comprehensively review </span></p>
<p style="top:357.3pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the existing, multidisciplinary studies and outcome data that </span></p>
<p style="top:369.8pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">have investigated the associations of cannabinoid exposure </span></p>
<p style="top:382.3pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">on amphetamine use and adverse outcomes in different study </span></p>
<p style="top:394.8pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">populations.</span></p>
<p style="top:430.7pt;left:306.1pt;line-height:12.0pt"><b><span style="font-family:MyriadPro,serif;font-size:12.0pt">Methods</span></b></p>
<p style="top:456.5pt;left:306.1pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">Study aim and&#xa0;scope</span></b></p>
<p style="top:482.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">We conducted a scoping review which aimed to identify </span></p>
<p style="top:494.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and summarize data on possible associations of natural or </span></p>
<p style="top:507.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">experimental co-administration of cannabinoids on ampheta-</span></p>
<p style="top:519.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">mine use-related biological, behavioural or health outcomes </span></p>
<p style="top:532.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">from different methodological or disciplinary approaches </span></p>
<p style="top:544.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(e.g. pre-clinical, human experimental, observational stud-</span></p>
<p style="top:557.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ies). Cannabinoids were defined to include all-natural canna-</span></p>
<p style="top:569.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">bis product forms or compositions (e.g. cannabidiol [CBD], </span></p>
<p style="top:582.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tetrahydrocannabinol [THC]) and amphetamine products </span></p>
<p style="top:594.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">referred to both amphetamines and the structurally similar </span></p>
<p style="top:607.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">methamphetamines. Both cannabinoids and amphetamines </span></p>
<p style="top:619.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">were considered irrespective of way of use (e.g. smoke, oral </span></p>
<p style="top:632.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ingestion) or user status (e.g. dependence); while canna-</span></p>
<p style="top:644.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">bis was considered regardless of the intended purpose of </span></p>
<p style="top:657.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">use (e.g. medical, non-medical); only extra-medical use of </span></p>
<p style="top:669.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amphetamines was considered. Considering the over-time </span></p>
<p style="top:682.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">evolution in amphetamine-type drug use, types of can-</span></p>
<p style="top:694.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">nabis products available and the fact that the potential of </span></p>
<p style="top:707.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cannabinoids for addiction-related outcomes has only been </span></p>
<p style="top:32.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">1212</span></p>
<p style="top:32.8pt;left:399.6pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">Psychopharmacology (2022) 239:1211&#x2013;1230</span></p>


<p style="top:733.2pt;left:503.7pt;line-height:15.0pt"><span style="font-family:Springnew,serif;font-size:15.0pt">1 3</span></p>
<p style="top:56.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">investigated more recently (Fischer et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015b</span><span style="font-family:STIX,serif;font-size:10.0pt">), we limited </span></p>
<p style="top:68.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">our search to studies published since 2000 with a goal of </span></p>
<p style="top:81.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">providing a comprehensive review of relatively recent stud-</span></p>
<p style="top:93.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ies and data.</span></p>
<p style="top:118.1pt;left:51.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">Search strategy</span></b></p>
<p style="top:143.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">The systematic search strategy applied was originally </span></p>
<p style="top:156.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">developed for MEDLINE through an iterative process by </span></p>
<p style="top:168.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the co-authors; the final search strategy was revised and </span></p>
<p style="top:181.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">adjusted using the Peer Review Electronic Search Strategies </span></p>
<p style="top:193.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(PRESS) checklist (McGowan et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2016</span><span style="font-family:STIX,serif;font-size:10.0pt">) and translated to </span></p>
<p style="top:206.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">other databases. Four databases were accessed: MEDLINE </span></p>
<p style="top:218.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(PubMed), Web of Science (core collection), CINAHL plus </span></p>
<p style="top:231.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and PsycInfo. The search strategy focused on related can-</span></p>
<p style="top:243.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">nabis/cannabinoid and amphetamine text words based on </span></p>
<p style="top:256.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">MeSH indexing terms (e.g. marijuana, cannabis, CBD, THC, </span></p>
<p style="top:268.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amphetamine, methamphetamine). Given the broad scope </span></p>
<p style="top:281.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and high heterogeneity/interdisciplinarity of study data spe-</span></p>
<p style="top:293.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cifically for outcomes comprised by our scoping review and </span></p>
<p style="top:306.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the intent to comprehensively capture and document these, </span></p>
<p style="top:318.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">we did not limit the search by specific outcome terms to </span></p>
<p style="top:331.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">avoid a potential restriction, or loss of relevant studies or </span></p>
<p style="top:343.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">data. Rather, we left the search for, and identification of, </span></p>
<p style="top:356.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">any relevant outcomes as defined by the scope of the review </span></p>
<p style="top:368.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">to the subsequent title/abstract and content screening. The </span></p>
<p style="top:381.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">full strategy details are presented as </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">supplementary material</span><span style="font-family:STIX,serif;font-size:10.0pt">. </span></p>
<p style="top:393.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Complementary search strategies included comprehensive </span></p>
<p style="top:406.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">hand-searching of the reference lists of included studies. The </span></p>
<p style="top:418.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">results from the multiple databases were collated and de-</span></p>
<p style="top:431.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">duplicated using the Systematic Review Assistant-Dedupli-</span></p>
<p style="top:443.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cation Module (SRA-DM) (Rathbone et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015</span><span style="font-family:STIX,serif;font-size:10.0pt">) and then </span></p>
<p style="top:456.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">uploaded to Endnote (v.X9.2), where all screening manage-</span></p>
<p style="top:468.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ment tasks were performed.</span></p>
<p style="top:493.1pt;left:51.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">Study screening and&#xa0;selection</span></b></p>
<p style="top:518.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Study screening and selection were based on the follow-</span></p>
<p style="top:531.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ing inclusion criteria: (1) original articles based on primary </span></p>
<p style="top:543.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">study data; (2) studies examining the direct/immediate, </span></p>
<p style="top:556.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">recent (i.e. prior 3&#xa0;months in humans or same life-phase </span></p>
<p style="top:568.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">in animals [e.g. adults, adolescents]), or lifetime (of active </span></p>
<p style="top:581.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">users) co-use or co-exposure of cannabinoid products with </span></p>
<p style="top:593.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amphetamine products in human or animal populations; (3) </span></p>
<p style="top:606.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">reporting biological, behavioural or health-related meas-</span></p>
<p style="top:618.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ures or outcomes (e.g. brain activity/function, craving, drug </span></p>
<p style="top:631.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">use/dependence); (4) with measures or outcomes available </span></p>
<p style="top:643.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">that somehow comparatively attributed to amphetamine-</span></p>
<p style="top:656.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">only use or groups versus amphetamine and cannabinoid </span></p>
<p style="top:668.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">co-use or co-exposure; and (5) in English-language studies </span></p>
<p style="top:681.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">published since 2000 to 28 October 2020. Following de-</span></p>
<p style="top:693.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">duplication, titles and abstracts were screened by one lead </span></p>
<p style="top:706.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">reviewer (DDB), with potentially unclear or ambiguous </span></p>
<p style="top:56.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cases identified and arbitrated towards consensus together </span></p>
<p style="top:68.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">with a second reviewer (BF), followed by full-text review </span></p>
<p style="top:81.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">of studies identified for possible inclusion by the same pro-</span></p>
<p style="top:93.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cedure. We excluded studies that did not meet the above </span></p>
<p style="top:106.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">criteria, as well as reviews, commentaries, case reports and </span></p>
<p style="top:118.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">case&#x2013;control studies that mixed amphetamine- or cannab-</span></p>
<p style="top:131.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">inoid-related data with other non-target drug use in study </span></p>
<p style="top:143.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">groups. To assess the eligibility of case&#x2013;control studies for </span></p>
<p style="top:156.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">inclusion, we verified the exclusive presence of data for </span></p>
<p style="top:168.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amphetamine use with/without cannabinoid use groups and </span></p>
<p style="top:181.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">attributable outcomes through information from the stud-</span></p>
<p style="top:193.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ies&#x2019; methods and results sections. Abstracts or full studies </span></p>
<p style="top:206.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">excluded predominantly did not match the content- or out-</span></p>
<p style="top:218.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">come-specific criteria for the review (e.g. no clear cannabis/</span></p>
<p style="top:231.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amphetamine comparison, no current cannabis use) or could </span></p>
<p style="top:243.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">not be accessed. The attached flowchart (Fig.&#xa0;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">1</span><span style="font-family:STIX,serif;font-size:10.0pt">) presents the </span></p>
<p style="top:256.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">main process steps for the present review.</span></p>
<p style="top:280.6pt;left:306.1pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">Data presentation</span></b></p>
<p style="top:306.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Given the aim of a comprehensive, scoping review com-</span></p>
<p style="top:318.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">prising evidence from multi-disciplinary perspectives, both </span></p>
<p style="top:331.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">quantitative and qualitative types of studies in different </span></p>
<p style="top:343.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">population/samples (e.g. animal, human experimental, treat-</span></p>
<p style="top:356.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ment, community) were included. For results documenta-</span></p>
<p style="top:368.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tion, we used a descriptive approach, inductively grouping </span></p>
<p style="top:381.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">studies principally by type of basic study population and </span></p>
<p style="top:393.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">methods/approach, further dividing into study sub-cluster, </span></p>
<p style="top:406.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and narratively summarizing the essential study scope, </span></p>
<p style="top:418.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">measures and results. As is common for a scoping review, </span></p>
<p style="top:431.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">no risk of bias or quality assessment (Arksey and O&apos;Malley </span></p>
<p style="top:443.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2005</span><span style="font-family:STIX,serif;font-size:10.0pt">) and no meta-analyses (also due to the heterogeneity </span></p>
<p style="top:456.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">of study designs and outcomes) were conducted.</span></p>
<p style="top:492.3pt;left:306.1pt;line-height:12.0pt"><b><span style="font-family:MyriadPro,serif;font-size:12.0pt">Results</span></b></p>
<p style="top:518.1pt;left:306.1pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">Characteristics of&#xa0;included studies</span></b></p>
<p style="top:543.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Overall, 6,705 article citations were identified from the data-</span></p>
<p style="top:556.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">base searches which, after deduplication, resulted in a total </span></p>
<p style="top:568.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">of 3,237 potentially relevant abstracts that were screened. </span></p>
<p style="top:581.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">From these, 48 abstracts were selected for full-text review, </span></p>
<p style="top:593.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">with the final 25 articles included in the present review </span></p>
<p style="top:606.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(Fig.&#xa0;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">1</span><span style="font-family:STIX,serif;font-size:10.0pt">). Eighteen (&gt; 70%) of the studies were published </span></p>
<p style="top:618.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">2010 onward. Articles broadly ranged across animal-based </span></p>
<p style="top:631.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">experimental models (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 15) and human population (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 10) </span></p>
<p style="top:643.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">studies. Animal studies involved rodents (rats or mice) </span></p>
<p style="top:656.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">experiments of THC or CBD (single or repeat) administra-</span></p>
<p style="top:668.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tion compared to controls (i.e. vehicle administration). On </span></p>
<p style="top:681.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the basis of the data, studies were divided into three clusters: </span></p>
<p style="top:693.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">non-contingent models of addiction (e.g. conditioned place </span></p>
<p style="top:706.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">preference and sensitization experiments) (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 6), contingent </span></p>
<p style="top:32.8pt;left:528.3pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">1213</span></p>
<p style="top:32.8pt;left:50.4pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">Psychopharmacology (2022) 239:1211&#x2013;1230</span></p>


<p style="top:733.2pt;left:52.5pt;line-height:15.0pt"><span style="font-family:Springnew,serif;font-size:15.0pt">1 3</span></p>
<p style="top:556.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">models of addiction (drug self-administration experiments) </span></p>
<p style="top:569.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 3) and amphetamine-induced human mental health </span></p>
<p style="top:581.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">models and neurotoxicity experiments (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 6). Human pop-</span></p>
<p style="top:594.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ulation studies comprised methamphetamine and cannabis </span></p>
<p style="top:606.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">users or dependents within small or larger population sam-</span></p>
<p style="top:619.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ple. Study designs were cross-sectional (e.g. case&#x2013;control, </span></p>
<p style="top:631.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">experimental intervention), prospective and longitudinal </span></p>
<p style="top:644.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">with biological, psycho-behavioural and mental health- or </span></p>
<p style="top:656.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">addiction-related outcomes, organized into three topical </span></p>
<p style="top:669.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">study clusters: brain structure/metabolism (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 3), neuropsy-</span></p>
<p style="top:681.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">chological function or psychopathology symptoms (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 3) </span></p>
<p style="top:694.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and methamphetamine use patterns (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 4). See Tables&#xa0;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">1</span><span style="font-family:STIX,serif;font-size:10.0pt"> and </span></p>
<p style="top:706.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2</span><span style="font-family:STIX,serif;font-size:10.0pt"> for animal and human studies summaries.</span></p>
<p style="top:556.5pt;left:306.1pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">Pre&#x2011;clinical studies in&#xa0;animals</span></b></p>
<p style="top:582.3pt;left:306.1pt;line-height:10.0pt"><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">Non&#x2011;contingent models of&#xa0;addiction (n = 6)</span></b></p>
<p style="top:607.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Four vehicle-controlled studies investigated the effects of </span></p>
<p style="top:619.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">single CBD or THC administration in rats with an ampheta-</span></p>
<p style="top:632.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">mine- or methamphetamine-conditioned place preference </span></p>
<p style="top:644.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(i.e. preference to a drug-paired environment) on amphet-</span></p>
<p style="top:657.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amine-reinstatement (i.e. return of drug-seeking after </span></p>
<p style="top:669.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">extinction of drug-seeking behaviour) and neurobiological </span></p>
<p style="top:682.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">outcomes. THC (0.5&#xa0;mg/kg, i.p.) or CBD (5&#xa0;mg/kg, i.p.) </span></p>
<p style="top:694.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">administration 30&#xa0;min before amphetamine place preference </span></p>
<p style="top:707.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">extinction trials (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 8&#x2013;12/group) potentiated the extinction </span></p>
<img style="position:absolute;transform:matrix(.31992127,0,-0,.319915,-619.1496,-562.9523)" src="data:image/jpeg;base64,
/9j/7gAOQWRvYmUAZAAAAAAA/9sAQwAGBAQOBQ4TDAwTFhMQExETFxUVFxcWFBQa
GhoXGBcXFx4cFxgZGxwcJRsZHx8fHx8iHx8fHx8fHx8fHx8fHx8f/90ABAD+/8AA
CwgHWgfwAQARAP/EANIAAQADAQADAQEBAQAAAAAAAAAGBwgFAQMEAgkKCxAAAQID
AwYICgUDBgMDbQAAAAECAwQFBgcRCBIhMTRzExc1UVRxkbEUFRYYIkFTYZLBMlJy
gaEzYtEjJCZCouElY/AJCoIZGicoKSo2Nzg5OkNERUZHSElKVVZXWFlaZGVmZ2hp
anR1dnd4eXqDhIWGh4iJipOUlZaXmJmao6Slpqeoqaqys7S1tre4ubrCw8TFxsfI
ycrS09TV1tfY2dri4+Tl5ufo6erx8vP09fb3+Pn6/9oACAEAAAA/ANUgAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAFMXjX6RKBOLISsFYsRPUmPyI+t/FUTXIv/AHQ4
+ap0F/7ocfNU6C/90OPmqdBf+6HHzVOgv/dDj5qnQX/uhx81ToL/AN0OPmqdBf8A
uhx81ToL/wB0OPmqdBf+6HHzU+gv/dDj5qfQX/uhx81ToL/3Q4+ap0F/7ocfNU6C
/wDdDj5qnQX/ALocfNU6C/8AdDj5qnQX/uhx81ToL/3Q4+ap0F/7ocfNU6C/90OP
mqdBf+6HHzVOgv8A3Q4+ap0F/wC6PHHzVOgv/dHnj5qnQX/uhx81ToL/AN0OPmqd
Bf8Auhx81ToL/wB0OPmqdBf+6HHzVOgv/dDj5qnQX/uhx81ToL/3Q4+ap0F/7ocf
NU6C/wDdDj5qfQX/ALocfNU6C/8AdDj5qnQX/uhx81ToL/3Q4+ap0F/7ocfNU6C/
90OPmqdBf+6HHzU+gv8A3Q4+an0F/wC6HHzVOgv/AHQ4+ap0F/7ocfNT6C/90OPm
qdBf+6HHzVOgv/dDj5qnQX/uhx81ToL/AN0OPmqdBf8Auhx81ToL/wB0OPmqdBf+
6HHzVOgv/dDj5qnQX/uj1R8oydpmD5qUeyGqomcuOBfNBrLarLw5hup7UU6LX4n6
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAP/Q
1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAZ6pSY2uifZXuNBrDRfUg4JOZBwS
cyDgk5kHBJzIOCTmQcEnMg4JOZBwScyDgk5kHBJzIOCTmQcEnMg4JOZBwScyDgk5
kHBJzIOCTmQcEnMg4JOZBwScyDgk5kHBJzIOCTmQcEnMg4JOZBwScyDgk5kHBJzI
OCTmQcEnMg4JOZBwScyDgk5kHBJzIOCTmQcEnMg4JOZBwScyDgk5kHBJzIOCTmQc
EnMg4JOZBwScyDgk5kHBJzIOCTmQcEnMg4JOZBwScyDgk5kHBJzIOCTmQcEnMg4J
OZCo8p5iJSl3jT77tK1/A6XbzMQn0jNcIdBq4nkAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAH/9HVIAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAABnqk/zF0T7K9xoUAAAAAAAAAAAAAAAAAAAAAAAAAAAFR5T/JLvttI
9dtNL4FAT81C2aHEzkQkUM/QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAP//S1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAZ6p
P8xdE+yvcaFAAAAAAAAAAAAAAAAAAAAAAAAAAABUeU/yS77bSLXbbFB+yhbtA1IS
Zmo/QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AP/T1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAZ6pP8xdE+yvcaFAAAAAAAAA
AAAAAAAAAAAAAAAAAABUeU/yS77bSLXb7FB+yhbtA1ISaHqP0AAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD//1NUgAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAGeqT/MXRPsr3GhQAAAAAAAAAAAAAq4DHEAA8Z6c55A
AAAAAAAAABUeU/yS77bSLXb7FB+yhbtA1ISaHqP0AAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD//V1SAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAZ5pP8xdE+yvcaGAAAAAB4cuamJRVucoiPRZvwOWl+Fdj7z4kyhq
hIuRZuSWHCx0uwXQXTZS1cG0sFsaA5FRU0pzHaAAAAAK3v5q8Wl098SA5WuT1ofR
cZVItTpkOLHcrnrjiqlgAEBvotg6zEi6KzQ9dCFZ3Z3cVKsrDqUWbdmO05mKmh4D
MxqIunBD9gAAAAAAAAAFR5T/ACS77bSLXb7FB+yhbtA1ISaGfoAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAH/1tUgAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAGeqT/MXRPsr3GhQAAAAAfmLqXqUzZT242ibox9Iua9
eDCiU+Lw+GbgVtkxsVjYqNx4L9r2k8vHvYg2OaiInCRF/aIukryFlNxmPakaSexj
l+kuOCJzl4UWtwqxCSNCcitVMdHqK7vBvzh2aicBLw+HiczdPcc6x1/7qxHbLzMu
6ArvW7H5llWptXBs7AWPFcmCJiiY6ymJnKejNxfDknuhp+204Fm3bXnwLbQs9mDY
nrh+tDiWqv0l7NziyUZuC4aF5/cc6yt+cauzXg/grmw8dETThhznsvGv/h2WjJLw
ISx3rrRP3iuryL51tJIRIUzBWA5dSOx09paVxU22Ro8OJEXBqIqqqkcr+Ug+VjOh
ysq6MxF+mmKp+BJLuL241rIvBxZZ0FOdcfmWa5cExMyZRF5UWM1ZRZdcxHfSwXAl
FyV6saoQoUmss5rWtwz9OB2allCy0jMRZRzf1SHqT6x9F3l8ca1MV0OLLOgsT9su
OGH3ny23v+bRI3g8rCWYcmvNxXuOfZLKQbUplJacgLL4/tnYon4lj25tuyy0os6q
Z7Ew1e/1lbzWUm2PCbEkoCxlVNKJiuHYe+xuUpL1tIjY7OBis1MXWpy42U66VjIy
LKubDVcM/Th1l2UStQ6zCbGhLi1yH3gAAAAAFR5T/JLvttItdvsUH7KFu0DUhJoe
o/QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAP
/9fVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAABnqk/zF0T7K9xoUAAAAAH5i6l
6lMi2xps5UK2jKe7Mi46F1H2W4dWbOxGMrMThZRypnYLihoS7mDJsk2RJBESG5uJ
mar2xbS65FiTEN0ZGuXBqacCb2kyhIFWl3wVkX4q1Ubi3V+B7rjq1MSdOmOEY5qY
OVuOOjQp+MnCjMrEePORfSe164Y6fWXjV7Hy9WekSKxFc3UqaCgr8Yzpmpy0kqrw
SuRFT7zQdNs7Ak4CS7WJmZuGGCGdaDJts5aV8OX0NVdKeo+a8uhQq5aFjI2pMFNG
zcJlKlF4NqejC0aPcURk/UllenZiajpi9j1wx0+slWUzZGBUZBY72+mzUqHtuwoi
2hs+ksi5qvaqIvcV7Ze2ca6Jz5Kal3RmoqqjkTH8cFLsu8vOlbXszoaJDf8AUXBH
E4KiyiWtSUT0UxxTThpJjdhDRKfBVERPQ5jPln7NQazaGK+MmKteuHaX7ejNLS6d
FdCRGrmKmjQV7kx0KHMSzp2ImdFV6piuk92U5ZuDEk2zObhEa9MHJoU5lo5507Zl
ueuPooh3MmuysCmSXCQ09J+vErG1FkZePXmuVMMX6UTQmsuq+WhwfFj0zUTMZ6Oh
OY5OTFMOjU30lxwepb4AAAAABUeU/wAku+20i122xQfsoW7QNSEmh6j9AAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA//Q1SAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAZ6pP8xdE+yvcaFAAAAAB+YupepTN0nLxW2h
a7MXNzteGguq8qyzbSSUSA5MVwxQq3J0rkSVfFp0VrkbDVUaq6jj25s1GsFUVqaM
SLBe7FUwxO0uUpTETZXY4afQb+gseyNpYFuZR7oENYbXIrcFRE1p1FGSFYjXMz72
RmOfAiOx9HSTaRv0iWsmWQafDe1q4Yq5D5r+bvJmYWFU5bTEg4K5PXoPmpeVLChy
6MiwYnhCJhq0YnsumsbHtDPLWppMGuVVai6zj2xlojrRtVGKrdGnDQaKjS3hMFWL
+2Zh+BmKmVaNc5PxFmWOfCiuVUzU9R5vYvEmrxpV3i2G5sJn00cmlSz7p6slmqIy
LGa70U0t9ZwY+U3TY2OfLPdhztRe9CPXe0d9qqstTlWLCl/q6kNLpoKkyiIL4soi
MarlxTUTG7Fisp0FHJguZqKQsRKxG1+M5WKjc9dOGjWX/bGgeP5WJL+tzVROszlY
e3Me52M+QnobnQs5VRWpiffa23MW997ZGShuZCzkVVcmBM707NLQqD4NDRXOajUX
D1r6zr3AQnQ6e1HorVw1KVrX5WItcaqMXNz9eGjWW9fJDdEpsVGoqrmroQjGTDAf
Bpyo9qtXPXQuguEAAAAAAqPKf5Jd9tpFrttig/ZQt2gakJMw/QAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAP/0dUgAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAGeqT/MXRPsr3GhQAAAAAD50p0NHZ+a3O58ExPoVMT5
oFMhQHK9jGo5daoiIp+5qSZNpmxGo5OZUxOd5ISfsIfwp+g++Tp8OSTNhNRqcyJg
h652jQZ/8rDa/wC0iL3n4k6BLyS4wobGr7moh9sWEkVM1yYovqU5i2TlFXHgYeP2
U/QdGBLtl0zWIiJzJoQ9b6dDe7PVrVdz4JifRqPjnqPBn/y0Nr/tIi954laJAlUV
sOG1qLrRGoiHuWnw1bweambzYaDn+SEn7CH8KfoPvk6fDkkzYTUanMiIh9B6o8qy
YTB6Iqe9MT9w4SQkwamCcyHpZTobHZ6MajufBMT6D4Z2hQJ5cYsNjl51ainmSocC
RXGFDa1fciIfTHl2zCZr0RU5lTFBAlmy6YMRETmTQet1Ohudnqxudz4Jie2LBbGT
NciKnMp+ZaUZKpmw2o1OZEwPaAAAAAAVHlP8ku+20i12+xQfsoW7QNSEmh6j9AAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA//0tUg
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGeqT/MXRPsr3GhQAAAAAAAAAAAAAAA
AAAAAAAAAAAAVHlP8ku+20i12+xQfsoW7QNSEmh6j9AAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA//9PVIAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAABnqk/zF0T7K9xoUAAAHEnrZysjGSXiRESI7U31qdtNIAAB65m
ZbLNV71waiYqp8NItHAq+PAPR2HMdIAAAAAAAAAAA5CWrlli+D56cIn7X1nXAAAA
AABUeU/yS77bSLXb7FB+yhbtA1ISaHqP0AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAD//1NUgAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAGeqT/MXRPsr3GhQAAAZivUhfshll/OTvNOM1J1HkFe28vZbZSM2A5mdnKm
nrJ1T5vwyG2JqzmovafQDiW2TGTjbtSrcnqHmo/7Sl2gAAAAAAAAAAGeIcP+Dz1/
ONDM1IeQAAAAACo8p/kl322kWu32OD9lC3aBqQk0PUfoAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAH//V1SAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAZ6pP8xdE+yvcaFAABGbwrZMsnKujv16Ub1lD2Zg2jtpnzUG
PwcLHFqKuGKcxEH1yPUa5LwZtFSJDciK5fXpNN3hWsiUWGkOAxz4kRMGqnqKonrH
WnjMdHbMo1MMUZjpwJTc5eHHqjXSE4v66ai+kUvfTZypwp1OFi52LvRXm5i6bp7M
1inoyJOx0fBzUVG44rgei19bqdq4ywKWjoKMXBXroRSF1VbQWEiMjzkfhYOKZyIu
JdcevstHTHzDNCOhqZ1sPW5+qPfI01FhxEcuL9SEhmLR1u7SO2LU4nCwHLhoXFC8
5+2jYUk2dhtV6Oaioia9JUszQ7RWncseXjcDDXS1rlwU8XcW8n7OTiyFXfwjnLg1
cSZ3z3mrZNjYMPREjaGu5iASFh7TzzUitm0zXaU9L1KXJYyVmqNKr4wfnvamKu16
EKir9vajbuaWWo7lhtauCux0HyxnV+wEVszPxuGl0VM7BcS/LNV9lfgMmIf0XJie
u1doEs/LPmXJijExM/06drl4rnTVPmEhwcVRGquBY92tlaxS4udUY6RGc2OJ897t
6TqQ5JGTRVmXalT1EIjWOtQkNJhszjozszHThrLLujvEW0kNZeNojwkwf71ONbm0
VRr0VZOmNdDc1dL10IQOuyFo7HK2ZjzHCQkX0kRcdBdVn7ZpaGnumoWhyQ17UQoO
zN6tWtfEi06XVUio5USJ6kLTs/MT9gZR8xWIvC4asFxIJITldvDe+PIxuBgovooq
4E4urrNRk4zpWpYvX1P1oVnby0T6JV3tgtV0R64NVPUp9doZO0lAhtnXx8YWtWY6
UTXgXLdjeC21cn4QuhWJ6X3JpKztJeBULbzaylHcsNGrgrsdB8Uyy0Fg4jZqdjcN
LtVM5EXEuCavGhMpy1NqYszccCmaVFrt4KunJCYSHBVVwaq4YFlXZ2Yq9KiKtSjJ
Eb6kxxLMAAAKjyn+SXfbaRa7bYoP2ULdoGpCTQ9R+gAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAf/1tUgAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAGeqT/MXRPsr3GhQAAUdlTZ6SkNUX0c9MSxrrnQ1p8Dg8MMxMcO
cou8yLCi2hl0hK1VRyY4dZat7V58OyjWwGpjMREwZ7lK7WXtXNQVi8I1Iapjhimo
5GT7w3jWJ4SqOiYLiqajtX/PwnoWn1tL2okZIEpDeupISKvYUjX7zZ+10y6XoKI1
WLg9VwQhV6UpX5eD/BKI1Ya+rFC4LAp/ABcPZu+RyMnyLCVYiIrc/FftHvyo5pkO
QY12GKxEwPoszbSFY+jsmJlFVM1ME9+BEabVbS2oxmZFzWQHaWIuCaCDyrJ5lYhJ
Uno6Ij01dZpK8i7mDbOAiPT9VYmMNeZSn0p1p7Hszs9HS8PSqYoq5qFlWbvHh23p
0V7EVHNhqjuvAz9dhJ1iLGjeK3Nb6a444Y6ya2ksNam0kLwaYe1WKunShcV1Flo9
mZRsvMLi5EJTVqWyqwnQIqYscmCoUFP3VVmysZ60R6NgriqNVUJBdre1HbMeK6rt
WOsrS+KFMvrjfA1RInqVdRL20m1rm4JEbgqc6HQuZutqNl48SannIqvxVcFPTbK9
ObtBNLI0NESKxcHuXAhl48laOXl1Wfit4LDTpQsi5fkSJz5r+4jOTUxvDRlwTHPX
T6yV5TTXrTvR1ZyYkkuTfDdTYPB4Y5vpYc5NWxYauwRW533YlAsY11dfnIi+l6y2
bzkTxfG+wvcVTk6p/Aua/kXcpWt2srV40zH8Vua301xxwx1k4tHYm1NoYKy0d7VY
7XpQs+7y7x9Pp3i+ewc1UwVCupq66t2TjPSivRICquDVVO4kt2N7kaNHWmVLam61
LlAAAKjyn+SXfbaRa7fYoP2ULdoGpCTM1H6AAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAB/9fVIAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAABnqk/zF0T7K9xoUAAEYvCsPDtjLLLxOtq+8pCk0O09mEWVlWosDHBFXXg
fqVuAnJaowajnK5yqixEX1L6yf31XWPtY1keX/Lwvo/cQeSh2qis8EisRISpmq7B
MUTrOtdDc9N2Rn3TEVcWORdK86nZv1uujWnYkeT/AC7VTBOo/N2LK5gkvU2IkFG5
uOCY4aiIVm6+q2OnHzFFTObEXFcT57Q3fV28CHhUERis+iiaEXsLZshZOPTKT4HE
/K5jkKkkrmqrZNyzkiuMdzlVW+o98O72t28mGJWUzYLVRdBbNuLtIdep6SLdCMRM
37io6JS7UWWb4NLMRYLdDcURdB+qZcpUXz8KoR1xcrkV6cxZt6M1WJdG+KWo7QmO
JXU2+1dVbwEaG1Ib0wcqIiaF1loXYXasslLOhL9KJ9P79ZX1qLsKhZiaWaomnOXF
WrqPn8cWuVU/U269OhC8LMPjvl2LNphFw9JPeeq1kSZhwHLJpjFw0FJLV7XpjhDb
r0aEO3dvddNR5rxpVUwmOY7l7V1flDhNSuKTLdSp6yDwJ61sq1IbYbVRqYIuCYli
3XTNWmmvSrtRq+rBEQrm1t1NSs7OunqMmLnrip8tasZaC3sJYNRRGNano4YJiv3F
k3a2Jj0Glvk435RWuRPvTBDiXJ3bTdlYkV0zqc5VQs61Nm4dooDpeMnouQz9TLKW
isTEiQqe1HwFX0ccF0E/ussjUGxXTVUVUeupvqPQl3M141dOYfqSroJ/bijvq0nE
gQvpuaqJ2ELuIu/mLKSsWBNppe5ezSRm1t1s/Zya8Lomty4q1dR8q1i164fqbdfM
haUeYqXi9HNanheGlPViVX43teiL+pt16NCHfuyurmPCVqdTTCZX1FzgAAFR5T/J
LvttItdvscH7KFu0DUhJoeo/QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAP/Q1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAZ6p
P8xdE+yvcaFAAAAAAAAAAAAAAAAAAAAAAAAAAABUeU/yS77bSLXb7HB+yhbtA1IS
aHqP0AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AD//0dUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGeaT/MXRPsr3GhgAAAAAAA
AAAAAAAAAAAAAAAAAAAAVHlP8ku+20i12+xwfsoW7QNSEmh6j9AAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA//9LVIAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAABnmk/zF0T7K9xoYAAAAAAAAAAHOq1o5ekJjHiNYnv
U5cheRT592ZCjsc7mRSSNdnaUPzGjJBRXOXBE1qRiNenTYLlY6YYiprTE/C3sUxP
56Yfad+lVuDVm58B6PbzofHWbZylFXCYitYvvU8Ua20nWlzZeM168yKdKoVKHTm8
JFcjWp611EcW9amJo8Jh9p9lLt/I1V2ZAjMe7mRSQAAAAAAAAAAAqPKf5Jd9tpFr
t9ig/ZQt2gakJND1H6AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAB//9PVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAABnmk/zF0T
7K9xoYAAAAAAAAAA5lpa02iy75h2prVUxZUYtRvin3woD14LOVPchMKLkm1CiR4c
ZkZFwcirguCmrqdAWBDax2lUaiL2HqrUgs/BfCRcFcioZVrGR9Oz0d8VIzURzlVO
cq69m5qNd5mJFio9XakQ0fdjNusbQlm3fSVvo49RQ1GoVQvrm34vVERV0rqQ/Fas
lP3PzkPNiKqK5MVTUaSvFrfj2gpHx0qxFXrwMu3fXTJbTPe6ZbBwVdDlLuuhyeH0
CZbNNmGxGtVF9FTS4AAAAAAAAAAKjyn+SXfbaRa7fYoP2ULdoGpCTQz9AAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA//U1SAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAZ6pP8xdE+yvcaFAAAAAAAAAAK3v9mFhUyJm
+tFMfXaXkzdk2vWRhq56quKomJObN5TFWlJhrZ7Hg3O9bVTvNfWerjK3BbHhrijk
Q6R8lWqbKZCdFiLg1qKpiidmYt5tbzHKroLX6PWmGJoG+6mNpFI8Hh6GtbgRDJIa
nBv0c+k+HK4b9DBNOKaST2IstGtNQUlmr6at0YlQzmSfVZZHPa9MNK4Iun8FOVdL
bKfsZU2yUR65quwciqpuaXjJGajk9aIp7AAAAAAAAAACo8p/kl322kWu32KD9lC3
aBqQk0PUfoAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAH/1dUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGeaT/MXRPsr3GhgAAA
AAAAAACC30UZ1Up0VrdKo1TKdwt4UrYGPEZUWaFVcFVMVTtPZfPeDKW6mIcOnswx
cmlEwX8DSdi55l3tJZEm1VG5qL79RIbB3nSttmq+UVVRNeJAMpy3jKPJOlUdhEiJ
95F8lC7tZSG6cjppdpaWvfXQlq1Oio3SrWquBme4K+KDYSJEhT2LW4rho0nxXw3o
LeROMhSbVdCzkw5y/n1iLdlSocTNx0JimvA5zMrWmLAxcruFzdLcPWUBZt0W3lbS
YhtXMV+OKJowxN206V8FhtZzIiH0AAAAAAAAAAFR5T/JLvttItdvsUH7KFu0DUhJ
oeo/QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AP/W1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAZ6pP8xdE+yvcaFAAAAAAAAA
APESGkRMFTFF9RTluMmORtVFWMqrDVV/a6D6LBZNshZKJwqYxHerOPhyoquyRpyQ
UwznLgiHoyWbHPosksWImCv0odq8zJ+l7exkjx4jmqnqQsGy1nGWdl2S0L6LEwxO
pFhJFRWuTFF1oU5bbJgkLTxVjYrDVfU06d3mT7JWMdns/VHc7kxLCrlBhVqEsCM1
FaqYYFHz+R5ITURYiRHpiuOCai0LCXXytjmIyC1FVP2yppJgAAAAAAAAAACo8p/k
l322kWu32KD9lC3aBqQk0PUfoAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAH//19UgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGe
qT/MXRPsr3GhQAAAAAAAAAAAVrby5llsJhseNEXNaqLm+osGmU9tPhthMTBrUREP
pAAAAAAAAAAAAAABUeU/yS77bSLXb7FB+yhbtA1ISaGfoAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAH//0NUgAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAGeqT/MXRPsr3GhQAAAAAAAAAAAAAAAAAAAAAAAAAAAVHlP
8ku+20i12+xwfsoW7QNSEmh6j9AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAA//9HVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAB
nmk/zF0T7K9xoYAAAAAAAAAAAAAAAAAAAAAAAAAAAFR5T/JLvttItdvsUH7KFu0D
UhJoeo/QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAP//S1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAZ6pP8xdE+yvcaFAAAAA
AAAAAAAAAAAAAAAAAAAAAABUeU/yS77bSLXb7FB+yhbtA1ISaGfoAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAH//T1SAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAZ5pP8xdE+yvcaGAAAAAAAAAAAAAAAAAAAAAAAAA
AABUeU/yS77bSLXb7FB+yhbtA1ISaHqP0AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAD//1NUgAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAGcLwLL1ai1l1Up0JHoqetMT0TN6tpYH0pdqfyE+R19NoW64Dew8cdlofYN
7Bx2Wh9g3sHHZaH2DewcdlofYN7Bx12h9g3sHHZaH2DewcdlofYN7Bx2Wh9g3sHH
ZaH2Cdg47LQ+wb2DjstD7BOwcddofYN7Bx12h9gnYOOu0PsE7Bx12h9gnYOOy0Ps
G9g467Q+wTsHHZaH2Cdg467Q+wTsHHZaH2Cdg47LQ+wTsHHZaH2DewcdlofYN7Bx
2Wh9gnYOOy0PsG9g47LQ+wTsHHZaH2DewcdlofYJ2DjrtD7BOwcdlofYN7Bx2Wh9
gnYOOy0PsG9g47LQ+wb2DjstD7BOwcdlofYN7Bx2Wh9g3sHHZaH2DewcdlofYJ2D
jrtD7BOwcddofYJ2DjstD7BvYOOu0PsG9g47LQ+wTsHHZaH2DewcdlofYN7Bx2Wh
9g3sHHZaH2Cdg467Q+wb2DjstD7BOwcdlofYN7Bx2Wh9gnYOOy0PsG9g47LQ+wb2
DjstD7BvYcG2ttK3baB4HHgo1iuRVVELGsTILIy8OE7W1ExLToTcEQksPUfoAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAH//V1SAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAeiYcqJoIpWJV8UjsWkPU9fiZw8TOHid
w8TOHiZw8TOHiZw8TOHiZw8TOHiZw8TOHiZw8TOHiZw8TOHiZw8TOHiZw8TOHiZw
8TOHiZw8TOHiZx7G0BzvWh4fQXN9aL1H48TOHiZw8TOHiZw8TOHiZw8TOHiZw8TO
HiZw8TOHiZw8TOHiZw8TOHiZw8TOHiZw8TOHiZw8TOHiZw8TOHiZw8TOHiZw8TOC
UZx90hRVapMKXK8Gh2WJgeQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAf/9bVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAB+Xtx
PliyaPPndTEU8eKk5h4qQeKk5h4qTmHipOYeKkHipOYeKk5h4qQeKk5h4qQeKk5h
4qTmHipOYeKk5h4qQeKk5h4qQeKk5h4qQeKkHipB4qQeKk5j9MpbURcU9SmJb47e
T1LnokOFFc1qOXBEUlmTRaqbrsy5keI56cymrnUpOY/PipOYeKkHipOYeKkHipOY
eKk5h4qQeKk5h4qTmHipOYeKk5h4qTmHipOYeKk5h4qTmHipOYeKkHipB4qTmHip
OYeKk5h4qTmHipOYeKk5h4qTmHipOYJS05j2Q6cjT7IUHNPaAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAf/X1SAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAMBgAMABgAAAAAAAADw7Ufz4v8AeUYn2lJrkjbY42mA
AAAAAAAAAAAABgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAf//Q1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AADw7Ufz4v8AeUYn2lJrkjbY42mAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAf/9HVIAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAPDtR/Pi/wB5RifaUmuSNtjjaYAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AB//0tUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA8O1H8+L/
AHlGJ9pSa5I22ONpgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAH//T1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAADw7Ufz4v8AeUYn2lJrkjbY42mAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAf/9TVIAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAPDtR/Pi/wB5RifaUm2S
NtjjaQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAB//1b7vXrr6HTo0xCXB7W6FKPsdYeu2ulmzrZ3NR+ODcVO1
xNV/p34qeOJqv9O/FTzxNV/p34qeOJqv9O/FTzxNV/p34qOJqv8ATvxUcTVf6d+K
jiar/TvxUcTVf6d+Knjiar/TvxUcTVf6d+Kjiar/AE78VHE1X+nfip54mq/078VH
E1X+nfio4mq/078VPHE1X+nfio4mq/078VPPE1X+nfio4mq/078VPHE1X+nfio4m
q/078VHE1X+nfip54mq/0790o4mq/wBO/FTxxNV/p34qOJqv9O/FTzxNV/p34qeO
Jqv9O/dKeeJqv9O/FRxNV/p34qEuZry6578VPmu0r1QoNZWlz0bhURNeOJoTwpFV
UPex2J+gAADn1i0MCjNzpiI1ic6rgcHjapfSYfaONql9JZ2jjapfSWdo42qX0lna
ONql9JZ2jjapfSWdo42qX0lnaONql9JZ2jjapfSWdo42qX0lnaONql9JZ2jjapfS
Wdo42qX0lnaONql9JZ2jjapfSWdo42qX0lnaONql9JZ2jjapfSWdo42qX0lnaONq
l9JZ2jjapfSWdo42qX0lnaONql9JZ2jjapfSWdo42qX0lnaONql9Jh9o42qX0lna
ONql9JZ2jjapfSWdo42qX0lnaONql9JZ2jjapfSWdo42qX0lnaONql9JZ2jjapfS
Wdo42qX0lnaONql9JZ2jjapfSWdo42qX0lnaONql9JZ2jjapfSWdo42qX0lnaONq
l9JZ2jjapfSWdo42qX0lnae2VvRps05GMmGKq+rEk8OKkREcmlF1H6xAAB4dqP58
X+8oxPtKTXJG2xxtMAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAA//Wui/nkiP1Ifm4LkiB1KWGAAAAAAAAAAAA
AAADMdcmvBrVK73F1SFV4Vy9ZKJSLnIfUAAAZ6ymYPh01JSzlXMe7ByIuHrJazJq
pLkRcx2pP2x+vNopP1HfEPNopP1HfEPNopP1HfEPNopP1HfEPNopP1HfEPNopP1H
fEPNopP1HfEPNopP1HfEPNopP1HfEPNopP1HfEPNopP1HfEPNopP1HfEPNopP1Hf
EPNopP1HfEPNopP1HfEPNopP1HfEPNopP1HfEPNopP1HfEPNopP1HfEPNopP1HfE
PNopP1HfEPNopP1HfEPNopP1HfEPNopP1HfEPNopP1HfEPNopP1HfEPNopP1HfEP
NopP1HfEPNopP1HfEPNopP1HfEPNopP1HfEPNopP1HfEPNopP1HfEPNopP1HfEPN
opP1HfEPNopP1HfEPNopP1HfEPNopP1HfEPNopP1HfEPNopP1HfEPNopP1HfEPNo
pP1HfEPNopP1HfEPNopP1HfEVvfpdHJWMlYczJo5sRIqJjiXjY6scLJS6qulYbce
wkkCPnn0ooAB4dqP58X+8oxPtKTbJG2xxtIAAA+KtTaycCJETW1jl7EM1WUnbQW/
WLHlJhGQ2PVqIq4Hd8grU9KT4jz5BWp6UnxHjyCtR0pPiHkFanpSfEefIK1HSk+I
8eQVqOlJ8R58grUdKT4jx5BWo6UnxDyCtR0pPiPPkFajpSfEePIK1HSk+IeQVqOl
J8Q8grUdKT4h5BWo6UnxDyCtR0pPiHkFajpSfEPIK1HSk+IeQVqOlJ8Q8grUdKT4
h5BWo6UnxDyCtR0pPiHkFajpSfEPIK1HSk+IeQVqOlJ8Q8grU9KT4h5BWo6UnxHn
yCtR0pPiPHkFajpSfEPIK1HSk+I4NrZu0F3/AAcxNTCPhueiKiLiaNolV8Ml4UVd
b2Iv4HSZEzj2AAAAAAAAAhl7tpolm6dFmYOh7cMPvKbs1RbTWll2TkOZRGxNKJjp
wOn5BWo6UnxHjyCtR0pPiHkFajpSfEPIK1HSk+I8+QVqOlJ8R48grUdKT4jz5BWo
6UnxHjyCtR0pPiHkFajpSfEPIK1HSk+IeQVqOlJ8Q8grUdKT4h5BWp6UnxDyCtR0
pPiHkFajpSfEefIK1HSk+I8eQVqOlJ8Q8grUdKT4h5BWp6UnxDyCtT0pPiHkFajp
SfEPIK1HSk+IeQVqOlJ8R58grUdKT4h5BWo6UnxDyCtR0pPiPHkFajpSfEPIK1HS
k+IeQNqOlJ8RzJK09ZsZU4MnUI3CMiqmpcTSLplEXD3HtY/E/QAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAP/9e6L+uSI/Uh+bguSIHUpYYAAAAAAAAAAAAAAAMrW0dm2nXq
LbokTF33k+p2o6AAABn7KJ5QkPtp3l/QPop1IfsAAAAAAAAAAAAAAAAAAAAAFK5V
mims3qHtsNU1WUgJ+YncWRSI+eh3GHkAHh2o/nxf7yjE+0pNskbbHG0gAADlWr2S
Nun9ylS5K2yR98vzLvAAAAAAAAAAAAAAKPyrlwkYS/w5PkSGx9azpWAn8LTuJ1Tp
nhEOo1cTyAAAAAAAAVnlFckRetp1Lk+SZf7BOAAAAAAAAAAAAAADNt/sXga1Ju6u
8t2VrHCuTqQk8lGz0PuQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAH//0Lov65Ij9SH5
uC5IgdSlhgAA9cSZbD0Ocidaoh+2vR2lNJ5PU+aZDXBXIi+9UQ9qLjqAAIjHvPlI
M4lPVy8M7Uh9dq7ey1l8PCFwztR2KZVGVGE2MxfQcmKKfQyM2JqVF6lxP2AAAAAA
ZVtt/MTr1Fs0P6RYNO1HQAAAM+5RPKMh9tO8v+B9FOpD9gAAAAH5fERmtUQ/SLjq
AAAPXFmWwfpOROtUQQZhsbS1UXqVF7j2AAAAAAAAAAAFK5VvJrd6hz7Cr+tYP2EL
WoWpCRMP0ADw7Ufz4v8AeUYn2lJtkjbY42kAAAcq1myRt0/uUqXJW2SPvl+Zd4AA
AAAAAAAAAAABR2VjsEPep8j82Li/reD9hC0aI7FEJCw8gAAAAAAAFZ5RXJEXradS
5TkmX+wTgAAAAAAAAAAAAAAzNlGrhV5TqTvLCpETFydSFg0lcUOsgAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAP/0bov65Ij9SH5uC5IgdSlhgAAyNlJ1OchzapLRHJgupq4
Fw5PNrHVWRbCmHYxm68dZZ1UnUkoToi/tWqv4GJbYWkqFfm3TLYjmQ2RMMEVcMMT
YlgY6x5KC5y4qrExU7zoqN1qnaGxEfqVFP0fhYzedO0zLV4aeVMJfehJMpaGjuCx
93eTqlykSaozYcDREWF6JG7jbL1GjxIiz7lci45unEuLOQ/PDt507T9nhz0brU/K
Rmu1KnafsAAAGVbbfzE69RbND+l95YNO1HQAAAM+5RPKMh9tO8v+B9FOpD9gHy1S
O6BDc9iYuRFVEKuurvfjWqm40pMMRnBquHqxLOrVRSmwXxl/aNVSn7sMoHywnnyb
mo1rVVEUuiaj8Axz19SKvYVVYm96NaeedLsYnBNVUVxbQKfv+qEWU4DgnK3F2nDr
LDsVFdFlWK5cVwTSd0AAKuBmW3UeYt9WFpkOK6ExPWmKFy3bXcrYyHwaxnRfe4mq
rhpKRvAvxmIMx4JSIfDREXB2jE/dkr1KpAjNhVeBwaPX0VRMC6mPz0RU9Z5PxHic
G1XcyKpTNk77o9YqSyDoWDEdhnYF0gAAAAAAApXKt5NbvUOdYXZYP2ELXoWpCRMP
0ADw7Ufz4v8AeUYn2lJrkjbY42mAAAcq1myRt0/uUqXJW2SPvl+Zd4AAPkqlVh0t
ixYq4NTWpXUxlHUmA5WrEdii8xL7JW8lbVtV0q7ORNfqU/E/eDKSEZJaI/CIq4YH
Rr1pINChcPHdms5zl2TvIkrVKqSsRHKnqO3VatDpUNYsVcGprU+Kzlrpe0SK6Wdn
Ims7D3oxMV1IQuFfDTokz4GkT9VxwwJqi4kerlvZWiREhR35rl1Id6BGSO1HN1Km
KHFtHbSWs9h4Q7Nx1HRl6tDmISR2r6Cpjj7jl0G3UrXYjoMB+c9utCQAAAFHZWOw
Q96nyPVYvZ4P2E7i06HqQkTDyAAAAAAAAVllF8kRetp1blOSZf7BOAAAAAAAAAAA
AAADMuUdytKdSd5P6R9JOpCxKRqOugAAAAAAAAAAAAAAAAAAAAAAAAAAAAAP/9K6
L+uSI/Uh+bguSIHUpYYAAMyXnS/hVWbDXU52B9Fjoq2UrfAO0Q3N+7SWBf1ap1Ll
Ww4Wl8RyJgnMpVFtrO+JZCG9UwdEVFUuin2obZejQ5pyY5sNME95VNDspUL03Om1
mHQISquaiKvyPokWzt0M0xJmMseFGXBMVX5ll3uXieTckkSH9OKmDfvQqeyN0FTt
DBWdizb2OVc5rMV0+vAjFjpiYfaGHDm0VHMVERV9fvLMyk/51fd3k8o8w6XozXsX
ByQtCkKuFtJM1WYjNmHq5ExwI3ejbKoU+qOl5RVcj1wwT1HotLdBVKbA8PSbcrk9
JWYro9eBaFyd4brTybnRfpQdDl6iu67aKcvQnFlJN6wYbFwVyKeuuXXVGwGFQbNu
jQ4eCuaqr8y77vrXpauVZMomCrrT3klAAAMq22/mJ16i2aH9L7ywadqOgAAAZ9yi
eUZD7ad5f8D6KdSH7ADkx0GYKhMusjXUwTBIr+9S4b4LRNp0k5i64jcEM12Ts95F
RIc4q4LEid6mprY19JKnrF+tD0fehWGT/JNosGPPTC5rVcq4qeKhf5PzsVzadK8N
Daq+lgqnfu0vriVyKsvUYfARP2qLox7T5MoyM2XbBiPXBqO0r95G5W+2el4SNp0t
w0JqfSwUn91l8bbWLwEw3gphP2hZoKrvJvpSzz0l5NqRoy/tU0kL84WpUuKxJ+U4
KE5UxdguhC1q3bh0WS8LpzUjYpqTSZfod4FQl6s6ZZLZ0ZVVFZgawsPXI9ZgcJNQ
+Cf9U70yzhGuRPWip+Bk2zVpW3b1iKs+3NZEeuD1T3mlqfUJK1rWxYatio3Si8x7
7T2mg2bgrFjORqImhOf3FJvv9qk4qxJWTz4KL9LBdRZ93V4PlXAc6I3MiNTS0iNA
t/Lx6msoyAjX52GfhpJ9bu3UGycFYkRUz8PRb61KciX9ViI1Y0KRV0L1OwXUWldn
eSy18L08GR0+kz1oR621+bLKzaysVv2V51IbUcoSqSeEVZP9QVfpYLq5y5rC21hW
sl0jw104JnJzKQu8e+vxFESXkWJGjetqacFOFQL8qg2O2FUJXgWuXXgpbFo7YQKH
LrMxHIiZuLfeUvEv7qs3nRJSTV8JNTsFJ9dZewlq28HMt4KYRfoaixwAClcq3k1u
9Q51hdlg/YQtehakJEw/QAPDtR/Pi/3lGJ9pSbZI22ONpAAAHKtZskbdP7lKlyVt
kj75fmXeAAfiPFSC1XLqRFXsMy2gqczehVEloL1ZLMdg5E1aC55K5umQGIx0uxyo
mlyppX3nx0C6Rln5nh5Z+Yxf2iaiprw4aOrUNfz07yyr+ISRacjV9afIzvdK2JYG
ZSdeq8C52Hu0mnrzJttQpborfouaip96ENyZoaMgxcOf5k+vUtJ4ikYj2/TVMEQz
XPXeuayBWkxR6vxd2mqrI1xtal2RW8yIvXgURfzBR9QhY/WQ0DQdEvD+w3uKSylI
KPWFjzoWPZ5v8CWJ/Ciqsn6EjalM4fnGigAACjsrHYIe9T5HpsXs8H7CdxalC1IS
Jh5AAAAAAAAKyyi+SIvW06tynJMv9gnAAAAAAAAAAAAAABmXKO5WlOpO8sCkfSTq
QsOkajroAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD//07ov65Ij9SH5uC5IgdSlhgAA
zReI7NrTF/PTvO5lFUZZKHAn4CYParc5U5tBErPWwW8mpQYGGLGNTHmxQmOUdCSB
BhQ01NVMD7LdQliWbbgmPoJ8ytbrLtqlXJVHSs5wbU/a4ro7CUTOTlUqtFhvnJzP
RioqJiqn5yiKS6lQJVrnYta5qY9ReNjJ9keShPbhmpDTH7k0meZmsQqraiGsByOR
HJjgSzKT/nV93eTmncipuivcnPaY/wB/eKs7Nry9Zb1ulwkYu7XuKeyZ250pNonO
75la2HsjOVqfjslZjgHZ66McMdJYlSuBrFShrBiz2cxdaKqlp3V3fusVLpLufn+8
m4AABlW238xOvUWzQ/pfeWDTtR0EAAAM+5RPKMh9tO8v+B9FOpD9gAobKNoWbEgT
rdCw1RV7ThXiWnW1kKTROdqKSa+yxLXSEDg0wWHmqq/chGbd24dO0mDBhri5Fa1e
46158qtIs/DzNCuaiqRa7e+OZs9KthwZFz0w0uRF09h8VprUT9tJ+BGZJuhZjkxX
BSxb+4Xh0CXZFT6WGchY921DhUmTZDgtRGqmkoq0LG060qLB9FVVMcDTkB2c1FXm
Q+WtRlgwXubrRq9xnjJ9kW1eozUaOmc9jlzVX1aS4r26TCqNOjpFai4MVU9xX+TB
MuSUfDx9FHLgh8Nk4mNon6vWaABFbaXZyVr24TUNHOw0O9aGb7UWTnroZ2HFlYqr
LPd9HH1Ykjv2tM6vQpRcFRr3Nzvv1l9WPo0OnSkOFDT0VYmP3ppPolrOwKdnPhMR
qqi4mfLI6a8v2vmenKcqb5SfgKiK9Ew9DnOtTr/ZyThthNp7sxEw1Lgcq5+YnZ2s
Pm3y7oUN6rowVE0nQt3RoVXrjWx0zkRU0FzWup0Pxe+HmpmpD0J9xT2TRMOgy85h
+1V2Cdp8mT/T2ViozMeNpex64Y9ZoSqUKDVMOGajsNWJQWVNHWnsgMhp6KKnop6z
02bv0m6TAZCh09ytRE0oi6Ti2cqs9Xq02dSWdBZ69CohqqE7ORFXmP0AClcq3k1u
9Q51hdlg/YTuLXoOpCRMP0ADw7Ufz4v95RifaUmuSNtjjaYAAByrWbJG3T+4qXJW
2SPvl+Zd4ABzrRqqS8XN18G7uKIyaEaseYx+lnr3miAZmvA5aZ9tO8si/bk9P4vU
QmgWLbamhOaiemzFyc+jScuxtvXT1LjSMyv6pDxa1F14ITHJrbmwoqe/5nKyhbWQ
5eagS0R2ENVTOX7zuWktdSHUx8qyYZoh+jz4nOyaLWpNQnSiOzs1VVFIxlIyb52b
YyEua5VTBToUy5atRITFbPKiK1FRMV0EFvLu+qFAiQ3TczwyYp61NJUBcaSzdFVX
A8pTH8iNEAAAFHZWOwQ96nyPTYvZ4P2E7i1KHqQkTDyAAAAAAAAVllF8kRetp1bl
OSZf7BOAAAAAAAAAAAAAADMuUdytKdSd5P6R9JOpCxKRqOugAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAP/Uui/rkiP1Ifm4LkiB1KWGAACo7V3OxaxPtnWvRGo7HAnVs7Jp
aOUdLLrVuCL78MCDXL3JeQqviRVR0RVXBU5jqXt3aRLZta2G5G4KhJ6PZVsKSZJR
0zkRmapUNRuVqlIjOfSI/BQ3Kvo44Hto939o4EZj4s2iw0X0kztaFpW0sPCtZLcB
HTFyJoXmXDWU1I3N16nfqMKaRJdV+jnfteY7dByd/ElRhz8J+rBXpzr6yU3s3ZRL
ZZnBuRubgSKVss6DT0ksfSRmbiRe6q6yJY+LEixHI5H44HifuriTFSWfR6ZqrqJ1
aOkLVJZ8Bq4K5uGP3EKuYuwiWGhxWRXI7hHY6DjXg3KxZuOk3S38DF1quOGkjr7u
rTu/nsT4i6bGyExIyzYc47PiprdrO4AAAZVtt/MTr1Fs0P6X3lg07UdAAAAz7lE8
oyH207y/4H0U6kP2ACGXs2e8dSMRrUxejVzTONw9mJybnOCnWORkN3o4poNSWyoq
VSUiQsMVzFw7DJt11jZ6YqayswxyQEeqpino6zTt4tgktNI+CNXBWomb9yFNWZvQ
mbu2rJTMs6KjVwa5qfvEss5lDLV5hsDwN7M5fpKmhPwPflE0WPV4UJsq1VfjoVPU
Q+gXwztg4Pgc3LvivamhyIp7Lr7HzFsaitZmWqxmOhq6zSCJgfiYgpHarV1KioZf
rNInboag6bl2rFgxXYq1vMdC0t8M1bxqSMrLvhJE0OcqKW5ddYBLGynBLpiLpcpX
dk6VHh198RzFRmn0vUX2fJVYD40NzYS4Ow0KUU+96esTGfCnYL46Kq5qtxOJPVGc
vmmIaMhOgwoS4rnY6SxL1bq/GsixkDQ+A1FT34EAsvf/ADNDgeCR5WI6I3FrXIi4
cxZ91tUna3CfMTWLWqi5rV1lcWVo8eHXFiLDVGZ2vDQS+/K7mJWFZPy/5SCiLhz4
EXpeUXEp0NIMaSe57UwVUTQv4E8uyve8s4jofg7oOCa1/wDURG0lJjPrnCIxVZj9
L1FuWshOiSURrUxXg10fcVHky0eLKsmmx2K3OeuGKYY6SN2ikJq6eoLNQGLFhRVx
VG4kghX1TlrozIMpAfBTFM5XYkqvcu1iWnlWPR2MaEmPWqEFoN/MezsJJWYk3vez
RnImhfwJpYC+5bVTHg/gr4X5ypo7i2QAClcq3k1u9Q51hdlg/YTuLXoWpCRMP0AD
w7Ufz4v95RifaUmuSNtjjaYAAByrWbJG3T+4qXJX2SPvl+Zd4AB65iDwzVavrRU7
TMc5Gi3U1TPVirLxHYq5NWkveRvOp80xsTwiGmKY4K7ShzYV7EGbmWy0u1YqKv0m
6UQp+8N6NrUNMf2yd5ZN/D0bT0x/i0IMn3CNTsNaKuH4FHZQtmYtj5vwmXRUgu0r
hqLNyaKq1ZKLMOXBNa/cQ+x1nWXq1OOs5i6FDcub2lq+bfSPZr8RWFDkYd2VcWG1
c2A9cEx9599+sw189Bci6FVqoaCoK4y8P7De4pLKViI10LH3Fj2eXGks3RTdyVpZ
amVGY4eK1irjhnLgX5K27kZp2ZDjw3O5kU7qLjpAABR2VjsEPep8j02L2eD9hO4t
ShakJEw8gAAAAAAAFZZRfJEXradW5TkmX+wTgAAAAAAAAA8Odm6VOJM24kpZ/Bvj
w0dzKuk7MGO2OiOauKLqU/YAABmXKO5WlOpO8sCkfSTqQsOk6jroAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAD//1bov65Ij9SH5uC5IgdSlhgAAAAAAAAAAAAAAAyrbb+Yn
XqLZof0vvLBp2o6AAABn3KJ5RkPtp3l/wPop1IfsABUxPWyXazSiInUiHs1nrbLt
auKIiLz4Iew9MSRhxNLmNXrRFPDKfDYuKMai/ZT9B7nQ0drQ9USRhxNLmtVfeiKe
yHCSEmDURE9yYH6B64su2N9JEXrRFPxDkIcPS1jU6kRD3n5SEiLjgmPPgfoHpiyb
Iv0mtXrRFP1BlWQfoNROpETuPYqYnzrToS6VY34U/Qe5kNGaERET3HhILUXHBMeo
/Tm52hT0LTYS6cxvwp+g/cGUZB0taidSIncftYSKuOCY9R+lTE/LISQ/ooidSYH5
iy7Y30movWiKfmHIw4WlrWp1IiHuVMT53U+G7SrGr/IU/QfqFJQ4S4ta1F9yIh7g
AClcqzk1u9Q51hdlg/YTuLXoOpCRMP0ADw7Ufz4v95RifaUmuSNtjjaYAAByrWbJ
G3T+5SpclbZI++X5l3gAA5dobOQa/CWDHaitXtKziZL9MeuOMRPdiTexV3ErY9qt
l0XT610qfip3ZSlSmEmojf1RFxxOraOy0G0ELgY6YtFmbLwbOQuBgJg3E9VrrGy9
q4KwJluc1e0+Cz12srQJd0pARUhu1n0WTsFLWXzll24K7WSMiVrLsZS08RsWO1c5
i4oqCtXYylYcx0VqqrMMPuJTLQEl2oxupEREOBauwMtafBZhMc3UdWVo0OWgpLtT
0Ebhh7itqrk2UyoxVjORyOdrwXA9tEydqfR4iRoavzkXFMVLRYzMRET1IeQACjsr
HYIe9T5HqsXs8H7CdxadC1ISJh5AAAAAAAAKyyi+SIvW06tynJMt9gnAACmbLfXk
VeLUPAqe7DF2CCsVK01kcJmaej4LdL8Fx0Fz3cW/hW0l0jw9C+tPeSwAAApq9+8e
bs5Mw4UuuDXKmJa9CmnTcCHEd9JzEVT7gRq8aqupcjGis+kjFwKJuduigW4hrUZ1
z8/hFwTE0lTpBshDSEz6LUwQ+kAAAzLlHcrSnUneT+kfSTqQsSkakOugAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAP/Wui/rkiP1Ifm4LkiB1KWGAAAAAAAAAAAAAAADKttv
5ideotmh/S+8sGnajoAAAGfconlGQ+2neX/A+inUh+wAAAAAAAAAAAAAAAAAAAAA
UrlW8mt3qHOsLssH7CFr0LUhImH6AB4dqP58X+8oxPtKTXJG2xxtMAAA5VrNkjbp
/cVLkrbJH3y/Mu8AAAAAAAAAAAAAAo7Kx2CHvU+R6bF7PB+whalC1ISJh5AAAAAA
AAKyyi+SIvW06tynJMv9gnAACmYpyM2DXUVyoiZ/rXD1ltXyWuladT4rIjmuc9io
1qKiqpC8ndq0WnRJyMithpiuHuOdM3lVq10Zz6MiLAaqppwJjd5MV98ZUqTUSHh6
sDiT98M3Saw2QjtwhOdoXAt20lbSkSz5j1NbiV1dheZMV5Y0eawbLsxwUi9UvUqt
qph0KiNRWNVdK4HcsBbypy814LV2YKupUTQRzKC2uEvvaWfX7QxLP0psxC+k2G3u
Kqp18dWtq3NpbPTb9LFNB0bBXxT8hOeBVpEa5y4NU++/2PVUgu8FRFl1bp6iF3Ex
64kNEgNTwbP044feWrejet5NMbLwfSmnInopp0ldz9qrVSMJJpzE4PXhgmOBal1F
6UK2sHDVGYmD095PgADMuUdytKdSd5P6P9JOpCxKTqOugAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAP/17ov65Ij9SH5uC5IgdSlhgA+Cu1hlHgujxNTUIVdnb2YtVEiLEZh
BTHMXnPvtde/IWUdwcy/B3MiYnAl8pOkx3IxHuRXLgmKaCzZGeZPMSJDVFaqYoqH
vByLW1h1HlokdqYqxuKIRq663sS1kNXxG4KiqTw59crsKiQ1jRlwYmtSNWVvfp9q
IvAy0TOfzE1ORaa1cvZuGsaZdmtQ5Vi7z5K2Kqko/Ow1ksABDb1bZxLIybpmEmLk
9SnxWOt1HtBSVn0anC5qqjfeh8d1N5sW07nwZlqNitVdGossAAGVbbfzE69RbND+
l95YNO1HQAAAM+5RPKMh9tO8v+B9FOpD9gHKtDaaDZ+Hwsd2DT6KNV2VeE2NCXFj
tR9oAAAAAAAOBaW3MtZxUSYdmquo+/x5C4DwnH9Twxx9x8Fmrcy1o1c2XdnK3Wd8
AAA8LERPWeQAARioXiykhMpJRHYRV1J6iTNdnpimo8gApXKt5NbvUOdYXZYP2E7i
16FqQkTD9AA8O1H8+L/eUYn2lJrkjbY42mAAAcq1myRt0/uKlyVtkj75fmXeAAAA
AAq4HhrkdqPIAAAAAABR2VjsEPep8j02M2eD9hC1KFqQkTDyAAAAAAAAVllF8kRe
tp1blOSZf7BOAAFMjW6sr5TVjgc9WYu1pr1ljyOS7BhxWRYsw+IjVRc12lF/EuCY
s9Ciy7pRGo2G5ubgmjQUBFsdWLt4720dnCwHKq4KmKExu7vniTcXwKqtSFMquhuG
BzsoazSwkZU4aaYapiqaz4bb2+bWKRDloTsYsVqIqes+yLQH2ds45qJhEVuKnRyZ
ZWGlPz0ROEVy485bMSRhvdnOa1Xc/rM/5QW2QutCd3hciJ9hncfm4WRhwJTOY1EV
da85W9/kNG1aVVNC56d5cV5z1bTX4ezTuOFk8OVacv21K0a1Ju1KNjaUx1KaYm4T
XQ3NVEzc1dHq1GarkkSXq8w2Hobnrq1azTYABmXKO5WlOpO8sCkfSTqQsOkajroA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAD//Qui/rkiP1Ifm4LkiB1KWGACpsoaurKySw
G634EguXkPBKbCTDSqYqUterS4VQrDGxW5yK9NC9Za9rroadMyblZBYx7YWLXImC
4omJC8metxs2LBiuVzWOXBV9SIXRTLWy1TesOE9HOauCoe2vWigUKHwsw7NZzkft
jV4dXpkWNBXOY5mhStrp7Yy1lZdXzb0YiquHrLMsxexT7TP4KVio53NqOffazPp7
0X1mWLtqc+yE4k+i4szvmbapFRSpQmRm6nNRTPWUJHdaiYhykJfQbodgerJpozaN
OxoLNSIpoO0FpYFAh8LMuzW85DYN/wDSIrkYkfSq4JoLBlplsy1HsXFqpiikbtXe
VI2VVGzcVGKupNZWF715EjaqmxUlImcqfcSvJ7bnUmEi+8r6mxn2btDEVU/U3qqd
poxjs9EXnPIABlW238xOvUWzQ/pfeWFTk0H3gAAGfconlGQ+2neX/A+inUh+wDP9
7tX8c1SBIouMNVRHIXpR6WylwmwYaYNamCH2KuARcQeM5DyMQi4hVwCLiAMcBnYg
8Zx5xxM/5ScNHxIWPOhYCN/gKifwkr/JshoyNHw9/eaAPGch5CrgEXEg96N4TrHQ
0iNajsec7Nh7SraOVZMqmCu9RU949Cq8zU2vlVVIGcmOnRgXhINVsNqO15qY9eB7
1dgEXEDOBReUVR2U1IdRYn6oj0RVLXsPVkqsnCiouKqxMes7oAKVyreTW71DnWF2
WD9hC16CmhCRsPIAPDtR/Pi/3lGJ9pSbZI22ONpAAAHKtZskbdP7lKlyVtkj75fm
XeAAAAACI3pzb5SRiPhrg5PWQzJ2q8aowoqx3q5UXRj1lwgAAAAAAFHZWOwQ96ny
PVYvZ4P2E7i1KEmhCQsPIAAAAAAABWWUXyRF62nVuU5Jl/sE4AAUz9HsLOLWUmcz
9SzscfvNAnNtFPRJKC6JBbnPRNCc5R0S+OvtVyJI6EXRoU8WLsROWyn0qtQhrBe3
U3UXPbOhNrMpEgO1K3uQx/dhZGYqNazMVWFCfq9WGJsytUNlVgOln/Rc3AzlKydX
uwmnw5KCseAqrhoXAmNg5iq2pm+HnWLAhppzdKHrvrsZN1mZhvl2K5rVTFSY23oU
adpKS8NuMTNamHUh+rn6HGpEqjI6ZruYgN89iJusVKXjQGK5jXIrl5tJZ14VKiVC
QdChJi9WYYfcci42gxqJJcFMNzX56rgRC+q6iNEjJVqeq+ENVPRT1nAj3jWhqUFJ
XwRWqqZqvwXEsm6C69LKsWPFXGNF0ux9RZQABmXKO5WlOpO8n9I+knUhYlI1HXQA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAH//Rui/rkiP1Ifm4LkiB1KWGADO+UpVOCmpe
Eup2Bddh4aQ5OEias1DN991XiUiptiwmZ7kdqOnaK9ur2lgtk4Mm6FwiI1X4Lq1F
nXUXaeRMk9Ii50SI1XOXm0Y4EMuXZhPRl/PXvJDlMtzqa7rPXYz0LNpu1ILctdY2
vufFnV4SFiuDF1HtvssBBsIsGdpqcEqvRHIik+txVVq1FbGd9JWJj14FZ0my61mi
xHQ0xe12JZl09umOpio5fSgtVFIfdlQX1iLNTsZcWrnK0/dwq41OY/kRH7xrTtrl
XWTnouZLMXUq6CRVyk2Wiy68G+G2Ixqq1yKuOKIfbk/3gLOS0dj3q5sPHMX3JqIn
YezCXoVKLHnPThwnr6Kro1nTyhLoINNk1jyCJBa36SJ6yxsnt2dSYX3ldXzq6nVK
FFRfpPTvNDU2JwkJi87G9x9IABjq+e06WYtCsdyYpgdCnZSsKWXHNJLL5XMBiYKw
9/ney/s/xHney/s/xHney/s/xHney/s/xHney/s/xHney/s/xHney/s/xIJbG96H
eHU5NsJubmPTvNhQUwanUh+gfmM7Naq+5TM1nHpXK4rlXHMf8zQ9pq82gy75h+pi
Yme5CFU714z4svHWXgoq4ayXWApNTslNcDNPWPCXRnaT83tXnRY0ZKXIY8M7W5Na
EVq1z9bkIPhTJxznomcrMV68Cf3I3putXCdLR0zY0FMFXnwKmiXgVObqkanQXKrX
uVEd9XSWhZCxs5YJsScnplYzWoq5qqpC4ESpXsR3RJWMsvARVwXFfkfpZSp3UR2z
E3HWYgOXDWvzNDUepNqcJkZup7UU+t7sxMV9Rni2lupu3E54vpzlho1cHPQ/cG76
sWPjMi+EOmGqvpN0k+vHvSSzEo1yt/VoiYI3mUrOl3Y1q1UJZtZt0JXaWsxU+y62
8WbszOeJ6ni9yroep9WUgnpwl96E+TkVNyQHJuT9Wj/f3ntvOvDmK5NeKqcqtei4
OeinHqdz9aozEmmzqvzEznNxX1aVQtO628RLTyroj0wfCTB3vwTWVbXrWTt5U4sp
T3rBYxcFcmJ0aTYyr2JmWOdHdMQ11ppI9lD2QnJlEmVjKjXYehzHVuWuwn2w4cys
0vBY/k8VOhexbObpk/CgwX4MxRFTnLFtxb9lkJFsxE0uc1ERPfgU/RbEVi3yOnPC
XQGO0sbiv3CxluJ67qeSnVNVitiKiNepL8oC2EzZ5sKLKOXT6k9ZD5SxdattAWeS
YdBxTFGYqh3rjbwZhJh1KnXK+KzH0lJxfbIJNyDs5McFxOVk+Vbw2Uc36i4FqgAp
TKwXMpaO5oiKU3Zm/wCh0+DDhq36LUQmlOyr4MsmCsQ6KZXsv7P8Tz53sv7P8R53
sv7P8R53sv7P8R53sv7P8QmV7LLjjD9XOZjvMtU20s06O1MEcqqSG4+8llh4zor0
xxL7XK9l/Z/iPO9l/Z/iPO9l/Z/iPO9l/Z/iPO9l/Z/iPO9l/Z/iPO9l/Z/ifFW8
rOXm5eJDSHpcxUTTzpgSTJNicPIRYn1ouPeXkAAAAfHWah4ugvjYY5rVXAqKcyi2
RIX61h8JHRcFhprPkszlGRI0wkCoS6wGroRy4p3k+vTjtmKc97FxaqYov3EKyafy
MXrJRRr2EqU6+SzMM1cMSSW4tSlmJZ8yqZ2amOByrubx2Wtk1nXJmNRVx+4gVpso
OPAjrDkJZY7EXBXJivcdi769qdtFHSFMSiwm/WVFLZAAAABRuVs7g6ax/NExKks7
lAQ5GFDYrfotRCZ0/Kwgy6YKxDoJley/s/xPPney/s/xHney/s/xHney/s/xHney
/s/xHney/s/xHney/s/xHney/s/xHney/s/xHney/s/xHney/s/xHney/s/xHney
/s/xHney/s/xHney/s/xHney/s/xHney/s/xHney/s/xIlenlKQLUSLpRjMHPVNJ
oG5iHmUqWT8wmoAAAAI/bybiyspEWAmc/DBEK6uDsbGpaxZmZbmviLjp6y5QAAAA
AAADMuUdytKdSd5P6R9JOpCxKRqOugAAAAAAAAAAAAAAAAAAAAAAAAAAAAAP/9K6
L+uSI/Uh+bguSIHUpYYAKCykaanCwZhU+jgW3d9NpNyUJ6alaUNePFRK0xF+unea
VlmJmN0ftU7hOw+EY5qa1aqfgZ0sPaGHZCpvgzipDznLgrtCHuylbyoMxKcBLYRm
uVMXN0ohKrIN/Y2m7X5ENuJvSg09z5ea/U24rg9dCKeMoS2MK1KwZSQckV2emObp
JvbSnrSaGyG/WjEx7D05PDEmpCIxdKKqp2opn+1saZsnNRpCDj+rxNH3qaisNRFo
1Ia1yYPWHi7nK2uAio6pzKJ+cRm8OysKSrTo1RYqy710O9RPGWDss9qKr2aU+v8A
vE2spZGmQJeIlMzVarVTFq46cCn7nLSMsVPzECdXgke9cFdoTWdjKMvVgRZNZeUw
jI76Tm6UQneTyn8CYX3lW3rTy1KsMgJpzXpo+80tIMzIbE5mt7j3gAGGMqiXdM1l
zWIqrm6kKmbZmYdqhu7D2JZGaX+dTuw8+R837J/YPI+b9k/sHkfN+yf2DyPm/ZP7
B5Hzfsn9g8j5v2T+weR837J/YSC7ikxadU5dIzFbjETWmB/RmFqTqQ/QPXMpi1yf
mr3GYLtZHwCtxM5fpPXDtLhv1l3x6ZFzPUmk42TbPQ305sNqpnoq53OWfHqcKGvB
q5EdzeszXT5hsjajGMuai6sTS9RmWwYTnuVEbmrp9WozpcOxZiozT2Ji3F2lNR67
s3fwcmPtr3l03sMV1Oj4Jj6CmbLo7H1arwneAzKQkzl9HHBSX1u4iuWgRrJubRzG
rjhjiXtYugvoUsyXeucrURMTqVRivhPRuvNXuM63BTDZGqTTIy4PVy4Y9Zoubn4c
p+UcjcdWJnXKaiIsaWi4+hnpp9Wsv+zU2yaloToaoreDbpTqM9XiRUnrRQkhekqZ
uOB2coluasFF1+iWAnIqbkgWTd+Vj/f3lb1ykTU/XorJSJwL85dK6CfTF09o5his
dOorXJgvpeo71310czYqUjNiREe5zXKuHUR/Jmm2S8eZhRPyivXDHXrL/m6lClME
iORuOrEqDKPiossxcdBMbmlxpsL7ypL6OVIX20OjlNsXxfLO/aorcV7C2bs52HN0
+AsNUVEhtRcOcpe/+YbNVSVZDVHORUxRNes7d9bFhtlEdr9HQW1ZZcZRn2fkUBYL
+Yni/eXNe7PJJyL1d60VPwIXkzy+bLRX87y6AAUnlackr9sxPBoEeMiOaxyourQe
9tk5p2qE7sP15Hzfsn9g8j5v2T+weR837J/YPI+b9k/sHkfN+yf2DyPm/ZP7DmzU
m+VXNeiovMp+5GlxJ5cITVcvuPv8j5v2T+weR837J/YPI+b9k/sHkfN+yf2DyPm/
ZP7B5Hzfsn9g8j5v2T+w/MSyc1DRXLCdgmvQbIyQtFLcnrzy9QAAADjWzdmycZf4
WpTOT7ZKBwsSaVuMTOXSp08qGmQ3yTImCI9IiYKms+pkw+PZ9vCepmjsPmyavyEX
rOLYxuNZi/bXvLIvuZnUyN9lSIZP1MSq0R8BVwz1c3HrQhNIqU3cxHfAWCsxDcqr
iiY/iW5dzfJAtb6L28DF9THa1LGAAAABRmV5yWn2zF0Kz8eKiK1jlRdWg97bJzTt
UJ3YfryPm/ZP7B5Hzfsn9g8j5v2T+weR837J/YPI+b9k/sHkfN+yf2DyPm/ZP7B5
Hzfsn9g8j5v2T+weR837J/YPI+b9k/sHkfN+yf2DyPm/ZP7B5Hzfsn9g8j5v2T+w
eR837J/YPI+b9k/sHkfN+yf2HqmLNzEmiPiQ3NbimlU0H9Drnlxpctu0JkAAAAAq
YhEwAAAAAAAABmXKO5WlOpO8n9H+knUhYlJ1HXQAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAH//Tui/rkiP1Ifm4LkiB1KWGACur87PeNZB6tTF7dKH4uLrbJmRZAx/VIetP
Wd+p3bSlSjpMxG4xEXFFJQxuamCeo8kItxdBI2yekSaaucnrTQfNR7j6dS4DpZrF
cx2vO0qSeUslAlJbwJqfqWGGBGazchTqrDSE9ioietNCn5sdcfT7KReGgNVXfnLi
TCu0CFW4awYyYtX1Hz2YslAs0xYcumDVXE5dZuukqvMtnIrMYrdSknjSjYrODVPR
wwwOBZ272Vs/FdHgNwe/Wp9NrLHS9qYfBTLcW/iV67JgpS+p/wARObEWAl7Gw1hS
2OavOuJzbb3PyNsnJEmWrnJ626D5aHcdTqPCfAaxXNfrztKknpVJgWTl8yH6MJiK
pR9gJBtpK7Fm/pQ0xwX1GikTAAAGUbfSzZm0ytemKYFm0SzsBztLE18xPafZSWVP
ybew+7yTlvZt7B5Jy3s29g8lJb2beweSkt7NvYPJSW9m3sHknLezb2DyUlvZt7Ci
r/aZDkqjILDajVV6Y4Jh6zREH6KdSH7B4cmOgzdaiRWz9ehLqR7kU0TPyDKlDWHE
TFjk0oZ/nrnqvZ2afFo8VGQnKuDVUlN3d29QhTHhVViZ7vUiLoPqveubS1GEzKeh
NNXQ7HAg77u7TT7Gy0eOnBJoXTpwLiu/sBBsjAzIafqjk9NedSEWMugmKLUos69y
Kx7lVELdnZNs6xYcRMWuTBUKKrtz1Socw6NRYnBtcupVPVLWZtWj2q+Ombj6WlNR
e9MY9kNqRVxfmpnL7z6VTEpG865eYmphs5SXcHFxxdpw0nPp13Fdq8Zi1OMiw2qm
hFLOtrdtL2mlPBojdLW+gvrRSnabdpaWhMdLysdOBVdGK6kJ9dZdEtCd4XPLnzSr
9LWey927KPa9zHQXImbgShLMP8XJJ4+nwebiRe6K7KPZCJEfGcio/HA9V6N0K1xy
TUiuZMouOdjgQ/yWtY1MEjpoTBNKFqXbU6oS0urKo5HxF9evQVzb65achTaTlGek
Ny6XJjhpFBu2rNUmWRarFRzGqmhFLFvGsA21Emsu3Q5E9FStrtrv6/Zd7YT4qLLo
7VjjoO7eHdLHtFNw5mG5ERqoqk8tHYuDaOU8EmUzkzUTqVEwxKPp11VoLLq+FT4y
JBVVzUVdSEvu1ubiykVZyqrwkdFxauOKHdvUu8jWrfCdCVERi6e0mlFpyyUBsJ2t
G4FXWYuhmKXWX1JzkWG7HBPWe3KVn1gyLYbfpOeiEjuasylDkIfO9qOUnYAKVyrd
NNbvUODYmhQYktBVWpirE9RaNDsvLORMWN7CQNsnLezb2HnyUlvZt7B5Jy3s29g8
lJb2beweSkt7NvYPJaWai/qbdXMYIv1lmy9QiNYmCZykzyUafDnZtyRERU95sRbK
Sy/zrb2DyTlvZt7B5KS3s29g8lJb2beweSkt7NvYPJSW9m3sHkpLezb2HMtRZiWZ
KRsIbfyTvV7iuMlVM2Tjp6kjL8y8AAAADjWxw8EjY+zUzDd9a2bsXFfMuasSXVy+
ims6FtLcR734kOSlYL4bWuRVVyKXFayhuplHSWamLmsRFw58CPZN8nEl4MVIrVbp
9fWRO8KHHu6qCTzGLEhvdiqNPVeDePNXlyb4VOhPh5qYvzvWTK4aK+ztHV8Zio5q
qqt9anNmMp+XznI6UiLguGr94jVnKdEvCqzalLw1gQm4YphhiabY3NREPIAAABR2
Vlpp8NP4anyOZY6hQXy8FVan0E9RZ9EsvLORMWN7DvNsnLezb2HnyUlvZt7B5KS3
s29g8lJb2beweSkt7NvYPJSW9m3sHknLezb2DyUlvZt7B5KS3s29g8k5b2beweSk
t7NvYPJOW9m3sHkpLezb2DyUlvZt7B5Jy3s29g8lJb2beweSkt7NvYPJSW9m3sK5
ygrPwJekxXMY1FRUwVE0kkuUXGky/wBgnAAAACrgfC2vQHOzEiMzubFMT7kXEHhz
s3SpzotppaEua6KxF5s5D7ZaaZMpnMVHJzouKHyzVfl5Rc2JEY1eZXIinp8qpX20
P4kPolK1BnPycRrupUU9UW0stBXNdFYi8yuTE/HlXKJ/O6H8SH2ydRhzqYwnI5Pc
uJ9AAAAMy5R3K0p1J3lgUj6SdSFh0jUddAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAf
/9S6L+uSI/Uh+bguSIHUpYYAPXMS7ZhqscmKKmkjVl7vJezkV8aDji/WnqJSAAAA
AAAAD46zS21WE6A/6L0wXA4dirvZeyLVbAx0rpVdZKAAAZVtt/MTr1Fs0L6X3lg0
7UdAAAAz7lE8oyH207y/4H0U6kP2AV1etd4+0KNjy/5dmGaS2yMvGl5ZjJn8oiaT
sAAAAAAAAAAAAAAAAFP3gXfTtpp9i4/rVqouBbFPlEk4bYaamtROw+gAFK5VvJrd
6hzrC7LB+wha9C1ISJh+gAeHaj+fF/vKMT7Sk2yRtscbSAAAOVazZI26f3KVLkrb
JH3y/Mu8AAAA4ttEVZONhpXg1KruGkuGa9sZmjOXQ5MU/EuSXpcKWXOYxrV50aiL
+B9L4aPTBUxQ/MKXbB+iiJ1JgfiZkmTWiI1HdaIvefiXpcKWxzGNbjrwREPakqxq
ZqNTDmwTA+RaBLr/ADqZ8KfoPplpJkqmENqNT3Iidx7gAAAAUdlY7BD3qfI9Vi9n
g/YQtOhakJEw8gAAAAAAAFZZRfJEXradW5TkmX+wTgAAAFJ313gz8k9ZOnNXOVNL
sDO930abhVdqTT3Z6u06VN3SX0G/ZQ9xSOUde6+x8FIMv9N+hTPVKulrNsILqixy
5q6dKqi8/OTzJ0vNm6ZNrTZxyq1Fw068TsXz3G1S1E54RKO/U11ekqdylW2quGq9
mZd01HiKjG6/SXHvJtkoyUep8K5HOVEx1qq9567cZOtZqs5EjQXeg5dHpKnzK5vC
unqdhYSRZuIua7Vg5f0mi8lGTjOkuGiOVWrqxXEvoAAAGZco7laU6k7yf0j6SdSF
iUnUddAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAf//Vui/rkiP1Ifm4LkiB1KWGAAAA
AAAAAAAAAAADKttv5ideotmh/S+8sGnajoAAAGfconlGQ+2neX/A+inUh+wAAAAA
AAAAAAAAAAAAAAAAUrlW8mt3qHOsLssH7Cdxa9C1ISJh+gAeHaj+fF/vKMT7Sk1y
RtscbTAAAOVazZI26f3FS5K2yR98vzLvAAAAPD2JETBdKHpl5Fkt9BqN6kwPeAAA
AAAAACjsrHYIe9T5HpsXs8H7CFqULUhImHkAAAAAAAArLKL5Ii9bTq3Kcky32CcA
AAA+Kep8NyOerUV2aunBMdRjKEv7If5H8zakl9Bv2UPcZBynEz6hCR2lM5NH3mjr
AQWsprEamCZi6PuMnzSugWg/Ukw9P5m2ZFf1Nqr9VO4y5lTXiRJqK2myzsWuVEci
c5bVwNgW2VkWr+2iIiqWbGipBRXOXBETSpjC+m1cW3lVbT4a50FH4e7Wauu9sq2z
EpDl2epEVewkgAAAMy5R3K0p1J3lgUj6SdSFh0jUddAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAf//Wui/rkiP1Ifm4LkiB1KWGAAAAVxerfRLWFYqOXGL6mlGJloTOdpgN
zcTQt2F5sG3EBIkNUz0T0kJqfJVatDpTFixnZrU1qZ6t1lbQ6bHSDIsSI3HBVUu+
wtpXWilmzDkwVyJoPjvCvFl7GQViRnIjsPRbzmdZnLOmGxFRkFqsx1l63T3wS9vY
WLFRIqJ6TSeTkykqx0R2pqKq/cZjtlleRKXMrBl4TXsRcMS7Lp7eutpK+EPbmrjq
JsAAAADKttv5ideotmh/SLBp2o6AAABn3KJ5RkPtp3l/wPop1IfsAAAAAAA+Oq1e
FSWLFjORrU1qpBlv/pCOzOHTHEnFIrMKrw0iwHI5q6lQ+04NqrcStlm5829GNIqm
ULRl/noQ+umX5UqpxEhQo6K9dSExnqvCkYfDRHI1iJjipBol/wDSIbsxY6Yk1olf
g1qGkaA5HMX1oReu30UyhRVgzEZGvT1HwecJR+kISGyt40lanZIiPJMAAAAAAACl
cq3k1u9Q51hdlg/YTuLXoWpCRMP0ADw7Ufz4v95RifaUmuSNtjjaYAAByrWbJG3T
+4qXJW2SPvl+Zd4AAAAB4zsBnIeUXEKuB4zkPJ4zkGch5AAAABR2VjsEPep8j02L
2eD9hC1KFqQkTDyAAAAAAAAVllF8kRetp1blOSZf7BOAAAARC2F5sjZvOhzUVGOw
XQY9hWvlkrXhed+pZ2OJsexl4kladqJKREfgmk9czerT5aY8EfFRIuOGaZ5ysqe6
nx4U0iYtVUUnFjsoGnSdLRIkREjNZhmevHApq7CJEtzWlmGtwTOxx9WGJsS1NcZZ
6UdFiLgjWKn34GObr7PRLeVl0w/F0JHquOtNZt6UlklWIxupqYIQO+62DLO0+Ji7
B72qjSgcl2wr6xMvnphFVMVVFU1+iYAAAAGZco7laU6k7ywKR9JOpCw6RqOugAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAP/17ov65Ij9SH5uC5IgdSlhgAAAFY2tuOl7UTr
ZyYXFE/akQv7u8plHp7nw4bYcTD0cNakNyNqbGa6JEXFIfq5lNXkWvAsWtrIKQM/
MTHT7zKF+t3EvY10NkFPSVyYqaduYXGnQ1/NTuM3ZSczEtBUocsrsG4onuLopFyc
hBpaNdCasRYeOf68SjbkpjyXrL5di4IrlT8S48pK811FgNk5df1WLoVE16TP9rLr
3WfprZyOmEV652nWaTyYnZ1NRfehcAAAAAMq22/mJ16i2aH9L7ywadqOgAAAZ9yi
eUZD7ad5f8D6KdSH7AAAAAAAM/X5WJqVr5tkvLuc2XX6SpjgVnb7JUdZeVdNpGz8
1MVQkOSHbCPMxHyr1VzGpo9xqwre+G6PjChJD4TMw9ZTUxkYNlmOe+Z+i1V1fvFW
XVWRV9aSWhrnNY76XUWTlMWqmeGh06E9Wt0IuHrOWzJRfHkfDkjYvzc7N/fwOlkt
2uj0+afIR3LmpiiIpNrxMlhLWzTppI+bnerD94qm9TJrh2FlFmVj5zvq6ieZHlnX
cE+YdoTHQadAAAAAAABSuVbya3eoc6wuywfsIWvQtSEiYfoAHh2o/nxf7yjE+0pN
ckbbHG0wAADlWs2SNun9ylS5K2yR98vzLvAAAAB4dqMm30Q6+s8vgXC8F6s3UV1V
p+0lJhrGjuitYnrUtfJetbPVtXvjxHRGtx16dRz7073KpaSZfJ0tjkSGuCq3HErZ
bf1yx8Zr5x0RExTQ71mraNbeJbOkLMS2KRsz1a8cDMcxAtQsR2bw2GcuBH65bGu0
CI2HNRYjHKqaFU2hc9NR5uRZEmFVXKiaVJyAAAAUdlY7BD3qfI9Ni9ng/YQtShak
JEw8gAAAAAAAFZZRfJEXradW5TkmX+wTgAAAFL3uZPCW+j8PwuYpX/mUp0j8P3iy
7orjm3c573Rc/FF9xQsGmutVaNXQkVWsiaV+81ja+wcC1Mt4PMNRcG4IvMUJHyLW
PiZzY+DcdWBdt3N10tYmEjITUV/rf6z03tXcvt1LeDNicGnOc25i5tt3UNzFfwjn
LrwLMKlvouTfeKrcI3Bo31EtuzsE2xMo2Vaucqa3c5LQAAADMuUdytKdSd5P6P8A
STqQsSkajroAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD//Qui/rkiP1Ifm4LkiB1KWG
AAAAcS1NsZezUNYkw9G6NCKulTLdedP31TqMhtVss12v1YGnLC2KhWSl2wISJiia
V5yRgyrlaN/VofWheFzTFbToWP1U7jNV9y8DWYav0Jnp3mppSZYymo9V9HgtZkax
0RsWrxY7PSRrlVFQ5Nq7fI2qpMzaLEaxdDeo618l/wDCt1LMloUJWZhYeS9e3Ccj
aYrVzlwwU0+AAAADKttv5ideotmh/S+8sGnajoAAAGfconlGQ+2neX/A+inUh+wA
AAAAADw96MTFdCJ6zMuUJe141d4rkPTc5cHYaSdZPV0/kdL8NETCLETFecuEFI5T
V4SUOTWWhuwivI7ko2C4KG6ejpjEdqVdekZS10kxWHpOymKubpwTWVDJV20jYSwP
1RsFEwXFFRMD7cnqHEfVF4TS/HSbefESE3OXUiYqYxv5tY+21TZJy7sYaORFRDU1
2dk4dmpOHCYmCq1FXrJWAAAAAAAClcq3k1u9Q51hdlg/YQteg6kJEw/QAPDtR/Pi
/wB5RifaUmuSNtjjaYAAByrWbJG3T+4qXJW2SPvl+Zd4AAAAAwMzZVd5CwkbS4WC
5+GOGsnWThd/5MSKOfripiWRTLKy1Ke6NCYjXO1qZcypLSQrTTDJGWRHREciKqF5
3DWOfZinMhxPpqmKk/qE42ShuiuwRGtVTFFeqES9utpDRPRY/DRq0KbQoNMSlwIc
BP2jUQ+8AAAAo7Kx2CHvU+R6bF7PB+wncWpQtSEiYeQAAAAAAACssovkiL1tOrcp
yTL/AGCcAAAAA41rqTEq0u+DBdmOcmGJCrpbnG2Kc+LEVHxXr9Is4AAAAAAAAzLl
HcrSnUneWBSPpJ1IWHSNR10AAAAAAAAAAAAAAAAAAAAAAAAAAAAAB//Rui/rkiP1
Ifm4LkiB1KWGAAAAY2ypWTtRnUaxj3MTVmoqp+BDbMXg1yzMPgpaG5rfsLiW7cfe
VWq7NJDnUcrMfW1U7zxerfFUKNVmSku/CGrkRULQvTtPO0mmsjyaKsZWoq4aV1GP
rXV6sWsdnTUN7lRdHoqWDc/eFWpWYhyrmvSDoTBWqiYdZYeUjdFHtGxk/LfTYiKq
JrxKTW3FfjwfFyo/g9WGaveXfk83FvojXTM5pWIn0V1k9qeTvSalEWLEhYuX3lNZ
QNyEpZ6XR9PgrnrrwTEmmTNdtAkpdJuJCVsfRr0F+gAAAAyrbb+YnXqLZof0vvLB
p2o6AAABn3KJ5RkPtp3l/wAD6KdSH7AAAAAAAM0ZTV8kxQXpKSq5qKnpKVxdXetS
rNuWYm4SxJhdOdhjpL9sFlJydsIyS8Jjmqq4Jiffba/2VsnNNk4rXK5yomKFhS9a
ZGgeE6mZud9xi68ep8aFabCgri1rsPdoU2PY6z7aFLQ4DUwwamPWQu9a+yFd+9rY
0NXNdzFU20ys5WqSz4ErCVHvTDSn7x+cle76YbGfUZhMGuxVMS7b4bcQ7JyL4j1w
VzVRDOOTTYZbRTz6hE0szlX8TYzW5qYJqPIAAAAAAAKVyreTW71DnWF2WD9hC16F
qQkTD9AA8O1H8+L/AHlGJ9pSbZI22ONpAAAHKtZskbdP7lKlyV9kj75fmXeAAAAA
c20dWbSoD4r1wRGr24GKbHU+NeLW1dE9JjX6F9Ws2/ISiSENsNNTW4dhQV8WUMyW
c6nSa4RV0K7mPiucuxk5N3jGox2Piu0oiuTQaIkKnBnE/UXtcifVXEqHKetqtEkF
hQnYRH+r14EPyTrCORiz8ZMHKujHWppkAAAAFHZWOwQ96nyPTYvZ4P2E7i1KFqQk
TDyAAAAAAAAVllF8kRetp1blOSZb7BOAAAAAAAAAAAAAADMuUdytKdSd5P6P9JOp
CxKRqOugAAAAAAAAAAAAAAAAAAAAAAAAAAAAAP/Sui/rkiP1Ifm4LkiB1KWGAAAA
emLIw42lzWqvvRFPx4rhfUb8KfoPlqkaHRoT46MT0UVdCIi/gZjsLY+LbytRJ6O1
Ww2uVUxNV+DNVqNVEVETDBUxPV4rhfUb8KfoPLKdDYuKMai/ZQ97mI5MFTQfP4th
a8xuP2U/QfQ1uboQ8nriy7Y2hyIvWiKeYUFsJMGoiJ7kwP2AAAADKttv5ideotmh
fSLBp2o6AAABn3KJ5RkPtp3l/wAD6KdSH7AAAAAAAK6t1cVIWziJGmUXOTmI15pl
I+q47tkbg6bY6J4RBRUVunFV0FB20k1t5aBIcFM5rH609xrRtBbElklXfRzEavYQ
mydwFPsxMrOQUcsRVx06iyyK24u2lLZtzJpuOHr9ZCqVkuUmnPSI1qqqL69Ja1Np
rKcxIUJMGpqQjV4F2UtbliQprHNTmPfYG7yWsRB4CVRc1efWScAAAAAAAApXKt5N
bvUOdYXZYP2ELXoWpCRMP0ADw7Ufz4v95RifaUmuSNtjjaYAAByrWbJG3T+5Spcl
fZI++X5l3gAAAAFZ36WSnrUyng8iuCrr04HFye7oI1iITlnEThVXWmkt6oQVjw3N
brVFRDH9rsl2qVSbiR4atzXOVUXHSc52SxW8MEf92cv6S+Lhrs5yxrFScdiqpz4k
KvjuVqttKg2MxU4BHJoVfViX5Y6zzaBLQ4CIiK1qY4c52gAAAAUdlY7BD3qfI9Ni
9ng/YTuLUoWpCRMPIAAAAAAABWWUXyRF62nVuU5Jl/sE4AAAAAAAAAAAAAAMy5R3
K0p1J3lgUf6SdSFh0jUh10AAAAAAAAAAAAAAAAAAAAAAAAAAAAAB/9O6L+uSI/Uh
+bguSIHUpYYAAAAB+YkJIqYOTFF9SnqlqfDlfybUb1IiHvAAAAAAAAAMq22/mJ16
i2aH9IsGnajoAAAGfconlGQ+2neX/A+inUh+wAAAAAAAD5apIJUIboSrgjkwxIhY
m6OVsnFdHhYue7HFVJyAAAAAAAAAAAAUrlW8mt3qHOsLssH7CFr0LUhImH6AB4dq
P58X+8oxPtKTXJG2xxtMAAA5VrNkjbp/cpUuSvskffL8y7wAAAAAAAAAAAAACjsr
HYIe9T5HqsXs8H7CdxadC1ISJh5AAAAAAAAKyyi+SIvW06tynJMv9gnAAAAAAAAA
AAAAABmXKO5WlOpO8n9H+knUhYlI1HXQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAH//
1Lov65Ij9SH5uC5IgdSlhgAAAAAAAAAAAAAAAyrbb+YnXqLZof0iwadqOggAABn3
KJ5RkPtp3l/wPop1IfsAAAAAAAAAAAAAAAAAAAAAFK5VvJrd6hzrC7LB+wha9B1I
SJh+gAeHaj+fF/vKMT7Sk2yRtscbSAAAOVazZI26f3FS5K2yR98vzLvAAAAAAAAA
AAAAAKOysdgh71PkemxezwfsJ3FqUPUhImHkAAAAAAAArLKL5Ii9bTq3Kcky/wBg
nAAAAAAAAAAAAAABmXKO5WlOpO8sCj/STqQsOkajroAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAD/9W6b+G51Ij4cyELuYvdptJpkKDGjo17cUVF1k3486R0ho486T0ho486
T0ho486T0ho486T0ho486T0ho486T0ho486T0ho486T0ho486T0ho486T0ho486T
0ho486T0ho486T0ho486T0ho486T0ho486T0ho486T0ho486T0ho486T0ho486R0
ho486T0ho486T0ho486T0ho486T0ho486T0ho486T0ho486T0ho486T0ho486T0h
o486T0hp5bfjSV0eENKBq1fg2gtEseWdnw8Naai6aGnpfeWDTtR0AAAChcpKhTUe
LLTUpDWIsJcVROvE5j8oaqwURFkVTBE9SnodlMVFuuT/AAU/PnN1Hof4KPOcqPQ/
wUec5Ueh/go85yo9D/BR5zlR6H+CjznKj0P8FHnOVHof4KPOcqPQ/wAFHnOVHof4
KPOcqPQ/wUec3Ueh/go85yo9D/BR5zlR6H+CjznKj0P8FHnOVHof4KPOcqPQ/wAF
HnOVHof4KPOcqPQ/wUec3Ueh/go85yo9D/BR5zlR6H+CjznKj0P8FHnOVHof4KPO
cqPQ/wAFHnOVHof4KPOcqPQ/wUec5Ueh/go85yo9D/BR5zlQ6H+Cjzm6j0P8FHnO
VHof4KPOcqPQ/wAFHnOVHof4KPOcqPQ/wUec5Ueh/go85uo9D/BR5zlR6H+CjznK
j0P8FHnOVHof4KPOcqPQ/wAFHnN1Hof4KPOcqPQ/wUec5Ueh/gpFLyL05+8KCyUd
KqxM9FVdJZtj5ZZeBCYutrURS0KGmhCRMP0ADw7Ufz4v95RifaUm2SNtjjaQAABy
rVNzpSMieyf3Gfsnm8mRs5AjwZqKjH8Mq4L95bKX6UjpDRx50npDRx50npDRx50n
pDRx50npDRx50npDRx50npDRx50npDRx50npDRx50npDRx50npDRx50npDRx50np
DRx50npDRx50npDRx50npDRx50npDRx50npDRx50npDRx50npDRx50npDRx50npD
Rx50npDRx50npDRx50npDRx50npDRx50npDRx50npDRx50npDSpso+8eRtHJw4Mr
FR7+ERcEJDY1uEvBT8xC06FqQkLDyAAAAAAAAVplEtV1IjYc6EeumvhplMpsCFFj
o17W4KmnEl/HnSOkNHHnSekNHHnSekNHHnSekNHHnSekNHHnSekNHHnSekNHHnSe
kNHHnSekNHHnSekNHHnSekNHHnSekNHHnSekNHHnSekNHHnSekNHHnSekNHHnSek
NHHnSekNHHnSOkNHHnSekNHHnSekNHHnSekNHHnSekNHHnSekNHHnSekNHHnSekN
HHnSekNHHnSekNPPHlSekNKJvotdLWnqsqsm9IiNwxVC2KOnpJ1IWHSdR10AAAAA
AAAAAAAAAAAAAAAAAAAAAAAAB//W09VaZDqcNYMZM5jk0oVfVrh6Q3FUhYL7iG1C
5anMX0YanPW5uQ+op44m5D6ijibkPqKeeJuQ+op44m5D6ijickPqKOJuQ+op54m5
D6injibkPqKOJuQ+oo4m5D6ijibkPqKeeJuQ+oo4m5D6ijickPqKeOJuQ+oo4m5D
6innickPqKeOJyQ+op54nJD6ijickPqKOJyQ+oo4m5D6injibkPqKOJuQ+op54m5
D6ijickPqKOJyQ+op44m5D6innibkPqKeOJuQ+op1aFd7LUV2dAZg7nLBoUoqLiT
qQbgh9wAAB64q4EarUFYvqTsIjM0lXLqTsPn8TrzJ2DxOvMnYPE68ydg8TrzJ2Dx
OvMnYPE68ydg8TrzJ2DxOvMnYPE68ydg8TrzJ2DxOvMnYPE68ydg8TrzJ2DxOvMn
YPE68ydg8TrzJ2DxOvMnYPE68ydg8TrzJ2DxOvMnYPE68ydg8TrzJ2DxOvMnYPE6
8ydg8TrzJ2DxOvMnYPE68ydg8TrzJ2DxOvMnYPE68ydg8TrzJ2DxOvMnYPE68ydg
8TrzJ2DxOvMnYPE68ydg8TrzJ2DxOvMnYPE68ydg8TrzJ2DxOvMnYPE68ydg8Trz
J2HlKOvMnYdCm0dWrqJpSpbMQ7LUwPIAPDtR/Pi/3lGJ9pSbZI22ONpAAAH4jwkj
NVrtKKmClZVu4ykx1WIsHBy6VwITU7lKbDX0YanJdc3IfUU/PE3IfUUcTch9RTzx
NyH1FHE5IfUU8cTch9RRxNyH1FHE3IfUU88Tkh9RRxOSH1FHE5IfUUcTkh9RTxxO
SH1FHE3IfUU88Tkh9RRxNyH1FPHE3IfUUcTch9RTzxOSH1FHE5IfUUcTch9RRxNy
H1FPHE3IfUU88Tch9RRxNyH1FPHE3IfUUcTch9RRxNyH1FPbLXRSMu5HNhrimrEn
dGp3B4NTUmosCjws1DusPIAAAAAAAB8NZpEKrw1gx25zHa0Kwq1w9IZirYWBDp+5
enMXRDU+Bbm5D6injibkPqKeeJuQ+op44m5D6innickPqKeOJuQ+oo4m5D6innib
kPqKeOJyQ+oo4m5D6innibkPqKOJuQ+oo4nJD6ijibkPqKOJyQ+oo4nJD6injibk
PqKOJuQ+oo4m5D6innibkPqKeOJyQ+oo4nJD6innibkPqKeOJyQ+oo4m5D6innib
kPqKOJuQ+op44m5D6in20q7CUpj0iQmYOTUqlgUWTVFTEntMh5qHUQAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAH/9fVCpifFNyvCHFmKGjz51s8nMePJ5OYeTycw8nk5h5O
pzDyeTmHk8nMPJ5OYeTycw8nk5h5PJzDyeTmHk8nMPJ5OYeTycw8nk5h5PJzDydT
mHk8nMPJ5OYeTycw8nk5h5PJzDyeTmHk8nMPJ5OYeTycw8nk5h5PJzDyeTmHk8nM
fptn0T1HSk6XwZ2IMPNPaAAAeHJifJHlEefI+lIp+PFCDxOnMPE6cw8UJzDxOg8T
pzDxOnMPE6cw8TpzDxQnMPE6cw8ToPFCcw8ToPE6cw8TpzDxOg8TpzDxOnMPE6Dx
OnMPFCcw8TpzDxOnMPFCcw8TpzDxQnMPE6cw8TpzDxOnMPE6cw8TpzDxOnMPE6cw
8TpzDxOnMPFCcw8ToPE6DxQnMPE6cw8TpzDxOh5SkIe2FTEafdCg5p7kAAPDtR/P
i/3lGJ9pSbZI22ONpAAABUPlmYGecWaoyPPjWz6cx48nk5h5PJzDyeTmHk8nMPJ5
OYeTycw8nU5h5PJzDyeTmHk8nMPJ5OYeTycw8nkHk8nMPJ1OYeTycw8nk5h5PJzD
yeTmHk8nMPJ5OYeTycw8nk5h5PJzDyeTmHk8nMPJ5OY8pZ5OY+qWoqM9R2pWX4M+
xAAAAAAAAAeHJifDNynCHGmKGjz5ls8nMPJ5OYeTycw8nk5h5PJzDyeTmHk8nMPJ
5OYeTycw8nk5h5PJzDyeTmHk8nMPJ5OYeTycw8nk5h5PJzDyeTmHk8nMPJ5OYeTy
cw8nk5h5PJzDyeTmHk8nMPJ5OYeTycw8nk5j9Ns8nMfdKUhIZ2peDmHvAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAB//0NUnhW4n5WEOBQcCg4FBwKHjgUPPAoOBQcCg4FBw
KDgUHAoOBQcCg4FDxwKDgUPPAoOBQ8cCg4FDzwKDgUPHAoOBQcCg4FBwKDgUPPAo
OBQcCh5RmB+gAAABgeM0ZozRmjNGAwGaM0ZozRgM0YDAYDAZozRmjNGaMBmjNGaM
BmjNGB5wPGaM0Zp5wPGaM0ZozRgMBgMBmjA84AAAHh2o/nxf7yjE+0pNckbbHG0w
AAAeFTE/KwzxwKHngUHAoOBQcCg4FBwKDgUHAoOBQ8cCg4FBwKDgUHAoOBQcCh54
FDxwKDgUPPAoeOBQcCh54FBwKDgUHAoOBQ8cCh5SHgfpEwPIAAAAAAAAB4VuJ+Vh
DgUHAoOBQcCg4FBwKDgUHAoOBQ8cCg4FBwKHngUPHAoOBQ88Cg4FDxwKDgUPPAoe
OBQ88Cg4FBwKDgUHAoOBQcCg4FDykPA/SJgAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
Af/R1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADw7Ufz4v8A
eUYn2lJtkjbY42kAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAf/9LVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAPDtR/Pi/wB5RifaUmuSNtjjaYAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAB//09UgAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA8O1H8+L/AHlGJ9pSa5I2
2ONpgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAH//U1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAADw7Ufz4v8AeUYn2lJrkjbY42mAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAf/9XVIAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAPDtR/Pi/wB5RifaUmuSNtjjaYAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAB//1tUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA8O1H
8+L/AHlGJ9pSa5I22ONpgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAH//X1SAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAADw7Ufz4v8AeUYn2lJrkjbY42mAAAAAAAAAAAAAAACv
L7rfRbFyaRoCYxHOzUK3kqza2dhtjMY3NeiKmrUp7vD7XfUb2IPD7XfUb2IPD7Xf
Ub2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfU
b2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb
2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2
IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2I
PD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2IP
D7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPD
7XfUb2IPD7XfUb2IPD7XfUb2IPD7XfUb2IPDrXfUb2IeilXpVqg1CDJVVqIkVUww
wNDujoi4H7Y7E/QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAP/9DVIAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAPDtR/Pi/wB5RifaUm2SNtjjaQAA
AAAAAAAAAAAAAKSyqtig75PkWrY/Y4G6Z3HYAAAAAAAAAAAAAAAAAAAAAAAABm+/
+LwNZkndXeXBL1nhXJ1ISOTjZ6H2oAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD//
0dUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA8O1H8+L/AHlG
J9pSa5I22ONpgAAAAAAAAAAAAAAApLKq2KDvk+Ra1j9jgbpncdcAAAAAAHOrdoIN
EZwkw7NanrIW7KBo6aOHTsOvZe9Wn2nicFKxc9/NhgS4AAqy2t8TrOzjZRGYo5UT
Es+VjcMxrudEXtQ9gB+Yr8xFXmQqyyl8j63VH01YaIjMfSLVABGrwrWLZaUfNNbn
K1NR8V1Vu3W1lEmnNzVVcMCZAAAAAAAGZ8pBcKrJ/d3lhUmMquTqQsClLih1kAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAB//0tUgAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAA8O1H8+L/AHlGJ9pSa5I22ONpgAAAAAAAAAAAAAAApLKq
2KDvk+Ra1j9jgbpncdcAAAAAAFT5REPhJJUU4lz9zlMqVPZFjQUc9yriqqWVZy7K
Qs2/hZWEjHc6HRba+VdG8G4RvC/V9Z9tUq0KlsWLGcjWJ611HimVeFVG58FyObzo
cSs3l0+iuzJiO1jk9SnQoNrZWvpjLREenuKCvf5Vh/bQ0D41h02Ax8ZyNbmt0r1H
2SU+ydbnw1RzedD4Zm1UtLRUgPiNSIupvrPunp9kixYkVyNamtV1ET43KXMKsNsw
xXLiiIUxde9Ilo4zm6UXE0fVKtCpbOEjORrU9akWbfJSnOzfCWY44Ewlplsy1HsX
FqpiinJtDbKUs9h4VFbDx1YlcXq28krQ02M2VitiKjdSH0ZM/JbftKWyAAAAAAAZ
nykuVZP7u8ntI+knUhYlJ1IddAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAf/09Ug
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA8O1H8+L/AHlGJ9pS
a5I22ONpgAAAAAAAAAAAAAAApLKq2KDvk+Ra1j9jgbpncdcAAAAAAFUZRCYyKomv
Aqq7q72vz0mj5Wa4OGq6G4l73bWfn6RDzahF4V3PjiVnfnYR9FjNrMnjntcmciEY
nryot7ToVMgorW6OEX3lt2rjJdrSM2AvptaiIvvILdZdHBtpCWfqaLEWJpTTgTuy
N0fklMrFlHZsFf2qrjoK4vf5Vh/aQnl+KY02H/Ie5Dv3QJhJM6kKavAZjaSBpX6S
d5JMom0sSJEhUyE7BIuCOw9599Jyb5GVk/or4Tm4o/HUpXVwdKi0muRYMd2c5MdP
uO1e9at1bqaUyNE4OXRdOK4IdOfuys0+B6EZiRGtxzkfpxROY+7J/t+s22NLRIme
yFjmL7kIbKUR17VViNmVVYMFy6MfVida+25SFQpJ0amIsJET00xxxJxkzrjSmfaU
tgAAAAAAAzNlJ8qyf3d5PqR9JOpCxKTqQ66AAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAA/9TVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAPDtR/Pi
/wB5RifaUmuSNtjjaYAAAAAAAAAAAAAAAKSyqtig75PkWrY/Y4G6Z3HYAAAAAABV
GUO9GySqp+7kbUSsCmw2ujMRUVcUVyIqFiyNoJefXNhRGPXma5FKdv4vEzsKXKYO
jPXBU14YlaU6zs1dDMwpyImMKJgr/cqlz3rQ221o6xpb0sURURNJzrhLfS6SiScZ
7YcSFoVHKid5OJG8uWn5nwWCueuOtulCmL4IiJVYeP1kLGvlkXzdMZmJjmo1Vw6k
PVc7biVfJ5rojGuZrRXIilOVi17LRWkhZjc1GuRMfUuklWUPKrT6hLTeaqsRW4r6
kLbS8uTbJ+EcKxVRn0Ucmcq4asCh7jbQJaCvRo7UVqLnaF1nrvdstDdWuEnkVJdy
/STR+JNoNydnozUdw2hUx/KNJnYm7OmUSG9KeqOxauKo5HdxU90dbbZSrTEKZ/U0
e5cFdoTWTDKHvMlpORdBhKkVz0/arjh2HTyZdNKavO5VLaAAAAAAAMzZSfKsn93e
T6kfSTqQsSkakOugAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAP//V1SAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADw7Ufz4v8AeUYn2lJtkjbY42kA
AAAAAAAAAAAAAACksqnYoO+T5FrWP2OBumdx1wAAAAAAcG2FjYNqoSwI+OavMVez
JRkIehsWIicyL++Sawdx8tY2KsaDEe5VT9sug+6VuflIE74xXF0XH16ju2xsdBtX
AWWmE9Fe09dj7FQrLQfB4SqrOZSB2iyapGsxnTGe9jnLiqN0ISiwF1EtYvFYCq5y
+t2s/dobrJWux0mYuOei4oSqJItiQ+CcmLc3N+7DAqKcyX5CYirGSJEaquxVEXBC
UtuZkWRYUwjcHwsMF58Ocktp7LwbRwXQI6YtVNfrQrKl5MEjT4rYqRIi5q45qroJ
nRLq5OizSzsBua9UwVE1HSthYuBauFwMdNHP6ysXZKsiv87Yvb++Ty7u7ODYdjoc
B7nI76x8N4NzEnbZyPjYscnrboVTm2eye5Cjw3w1V0RHpgudpw6ia2PshBspB8Hl
/oIuJ3AAAAAAADM2UnyrJ/d3k+pH0k6kLEpOo66AAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAA/9bVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAPDt
R/Pi/wB5RifaUm2SNtjjaQAAAAAAAAAAAAAAAKSyqdig75PkWrY/Y4G6Z3HYAAAA
AAAAAAAAAAAAAAAAAAAABmbKT5Vk/u7yfUj6SdSFiUnUh10AAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAB/9fVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAPDtR/Pi/wB5RifaUm2SNtjjaQAAAAAAAAAAAAAAAKSyqdig75PkWtY/Y4G6
Z3HXAAAAAAAAAAAAAAAAAAAAAAAABmbKS5Vk/u7yfUj6SdSFiUnUh10AAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAB/9DVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAPDtR/Pi/wB5RifaUm2SNtjjaQAAAAAAAAAAAAAAAKSyqdig75Pk
WtY/Y4G6Z3HXAAAAAABAL7qtFpdPiRIDs16JoVD5rgqxGq1NZFmHK56qulSyAACr
7+K3HpMsjpdytXnOhddXokameER1znIiqv3Icq7+/BtrJt0mkPNzVVMeotUAA+Wo
1OHTm58VyNbzqfilVqFVm58ByObzofaAAAAAAAAAZmykuVZP7u8n1I+knUhYlJ1I
ddAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAf/9HVIAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAPDtR/Pi/wB5RifaU8XK3pssBGdFiMz8fUXr56ct
7Bx489OW9g4eenLewcPPTlvYOHnpy3sHDz05b2Dh56ct7Bw89OW9g4eenLewcPPT
lvYOHnpy3sHDz05b2Dh56ct7Bw89OW9g4eelLewcPPTlvYOHnpy3sHDz05b2Dh56
ct7Bw89OW9g4eenLewcPPTlvYOHnpy3sHDz05b2Dh56ct7Bw89OW9g4eenLewcPP
TlvYOHnpy3sHDz05b2Dh56ct7Bw89OW9g4hF6uURBvBhwZWFCVi8KiqqmtrJszJS
Cn8KZ3HWAAAAAAKqvLv5hWPipAhw1jRF9Tf3iurfX2+UkhFhTEF0BVTRnY6e0n1w
06lOoqRl0o3OUldhLx4drc7Mbm5qqh6LzL0IdhWNfEars5UTQffU7dskJFtQVvou
ai4dZBK7lGQpdrXSkJY6qmlG4rh2H2Xd3+QrURVgR4awH+pHevtPXlFbI06lzqtS
lIr9LcHYp7sDk3fWkp0zPvgysHMi4ri7AnNubdwbJQVixVRXepuOlSqIOU7Ec5Fd
JvSGq/T04Fy0S00KqS6TKKiNVMV9xWdq8oLxVFWFLS7o6J+2bjge+7u/5lqZhZaP
CWA71Z2jHtORlG27fTYPgzYTnIv7dNRB7kb44tKh+DJLPejnfSTHQaFtLbqFZ+VS
ZjYIqtRUYq6eoqSPlRRWek2SerMfpacC3LCW5hWtgJGh4I5U0s9aEbvHvnh2TXg4
LFjxfW1utOwidJyj489EbDWSe3OVEx06C75OP4Qxr1TDFEXA9wAAAAABmbKS5Vk/
u7yfUj6SdSFiUnUh10AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAB//9LVIAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAPDtR/Pi/wB5RifaUryTpsSd
XCE1XL7kxPu8kpv2L/hUeSU37F/wqPJKb9i/4VHklN+xf8KjySm/Yv8AhUeSU37F
/wAKjySm/Yv+FR5JTfsX/Co8kpv2L/hUeSU37F/wqPJKb9i/4VHklN+xf8KjySm/
Yv8AhUeSU37F/wAKjySm/Yv+FR5JTfsX/Co8kpv2L/hUeSU37F/wqPJKb9i/4VHk
lN+xf8KjySm/Yv8AhUeSU37F/wAKjySm/Yv+FR5JTfsX/Co8kpv2L/hUeSU37F/w
qPJKb9i/4VHklN+xf8KjySm/Yv8AhUeSU37F/wAKjySm/Yv+FR5JTfsX/Cp7ZGhx
5CNCdFhuaixG6VRUTWf0lsvssHdM7jpgAAAAA+WqzHg8J701o1e4zncfS2WkqUxM
THpOY9cMdPrJvlIWPgVWnuivb6TE0YJgfLdAuNnne5rvkfjJ9b+U+0p8GVSzGBCX
89Du2u/mH4ac8NqfgeMn+xMvTJZYrW4ufrVdJDsoelsp89KxoKZr1cmOGj1knvsj
umKbCc/6StQ710nJH8hd3Fc3Pt/gxE61PTeN+yG0MOUiKvBoqaPUaCi2YgRoCSzm
JmIiJqQ+LyVladLugr6MJU04rgVLEvnp1jojpWVlnRUaq+m1McfvwK2tbeMy1E/C
fBgugrnpiqpguv7i+L3mo6ltVyIq5rdfUfBk6wWrJuXNT6XMhW+UbXfA6nBSIivh
JhixPWd+TyiZSXhJA8CfmI3DDN0dxxriLQxJmqRYjITocB6rgioqImJ9t4NnJiwd
SWrtbw0J6/Q14EvsZlASdfjJAiQVgrzuRETHsLghREiIitXFF1Yaj9AAAAAAGZsp
LlWT+7vJ9SPpJ1IWJSdSHXQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAH/9PVIAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAPDtR/Pi/wB5RifaUmeS
VAZFm3I9qO60xNl+KYPs2fCn6Dx4pg+zZ8KfoHimD7Nnwp+geKYPs2fCn6B4pg+z
Z8KfoHiiD7Nnwp+geKYPs2fCn6B4pg+zZ8KfoHimD7Nnwp+geKIPs2fCn6B4pg+z
Z8KfoHimD7Nnwp+g8+KYPs2fCn6B4pg+zZ8KfoPHimD7Nnwp+geKYPs2fCn6B4og
+zZ8KfoHiiD7Nnwp+geKYPs2fCn6B4og+zZ8KfoHimD7Nnwp+geKYPs2fCn6Dz4p
g+zZ8KfoPHimD7Nnwp+g8+KYPs2fCn6Dx4pg+zZ8KfoHimD7Nnwp+geKYPs2fCn6
B4pg+zZ8KfoHimD7Nnwp+g8+KYPs2fCn6Dx4pg+zZ8KfoKXypJOHBkoKta1F4ZNK
Iicxblj9jgbpncdcAAAAAHrmYPDNVq+tFQy7L1CNdBUYkWYY50KK5VTNT1HuvUvO
mLw5RzKXDekNqennJpUsW4+lOmKJwDkVrnI5NPOV3QrdrdVOxJechvdDVVwVqYnG
vntTN27SHMSrHeCI9NCppLdtmzNoDEVMF4NuHXgVzdnexGsNCzKgxzobvoZqHqn6
rFvgqMKLKsc2FCcmOcnqLIv/AJVzJJjGNVcERNHuOpdLDcyk4ORUXNdoXXqK6uhg
RGVeIrmKiYrpVNB0L9LKR6TNNrMumKMwzkTWftuVBBmIDWQoUTwhURNKaMSUV2Un
bU0h6u9GI9uKImhSp7tLz5SwrFlZ+Xc6K1Vxdm5y/ihyLZ1mLaeehTUvAVssr0w9
HBdfuQ0LeNQ4lXpmZC+kkNFw/kJUFyt8MKzLXSM1Cej8/DFE0EkvqsVFn4kOry6Z
zWIiq1deHUeim5RFNgQ2sjyq8IiYOwYmHcTy7e9CStg5zZWCsNW68Wonchx7V5Qc
jR4yy0eC96t/NRU/FCsbfWul7zVhy9NgOhxUeiq7Nze5ENH2Mpj6ZKw4UVcXNaiK
dsAAAAAAzNlJcqyf3d5PqR9JOpCxKTqQ66AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAA//9TVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAPDtR/Pi
/wB5RifaUmuSNtjjaYAAAAAAAAAAAAAAAKSyqtig75PkWtY/Y4G6Z3HXAAAAAAPj
qFGg1H8tDa/D6yIp+JOgS8mithw2NRdaI1ExPrl5ZssmaxEanMmg+Oes7Lz650WE
x686tRT9wqHAgs4NsNqM5sEwIXfXD4OnORqalTBEOddBSIVRk28PDRyon7ZEXvLG
p9Fg078jDazH6qIh75iUZMpg9qOT3pieYMs2Cma1EROZNR6oNNhwVzmsai86ImJ7
JmVZNNzYiI5q+pUxQ5rLIScNc5IENF581DqshIxM1EwTmOZMWTlJlc58GGqr61am
J74dCgQkRrYbURNSYIfbmJhh6jmLZWVV2fwLM7nzUxOg+Wa9uYqIreb1HLdY6Teu
KwIeP2UPqp9CgU7TBhtZj9VEQ9EzZWVmnZ74LHO51aiqfuSs1LSK50KExq86NRFO
kAAAAAADM2UlyrJ/d3k+pH0k6kLEpOpDroAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAD/1dUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA8O1H89b+
o6PqMVE+spO8kKCsSbfh6jaAAAAAAAAAAAAAAAAKSyqtig75PkWtY/Y4G6Z3HXAA
AAAAAAB6ZuTZNtzIjUc3mXUJSSZKJmw2o1OZD3AAAAAAAAAAAAAAAzNlJ8qyf3d5
PqR9JOpCxKTqQ66AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA/9bVIAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAPD9S9R/Oi+xP4JxvtL3lq5Gu1Re
r5GwwAAAAAAAAAAAAAAAUllVbFB3yfItWx+xwN0zuOwAAAAAAAAAAAAAAAAAAAAA
AAADM2UlyrJ/d3k+pH0k6kLEpOpDroAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD/
19UgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA8P1Kfzovs5Tj
faXvLVyNdqi9XyNhgAAAAAAAAAAAAAAApLKq2KDvk+Ra1j9jgbpncdcAAAAAAAAF
IX+3vx7NKklJsVYz00KhnmevKtHTP1WM6I1uOOlMENLZP17i24gqyJ+UYmlS3wq4
GYcom+uYpsfwOnvVHJrVuk+DJxvKqFem0hTUVXt9aKXvepePDsTLOiu0vw9FDJ87
e7X7UvWJJpERmOhGpiXVk42vqdWe+FUmu9FNCuTA4t/l/celx1p8iipERcMU1lQz
N4dpKciRozoqM14qmjA05cJesttpfCL+UbrXnLYAAAAAAAAAMzZSXKsn93eT6kfS
TqQsSk6kOugAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAP/9DVIAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAPD9S9R/Oi+zlON9pe8tXI12qL1fI2GA
AAAAAAAAAAAAAACksqrYoO+T5FrWP2OBumdx1wAAAAAAAAV1ehVJCyuFRmoee9ur
RiZ+vWyh5S28DwaBCViroxVC08mC7ltnZZZnPRzoier1F5kCvjt62yUm92PpuRUa
nrM/3W3ZxLQQY9Wm8VxRytRdZ8uTSzCrRETUj1wPryt6ysWchwFXBiKmJ2bIZQ1K
sRKsgMhZz0RM5W/+ouK7G9mTtzisuiNd600YlAZRtholmp9tWRUViuxwPit7lEwr
XSLJBkPMiKiNV2GjmLmybLuks3KcK5yPc/To9Rc4AAAAAAAABmbKS5Vk/u7yfUj6
SdSFiUnUh10AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAB/9HVIAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAPD9S9R/Oi+3lON9pe8tXI12qL1fI2GA
AAAAAAAAAAAAAACksqrYoO+T5FrWP2OBumdx1wAAAAAAAAq4FaW5qVMtO/xbOqiK
vOqIVHetcNSKBJujyr0R7dSZyKq9hzsk22Ey+K6XVVdDNYRKjDhLmue1HcyqiKZT
yrHx5iMiQ2uc1NWCKqfgV1I30VinSqyjGKkLNwX0V1dhwLuLbTlCnOFlmqr3P0pg
TnKQdEm4kvHmEwV6JnfMsGzlyVDqFObNPenCKzFfSTXzYFcXTRH0aqubJKqw2uXV
zHYvEtjEthVWyU27CAipoUmV5VylGpsl4RAc1IiN0YORcdHuPkyVbcR3RHSTlV0P
HQqmpgAAAAAAAADM+UlyrJ/d3k9o/wBJOpCxKTqQ66AAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAA//9LVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
APD9S9R/Oi+zlON9pe8tXI12qL1fI2GAAAAAAAAAAAAAAACksqrYoO+T5Fq2P2OB
umdx2AAAAAAAAAUPflcNEtO7wqScqRk9SLgU1L5OVdm3IyOrsxdeLlU0ZcvcvDsA
xXY4xHJp9xQt7FUjzlebCgRHaH6URVw1msqXRWRYDEjsa52amOKIvq958dprIQZy
XfDhwmZytVE9FEKNuZuOnLPVB8xNw28GrlVPWWXfNdDCtzA0J+qtT0TNS5N1dhKs
Niu4PH6y4YdRfNyVwzLHN4WY9KM5NOJD768m+NV43hdO/KKulMcCuIOTfXZpUZFV
2Z6/SVTSFzVzkOw0LF2mKutSzwAAAAAAAADM2UlyrJ/d3k+pH0k6kLEpOpDroAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAD//09UgAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAA8P1L1H86L7OU432l7y1cjXaovV8jYYAAAAAAAAAAAAAA
AKSyqtig75PkWtY/Y4G6Z3HXAAAAAAAAABz6/FiQoD1gJjEzVzU95Rl110UxEqMS
o1FulVVWopoNEwAAAAAAAAAAAAABmfKS5Vk/u7ye0j6SdSFiUnUh10AAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAB//9TVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAPD9S9R/Oi+zlON9pe8tXI12qL1fI2GAAAAAAAAAAAAAAACksqrY
oO+T5FrWP2OBumdx1wAAAAAAAAAAAAAAAAAAAAAAAAZmykuVZP7u8n1I+knUhYlJ
1IddAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAf/V1SAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAADw/UvUfzovs5TjfaXvLVyNdqi9XyNhgAAAAAAA
AAAAAAAAqDKXocaqyLPB2q9zImdghDaVlFTdLgQ4LpF2LGI1V0+pMD2rlTTDdcm7
8Tx51UfobvxHnVR+hu/EedVH6G78R51UfobvxHnVR+hu/EedVH6G78R51UfobvxH
nVR+hu/EedVH6G78R51UfobvxHnVR+hu/EedVH6G78R51UfobvxHnVR+hu/EedVH
6G78R51UfobvxHnVR+hu/EedVH6G78R51UfobvxHnVR+hu/EedVH6G78R51Ufobv
xHnVR+hu/EedVH6G78R51UfobvxHnVR+hu/EedVH6G78R51UfobvxHnVR+hu/Eed
VH6G78R51UfobvxHnVR+hu/EedVH6G78R51UfobvxHnVR+hu/EedVH6G78R51Ufo
bvxHnVR+hu/EedVH6G78R51UfobvxHnVR+hu/EedVH6G78R51UfobvxHnVR+hu/E
edVH6G78R51UfobvxHnVR+hu/EedVH6G78R51UfobvxIHa22ke8aoQI3ALCbDw14
l30ZMXJ1IWHSdR10AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAB//W1SAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADw/UvUfzovs5TjfaXvLVyNdqi9
XyNhgAAAAAAAAAAAAAAA/ERMdaYkdrMq2J+0b2IQydo6OX6Dew+PxH+YnYPEf5qd
g8R/mp2DxH+YnYPEf5qdg8R/mp2DxH+anYPEf5qdg8R/mp2DxH+anYPEf5qdg8Rp
9VOweI/zU7B4j/NTsHiP81OweI/zU7B4j/MTsHiP81OweI0+qnYPEf5qdg8R/mp2
DxH+anYPEf5qdg8R/mp2DxH+YnYPEf5idg8Rp9ROweI/zU7B4j/NTsHiNPqp2DxH
+YnYPEf5idg8R/mp2DxH+anYPEf5idg8R/mJ2DxH+YnYPEf5idg8R/mp2DxH+anY
PEf5qdg8R/mp2DxH+YnYPEf5idg8R/mp2DxGn1E7B4j/ADU7B4j/ADU7B4j/ADU7
D9MomGpqJ9x3KPS1YpNafCzEOigAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAP/9fV
IAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAPD9S9R/Oi+zlON9
pe8tXI12qL1fI2GAAAAAAAAAAAAAAADw5D5Y8rwh8MSko4/HiZOY8eJU5h4lQeJU
HiVOYeJU5h4lTmHiVOYeJU5h4lQeJUHiVOYeJU5h4lQeJU5h4lTmHiVOYeJU5h4m
QeJU5h4lTmHiVOYeJU5h4lTmHiVB4lTmPPiVDx4lTmHiVOYeJU5h4lTmHiVB4lTm
HiVOYeJU5h4lQeJk5h4mTmHiVOYeJU5h4mTmPPiVDx4lTmHiZB4lTmHiVOYeJU5h
4lTmHiVOY8pR0T1H0wKajD74cPNPYAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD//
0NUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA8P1L1H86L7OU
432l7y1cjXaovV8jYYAAAAAAAAAAAAAAAAwPGaM0ZozRmjNGaM0ZozRmjNGaM0Zo
zRmjNGaM0ZozRmjNGaM0ZozRmjNGaM0ZozRmjNGaM0ZozRmjNGaM0ZozRmjNGaM0
Zp5wAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAB//0dUgAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAA8P1L1H86L7OU432l7y1cjXaovV8jYYAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAB//0tUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA/ExHSXar3LgiJiqkBn
L+aTKOVjo6YouC6D0+cHSPb/AIDzg6R7f8B5wdI9v+A84Oke2/AecHSPbfgPODpH
t/wHnB0j234Dzg6R7b8B5wdI9t+A84Oke2/AecHSPbfgPODpHt/wHnB0j234Dzg6
R7b8B5wdI9t+A84Oke2/AecHSPbfgPODpHtvwHnB0j234Dzg6R7b8B5wdI9t+A84
Oke2/AecHSPbfgPODpHtvwHnB0j234Dzg6R7b8AuUDSHIv6v6uYxFepV4dXn4saC
qqxXLgpYuS9baVspHiPnHZqKmhTTC5QVI9v+A84Oke3/AAHnB0j234Dzg6R7b8B5
wdI9t+A84Oke2/AecHSPbfgPODpHtvwHnB0j234Dzg6R7b8B5wdI9t+A84Oke2/A
ecHSPbfgPODpHt/wHnB0j234Dzg6R7b8B5wdI9t+A84Oke2/AecHSPbfgPODpHtv
wHnB0j234Dzg6R7b8B5wdI9t+A84Oke3/AecHSPbfgPODpHtvwHnB0j234H7gX+0
iO5GpH0qujQT6VnGzbEiMXFrkxRT3IuIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAP/T1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAADgW/erJCYVNfBO7iksny7SQtFIvjzUJIkRYrkzl1ln8RlJ6O0cRlJ6O0cRdJ
6O0cRlJ6O0cRlJ6O0cRlJ6O0cRlJ6O0cRlJ6O0cRlJ6O0cRlJ6O0cRlJ6O0cRdJ6
O0cRdJ6O0cRlJ6O0cRlJ6O0cRlJ6O0cRlJ6O0cRlJ6O0cRlJ6O0cRlJ6O0cRlJ6O
0cRlJ6O0cRlJ6O0cRdJ6O0cRlJ6O0cRdJ6O0cRdJ6O09rblaU3R4O08RLkqTE1y7
T18RdJ6O0cRdJ6O0cRlJ6O0cRlJ6O0cRlJ6O0cRlJ6O0cRlJ6O0cRlJ6O0cRlJ6O
0cRlJ6O0cRlJ6O0cRdJ6O0cRlJ6O0cRdJ6O0cRdJ6O0cRlJ6O0cRdJ6O0cRdJ6O0
cRlJ6O0cRdJ6O0cRlJ6O0cRlJ6O0cRlJ6O0cRlJ6O0cRlJ6O0cRlJ6O0cRlJ6O0r
XKBuvp9Bp3Dy0FGRGvbg5McSybtqxnU2XxXTmITOWmeEPrRcQAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD//1NUgAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAj14XJ8xuXdxXmS1ya7euLkAAAAAAAAAAAAAAAAAAAA
AAAAAAABUeU/yS77bTj3a1BfAYCfmoWpRo+eiHeYfoAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAH/1dUgAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAj14fJ8xuXFeZLXJjt64uQAAAAAAAAAAAAAAAAAAAAAAAAAAAFR
5T/JLvttItdsv6yg/ZQt6groQksPUfoAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAH/9bVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAI9eHyfMblxXmS1yY7euLkAAB+IsZsFMXKiJzquB8qVyAv87WfEn6Q6twG64jP
iT9J7oM/DjpixzVT3Kin7hTLYv0XIvUqKew8PfmIqr6kIfTb05SoTXgbFXhMcCYg
AAAAEattb+XsexIszjmquGg7FFq7KvBbHh/RemKH2gHrmI6QGq9dSIqqRyzV4Uva
F7ocFVxauCknAAAAAAAAAAABUeU/yS77bSLXb7FB+yhbtA1ISaGfoAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAH//19UgAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAj14fJ8xuXFeZLXJrt64uQAAHFtbZpLRQFgK5WY
+tNZRNtMnVtGl3zEOaiZyc6rh3kYumubW2LXujzMRM1dGCr+kuui3TrZaUiwpeK5
8R7VwV3qOPcjYyoUGLEdPPzmrjhpxPdb+9+LZ+cbLQ0arVciKugtGFNpNQc5FRcW
Y6Fx9RnKw8JErqrh+2U00q4HqWcYn7Zvah7GuR2lNJ5PDno3XoPX4Yz6ze1D2ouJ
+eETnQ/CTbHaEcnah7T8PmGw9aonWqIUZlSq2NKMVFRfTTVpLMuuTCnS+7QlR+Xx
EZrVE6z8JNsdqcnah89a0wIn2HdxSFxrUhzMVV0empfDZlr1wRyKvWh7D1OmmM0K
5E+9D9Q47Yn0VRepcSpLwr3otnZxstDRqtVURdRalPnUmobX4pirUXQqcx9Cxmpp
xTtPEOO2J9FUXqXE8PmWs1uROtUPMOO2J9FUXqXE/Z6nTbG6Fcnah+lipgqoqYYf
cU9L3yxolT8BVG8HnYY6C4mREfqVFPy+aYzQrkRetDzDjtifRVF6lRT9gAAFR5T/
ACS77bSLXb7FB+yhbtA1ISaGfoAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAH/0NUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAj1
4fJ8xuXFeZLXJjt64uQAAAiN6uwROor/ACafycbr+ZbFq4zoMtEc1cFRq4KU3cfW
Zisx5iFHiKqYOw9xVl6l2cSUqCM4dy579C82Jfl2l1kSyrOFfMOi4w/orjhqK5sU
udXl+0Ti+68eJSFbT5dP1WLhp5sSJS+TrOVGCkZ069sVyY5uK4dRJbmrbRZeM6kT
S5z4WOD8ccS5ytLxYM/XIngUumZCXXE1FbWmuAmqPBWZZPPVzdKoqrh3lkXIW4fa
KXWFF0vheiq85UVbr1SnKnEkZZyrDe5UVfq6T3W0uknrFMSfhzb35mlzcVwLju9v
C8c0xZ6JrY1cfuQpeQpM7e9OvitjugwGqqejiR++Wyk5YxjJZXujQVenpux0GoLs
kwp8DD2aEoKittRqjbKMss1eAgtXQ9NCqV9a+5yasWxs5DnHvzFxVqqqYlx2Dtet
q6a6M5MFRitX7kM/Wakp20E3EkZfFkNXrjET1aTt2su8nrsMKjDmXxmtVMWqqlqz
V6Ln0bxlDbi/N0pzKVTY+7mPeW1Z5Zx0NzlXFiKugtm7+6aJZZHo+ZdFzkwxXHQZ
9vYu0iSlQRqx1XPdr06MS87vLrIllYSxnzDomMJVRFxwTRiU1ZWrVO1k7HpzYjkh
Oevp6dGkumyd3Uxd/BiRIcZ0zE9TXYkamboJ62blmJmYdAVf2jVUjlCfNXV1BIEW
MseHEXDSuJbl7d4vklKJEYmL4iYN+9CqrP3NTtsYSzsaafDc7S1qY4E1sfZafZLx
JCYe5G4LhE04lDJdZEjVTwVJhyKrvp6cdZoaFRIt18hFjpEdHc1vrxKushYWPeln
TyzjoTlVfQRV0fcW3dtdNEshEWI+ZdGRfUuJZIAABUeU/wAku+20i12+xQfsoW7Q
NSEmh6j9AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAA//R1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACPXh8nzG5cV5ktcmO3ri
5AAACI3q7BE6iv8AJp/Jxuv5lq2w2SL9hSlMnfa4/wB5zb6IqNqsPH66GiJXTLt3
af6KZ2sNy6v2vmfJlLU181UoCNdweKN9PmO3IXF1OZY2IyoLgqaNKncu5uAi2Xml
nI0xwj116y60KBvSvGmKxO+JZReCcq/lNRH7W3NVCjyro8xPqrUTSmKkgyVUwgxk
xztOvn0nrsW/NrEX7S95Yl+C4UyL9lSvLrJdY9nIyN14OPryWagzweLB/bo9es+b
KptFAhwGSyuThVcnolrXXtzadA3aEoe7NRV5kM42otnN3izzqZJv4Dg1VFdqxI9e
bdTO2bluFmZ5Xt5lVdPaWdcMmNHfhzO7lI5cnaCDAnYsu5yJEV64ITHKPqjZOmPa
q6XKmB+LiaUk3S2sjNxY9NS6lI3XcnWaSM+LT5pYDXKqoxFVEPddFeJMSk46izeL
3sx9PWcG+2IjKnDx+shfzdMp/cn/AGkoPJ8fhPTCfnr3l03j2z8kJR81m52b6ijr
OWRqd5aLPsm1gscq4NRV0dhCK1ZuLZ6qQoMxMcO9HpjivvLQymJNzoErFT6LVbj+
Bb1gatDqElCfDXQjERfuQ6EtX4E6rocN6K5EXFDOchFRK+iLrz/maYnJNk4xYcRE
c1UwVF1FG2iydph0d8anTPANdqYmKJ+B67r7wpmizq0WcVYjmr9PWX4AAAVHlP8A
JLvttItdvsUH7KFu0DUhJoeo/QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAP/0tUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAj1
4fJ8xuXFeZLXJrt64uQAAA4lsaAtelnS6LgrvWRu6i7Z1imva92dnKTGuU9ajBfC
RcM5MMSA3YXUPsfGiRnPzs/HQeq+O55bbNR8ByQ4zVxRx4uxsHU7P4tnZjhWZuCJ
jieuhXOPplRWfz0VqrjgSq8G7+Da6CrHonCInou9aFSwrma9JpwcGdwhpqTOUnF1
tiapQYjnVCY4Zq6kxxLOKkvSuVdaSKk1JvSFH+tqIxLXIVeoJwNQm+Eg4fRxUnl0
d1i2DbEZnZzXro9x6aFdQ+mzz51X4o5ccCUXgWWW08o+WauarkwxOVddd2tkpJZK
KqPRVXHqUr20twc5LzKx6RH4BrtKpjgemdybY1dgIs/Gz5lHYo/HEuuylGWiy0OX
VcVY1ExOsqYlI2+uHjz0ws3TIqQYiriq6jl8QtSrjVh1OZ4VuHopiq4Fl3dXfusn
JOk1dnY44L1pgV7OZOL2K+Yl4ubMK5VR2Oo+OQuDqVSjNWqTPCwUVMW44ltWisrF
8D8Ep7uCVEwauoqPiitHgqeHfulJ7djdN5NOWYmnJEmV1vPVfHdAttmI6A7g4zV0
OPRdxd9VKG10OdmOFYrFaiY4+o/d29z77JTMWYc/OR7lVEJ7aizkO0MB0vFTFrkK
Lh3EVijvckhN8HCx0NxVD7IWTjGjRYc1HjZ0drkVzsdZcVorKQq9LLLRkR3o4IvM
uGGJR0rcRWqTnQ5SczILlX0cV1Fo3YXdOssxVju4SK7W7WQ+9K4iNX5ls5T4qQYi
Liq6juUWxFVlpV8KNM50VU9F2OohPFFaPT+vvX9ZSb3aXQrZ9/hM45IsyutxZ4AA
BUeU/wAku+20i12+xQfsoW7QNSEmh6j9AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAA//T1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAACPXh8nzG5cV5ktcmu3ri5AAAAAAAAAAAAAAAAAAAAAAAAAAAAVHlP8ku+20i
12+xQfsoW7QNSEmh6j9AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAA/9TVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAI9eHyfMbl
xXmS1yY7euLkAAAAAAAAAAAAAAAAAAAAAAAAAAABUeU/yS77bSLXb7FB+yhbtA1I
SaGfoAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AH//1dUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAj14fJ8xuXFeZLXJrt64uQA
AAAAAAAAAAAAAAAABVwKbhXvTDq0lMzU4Ln9ZcgAAAAAAAAKjyn+SXfbaRW7fYoP
2ULeoGpCTQ9R+gAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAf/1tUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAj14fJ8xuXFeZLX
Jrt64uQAAAAAAAA+eoVBlPYsSKuDWpiqlcxMoykQ3K1Yq4ouC6CZ2WthL2oh8LKu
zm9WB89rLwZSyiIs2/Nx+9Tj2cvrptoYiQoETFy6kVMCRV+18tQFakw/Nz19EjlT
vtplOjJLvi+m7VgmKElqlq5elwEmYrsIapiikJblGUhzszhVxxw1FiyE+yfY2LDX
FrkxRTj2rt1K2Vajpp+aikZpd/8ASqlEbBhxVznLgmKYFgxptsFixFX0UTHH3EVn
r2KfJQ1jPipmouHvPjs5fZTLQxeAgRcXr6lTAnePrIFX77qZQoiwo0XBya0RMTp2
NvNkrYKqSj85W601Ejnp5kixYkRcGtTFVK8XKFpCv4LhVzscNWjEqelzjJ60zYkN
cWrpQ1EAAAAAAAACo8p/kl322kWu32KD9lC3aBqQk0PUfoAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAH/19UgAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAj14fJ8xuXFeZLXJrt64uQAAAAAAAAp/KMkJyYlmOlMVai/
qiJzEUsZULMzEFjZlkNsfQjkci44l10uQlaFLOfJtRsPMVyZurVoKCsDR1vNqMWL
OLnwoTl9FdWstWqXHybojIso1ILm/VxK8yp5B0WDLQUcufiiI4mV2Vz8nClYUSaY
2LGwRc9dKlZXqWjZM1RsjMv4OVbho9RJag2ykeArEWGjmt0OTHOxwPOTtbnwnh4G
er4bMeDx5k1EJ8o5a0NViJV4uEKG5cGrjhrJJbuNZpZZ0WUcxkdiegrMUXH7yXXR
2tdX6PE4Vyuc1rkxXmwK9uiuxbX5uJFmHZ0FHL+pqug+6/ewctY1Yc7IsSE/ORNB
O7a2wjU+gsmWKqRHMTFSubspugxIPD1N7YkZ+vPxXA+G09oabZuegPokTBHuTPa3
HDWTi/62bokvAgQXKnDYI77yQWLuJkJaTRIsJror245660VU0FQWFsy6zVpOBc7O
THR7kNcAAAAAAAAAqPKf5Jd9tpFrt9jg/ZQt2gakJND1H6AAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAB//9DVIAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAI9eHyfMblxXmS1ya7euLkAAAAAAAAOPaO0UrSmKk3Eaxr
kw9Ipq0tnrLzMN8Vj4aRcFVqtcuOd6j2XARJupQI8GYVVhYOSHjzeojV3dfbdtUo
0Cc/U2RXrg5dWst2sX0ScvEZCl3tjOd6mriV3lMTXCJKPcmaquTR95c1hFxk4f2U
7jPF7dlmSVXSanYaulnLr9RMIFmrKRWI5XQ0xTVnLiTqwtn6TDhu8VZipgqKrVxK
Bh2XlaPVYnjiH+pvcuDlxRNZZDrK2TTW6F8S/oJ3JUySkafFWnI3glYululNRA8n
+Kj3xMPrKerKqiI2Wh4/XQ6FqKBErtnYUOCmLuDauHuIFdhRKDFg8FUWthxma89V
TEn9HsxZdsVvALDWJj6PpKq9xx8pCzjoTJePLsVWw3Iq4epEJhZm+iQdJtc6M3hG
sRMz9sqomopWxFp3WjtJwr2KzToxTWhrgAAAAAAAAFR5T/JLvttItdvsUH7KFu0D
UhJoeo/QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAP//R1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACPXh8nzG5cV5ktcmu3ri
5AAAAAAAACL20u5lbYtRk2iqicy4EQh5M9IYqLmO0fnFlUejQqRDSFBbmtRCPW1u
tkrZKjptmKpqVNCnMs1cXTbOxEjQWLnJqVVxJFaiw0tafN8JbnZi4tOxIyLZFiQ2
Jg1E0Hw2jszAtFDWDMNzmqV67JnpDsVzHafziYWJu7lbGtVkoioi68VxP3bC76Vt
a1GzTc7DVhoUha5MlIX9o74ie0Kx8CiS/gkFF4LDDBdJ4oFjJegqqwG5qquk8Wqs
VLWoajJpuciLih06bTGU6G2DDTBjUwRPcQW0Nw9Mr0RY0Zi5y68FwPmpWTvS6ZFb
GhsdnNXFPSLDnqYyehrBiJixUwVCuIeTjSYcRIyMdnI7HXoxJZAu6k4Eds02GiRG
pgioSUAAAAAAAAFR5T/JLvttItdvsUH7KFu0DUhJoeo/QAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAP/S1SAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAACPXh8nzG5cV5ktcmO3ri5AAAAAAAAAAAAAAAAAAAAAAAAAAA
AVHlP8ku+20i12+xQfsoW7QNSEmh6j9AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAA/9PVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAI9eHyfMblxXmS1ya7euLkAAAAAAAAAAAAAAAAAAAAAAAAAAABUeU/yS77bSLX
b7FB+yhbtA1ISaHqP0AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAD/1NUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAj14fJ8xuXF
eZLXJjt64uQAAAAAAAAAA+SrVVlKhOjRVwY1MVUzHbLLAiScZ0OSho9iLrVDtXXZ
VPlDHSBONRmOhMDRcKIkVEcmpUxQ8RoqQUVztSJipn29DKnh2firBkm8I5NC46iL
WWywo03HbDmobWsVdKoaYlbTwZiW8MR36lm52JnS3OV46nx3Q5GGj2IuGKofbdpl
XrXZhIE6xGIq4IqFlXyXoRLFSqTMu1H4pimOooVmWZPLrgNOnZjK5nKrMMgOgtRH
Lh7zU9KnFnITYi6FciKfUAAAAAAAAAAVHlP8ku+20i12+xQfsoW7QNSEmhn6AAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAB//V1SAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACPXh8nzG5cV5ktcmO3ri5AAAAAAAAAAD
kWroLa9LPlnrg16YKpT0tTLN2ShulozoboqY446XYlCU6x62qrCLTm/qTXouKcyK
bqpsustCYxdbWon4H7npbwpjof1kVCtLMZP0hSokSNGYkVz1VfS9RnzKhs5J06Yh
w5FqI5V0taaAunsy+bojZaOqpnsw6iOSdEs5Y1rpeZdDdF0qudpUoKasqlq6u1KW
39SR6Lo5sTbEOy0KdlocvNMR6NYiKi6fURu0li6TZ2XfMRJeGjWtX1GWrsLONtZW
1jy7MIDX44Jq1m44UJISI1NSJgfoAAAAAAAAAAqPKf5Jd9tpFrt9igfZQt2gakJN
D1H6AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
B//W1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACPXh8nzG5cV5ktcmu3ri5AAA
AAAAAAAD5KnMw4LFSI5GoqYYma7XZKDrTzD5uDMJmvXFE/iQqikT0zc/U0l0dj6S
IvabhsxW0rUBkdEwzkTE6q6CsL1L5YNmYTocByPjroRqLpRSpLqboJq2E140qaKj
ccWtU07G4Knw8xVRjETDmM521yWXWvmXTkGYTNdqTWU+xJm5qpNhNdiucmPabesd
aHx/LMj4YKqJiUNlZXhukWNp8P8Ab68CTZMFhPEMnwzk9KImOK6y7gAAAAAAAAAA
VHlP8ku+20i12+xQfsoW7QNSEmh6j9AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAA//9fVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAI9eHyfMblxXmS1ya7euLkAAAAAAAAAAIhehZeJaKUfCgOzX4LgZJjWvtJZBVk
2LEVrVXBc1VPFkbrKneBNtm5pFRc5Fcrkw9Zpa9aqRLD0pFlVzXNbhj9xELirwJ+
08lGiTDle5EXBTNlp6ZUXT8SOkKI5yPXBVaqoSaDeraSWYkNiRGtTVgxS8LEJUrd
U98ObVzYmboVdClMzdpbR2Ie6UhrEVqKuCoiqh8tn7tqreRNNmJpHIqORVVyKnrN
nU6QSzUmjGJirGer1rgZDfTJu8CtokzCckNr9Cqi4YY85s6kU1tMhNgs1NREPsAA
AAAAAAAABUeU/wAku+20i12+xwfsoW7QNSEmhn6AAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAB/9DVIAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAI9eHyfMblxXmS1ya7euLkAAAAAAAAAAB6nybH6Va1V6kP1DgNh/RR
E6kwM/ZT9ddUWsp0Frlc52lU1FjXMWH8lJFkN30nNRVJwsjDX9q3sQ8eAQ/qN7EP
bDhJD+iiJ1Jgfh8oyJpVqKvvRFP1DgNh/RRE6kRD9qmJ6mSjGLijURefBMT2gAAA
AAAAAAAFR5T/ACS77bSLXb7HB+yhbtA1ISaHqP0AAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD/9HVIAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAI9eHyfMblxXmS1ya7euLkAAAAAAAAAAAB8MxQ4Ey7hHw2q7nVNJ9r
W5uhDyAAAAAAAAAAAAAACo8p/kl322kWu32OD9lC3aBqQk0PUfoAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAH/9LVIAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAI9eHyfMblxXmS1ya7euLkAAAAAAAAAAAAAAAAAAAA
AAAAAAABUeU/yS77bSLXb7FB+yhbtA1ISaGfoAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAH//09UgAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAj14fJ8xuXFeZLXJjt64uQAAAAAAAAAAAAAAAAAAAAAAAAAAAFR5T/J
LvttItdvsUH7KFu0DUhJoZ+gAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAf//U1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADnWh
pvjSXiQPrsVvaZ1kLn69ZVHw5KYzYSuVcMT5Jmm2ll9CzP4nyKlpE/noXtH7JOkL
2j9knSF7R+yTpC9o/ZJ0he0fsk6QvaP2SdIXtH7JOkL2j9knSF7RhaTpC9o/ZJ0h
e0fsk6QvaP2SdIXtH7JOkL2j9knSF7R+yTpC9o/ZJ0he0fsk6QvaP2SdIXtH7JOk
L2j9knSF7R+yTpC9o/ZJ0he0fsk6QvaP2SdIXtPLW2kX+ehdCc5XNav2rdHiugvj
ri1TrWNvRrtrnKyFHXFPuJeqWkT+ehe0fsk6QvaP2SdIXtH7JOkL2j9knSF7R+yT
pC9o/ZJ0he0fsk6QvaP2SdIXtH7JOkL2j9knSF7R+yTpC9o/ZJ0he0fsk6QvaP2S
dIXtH7JOkL2j9knSF7R+yTpC9o/ZJ0he0fsk6QvaP2SdIXtH7JOkL2jC0nSF7R+y
TpC9o/ZJ0he0YWk6QvaP2SdIXtOfXLN120jEgTcbOhY4qmJZ1kqUtPgsg/URELOo
TMEQkcPUfoAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAH/1dUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA8Kc+fhLETAi89R1iKc
9aAo8n1Hk+o8n1Hk+o8n1Hk+o8n1PHk+p58n1Hk+p48n1PPk+o8n1Hk+p48n1PPk
+o8n1Hk+o8n1Hk+o8n1Hk+o8n1Hk+p+4Vn1wX7KmIb1oXBT8VPzl7yw8l+S8KmHo
aZdZ9Tx5PqPJ9R5PqPJ9R5PqPJ9R5PqPJ9R5PqPJ9R5PqPJ9R5PqPJ9R5PqPJ9R5
PqPJ9R5PqePJ9Tz5PqPJ9R5PqPJ9R5PqPJ9Qln1PtkqFmKSenSvBodRqYHkAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAH/9bVIAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAB+HsxPS6URT8LIoePAUPPgKDwFB4Cg8BQ
8eAoPAUPPgKDwFB4Cg8BQeAoPAUHgKDwFB4Cg8BQeAoPAUHgKDwFB4Cg8BQeAofp
sojUXqU/nffQ3NqUZPzl7y0sjuDwk1Ex5jXrpFDx4Cg8BQeAoPAUHgKDwFB4Cg8B
QeAoPAUHgKDwFB4Cg8BQeAoPAUHgKDwFB4Cg8BQ8eAoPAUHgKHnwFB4Cg8BQeAof
psoiHvYzA/YAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAB/9fVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAPD9
S9R/Oi+zlON9pe8tXI12qL1fI2GAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAf/9DVIAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAPD9S9R/Oi+zlON9pe8tXI12qL1fI2GAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAf/9HVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAPD9
S9R/Oi+zlON9pe8tXI12qL1fI2GAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAf/9LVIAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAPD9S9R/Oi+zlON9pe8tXI12qL1fI2GAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAf/9PVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAPD9
S9R/Oi+3lON9pe8tXI12qL1fI2GAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAf/9TVIAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAPD9Sn86L7OU432l7y1cjXaovV8jYYAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAB//1dUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA8P1L
1H86L7OU432l7y1cjXaovV8jYYAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAB//1tUgAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAA9cxMNl2q9y4NRMVUr6cv8A6TKOVjo2lFwXBMT0ecTSPbL2Dzia
R7VewecTSPar2DziaR7VewecTSPar2DziaR7VewecVSPar2DziaR7VewecTSPar2
DziaR7VewecTSPar2DziaR7VewecTSPar2DziaR7VewecTSPar2DziaR7VewecVS
Par2DziaR7VewecTSPar2DziaR7VewecTSPar2DziaR7VewecTSPar2DziaR7Vew
ecTSPar2DziqR7VewLlD0hyL+rLq5jE96VWZWZ+LGg4qxXLguBYeTFbiVslHiPnH
K1FTQuBpVcomke2XsHnE0j2q9g84mke1XsHnE0j2q9g84mke1XsHnE0j2q9g84mk
e1XsHnE0j2q9g84mke1XsHnE0j2q9g84mke1XsHnE0j2q9g84mke1XsHnE0j2q9g
84mke1XsHnE0j2q9g84mke1XsHnE0j2q9g84mke1XsHnE0j2q9g84mke1XsHnE0j
2q9g84mke1XsHnE0j2q9g84mke1XsHnE0j2q9g84mke1XsP3L5QlIjuRqRtKroxQ
sGUnWzbEiMXFrkxRT3o7E8gAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAH/9fVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAOBb96
skJhU18E7uKVyebuJC0Ei+NNQUiPWK5M5dZaHElSejtHElSejtHElSejtHElSejt
HElSejtHElSejtHElSejtHElSejtHElSejt/EcSVJ6O0cSVJ6O0cSVJ6O0cSVJ6O
0cSVJ6O0cSVJ6O0cSVJ6O0cSVJ6O0cSVJ6O0cSVJ6O0cSVJ6O0cSVJ6O0cSVJ6O0
cSVJ6O0cSVJ6O0cSVJ6O0cSVJ6O0cSVJ6O09rbnKU3R4OzsPES5mlRNcuw9fElSe
jtHElSejtHElSejtHElSejtHElSejtHElSejtHElSejtHElSejtHElSejtHElSej
tHElSejtHElSejtHElSejtHElSejtHElSejtHElSejtHElSejtHElSejtHElSejt
HElSejtHElSejtHElSejtHElSejtHElSejtHElSejtHElSejtHElSejtK0yg7s5C
h03hpaC1j2vbg5NZYV21ZzqbLoq6cxCayszwh9qKAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAf/Q1SAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAACPXhcnzG5cV5ktcmu3ri5AAAAAAAAAAAAAAAAAAAAAAAAAAAAVHl
P8ku+204t208vgMBPzULUosbORCQMU/QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAP//R1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAACPXh8nzG5cV5ktcmO3ri5AAAAAAAAAAAAAAAAAAAAAAAAAAAAVHlP8ku+20i
126/rKB9lC3qDqQksPUfoAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAH//0tUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAj14fJ8
xuXFeZLXJjt64uQAAAAAAAAAAAAAAAAAAAAAAAAAAAFR5T/JLvttItdvscD7KFu0
DUhJoZ+gAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAf//T1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACPXh8nzG5cV5ktcmu3ri
5AD0zk02UYsR2pqYqVfUcpSlyL1hKrlci6cExP3SMoynVWIkKHn5yrhpQtGFESIi
OTUqYn6BTVUvemJWppIo1MxXYYkqvYtvFsnLpGgpiqn33Z2piWmlGzEVMHKpLDw5
2brPDIiP1Kin6AACrhrPyyIj9Sop+gAAAAAAAAADmWlqTqZLvjN1taqoQC5C8yPb
ZsZY6InBuwTDrLSKuvkvTiWSzIMsiOjRNSHousrlcqL8alDRsNdWjAtgAAAFR5T/
ACS77bSLXb7FB+yhbtA1ISZmo/QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAP/9TVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAI
9eHyfMblxXmS1yY7euLkAORa7ZYv2FM+3GWWlanOxljwmvwx+kmJfMtd/ISzs9kC
GjudEP3O2yladFSWe7B66kOxFmmwmcIq+iiY4nFs3biVtG57JZ+crPpe4oOv8ut+
38ywMojY2nYuK5OZ1lhlb3028g2flXQ3PVsRyaMCsrkL7JaTa+HORnK5y+jjpNDN
rkJYPhOP6nhjj7iBTeURSZVysdFXFPcTazdqIFo4SR5Z2cxfWc9l48m6Z8Cz8I3M
p1LQWig0CFw0w7NYnrIHeFerKQJJz2RFRXJ6KohWFyl9ktIuiNnIzlzl9HHT6zSd
LqbKnDSLCXFrtSn1EQtZerI2VdmTL8HcyJifJZi+mm2lipAl4mL19SpgTiLFSEiu
cuCJrUrmpZQNKp8R0F8Vc5q6cExJDY+8eUtbj4I5XYa9GB+rYXhydkWo6bfm482l
SNyOUHSp1yMZEVVVdGgsWFMtitR6fRVMfuIFWr9qXR4iwosX0k14Jiduxt4snbBF
WUfnZuv1KditVuFRoaxo7s1rU0leplH0hVw4Vdf1SeWdtJBtBCSPAXFi+vURq1F8
9OszE4GYiYP5kTEWZvmp9pIiQZd6q9fVhgS+pVJlNhrFirg1utSvJjKLpEBytWKu
KLzaCd2ftDBr8JI8u7OY7Up8lrLbStlYfCzb81v4kDql9dNtFAiwYERVerF1ph6i
NZKn0JnefMvefnmyLFiRFwaiaTKN7F4kjVapAjI5c2E5M77lNH2OvAlLUt/Wjldg
ierA+O1d7UhZZ/BzMTB3MiYnqspfJTrUReAlomL+ZUwJNXrQQaDD4aYdmsxwxItW
76qbR2tdFi6H6sExJTQa/CrkNI0BcWLqU6IBUeU/yS77bSLXb7HB+yhbtA1ISaHq
P0AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD/
1dUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAj14fJ8xuXFeZLXJjt64uQA5NrE
xlYv2FMnWEt3O2cnYvgkusbFVx0L8i5bCXrVOtzCQpmTWGzH6WCnAvHhItahr1F0
VdMZN27+RRmS9DzZqc+0vefBaDl1v2/mWBlEbG0++5yoMptLbFirmtTSqn3LfrSU
dm+EJjjhqPhvUpsnaSnumc1H6PRd6yv8nuwMjUmRHxYLXOauhV6z6Moy0zqOsGSh
u4OA7BHYaEwPFCdZeHLthRlhueqek5UXOx6zkXV2yg02rvlJJ6ulVxwT1Ejv5sAs
oqVeT0RWqiuw5iDSVuJi+CNCp6pmwmYZ6+9C6LbXfykpTFhOhovBswRfWVpk/wBg
pKpuirFhNcrV0Y9Zo6SkWSLEhw0wampDzPQFjscxq4KqKiLzFLT9Fo9n4qpV4qRY
qrjg7FUQri8OrUmSjw41HVGxM5Po4ohc9t2TdYojXSqrwysaq4a15yrru6lQ4ULg
6sxrZlPpK9F0qXzYij0+Xh8LTmtRjvW0oO3EF1Mq7olXar5NV9HHUWRZOVs3WYiN
k2w1iJpRNKKfVf5aOJZyn/qC5uK4Yp6kK0u5mrPtl+EqD2RIz9Ls7FcDmVC1EhZy
qQUoz/1N6pntbqJxlCy83OMgTEBFdL4IsRE1Yes9Flp+y88xjHMhpFXBFRUXHEt+
LRmSkm+FIojcWLmZvPhoM22MjSVMmIkO0TE4RXLmufiugvKwVLo04vD0xrFVPW3H
H8Stco61r5eZhSjnqyC7DOU+imLZVJdIMRYauw0uVFzsTlXLWzhSlTiyks9XSunN
T1HotZCW8Ot+AxFxhMXHN9RPrw7lZNJBySjGwojGfTTWuCEaySISy8GPDVcVa/BV
59Jf81Ktmmqx6YtXWhma9Kw8lL1SAxkJEa5yZyc+kt+08pAsFIRY0lDRjkZoVOor
a5KwcK2rXVOoIkVXOVEa7Sh81+120GyLWVGnJwL0eiKjdB2byKy6t2cbEifTVExX
34az4rg7pIE7JpFnkSNj9HO04F9UykwqWxIcFqNampEPrAKjyn+SXfbaRa7fYoP2
ULdoGpCTQ9R+gAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAf/W1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACPXh8nzG5cV5ktcm
u3ri5ADkWuXCVi/YUo7J4io+djfyI0RgZ+vnzqFUIc89P1LFMV9RL7QXwyayCulo
jYsVYeiGmldRX2SbNrOxZqK5M1zlXFObSfJaGKiV5qfn/MsHKKejZNuJ99zchDqt
KbCipnMXQqH1LcDSFdncBpxx1n228oaSVNfAlm6Gt0IVVk827lKXwsCYiNhxM7U7
R6z3ZR9mnVd0GcY3hIDcM7DSmB+7O0iy87Aa+LmMfhpRXKi4k1sNZ6gti407MWIn
MqqpDr77wHVaK2jyK4xFciOwIXOWNmbn40KeauMJ2Gf1+svmq1xtrKU6NL+lnMxw
T8SpbgLbytGixoM1ESG/FdDtHrNHSc4ycaj4a5zV1Khy7ZR4sCUiugflEYub1mZr
uEp1bixHV9ycMjlwz1VDk3uQKXIx4baYxFbnJi9uKoaes3WoNKp8GJMPRrODTSuo
gFdkLL1pzosZ8NXuxxVFVFxI3cfMzEGoRYUBVWSRVzF9WBaFta7Rqp+tqhEhrh+1
VSkrxKfTaSsOJZ96cOr0xRiqugsG8+z0zaGiw85FdFRqK5PWQy7ik2fmJdGT7Ww4
zNDkcqopO6BZyzPDN8GWGsXHRpVVJ9aSvyFJh8BORGsY5MMHcxTVsqDZvgHxJV7E
mERVZmquOcSjJ/q00kk588qo1qrmq7mPqtVN2dtK9XTcSG56aMcVRSr6ejaVV4cO
hOVZVVTPw0p7zt5RtlHzExBmojFfBbhn4fifdRaNZacgte/g2uVNKK5UVFJrYKz9
Da9fFuYr/XmripVNXmFsPaBZqMmbBcv011Fh3kXzSiST0k3JHiOYvot0qmgi+SPH
WYgx3qmCufiqc2k0IZ4vbio2ry6fnp3ls3l0N9ap0WFD0uVmhOfQU/cDeRBsxDdT
Z9Ugva5VRXaD6L8bdQbYNZT6eqRXK9FVW6UPvvLoy0GzzIUT6SI3EldwD86nMw5k
LMABUeU/yS77bSLXb7HB+yhbtA1ISZh+gAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAf/X1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAACPXh8nzG5cV5ktcmu3ri5AD1Tcq2barH6WqmCnEs/YSVoD3RJdma52skByLT
2VgWmhLAmW5zFIlZ+4amUKLw0Fi53vXFCT2fsTLWfe+JLszVf9I+eYu7lJiOk05n
6oi44n32hsvAtAzg5huc091DoMKiQ0gwEwYnqOgfmJDSIitXSippK5nLgKXNRlmF
hqj1XFcFwJulAhJA8FVMYebhgvMQCaycaVMOV6sdivMp2bIXPSNk3rFlWqjl14ri
fdJXaycpNLPNZ+rL61OraOzUG0UJYEw3OYvqPXZyykCz0PgYCYM5iI1O4Ol1GMsw
+GqPVcVwXAndJpbKXDbBhaGt1H1PYj0wXUV5aG4amV6IsaLDXOXmXA99PuRpslD4
JsPFuOOnSp3q1YiXrEukpFReCRMERFIOmTNSE0ZjviJ9ZqyMvZyFwMu3Nb+JEq7c
JTa3FWPGY5Xrr0nts1cZTbPReGgsXO964k/WGipm+rDArut3B0ysRFixGLnKunBc
DxQ7gqZRYzZiCxyPbq0nYtpdZJ2wwWaaq4asFwI5LZN9Jl3I9GOxaujSWE+gwnQf
BkbhDwwwQruLk2UmK5XKx2Ll0+kSixt2MlZHHwVmCr610qSGqUuHVIawoqYtcmlC
uI+TfSYzlcrHYr7zv2LumkrHPWJKNVHLrxXE6dsLCytrYfBTTc5E7SPWbuMptn3r
Egw1xVMNK4oSazdjZazmd4M3Nz1xU7ZH6tYWVqsZsxFbi9q4opIETDQQO1VylOtP
FWPMMXPX1ouB7rI3PyFlH8LLMwdzquJIrR2ag2hhLAmG5zFXUfqg2ehUKGkGAma1
PUdIAFR5T/JLvttItdvscH7KFu0DUhJoeo/QAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAP//Q1SAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAACPXh8nzG5cV5ktcmu3ri5AAAAAAAAAAAAAAAAAAAAAAAAAAAAVHlP8ku
+20i12+xQfsoW7QNSEmYfoAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAH/0dUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAj14fJ8
xuXFeZLXJrt64uQAAAAAAAAAH5fGbD1qida4H6a7O0oAAD8viozWqJ95+kXEA8Oc
jdK6DwyKkTUqL1aT9AAAAAAAAAAAFR5T/JLvttItdtscH7KFu0DUhJoeo/QAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAP/9LVIAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAI9eHyfMblxXmS1ya7euLkAAAAAAAAABR2
UTUo0osPgnq3VqJxSq6+mUhsz9J7YePPicO529iNbZ8RsaHmZmOGjAtUH4jPzGqv
MiqUzZu+6YqlTWQdCwYjsM7A8X61GLKzEukN6tRVTHDrLWsy9Xy7FcuK5p1Cmrwr
6Y9m59snDh5zVVExwxJTedUHrTVisVWuVqL2oRzJ3qEWalojorlcqL6z45C++YmK
p4vWF6GdhnYFp2itXAs81HzDs1FPro9Yh1eGkaCuLF1KfaAAAAAAAAACo8p/kl32
2kWu32KD9lC3aBqQkzD9AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAA//T1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACPXh8nzG
5cV5ktcmO3ri5AAAAAAAADlWltJCs/BdGjORqIi4Y+tSkIt/VVnlc+Sk+EhIq+lg
pNrrL3ltPjBnG8DMY6GLoxIrlJa4f3Fg2emmylJY96ZzUh4qnOcK6O3EGvxYkODB
SFm44qiYYnm9O+dLLuSXlG8LMY6Wayu6zlIVWhsR8zJ5qO1YoqFr3UW7mrXQFjzU
Hg0wxT3kbpF4MvEqngjICI/Owz8NJz8oabZJRoEWKuDE1r95yG34VGFDTwGV4WC1
ND8FLHusvaZbFvBxEzJhv0mHFvHt7L0OcZCiQEe5VT0lQ716cZI1MVyJgitRcPuI
1k27NE+0eYV4Mu2qeCpARH5308NJCcpa1E4jkgcD+pJqdznvujvHqkGWbCbK4wm6
n4KTixl9y1qfWnxoeY5Cf2ytO2zcu6Yd6tRwrrbfxLZQ3xXszERdHvJyAAAAAAAA
VHlP8ku+20i12+xQfsoW7QNSEmh6j9AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAA//9TVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAI9eHyfMblxXmS1yY7euLkAAAAAAAAKDyrZx0CXhZurO1c5w7I33zlGl2QoVPc
rUamlEXT79ByJKsz9pqzDnElXQWoqY6FRCbZRy5yQlXXoJzT+RU3RX+TntEf7+8i
NbrkCzVo3xJtfRV2tdSExvqt/JWklocCTe2NEV6LmppVC07vpSJKyLGxUwXM1c2g
o+z3L38j+ZJcoaTbPxpeFETFq4Yp95a9iqPCpsoyFCaiNzdRQFHRtPtM/gdCK5cc
NR91+GmowvtIWXeTySn2G9xHsm7Zon2iEpy8n2/mTjKOdhLs/i9ZLLm9NOhlUXsU
jyTqbKixMEe5ExOrfraXxxKQZaXXF781Vw+4tG7ahJR5KEzDBysRV6yUAAAAAAAA
FR5T/JLvttItdtscH7KFu0DUhJoeo/QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAxAP//V1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAACPXh8nzG5cV5ktcmO3ri5AAAAAAAACvb5LvFthLpmLg+HpT3lYWevvmLJw/B
JmUfEczQjkTRo+4mVhr9ltLMpLLKPh4/tlRcO452URS406sPgWK7VqJrISj0o6MV
q5/BavWQPJ9pUaSjx1jMVqLjgqkKvFp0rT6k+Ymm+FYqvoN0qnYfigW7ptnYqRoV
Pei461RcENIWVtZBtPL8NAXRhpTm0aij6BRZhlc4RYaozP8ApYaNZ3somgTNYdBb
KIuf9ZPUR+mX3Ttj4PgcxLPixGpgj0RcD7bl7Cx6tOurM01Wo7FUaus8X00iPNVC
G6GxXNRyaUQsa8WUfHpeYxqq7Mbo+44GTvToslLREjNVq53rIalFmPHiRODXMz/p
YaNZYV/NlYtbk1dB0uYmOHOQS5y96NJw2U+NKvRyOwzsFwLIvosylfkHL62JnJ2G
dsnyRma/UldMKroUNcNOrQbJa1Gpgmo8gAAAAAAAFR5T/JLvttItdvsUH7KFu0DU
hJoZ+gAAAAAcm1lRWmysaM3WyG5UM5WMlbQW+hvm4E1mMz1RGqp3uLK0vTE+IcWN
pemJ8Q4sbS9MT4hxY2l6YnxDixtL0xPiHFjaXpifEOLG0vTE+IcWNpemJ8Q4sbS9
MT4hxY2l6YnxDixtL0xPiHFjaXpifEOLG0vTE+IcWNpemJ8Q4sbS9MT4hxY2l6Yn
xDixtL0xPiHFjaXpifEOLG0vTE+IcWNpemJ8Q4sbS9MT4hxY2l6YnxDixtL0xPiH
FjaXpifEOLG0vTE+IcWNpemJ8Q4sbS9MT4hxY2l6YnxDixtL0xPiHFjaXpifEOLG
0vTE+IcWNpemJ8Q4sbS9MT4hxY2l6YnxDixtL0xPiHFjaXpifEOLG0vTE+IcWNpe
mJ8Q4sbS9MT4hxY2l6YnxDixtL0xPiHFjaXpifEOLG0vTE+IcWNpemJ8Q4sbS9MT
4hxY2l6YnxDixtL0xPiHFjaXpifEOLG0vTE+IcWNpemJ8Q4sbS9MT4hxY2l6YnxD
ixtL0xPiHFjaXpifEOLG0vTE+IcWNpemJ8Q4sbS9MT4hxY2l6YnxDixtL0xPiHFj
aXpifEOLG0vTE+IcWNpemJ8Q4sbS9MT4hxY2l6YnxDixtL0xPiHFjaXpifEOLG0v
TE+IcWNpemJ8Q4sbS9MT4hxY2l6YnxDixtL0xPiHFjaXpifEOLG0vTE+IcWNpemJ
8Q4sbS9MT4hxY2l6YnxDixtL0xPiHFjaXpifEeOLG0vTE+I88WNpemJ8Q4sbS9MT
4hxY2l6YnxDixtL0xPiHFjaXpifEOLG0vTE+IcWNpemJ8Q4sbS9MT4hxY2l6YnxD
ixtL0xPiHFjaXpifEOLG0vTE+IcWNpemJ8Q4sbS9MT4hxY2l6YnxDixtL0xPiHFj
aXpifEOLG0vTE+IcWNpemJ8Q4sbS9MT4hxY2l6YnxDixtL0xPiHFjaXpifEOLG0v
TE+IcWNpemJ8R89Ru8tJJQnxlnE9BqrhncxL8ny28e0MpEWbdnRIblTEtaDMZ59C
Lif/1tUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAj14fJ8xuXFeZLXJjt64uQA
AAAAAAAHodIQ36VY1fuQ8w5JkNcWtai+5EQ9j4SP1oinnNTV6j0TUpwjHNbgiqip
imgy42bW7WrRJibhPjNdjhox/Sd202UHL1mCstAlH58RM1FVqaMfuJxk/wBg49lp
d7phdMVc5E5kUtTgWouOCY9R5cxHa0PU+RhvXFWtVfeiHtZDSGmCJgnu0Hh0FHaV
RF+48qxHaFPDIaM1IiHjgW444Jj1H7VM7Qp6WyUNq4o1uPUhDb360+mSTkhtVyvR
W4IRzJ4sutJlXRIjcHvdjp1ltgAAAAAAAAqPKf5Jd9tpFrt9ig/ZQt2gakJMzUfo
AAAAAEevD5PmN04r3Jc5NdvXFxgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAA5dqdljbp/cpnjJ6qXg8KYb/DF7y9KRPcISOE7FD//X1SAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAACPXh8nzG5cV5ktcmu3ri5AAAAAAAAAAAD5Zq
lwpr8oxrutEXvPS2zssxcUhMx+yn6D72tzdCHkAAAAHrjS7Y2hyIqe9MT9Q4SQ0w
aiInuP0AAAAAAAACo8p/kl322kWu32KD9lC3aBqQk0M/QAAAAAI7eJyfMbpxX2S5
ya7euLjAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAABzLUbL
G3T+5TL1x8TBsfeL3l92dfjgTOX1H//Q1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAACPXh8nzG5cV5ktcmu3ri5AAAAAAAAAAAAAfl0VGa1RPvPLXo7UuIc9G6z8pM
NX1p2ofsAAAAAAAAAAAAFR5T/JLvttItdtscH7KFu0DUhJoeo/QAAAAAI7eJyfMb
pxX2S5ya7euLjAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
BzLUbLG3T+5TLlyP0Y+8XvL7s56iay+o/9HVIAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAI9eHyfMblxXmS1ya7euLkAAAAAAAAAAAAPkq1TZTITosRcGtRVxML3oXq
z9emXvloj2wmOXS1cEL+yW65Hqks90d6vwRNK6Sub8L5Z2qTq02SxarVwRU0KpX1
Wl7Q2XRszMuitYmC6XaFNTXA3kvthKIsX6bU1lrAAAAAAAAAAAAFR5T/ACS77bSL
Xb7FB+yhbtA1ISaHqP0AAAAACO3icnzG6cV9kucmO3ri4wAAAAAAAABiAAAAAAAB
iAABiAABiAMQAAAAMQAABiABiAAAAAAAAAAAAAAAAcy1Gyxt0/uUy5cj9GPvF7y+
7OeomsvqP//S1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACPXh8nzG5cV5ktcm
O3ri5AAAAAAAAAAAADOWUteE6Nm0yVXF71RFwI5aa6xlkKFwr8FiRExVfWmJLMkP
TKPxK8ygLHrYaoNqkN2Kudjm/ecO32UA+8CDDkXs4NNCK75mlrhbEwbNyLeCekRX
JirizQAAAAAAAAAAACo8p/kl322kWu32KD9lC3aBqQk0PUfoAAAAAEdvE5PmN04r
7Jc5NdvXFxgiF4N5krYuEsSO5M7DQ31qUXEy1GI7BJf0cdeP75d92t58C3EFIkJU
R2GlpMZiMkBqvXUiKqmeLZ5W8OhTCwIULhERcFXEti6+8JLby/hCNzPcTIA+aoVG
HT2rEiuRrU1qp8FEthK1tVSXiNeqa8DsAAFSZStoI9DpyxZZ6sfjrQ5GS7amZrUj
EizT1erVXBV1nroeUy2qVPxakHD01bndReyAAAAAAAx7efeHPyFeSXhRnNh8IiZq
LowxNc0t6xITFXWrG49h9IAKKyq7UTNAlIb5V6sVV0qmvWd/Jwr0et01sWZcr346
1LWABQ2VbaqZoEtDdKxFYqrpVNesk+TpXY9aprYsy5Xvx1qWZPOVkNyprRq9xkiz
14U/Grqy7oqrCz/o46NZruEuKJ1IfoAAAj9vpt8nJRokNcHIxVRTOuTHbqdrtQiw
5mK57Ux0KvWT28rKObY2fSQ4LPxVEVetcC4qRP8AjCEyNhhnNRcOs+sFYX03zJdu
xjuD4RX6kOrZW3q2upjp5jcxVYuCc2goS6K38/Uaw+BGiq6GjlwbjoNaofmI/MRV
5kUouRymmzVT8WcD+3zc45+Vja6as/DhLKxFh468Nesmd0dq4q0VJ2YVXva1VXHW
uCHIuqyikt1OOk0hZmGOClq1y1UtQ0RZmIjEXnPppdXhVRnCQXI5q+tD7AAAAc60
VXSjy8SYVMcxqrgVRdNlDpb2bdKpCzM3HBS0q5auWoeCzMRrMec+umVWFU2cJBcj
mr60PrAB6J6Z8FhuifVaq9iFJ2JylUtLUVp6Qc30lTO6lwLzAAAABzLUbLG3T+5T
LlyP0Y+8XvL7s56iay+o/9PVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAI9eHy
fMblxXmS1ya7euLkAAAAAAAAAAAB65rHMdhrwXuML3qUSotqLo8GE9VR2hURVODa
y1tcnYHBTqP4JPrJgned64S0lTpsVElkcsH9tzH31C03lJWeDqL8YSO1LqQsC+Wy
1Cl5PhJRYaRcNGauKn6yTLTx4+dLOxWEmOCqabAAAAAAAAAAAAKjyn+SXfbaRa7f
YoP2ULdoGpCTQ9R+gAAAAAR28Tk+Y3Tivslzk129cXGCqby7kW24mocaK79Tbrbz
kYvXuRpNGkHxYcNGPa3QvOVvkgS8ZZuJm48GnYXFlD3neTMt4PAX9ViaME16TMto
LtH06n+MJhMIj1x06zS+S67Op2PUXMRC8G8uXsXD4SMuLvU31lX0DKygVWO2BwDm
5y4Iuk+W/m/CDKQXSaNVXObr6ymblb6YViIirEYr893q9WJrOrXrwqfTvGatVWYY
5vrPnujvhhXjMe+GxWZutFPVe7fTCu5RnCsV+fqwJPYm2TLUSjZ1qZrXJjp9RWdv
MqOUstGWAjFiKnrRSub379ZW3lMWHDTMfrzV1kwyQ1zadEVdWOn8T47PW8o0xWFg
QpbCYz8M/D1l42vtpL2VhLFmHImjQnrUpCayzJSC9WJBcqIusty7q9GWtxDz4Cpn
etvrONeZfnK2IXMcmfE+qi6SP2Byl4NrI6S/BKxV58S62rjpOBbG20vZWEsWYcia
NCetSkJnLNlIT1YkFyoi6y3Lvr0Ja20HhZdUzkTS3HSQmr5SsCkTySEaErXK7DOX
USi8S+KXsbAZHd6avwwai6TtWNts20Mqk45vBsVMfSKwtplWylnYqwWMWJguGKLo
JjdbfPLW/ReCTNcifRXWZiveTC0bd4neakt5eRDsBIw5mK1XJmtTBOpD33VXnQ7w
JdZiGxWIi4YKcC9e/qDd7GZAiQ1ersNRPaDaZlUlWzi+ixzc7T6inrX5WUpQIzoL
YaxMF1opWV/d8Utb2RZwPouRcVausuLJbXg6S1V1IvyP3eFlKyVknrDanCuTXgpy
bH5WUlXoyQXsWHiutVLuWpw0h8NnJmYY4+rAo61uVnKUGMsFsNYmC4YopWN/178t
b2Sh8D6Lk0q1dZdOS8mFKZ1lsVD8m/7K9xh2WrLKJXXR4q4NR6r+Jb8fLGlJeJwS
QnKiLhneotyzV5MvaKVWbl1zsExVvrIjZDKFgWgm3SSw1Y5FwxUsq0Neh0OC6YiL
6LUx6yurtb/IVuZh0vChq3NVUzi11XAqq8fKEk7GuzPyjk1oikTs3leydWithPhr
DRVwxUtO29QZUaZGiwlzmuhKqKhmfJJ5Sjdbiwb3LcUimVJsGcl+EjZyelhqLnfa
OBSZNsy5UZCzEVE+7UUjUcsqUlYjmJBc5EXDHnPsszlby1cmGS7YLkV64Ynfv8tV
TqPBhuqMHhkdhmprO3YqrS1VpDokkzg4Ssdg37jLl31p4VmKtFmIy4NRylvsyyJR
0Tg+CciY4Z3qLusxa6BaaBw8ByOaqaU5iiqfbyjRKzwDZb9cZ+HCYevE+TLQ/Iwf
4vWTy5SOyWoCPipixGKrk50wQjN0VvKROzcXwKX4OI3FVdhrKvyhr44Vp3+Dw2qm
Y7DHqJbcRlAQZNjKe6G5Vw+kWPWcouDSZpspEhKmcqel6i2JSosmYSRkX0VbjiVJ
MZSUu2oeLmQ1cudhnJqLjhPz0RedEUjVubwZeyEJYsZyY+puOlSnpDLGlJmKkJ0J
Woq4Z2OguWettCl5Lw9vpMzcdBVSZWckjXOVi5zfVjpUkFjL6pa3krGiLDVGMauc
1fWhE7n7eUicmo3gUvwcRmcquw16yqcoO+KFamJwENqpmO19RNbicoGDLtZT3Q1x
0el6iz7wcoaSskifzsdzIuoidncr6TqsVsJ8NYaKuGKroLti2ih+DLNw1zmI3O0F
QedZJsV7XsVFbj69Z2bu7+5e3ixIbYatRrVxx9aEQsBbejztWdAlpbMj56pn4evE
s68692XsC1HRtLlTQ31lUw8tGVcuCwHInOXVYK8GBbKCkWAunDSnrQhNusoiBZOc
SSfDVzlXDFC06TUUqMJsVuhHIin1gAHMtRssbdP7lMuXI/Rj7xe8vqznqJtL6j//
1NUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAj14fJ8xuXFeZLXJrt64uQAAAAA
AAAAAAA9bpdrtaJ2IQO+G799r5RZeAjUevrVEORcVdVFsNAdCmVa5V5tJCb3Ml5b
QRlmJBUY9y4riQWRyP6g96cNFRWevT++aUu0u0gWJgJChp6XrUmYAAAAAAAAAAAB
UeU/yS77bSLXb7HB+yhbtA1ISaGfoAAAAAEdvE5PmN04r7Jc5NdvXFxg+Gr1qFSW
LEjORqInrXAyteVa6cvWm0kZFruBR2CuTVrL3u6u/h3fySoiJwiNVXL9xlC3NvWT
tX4adxdDY/FE6lO5fRftJ2xk2SssxW5iJrJzku3py6Q205UXhFwwU00ZnyqbATVT
VkzAar2t0qiaSOXY2zpUDgpefl1ZHRURHKmGks2+q7OQqMm6cRuLkZi1fVq0FN5P
V1snauI7wpudmO0F5X9UiHR6I+DBTBjUwRPuINkYN/UI3X8z5MtFvowV/i1kxshU
Vptmc9uvg17ikLhLuYN4M3FfOrnNRV0esm+UFcdIWUkVmZRqtci4YElyR1/gZF+/
uUqGxLP2TLvF7yR5XtcfMzEOFpRrcNBxaE2kOk0R8lEfHw+miLhifbk9SczTqk5Y
UJ8OE5VwxRUTA/V/dhJunVFJ3g3RIWOK4Iqk9uktfRqpGZC4LgplETWmGk0cxERN
Gox1lc1181MshKqo1q4YHKorKQ6TRHyUR8fD6aIuGJ0MnWWmaXUnOhwnshKq6HIq
JgTvKnu8guhtqUNUbGRe0oqwk5FtzOwpacfixqphjq0Gnb/Jl1m6MkGXXNRGomKa
PUVFk5XMyttIb5ifTP5ucuSwtxkKx06saWfgxcfRx0lAXvLjaNm8TvLkypORofUn
ch+skFMKav2iussNv69gfyEs60tXdTLNMVmhVhomgp/JyullrdLEjz3p4Y6PWffl
J3OyVjZdkaTRW4rgqE7uhqi06zj3t15q9xnWw8xLTE9EdPw3RmZy6E0rrO5eJTJW
cc1aXKRYeDk/aqXfU7QTFPs7mxUVrkZhp0LqK2ycro5a3XCR5708FXR6z6spW56S
sZAZFk0VuculFLmyXlxpLOstiofk3/ZXuMKxLOstHXHS8X6KvXvLsvBybabISD4s
FubEa3HOXqIXkjzSykxFlnLnNXFOdDi3rUCLYettm2ejDe/H8SbZQV6LanTocKXd
+qPRMcCXZL1iUpUikxEb+qv9frLYtZUFp8tEiJrRq9xgSnzkGcqkR86x0VmeuLU0
rrJNePT5GdYiUyTisdo05ql6XdPjts/FhzDVTNYuGdr1FZZJPKcbrd8zn5SSfwch
/bb3oWpf/DiLQ4KsVUbmJjh1FFWSr1Al5VWzkJXR83Xh6zvZPdh4VfqCzCMVITXY
t0E/yzWo2Xgonq/STS5HRZ/+QO7jOlh7HQrW1d8CP9HPXvLZvjyd6dRpF0eVbmPa
mtfWejJBqLocGNAVcUwXqK2pTcLUf3N+ZZeWf+Rg/wAXrJjdV/MNu3bu5CmMmCCk
WrRmKmhVci9qnYynLt5OhqkeA3B73Yr95Nbg7nJCNAZOuZjFwTT6jiZWFhHN4Odl
0wRmGOB1qDe9DSgq17v1VGK1CH5LVklrc3EnpluKIqq1VNcr6KGIr/pyNXqw2Wc5
c1XImHq1lxJktU6Yk2KxM2NmtXO9WOBJKnZlbN0WJAV2eiNXD1mb7jrs4FuJyIkz
pajlxQ1DNXdSljKfMJJszcYa4md8leEkepxmOTQqux7VOhlNXbydCckaA3Bz3afv
JddZdPIytOWo5irG4NVx+4z5ITMGYqb1nGOiw89fRTSpKLx6fITrESmSUVjtGnNU
vy590dtDfDmGqmDFwzteoz3d3YSHbKqvgxvoo5ce01rQrp5GxkGI6UZmuWG7FfuM
v3L6bRuX+GL3l835UimTL2RKgucqJ9BNalG2w8SrLu8Gk3tdhoeqLgSPI1m3LGis
xXNwXBC/LS3N0+0cdJqYZjERccSZSUm2SYkNmhrUwQ94ABzLUbLG3T+5TLlyP0Y+
8XvL7s56iay+o//V1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACPXh8nzG5cV5
ktcmO3ri5AAAAAAAAAAAAAAAAAAAAAAAAAAAAVHlP8ku+20i12+xQfsoW7QNSEmh
6j9AAAAAAjt4nJ8xunFfZLnJrt64uMGS8ratzUSMyDDzkZ+ai/IrSxF71SsczMl4
P3q1VXuLUuyv1qtqo/g00z9TdoX0VTvQsmrZL9Lq7+GiI7OdpUqC/i4WTsfLJFk2
uVy+rWTHJfuvl4cJJ97VSMmGGJpAo2+i9idsRFRGwuEhu92JQFbrExeVOQ1gy6w1
zk0o3A1NV7IR3UZZZVxiJD+RkiyFt6lYGZWHAYqKr8Fxaq+s1haWkzFvaNmxEwiu
bjhq9RlGzdr6pdXFfAgMXWqalVO49151Wq9sobJicYqtTDDBDTt1tDWr0BJZyYOc
xUwXnwMxxfGV0U690u1dKr6lVPwPvtlbSt2/lMY7F4JPUiKhdGSbLvgU6K17Vaun
WmHqUqGxcrFbaVXKxyJwq6cFw1lr5Ud1ce0CNm5VMVYnpJ1FN0a/CpWehpKtlmqj
dGKsVV7i4bgL2Z218w+FMwWsRE0KjcPkfLeTfrOWZmnysWBwjNOC5uJWViKTNW4q
jZqDCWEmdiujA23T4CwIbWO0qjURTPWVFdTHrubOSqY5mlyFP0e/GpWfhpKtlmrm
6MVYqr3FxXAXuzdqY72zcFrGNbjijVT5EHvjtDM29qjZGA13AI9EXXhrOZe9dXFs
HFgTUmi5qI1XYY6/XqLmnJd161C4NiK2M1vr0YrgZzs9bOr3VvdLwmLrVNSqncXV
cHVqpa6aWanVcjE0+tEK1vclIj7RNVGOVEiJpwXDWaHvosTEtZSmwoX0msRcPuQy
zY+8irXcqspLsXDOw0tVfkei8uPVbSxIc1PMculMMENXyll1tJQGS2GDlhaEXnMq
0mu1S6OYfDgNXWvqVUPqvDtFWbcy6RppirDTSiIimgbgaItSoTpd7VRXIqJj1Gfa
hR6hdROvithI/FyqmKYp3KdeFlI1Rzk/WzExVP2i/oNL1WkOt1Rka5qNiRIeOGGG
kyRSLQVS6SYfCgNXWvqVUPpvFtBWbcS7Y00xVhppRERTS+TDCdCpTUeitVF1LoLW
qH5N/wBle4wlWaZPJVXxpNjs5rlXHD3n02uvprVXhrT4zVw1Lg1UXuLmyWrsYtAh
umphMFfpTHWd7KWsQlblOHRPShoq4mVLuKPHtdOMgquLWOTR95/QWi05tOgshNTB
GtRPwPZU5FJ6G6G7U5qoYetlZCfu1qD5tkPParlVNGKaz6lykqp6pZif3LX9Bo+S
rkWv0F8eIzNiOhLi1EwKOyTJWJCqUZXsc1PS1oqc58OUdKRIlchq1jlTObpRFVNa
FmX9uitpEBEVEZmtzk9eorKxVmaBUIDXR2ROERPSwRcC/wC6q0dJl2+DSODF1YLo
VSu8sqXfGgwcxqu0+pMfWTK5WE6HQMHNVFzHaPXqM0U2TqMjPxJiSY5HNcq6j32z
vdrNsWeAx2rhjhoaqfI0Tk3XcxLKSTnxkwfETRzlEUiUi+U2crHYcLrwXDWWTllS
740KDmNV3PgmPrJhdXCc2zjkVqo7g3aPXqQp3JdlYkOrxFcxyJi7SqKnrUs3Kqst
GqEskaEmcjfUhV1x17FUlY7JBGLwehFxav6DUdv7N+Ukg+C9PSVmP34GB6hIx4E0
tOYq4Z+GBum5myfk5T4cNUweqYqTtdJknKSutmpabSpyqKrU06NZDpS/SuT7GyTG
uw0JqXHtwNEvpseWoT1mMXRHMxVPXqKqyT5aJCm4uexzdK60VPWaTt+1XSMdETFe
DXQZXyVJWJCqsVXsciYu1oqc5YuVbZaPPy6R4SZyN9SFZXN3nVOYclLVq8E5ubpa
pw7XWNn7t55ZxsPPzlxTRih9jspKqa0lmJ/ctf0GmLMV6LaCirHiszYjoa4tRMDP
2T9KxIdZiK5jkTOXSqKa8rSYwIn2HdxjG5eUiMtC5XMcicIulUXDWSfKms5NwZts
3CRXMTBfWqdhAn3q1Ovy/gSS7c3DDORiovcWBkg0yLIzUZsVitXBdaYEovXvnqVn
ai2VlmKsJXYKuGPyL4s9OunYDIj9DnNRVOiAAcy1Gyxt0/uUy5cj9GPvF7y+7Oeo
msvqP//W1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACPXh8nzG5cV5ktcmu3ri
5AAAAAAAAAAAAAAAAAAAAAAAAAAAAVHlP8ku+20it2+xQfsoW9QNSEmh6j9AAAAA
Ajt4nJ8xunFfZLnJrt64uMHxTtEgTy4xYbXL70RT5/JSU9jD+FD2y1npeVXOZCY1
edGoh0D55ynQ51MIrUcnvTE/UpIsk0zYbUanMiYHuPkn6RBqH5ZjX/aRFPTK2clp
RcYcJjV50aiHQVudoU50SzMtEXOWExV581MToQ4SQ0zWpgnMfBHs5LTC5z4TFXnV
qKex9EgPbmrDarebBMD6ZeVbLJmsRGpzJoQ+WcocCdXGLDa5edURTyyhwGNzEhtR
vNgmB7ZSnQ5NM2G1GovqRMD0soMCG/hEhsR/1sExPsiQ0iJg5MUX1HNdZaVcuKwY
eP2UPfJUSBIrjChtavOiIh+J2z0vPLnRYTHLzq1FU9klRoMj+Shtb1IiH2H5iQki
pg5MUX1HNdZWVcuKwYeP2UPfKUOBJ48HDa3HXgiIfmFQYEJ2e2GxHc+CYnvnKdDn
UzYrWuTmVEUSdPhySZsJqNTmRMD5pmzsvMrnPhMcvOrUU+qUp8OTTCG1Gp7kwPRG
oMCO7hHQ2q7nVExPtzEww9RzolmZaKuc6ExV581MT2xqHAjJg6G1UTViiH1QYKQU
zWoiInqTUfFNWfl5pc6JCY5edWop+/EkDNzODbm82CYHvlJJkombDajU5kTBD1Tl
HgzumKxrutEU+XyTlPYw/hQ6cKEkJM1qYInqQ+GZs9LzS50SExy86tRT9rRICtzO
Dbm82CYHvlZNkombDajU5kTBD3KmJ8bKNBYuckNuK+vBMT0vszLPXOWExV581MTo
QoSQkzWpgiepCtL/AK1KUSQe3BVV6KhT+STY9yRnzr00LjhoNWg+WcpcKd/Ksa7r
RFPj8k5T2MP4UOgySZDbwaNRG82Gg9EnRYMkudChtaq+tERFEzRIE07PiQ2ucnrV
EVTPGVTQpyYRr4KKsFuGhNRTNBvtj0OEkBssxcEwxVNPcde6mg1C1tSbNsYsOGjk
V2GKIbXj0iFNtRsZrX4In0kRe890CSZAbmMaiN5kTBD0w6LBhKqthtRV16EPQlmJ
VFzuCZjz5qYnSaxGpgmo+FtBgNfwiQ2Z/wBbBMe09s9SoU/oisa/rRFPZBkWQW8G
1qI3mRNB6JSiQJN2dDhta5fWiIin0zEs2ZTNeiOTmXSh8UvZ2WlnZzITGu50aiKe
q1VXSkS0SMqY5rV0GMrv6K62NcWZzVRqRMV0e83DDZwaIiepD9HqmJVsyma9EcnM
qYofDCsxKwlzmwmIvPmoffEl2xG5qoit5vUfPJ0eDJLjCY1qrzIiH1RIaREwcmKL
6j5JSiQJNc6HDa1V9aIiKfRMyrJlM16I5OZUxQ+SWs7Lyzs9kJjXc6NRFPfOUyFO
/lWNd1oinxeScp7GH8KHQhSbITcxrURvMiaD0S1EgSzs9kNrXc6IiKfa5udoU+GB
QoEu7hGQ2o7nRERT3zdPhziYRGo5PemJ8kGzUtB+jCYnU1D6JWlQpRVdDY1qrrVE
RD8TNEgTLs98Nrnc6oiqfYxiMTBNCHkAA5lqNljbp/cply5H6MfeL3l9Wc9RNpfU
f//X1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACPXh8nzG5cV5ktcmu3ri5AAA
AAAAAAAAAAAAAAAAAAAAAAAAAVHlP8ku+20i12+xwfsoW7QNSEmh6j9AAAAAAjt4
nJ8xunFfZLnJrt64uMAAAAAAAAAAAAAAAAAAAAAAAAAA+KqUWDVUzY7EenMqYnmm
0eDTG5sBjWJzImB9gAAB6JyRZOtzIjUc3mXShxFu7p66fB4fwnVptFg0xMIDGsT3
JgfaAAAAAeqalWzTVY9EVq60XUfBTbLS1MXOgQmsVfWiYHUAAAAAAAAAAAABzLUb
LG3T+5TLlyP0Y+8XvL6s56ibS+o//9DVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAI9eHyfMblxXmS1yY7euLkAAAAAAAAAAAAAAAAAAAAAAAAAAABUeU/yS77bSLX
b7FB+yhbtA1ISaHqP0AAAAACO3icnzG6cV9kucmu3ri4wAAAADlxLTy8OLwCvThP
q+s6iLiAADl1u08vRERZh6MxXBMToS0w2Zaj2Li1UxRT2AAAAA+Sp1WHTG58ZyNb
zqfmk1qFVm58ByObzofaAAAAAAAAAAD4arXINJRHR3I1F1Yn0Sk4ycaj4a4tX1nu
AABza3aOBQ2o+YejEVdan2Sc42dYkSGuLXJiinuAAAAAAAAAAAAAAAAAAABzLUbL
G3T+5TLlyP0Y+8XvL6s56ibS+o//0dUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AA59fpvjSBEgas9it7TO8rcfWrNI9klNZsJXKuCKc+asvaGX0eFr2nyLSbQp/PUv
aePFVoelL2jxVaHpS9o8VWh6UvaPFVoelL2jxVaHpS9o8VWh6UvaPFVoelL2jxVa
HpS9o8VWh6UvaPFVoelL2jxVaHpS9o8VWh6UvaPFVoelL2jxVaHpS9o8VWh6UvaP
FVoelL2jxVaHpS9o8VWh6UvaPFVoelL2jxVaHpS9o8VWh6UvaPFVoelL2jxVaHpS
9o8VWh6UvaeW0i0K/wA9S6E5ys67fLWaNFdBfMOxauB2LEW/rdr3KyHMqip78CaL
SbQp/PUvaePFVoelL2jxVaHpS9o8VWh6UvaPFVoelL2jxVaHpS9o8VWh6UvaPFVo
elL2jxVaHpS9o8VWh6UvaPFVoelL2jxVaHpS9o8VWh6UvaPFVoelL2jxVaHpS9o8
VWh6UvaPFVoelL2jxVaHpS9o8VWh6UvaPFVoelL2jxVaHpS9o8VWh6UvaPFVoelL
2jxVaHpS9o8VWh6UvaPFVoelL2jxVaHpS9p8VYsXWq+xIM3MK6FjjhiWfZSlLT4T
IP1URCzaEzBEJHDP0AAAAACO3icnzG6cV9kucmu3ri4wAVve7fDCsPDzUTPjO0I1
NaFT3F3pVC09UdDmnKkNcVRimoDlWntBDoMB0eKuCImjrMoUq9WqTdXRqxFSXe/0
U9WGJr+Ter2NVdaoh7TPVaZ/B5VxXWaCg/RTqQ/YABn3Kqh5zIP20LmsOmElA3Te
47gAAAAK2v5bnSC9anw5Obc2RX7Ra4AAAAAAAAAAKhyiW50CF9sml2qYSbOpO4lR
TF99VqknGhpTkcrVwzsC0LJRIsWVhrH/ACitTO6zrgGd75Iq2uqUOmMX0UVFXAvi
z9KSkwIcBP2jUQ6AAAAB8tUc5sJ6s+lmrh14FK3WVerzNQe2dR3AYrhjqL0AAAAA
AAAAAAAAAOZajZY26f3KZcuR+jH3i95fdnPUTWX1H//S1SAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAADwpz56CsRCMz1GV6nPWz6njyeUeTyjyeUeTyjyeUeTyjyeUe
TyjyeUeTyjyeUeTyjyeUeTyjyeUeTyjyeUeTyjyeUeTyjyeUeTyjyeUeTynshWeX
BfsqYgvXhcFPxU/OUsPJekfC5h6GmXWeU8eTyjyeUeTyjyeUeTyjyeUeTyjyeUeT
yjyeUeTyjyeUeTyjyeUeTyjyeUeTyjyeUeTyjyeUeTyjyeUeT6jyeUeTyjyeU8pZ
5T7JOh5iknp8pwaHTamB5AAAAABHbxOT5jdOK+yXOTXb1xcYAIjXbspOrxfCY7M5
6aUx1FJ2BYkO0r2tRERMURENNKuBRF69bW1U9DpMJcWKqZyoRK8Gz7LP1OUl4afR
zTTsh+Tb9lD3mXr0LRrQauqsarnu0Nw9Sn0VtLTUyEk7wv6l9LNx0ohb9094aWwl
eEX6bNDusiVrbR1S1EVYFKR0LMXBXLoRSH1CoWhsNFZGnoyRIGKZ2C4l8SFsYU3J
+Hp9DNxUoRLX1y8CcelLicHBaq4Kq4IQy9yrz8k6DI1L04iPT09aGs7FJmycBP4W
3uOy9cEM2Vy+WoQZ2JT4KKrnOVGKnqPmr87aSxqtmpmLnwcUVyIuOgvOyVvIVbkU
nl0NRuLvuKgqVu6pb+adCozuDhtXDOXUc6LbKt3bTLX1Z/Cy6qiYouKGiqDW2VuC
yYhfReiKh0Cjbyr1pidmEp1KVUjIuCuOUyBaOy8RkWai8LDVdKIuOBNL357xhS0i
YKiqmKovUevJ7iJCp7nLqRcV7CL2qvJn7XTSydFVW5q4Od6jnzMa0ViIjZmei8LL
tVM7BcS7qXbSHUpLw6Giq3NxwTX1FUVOZrtsYixKc5YELHRnLgcqgW0q1iJ1INYf
wkNy4IqLihYd9ttI1naek3KrguKL92GJWdn7UV28mEyPIP4FrcM7HRiX/ZWWmJaA
1s27OiomlT6q1V2UeC6PE+ixMVM/PtdWLw5h/il/BQmqulVwQkl39Zq1FmvBqoqx
EXQjk0oSO8a2EyxyScgx3DO1P9SFZ1ui2po8Pwl0dFai4q1F04Fs3UW+8q5f0vys
NMH9ZVFpL5Z+TnokhCRXK5yoxU9R8loJq0tks2bmIudBxxc1FxwQuuylt0tNT1m4
WhyMXtRCkqfe1VbSRn0+WxSKjlRH+o/Uzaqu3fTLH1OJwkBVTHBcUL8i2vYyTSea
1XNVqKiJr0lRTkG0Nq3LGkonAwl1I5cD0WHt9UrLznglZdn5y4NUkmUZMJAlIcXW
iOxw5yB2ama5a2AkSmO4GE1MMF0YkjuzvRnKZN+KquuMZV0OO7fbbqZs26Gkvh6W
GOJJ41uPE9LSfjpiuYirhzlQUyatBbpVm5COjIDl9FFXAsu7GhVinvVapFSI31YL
iTi0VRSnS8SK5cMGL3FHXIUV1opuJU4n7V6ohNL3700sy1JaBisw/wCjh6ivW0y1
DYaTqx0Vi6czHTh1FtWWtuqSSx5xFa5ielj6yqYlrqxeFMO8Uv4KC1V0quCHySd4
NXu5m2srLliwXrgippQu6014ECiSaTztLHNxb96FLU6ctDbnOmZKLwUHH0UVcMUJ
/dRaSeznS1SRVemp3qPltxaioVuKspS2uY5ut66iCVrylscrJiZjo+Ci+kiLjoLz
sva9topPwqF9VcetEK1u8vGm6vU3S0XDg0VdR5vqvUmrGTTGwfSY5E9FOdSMTyWm
qMHw+BFzYa+kjMdOHUWJclea+1UN0CY/Lw/pHEvNvUjzEfxdSseHxwV3qQjdQpFq
aCiTMSMj4bdL2ouK4esuW7m3UO18ukVmhzdDk95KwAAAAAAAAAADmWo2WNun9ymX
Lkfox94veX3Zz1E1l9R//9PVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAB+Xsx
PQ6VRT8rJIePAUPPgSDwJB4Eg8CQ8eAoefAkPHgKHnwJB4Eg8BQeBIPAkHgSDwJB
4Eg8CQeBIPAUHgSDwJB4Eg8CQeBIfpJRGovUp/O6+lubUoyfnL3lpZHUJIk1Ex5j
XzpJDx4Cg8CQeBIPAkHgSDwFB4Eg8CQeAoPAUHgSDwJB4Eg8CQeAoPAkHgSDwFDx
4Ch58CQeBIPAkHgSDwJB4Eg8CQeBIfpsqiHuYzA/YAAAAABHbxOT5jdOK+yXOTXb
1xcYKlvEhWgdF/gYqZnvwPZdvDrzYn8FFTM92BakZMUXqUzTYNi+U0XRzl8W6ri0
aViRWoqrmqiYdRmi7K9iVoMaLHnoMR0ZXLmrgvOcu8a+OXrlSgzbIbkaxUxRU0qa
bu6vDg2whZ0Frm5qJrJgZ7rcNr66uciLp9ZcNuETwCLo/nWvcVHktxUgQJl66keq
n4r16E/aiZdAoDUTMXB6qiayEXpJX4UJEqTm8H7sPkWXL5yWZXg/qH05MPBrILhh
n5y4r6zgZVD4WbBT0eEz0+0XTYjYoG6b3HZial6jPlhYTX1iKrmoq566V16ywr9k
RaZFx+qpXVgsfJmLhzKdzJXcxZB+GGfwi4850MphWeLfSwxz0wx1nYuMRUp8PHHU
hP5vHMdm68FwM23M5qVuZ4fDOxXNx6zSUdWInp4Ye/D5ld35qi09c3V7tRxrk+SY
v2XdylKXcsqzpqY8VK1Fz1xxwx1k5tHZm1doYLpaMrMx2vUWHYKnxLuaYvjBcWsT
FcNJBINt65bGI6LRka2WxXDHBCv7deNmzcJtVc1Vz00Jhzlw3+8jQv5B3ISq5CG1
lPh5qImhNRYJX9+aPWmRszm0nDyaVh+LkzcM/Fc7nLVesPHTm533YlRXoXrulI3i
+nNRZxdS4IQq0bbUtlnOmHNSHhp1HbyWM5WR8/S7HT2nosnCa+tRVc1FXOXX1lkX
2Ii0yNj9VSG3A6KJF/kfcei4WE3hoq5qZ2cun1nuypkRZNv2kJNZ+1MGy9EgzExp
YkNNBXklam0Vq3LHpma2WXHNxwTR95AqotR8ZwUqjkV+emrrLpv/AMPBIOOrFMfw
JrdisNZNnBYYYJq1aikbz5hsS0UFGfSRW6tZ3ModNEHHX6JZln6FCr1Lhy0dMWPh
oilRxLu69Y6I9lHcng+K5qKqdxMbrb3IlRirTp9MJpus+bKVtG6RlWQIS+k9+Con
MTC6KzSUORYnreiOUp28bFLRQeH+himvUaThqzMTDDNw0c2BXF+qotMi8Hhq05uH
yPiyaXMWltzcM7OXHDWcrKkzFlISLhncJo5yIXmNipRZfHHN9EvC6xYa0+DwWH0E
xw5ySLEhtxX0cU6sSjrYXqzVbmVk6E1OFYuD1VEIXeQ20cKXXw9zeCw06U+RalxH
JC9Tsewg103LL+tTsXwMR9Vgo5EVMG6FLlVqJKYImjg9X3FC5OqYVOcw53d5CZls
+tcjeLlRImcv0iez9NtbOw3QnqzNc1UXUSy4e7ydshDc2cVMXLiuBboAAAAAAAAA
ABzLUbLG3T+5TLlyP0Y+8XvL7s56iay+o//U1SAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAADw/UvUfzovs5TjfaXvLVyNdqi9XyNhgAAAAAAAAAAA
AAAAAAAAAEdvE5PmN04r7Jc5NdvXFxgAqu8irVyWerabDRzOfApumWLtLTJx1SZC
ThXa0NAXdzFQqcFfG0NqO5sEwJE+yUo9cVgw1/kKfoKevFudiVOpQY8tBakFqpnI
iIiKXVSqVDpzEbDY1mhMURMD7Snqnd7NR6ss41P1LEse1VNfPyj4LPpKzBOwrq4m
7yZszBmIU4mHCOXDqUhVQu5q9h5t8ejsz2xFVVx0nptLYau3hw/183g1Z9FE0Ipc
Ni7GOhUtJCaTBVarXFRNsXXLv472UlnCQFVVTFMT47VXK1S2TYc9NKqTKPRVZ6sD
R9mZN0lLQoT/AKTWIinSemKFPWTu9m6fUokzET9Tc5VQmF7FnotfkYkCAmL3JoON
dDYOLSaWsjOppdiip7lK1mbt6vd9NuiUVM+C5ccF1H1yth6xb6Yb45bwcFFxwTQh
f9JpbKVCbBhJg1qYIfWUPepdTNysy2oUdP1VVxch8LINpLTRGQ5xiQ4aKmKtTAsa
8GxsWoU9JWX9J6J6zxc7ZGNZ+TWBNJpVdXuIJa27CesxNeGUVFVXLi5q6j5nWota
v86G6/qoWm6iRrVU1YE+mbFe30kTnKWo1nbRWBc6BT4aPgYrhimJ6qzdNV7UxYc/
NJhFRyKrPVgWhe7YqZtFTIcrLpjEbm4p1ISG62z8WhSbIMfQ9ETEl58dYpLKtCdA
i6WuTBTO3kXXLBTT1pLOEgKq4IqYoSywFnatVprwmq4sT1NTQh8V691E14U2pUxM
Yyeo5ExLWltZD8DnIaQ4appciIikwuFu6mbGNiw5jUq+ivOeqzt3s3J1OJNPT9Tc
5VQmt6FBi12RiQICYvci4EauisRM2epb5SYTCI7OwTrQ9d0lhJmz0SI6YTBHOVUP
3f1YeZtXLNhSqYuRyKfbGu6dVqMynx9D0YnaVZQqfaWxaLLScJHwUX0cURT8Oueq
lUnIVRmPp5yK9vqQtS+KxEa1cqyXg69GcvNqK0kbMWgsE3wenN4SGqa104Kd27G6
eanJvxpV0wjouhp277LBTVp3Q1lkxRuGJJY0vO0amshyrc6Ya3DBSrvKe12C/qDf
hQkF112caWmHVapJmzC4qqEZnJ51ta7wCpnQWLo5tBomXgJAajE1IiIhWV891y2m
h+ES2iZZ9H3lfS8a1T4KSb4SIzVn4acOstuzlg86RWWnFVzoienj6inoFha3d5Mv
Skt4SXVVwRdKHSo13dUtxMpFraZkNq4o1NRcNqrCwa7KeBuTBqNwb7sE0FF0SlWl
sWr5eTho+Dj6KqmOCFi3W2SncXx6mqo937X1aSDWouxqdlZ509R25yvXFT569ZWv
3hQlhT7Uho1PRzUwxUtO6eyUez1OWVjp6fpdxFLvLtZyj1N01FT9TVVwOleNYGar
NQhTEFPQbhiWW6Tcsvwf7bMwKkuYu4m7NT0zHmEwZEVc3tP1eddRHbH8YUvFI+OK
p6lOEtprWomCQG6PzULZu2nahNwM6ptRsXHUiYEtAAAAAAAAAAAOZajZY26f3KZc
uR+jH3i95fdnPUTWX1H/1dUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAA8P1L1H86L7OU432l7y1cjXaovV8jYYAAAAAAAAAAAAAAAAAAAABHbxOT
5jdOK+yXOTXb1xcYAAAAAAAAAAAAAAAAAAAAAAAAAAAAAPnqMn4ZDdDxwzmqmJE7
E3YQbLvdFauc9yrpUmgAAAAAAAAAAAAAAAAAAAAOZajZY26f3KZcuR+jH3i95fdn
PUTWX1H/1tUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA8P1L
1H86L7OU432l7y1cjXaovV8jYYAAAAAAAAAAAAAAAAAAAABHbxOT5jdOK+yXOTXb
1xcYAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAOZajZY26f
3KZcuR+jH3i95fdnPUTWX1H/19UgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAA8P1L1H86L7OU432l7y1cjXaovV8jYYAAAAAAAAAAAAAAAAAAAABH
bxOT5jdOK+yXOTXb1xcYAAAAAAAABzahaSXpzkZGiNa5dSKp0IUVIqI5q4oupT9A
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAHMtRssbdP7lMuXI/Rj7xe8vu
znqJrL6j/9DVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAPD9
S9R/Oi+zlON9pe8tXI12qL1fI2GAAAAAAAAAAAAAAAAAAAAAR28Tk+Y3Tivslzk1
29cXGD8RoyQUznLgietTjLbmRR2Zw8PO5s5MTsQJhswmcxUVF9aaj4qjaSWpi4Ro
rGL+cqIfinWplam7NgxWPdzNVFU+6anGSiZ0RyNTnXQh8M5amVk0RYkVjUXVi5D2
yNfl59qvhRGuamtUXFEPlZbOTe7g0jw87mzkxOusRETOx0c58ceuQIDOEdEajU9e
KYHzyFrZSoOzIMZj3cyORVOscietdKSC5sWMxq8yuRFPfTLQS9Vx4CI1+GvNXE+m
bn4cphwjkbjqxXA+CctZKSbkZEjMa5dSK5MSq71rsltbMw5mHMIxqYaMdZbdClPA
oDIarjmsRMT45i28lLOVj48NHJrRXJifZTK/Aqn5CI1/2VxPfO1CHItzorkanOq4
IcqHbqRiLmtmIarzZyHca9HJimrnPiiVyBDRXLEaiJrXFNB8krbKTm3ZkOPDc5fU
jkxOyAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADmWo2WNun9ymXLkfox94ve
X3Zz1E1l9R//0dUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
8P1L1H86L7OU432l7y1cjXaovV8jYYAAAAAAAAAAAAAAAAAAAABHbxOT5jdOK+yX
OTXb1xcYKPv4t1HgRYdMllwWLgiqmvSfPJ5MctFl0iPfE8JVMccdGJL6XEmLA096
zK5yQ2rm+srCxNiH3vRHz0+9yQc5URGrgfJeFds+6Z7KjTHuzc5EVHLiTe9G0Tq9
QEmEVWvciKuHOQ25+6d9tpTPqj3q1E9DBSISVFnbI1N1Ok4jlgRHYLiunAnF49xE
Kzsv4wgRH8Mz0nadGOssO621cS0lHdFir6TWubj1IVFYay05bKYiS0aIvgmeuOnS
dO8m6Ft2rG1GnPfnNcmKKpcFmrSzFpqY2LLqiTCtTHHnIMty0nV3LFqsx+rLrRHo
3DtUhdNhsu1qbYUhF4SHEdgqY52gmeVNMxGycF0FytertGHPoPhu8uRS1MCHOVR7
1jJgqYLowPlvxlVpUaDCgvcjUVqaywLc1qZpFEbGlUV0RGN68MCrLvrtKXbOF4TO
RlbMO+m1Xo3BfvLru/u1lLHNV8q5zmqmtVxQqS11dmLyqktKhOVsFi+lho0HQtZk
xS0lLrGk3xEjQ252ldCqmk7Vwl4EevS8WXm1xfCRURfcmgrGk2bnLTVKLLNeqSyv
XO0+8616FzEKwMNtQknvzmKmOK6C8LqbRvtDT4UxE+kqaSXgAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAHMtRssbdP7lMuXI/Rj7xe8vqznqJtL6j/9LVIAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAPD9S9R/Oi+zlON9pe8tXI12
qL1fI2GAAAAAAAAAAAAAAAAAAAAAR28Tk+Y3Tivslzk129cXGDNt+cotJqsvOORV
hoqKq+ovaStdLx5ZJrPbmZuOtCI27rTLWU2P4Li7BqkRyYLVQYcq6SeubFa9VwVc
O89+UpaKFMSzZOGudFV6aG6e4+G2dMfTLOMbE0LghM7gn51PZ1IVhWIn8HWpj+3+
Zb19bsKZF+ypDbgEzqJFw/P7iP3I23gSU5ElIi5rlculdCEmylbRw2SCQWORznOT
Qioq/gemVrUaw9AZMwW4vVqaOYiNhrrIN4UPw+bmnNiP0q1Hau1UITP2dlrO1eFL
y8R0RUemKquPrLcynHZsrLfaT5FnXZuzpGF9lO4qHKHciTULraXXZxGPkoSRMM1Y
aY44YfiVZaPJ2p9ViPjsmFhq5VXBrkRvecu5e1kzBm4tJVc+FDxRr9f4kesnVWWT
tHF8Kxaj1VEVdCaS/wC2dqpemSkSI97cFY7DBUxXFCn8nGlRHpMzKoqMcrsMfXrP
fdHFxqMbBf2695KMpB2FMeffk/ckwfvLHAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAOZajZY26f3KZcuR+jH3i95fdnPUTWX1H//09UgAAAFfXy3kPsNLNiwm5z3
uzURecriBeZaaO1IjZRM1yYp6PqP1xjWn6InwjjGtP0RPhPPGNafoifCeOMa0/RE
+EcY1p+iJ8I4xrT9ET4RxjWn6InwjjGtP0RPhHGNafoifCOMa0/RE+EcY1p+iJ8I
4xrT9ET4RxjWn6InwjjGtP0RPhHGNafoifCOMa0/RE+EcY1p+iJ8I4xrT9ET4Rxj
Wn6InwjjGtP0RPhHGNafoifCOMa0/RE+EcY1p+iJ8I4xrT9ET4RxjWn6InwjjGtP
0RPhHGNafoifCeeMa0/RE+E8cY1p+iJ8I4xrT9ET4RxjWn6InwjjGtP0RPhHGNaf
oifCOMa0/RE+EcY1p+iJ8I4xrT9ET4RxjWn6InwjjGtP0RPhHGNafoifCOMa0/RE
+EcY1p+iJ8I4xrT9ET4RxjWn6InwnnjGtP0RPhPHGNafoifCOMa0/RE+EcY1p+iJ
8J8k5fhW7PRYaVCXRkOI5ExwwNCSc8kxDZE+s1F7UPqbExP2AAAAAAAAAAAAAAAA
AAeH6l6j+dF9nKcb7S95auRrtUXq+RsMAAAAAAAAAAAAAAAAAAAAAjt4nJ8xunFf
ZLnJrt64uMHBtnY+FaqA6XjImlNDsNKFQQMldIPopNxMzH6OnDvLisrZSFZ6Akux
MURNK8/WVvbLJxg1yYWagRVgOX1M0J+B9FiMn2DZ6N4RGirHcn19PeTe3ViYdrZZ
ZSIua1VTUfuxNjmWUgJLw1xRCOzVzcCYnUn1cuci44EptdZhlpJd0s9cGuTDE4Fn
bCQ7EU6LLQnK5M1y4r1FM2Gu+hWw4Rirwb89fTTWTSzeTRCpswkePHfGRP2rtX4l
s1Kz8KoQFlnNTg1TDD1IUxN5LbViOfBmnw2qv0UxwT8TtyWTnKy7ocRXqsSGqLne
tSV3h3Zwraw4cKK5USGuKYEhs9RG0WC2AxcUamBF7dXUwbXRGxYjlRWqn4H3WosJ
46k2yTYiw0amCOTWVYmS07DDw2J+P6S0LAXbQbHszWLnv9b11qfDeZdFL25aiP8A
1OIi/TRPSIJJ5LrWPasWae9rVT0Vxw7y6aZRIdNgpAhNRrUbhoTD1YYkXsvdbBs/
HdMMcqucuOB0rfWIh2wl1loiq1F9aHvsRZJllJZspDXFrfWp3gAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAADmWo2WNun9ymXLkfox94veX3Zz1E1l9R//1NUgAAAF
GZVGzy2+T5FxWc2aFumdyHRAAAAAAAAAAAAAAAAAAAAAAAKFyrnZsGWX+G/oJ1Z+
tZ8CCn8Lb3EvkZjhEOginkAAAAAAAAAAAAAAAAAHh+peo/nRfZynG+0veT7JWtfK
2bjxHzb0YipoVTT/AB4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpDRx4Unp
DRx4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpD
Rx4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpDR
x4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpDRx
4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpDRx4UnpDTiW
4vlpc3Ix2MmGq5YbkRPWqnxZLemmKvqWK5ULjAAAAAPnqMn4bDdDX9s1U7SHWDuy
bZR7ntfnZyqpOQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADmWo2W
Nun9ymXLkfox94veX3Zz1E1l9R//1dUgAAAFGZVGzy2+T5FxWc2aDumdyHRAAAAA
AAAAAAAAAAAAAAAAAAKCys9nl97+g6tl46rChfYTuLKozsUO6w8gAAAAAAAAAAAA
AAAAA8P1L1H86L7OU432l7yCYjEYjEYjEYjEYjEYjEYjEYjEYjEYjEYjEYjEYjEY
jEYjEYjEYjEYjEYjEYjEYjEYjEYm8MlTkdn2i4wAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAcy0+yxt0/uUy5cj9GPvF7y+rOeom0vqP/W1SAA
AAUXlUbPLb5PkXHZzZoO6Z3IdEAAA+edqEORTOiuRqc6rgh+5WabNNR8NUc1dSpq
PafJPVeDIYJFe1uOrFcD6mPR6YppRTyAAAAAD1zEy2WTOeqInOp65Oow51MYTkcn
uXE+gAAAAAAHqmZpsq3OeqNRPWuo/ElUIc83OhORzedFxQ+gAAoLK02eX3v6D77L
fkoX2G9xZ1E1Id9h5AAAAAAAAAAAAAAAAAB4fqXqP50X28pxvtL3k2yYrBylro8R
k43ORE0IaUXJwo3sPx/ePHm4Ub2H4/vDzcKN7D8f3h5uFG9j+P7w83Cjew/H94eb
hRvYfj+8PNwo3sPx/eHm4Ub2H4/vDzcKN7D8f3jz5uFG9h+P7x483Cjew/H94ebh
RvYfj+8PNwo3sPx/eHm4Ub2H4/vDzcKN7D8f3h5uFG9h+P7x583Cjew/H94ebhRv
Yfj+8ePNwo3sPx/eHm4Ub2H4/vDzcKN7D8f3h5uFG9h+P7x583Cjew/H948ebhRv
Yfj+8efNwo3sPx/ePHm4Ub2H4/vDzcKN7D8f3h5uFG9h+P7w83Cjew/H94ebhRvY
fj+8PNwo3sPx/eHm4Ub2H4/vDzcKN7D8f3h5uFG9h+P7w83Cjew/H94ebhRvYfj+
8efNwo3sPx/ePHm4Ub2H4/vDzcKN7D8f3h5uFG9j+P7x583Cjew/H948ebhRvYfj
+8PNwo3sfx/eONbXJ+pEjJR4jIODmw1VFx9aHtyWtFLVvqSIqIXGAD4qpW4FKTOj
vaxF9blwOfK26kZpc1keG5V9SOO6i52lAQ22N5cKzEZkCI1VV+GBK5GbSbYj01Km
J7wACO26tmyyMuszETFqepD9WGtgy1ss2bhpg13qUkAAAAAAAAAAAAAAAAAAAB+Y
r+DRV5kVSFWZvSg16YdLMaqOauGJNz8xYqQkznLgies+WSrMGdVUhPa5U14LifYA
AAAAAAAAAAAAAAAAAAAAcy1Gyxt0/uUy5cj9GPvF7y+7OeomsvqP/9fVIAAABReV
Rs8tvk+RcdnNmg7pnch0QCF3p2xdZuWVYS4RXYozrKwuMvdn65OPk6joVMc35Ggw
VBlMuc2nKrVVNKaiR3HOV1KgYriub6yeGdcqB7mxZbNcqemmpfeWDbu0UzQaVDjS
aK6JmN1aV+ih9FzVqJuvyixZ1qtei+vQfVK3sy0xN+Aoi8Jjh7juWzqESnSsSLAT
GI1uhCu7kLc1C0b4iTzFajccMUwLfAAABB741VJB+C4dREsmtznS0TOVV9L1lygA
AAAAAgd9aqlNi4KqeiuojeTC5XU30lVfTXWXAAAUFlabPL739B99lvyUL7De4s6i
ajvsPIAAAAAAAAAAAAAAAAAPD9S9R/Oi+zlON9pe8tXI12qL1fI2GAAAAAAAAAAA
AAAAAAAAAAR28Tk+Y3Tivslzk129cXGACqbX3WRrazCpOPVJZPooi6Sub2Lk5axk
Fk1JPe17Xet2suW6C0sSvSTHxfpIiJjzk3KKvxZnT0D7i1aPaCXloLGvisaqImhX
IincgTDZhM5io5F9aLih4mZtkqmdEcjU51XBD4GWolXrgkaGq/aT9J02uRyYpqPm
natCkfyr2s+0qJ3lXX+VSDP0yJwT2vw+qqL3H35O6YUmF1qWYel84xi5quRF5sUx
PjdaaWauasaHjzZyY950IcRIiYouKL6z1Tc/Dk0xiORqe9UTvPkgWllo65rIrFVf
UjkVe86QPxGjtgJnOVETnXQhz2WmlXrmpGhqvNnJj3nQWO1qZyqmHP6jxBmWx9LF
RepcT8TE/Dl8Ee5G46sVRD9RptkFEVzkRF1Kq4HzTNegSyoj4jGqurFyIe1KlCXB
M9unVpQ9PlBL53B8KzO5s5Mew+ianocqmdEcjU51VEQ+OFaeVirmtjQ1VfUjkx7z
pK5ETH1HzRKrChpnK9qInrxTA9UraCXm1zYcVjl5kciqc+29fSiSz4ucjXImjFcC
urnL132hfEbNxWJh9HFUQuGDGbGTOaqKnOmlD9n4jzDYCZz1RE510IfAy00rEXNS
NDVebOTHvOi1yOTFNR8M1X5eVXCJFY1eZXIh7JKrQZ78k9r/ALKovce+NMNg/SVE
61wPkma9LyuiJFY3rciH0Sc/DnUzoTkcnOiovcfqJNshLg5yIvMqnxxrSS0Bc10V
iLzK5EPtgTDZhM5ioqL60XFDxMzjJVM6I5GpzquCHwstRKvXBI0NV5s5P0n2zLs6
G5U+qvcUDdZEbL1CM9yo1ueuldCay9INopaO7NbFYruZHIq9567TU91RlokJq4K5
qoilX3M3aR7LR4kSNGSIjscExxwLdnJ+HJJnRXI1OdVRE/E+JlqZV+hI0Nf5En6T
psej0xTSh4iRUhJi5cE51PzBmWx9LFRepcT8TE/Dl1we5GqurFUQ9qxERMcdHOc1
1qZVq4LGh4/aT9J9spPw5xMYTkcnOiop4m6jDk0xiOa1PeqJ3nywLSS0wuayKxVX
1I5FXvOkAAAAAAAAAAAAAAADmWo2WNun9ymXLkfox94veX3Zz1E1l9R//9DVIAAA
BRmVRs8tvk+RcVnNmg7pnch0QCgbxozrXVOFLQ8VSE/SidZ+L1acli5uDOwm4I7N
RVQvKk1Rs3AbHRdCsRVX7tJRVsL46lVZ3wOitRyIuCqqYkKvbtnU5SUWVrDcHuVM
1U1fgXndPUWUiiwo0RcGtYqqVnxq1y1k09lJYiwmquCqiYfiQW9O2E1PxpeUqLcJ
hsRMebWaPtZaB1n6YyMxqOVIbdC6tRx7E2xm7TU6JGl2NbGTHBPUZ0lI9YSqZ0Nq
eEZ2jtNO2dqlSlZOJFqbW57W6ETDA5Nzl4cS08WKx7GsRuOGCYC9S951GekpIenM
quGGvAglVtpaigsbMzENFha3YImKIXHd5eNBtnLcNBX02t9JOZcCp52/6bWYiSMJ
mMbOVGaNB8c7eZaCysVj6ixEgKqYrgmovmlWthVCUSdb+TzcVwKorluq1aCIq0dn
6ki63J+k+CzF61Voc4kvW2o1jtCKiFj3uRkj05z26lTFPvQiuTXs0T7RcpUt+d7E
awCwnw0xY5fSI5S7b1+1MRkxIsRJV2GOKISS8S9t9CY2VgJnTioiK3XpIVNWmtXI
tSO+Giw9a4ImKIXDd3byHayBntX9UYmD05l9ZALwb4ph8wklSEz4uOC6NGJzaZbe
v0KOxKmxODcutET5FoWxvEgWdlfCHrpc30U9eJT8G2lpq2x0zKQ04LThiiYqhKro
r531iIshUkzJtF1akPlvdvujWGnmQM3GG5E9WnFT82ZtDaGsTDY2YiSjtKY4Y4Ho
vMvlnIcw2SpLc6Nqd69JEbf2zrNIk3srDEzHt9HNT9BPcnOfbT6O6O/6KKrl6jgz
t51ZtZGctFaiwWrguOBK7vpu0ESOiVJqJC9eGBbYBQWVps8vvf0H32W/JQvsJ3Fn
UTUh32HkAAAAAAAAAAAAAAAAAHh+peo/nRfZynG+0veWrka7VF6vkbDAAAAAAAAA
AAAAAAAAAAAAI7eJyfMbpxX2S5yY7euLjB6Is/Dg6HPanWqIIM9Dj6GPavUqL3EL
vPmKrBYnipqK714lH2wfVo2Y60CZssjv2v7xoK7eflJyUYsj+TREQlJnzKPiRWTE
Hwb8rowPRL5PC12U8Kmoz2zDm44Iug+vJ7tTGgTEWlRXK5IWOCrr0Eut/ZictNGW
BEekKV+tjgpXNs7hpShwPCZeadwjNOl6YL2KWVctbd9bknOja4SYY86IhUkWmx74
ak5jnuZAhOwXNU9V810sWxEorpB73wnfTzlxwLjye1xpUIsozPfNMzi1VIck5cXY
Iqe4+uv5OSJK+F8PE8IRucqY6MdfOSfJ7tzEqkvFhR1x4DRj1EOnZ2Zvgn3yrXKy
XhLgqt0aD927yf1sjC8Pp8aIr4XpKjl5iz7k7wX2vlEfH0RW6F+4sUoS+a20xUpt
tHlVwzsM5U1n4iZMjJeE2NBjRPCNCriujHtJnV5eZp9HfDmFwe1uCL6z47go74su
ue5XdZC8paaiQZmWRj1amempcPWdjKJnIstSoDoTlR/o4KnrXBDg3eXPRLcy8Obq
cV7XtwzUautDi35QpmgT8vAkHuxwamGPqLBsjcNDzmVGZixOHVEc5uPo4kQtNXY1
4k+tN4Tg4MJcFXHBVRD67S3BytAhLOSk07PhJnYK9MFw6lLBuvt261lNiPiKmexr
mqqdWspeyNnp62E3ElHRHJK564rjpPrvCu0W6t7J+UivciKmKOUsi2lCZb+ksnIr
nNdweOjUVLcvcvAtDEesSK9MxdGavvNV0Cito0FsBiqqN9a6zolAXwWzmK3OpR5Z
cEVfSVNZ+o+TK2UhNjQI0TwhMFVFXRj2lmUyFPSUjweCLHamDSun3IMtG5Y1TmVb
FXW1rkTD8SIUyAt1tSbCloyxYcR2GCriWRlCzkSHJMfBVWvVcUw+4hNi7l41uZfw
ipRXtfhg1GqfPdnPxrB1bxSr1fDcuhV0nayi5yZl5iD4G5UiKiaEPmh5PC1yU8Km
oz0mHNzsEXQfbk82qjQ48WlxlVyQscFXXoJVb2y85aeMsCK9IUr6nY4KV1bW4iUo
MHwmXmncIzTgr009ilm3M2wiWkkXcLpWGmbjzpgpSVPoc3aCoxZWCubAc9c5U16y
RW7uL8iYK1GTjPc+Hgqoq6CybB21famkOjRFwioxUUhVwc7Fjz0ZIj3OT0tCqcu9
SsRLQVXxZNudClsdDk0J2kkpGTdT2Oa+HMvcqYKiI5F+ZdVPkkkobYaaUamBG703
qynxVauC4ayK3BxnxZdc9yu6yFZSU3EgzcsjHq1M9McFw9ZKr67VzNAp0FZdFVHt
aj1TWiYIQ6yVxVPtHBbMumn579Lkzk0L96lzWJsTCsVAcyE9z24Y4u06ijqjUot6
s+6WiReCgQ3YLguC4Yn1WruUl7Hw/GElNKroWnNc5Fx7FLeultqtrJNsZ+GemhcC
agAAAAAAAAAAAAAAHMtRssbdP7lMuXI/Rj7xe8vuznqJrL6j/9HVIAAABReVRs8t
vk+RcdnNmg7pnch0Qc60NYbR4D479CMaqmUrN1arRahFqFNhcKx6rrTFDo3j1C0N
o4GEzLI1jPSVUQsK6W1LqnRoqL+UYxyYfccfJfl2RXTER+HCI9cOfWd7KdkYUWnq
96Ir0VMFXWceYjvh2WarPqklyb5WGymte1Ez1Vc5fWQfKfkoTI8vEaicIsRMV9es
n95vI7N23/RT48nXYX/a/SQOiPxr2v8Ab/Mvy3GxxfsqU5k5/lo/3nEu5hNnLSR+
GwdhnYYmirRQWxZeK16IreDdoXVqKAycF4KLNNZobi7Qmr1n13XSEKNVIz3tRXI9
cF5tJMMo6GjqY9VTSfm5mowqdQ2RZhf1NqLnY8xEYl7NTqMVzaHLNfLoq4Lmld3g
V+q1OZhJUoSQ/TTUmBoG8Dkdu7b3HCya9mifaLlM95UMNIsSVa5MUV2lPvLmsNLM
lpSG2Gma3NTQhmC3k/NS9fc6UZwkTHQik3j22tRGYsNZRMHNVPonuuWsnU7PsmIk
2zMWIjlwPgyeoDJqoTT4qJno5cMdes0RMyjJj8oiL1mdMpH0ZqVh6mZ6aPVrNB0G
XZAgQ2sREbmN1atRnW3EFstaSGsNERVVMcDzfNAbNVmXSImcno6FNCy7eAlkSGmG
EPQn3GfrjoTZurzTo+l6OXDHrLTvxkoUzTYqxURVRq4YkXyc5FtQpDoL/ouVyL1K
RiZsZV7t5h/iZixYLlVVRUxQl1319MWZi+B1ZiQphV0NwwLiRcQCgsrTZ5fe/oPv
st+ShfYTuLOompDvsPIAAAAAAAAAAAAAAAAAPD9S9R/Oi+zlON9pe8tXI12qL1fI
2GAAAAAAAAAAAAAAAAAAAAAR28Tk+Y3Tivslzk129cXGCrLfXH+VsThfCHw/cmJ+
7vrlfI+IsTwh8T3LiTOn21lp+M6WY/8AVG60XQR6+WoS0KQiJMYOxauamhdJEslu
TiS8k9XoqNV/o48xdZRV+Ls2el/uLfprsZVF/M+RQFynpV2Z/kR+rwLVx7aVJaOr
1gQ2r9JNBzbw7joNl5RZh8492jUq6F/ElmTnCSYpkdjdSo5EX7lONk6VRlNnZmXi
Lg5z1wx0eslWUxbOXpsg6A93pv1Imk7uTymFJhfeWWZ/tm/NrjcOdC5LRu/Wb92v
cUbk2wuHbOtbrVXHw3BVuHRKnNS8wuY97lwx0esuW920EGnU+Mj3Ji9io1PWpC8m
alRIEqsV6YNc5cMS6zMtsv2OWiZMxvyaqmn1GiJi0UGXgpMOciMVEXHFCMW0qzK/
TYrpdc5MCK5PlUhvhOhY+m3HFPWV/lG2ogT1Ql5aGuMRsRMebWS7KK9Gly/WzuQs
O6V2dIQvsp3FPX2uza3L/wAhNDSCZ8BvOrPkZCbYptYrMaFMRXQM5y4KmjHSWZFy
X4cVFa6diK1daY/vk6sddlBsLJxYcF6vRWO0r1ENuIiYzEVPz1PrypHYSCfaQ69C
/mHmYexInk1zjFiR24oi4rox06zQCLiFTEzJaB/kzaRsxG+gq6/UaJnLRQZSEkd7
kRioi44oRG3t5aUqQfOSiZ6pq0FRWMuydeUxZ+PNvY5+PoNXV92KEJqtmIVmqtCl
4cZYrkemOK4+svW/tcJOD1p3ITO7R+dJs6k7ij6q7G1EPrQk19zs2oS/3FvyLsZV
F/M+RQNxumtzX8iFvLUx7b1JaQr1gQ2r9JFwxObeNcfBstKLHfOPdo1KuhfxJvky
4LT4mGlNOC/cpGburXQKTVYkCKuDnPXDm1lm37V6HJ0yKmciq5MERFTEi1yEm+FR
XxHpgjkXA5GT+uM/G/kRad413MtbKHwcRUY/66YZxSVrbCRbpEbPy0y6L6SJmKvy
xU0FYO0D6/KQ5iImDnNRVQ+S9GCsWQio1MVwIRk+1SG+E6Fime3HFPWV7lE2ogT1
Rl5aGuMRr0x5tZonxZCqUo2FHRFasNE04cxS1cybocoj5iXm3MzcXI3HBujThrOz
chb6YtHBjSsZMeCa5qO58NBT1m7ANrlTjwY8Z0ByvXDDRjpLNmMl2FHTMfOxFaut
FX98tC7m7uFYqDwMFyuTnUl4AAAAAAAAAAAAAABzLUbLG3T+5TLlyP0Y+8XvL7s5
6iay+o//0tUgAAAFF5VGzy2+T5Fx2c2aDumdyHRBW9+EnNVOUWWlGq7P14H3XM2U
dZmnsgxEwfrcTGpynhkJ8Nf2zVTtQoe7uys9QKhFlVhr4LExxdho0nHn7OVO66df
Ep0JY8OIuK6MdZ8NuLM1i9GXWPGYsFWKmEPSmJcFlrEunqK2nzCZjlZgvuUqajTN
ZuxiPlZaXWPBxXBcFU51sbt6ta6JBqcVFR2eirC5tPMXdeFQo1QpbYMJuMRGNTD7
j5birOx6LKOhzLc1yu1FZ3jWOqNlqk2fp8NYqY4qmGJaNDrk7auRipNQeCiK3QnO
R24myM1RI0Z0yzNR2OHacW9i6+aos343pWLoquxcxD4Knb+v2lhpKLKrCR2hz8FL
Vuwu2bY6Wc1FzosRuLl96pqIldrZGap0/FixWYMVy4KSa/Wgxq3T3wpduc9fUc2x
FhosxQvAJhFZEc1UwKxsxO1m7JXSsvKrFhYrguCnzWospV7axoc/FhqzByYw8NRe
VtaLGnaWkGG3GJmNTD7jj3CWbmKHAe2ZbmqrtBahSeUHZCar0SXdLMzka70vdpLW
spKulZaGx6YORqYlVXs3ZxocdKpT8VjIulqes4jL5K/CajfAcVRMMcF0lm3ZWpnL
SQXLPweBdqwwwKptzYiesPPeHUpixUeuLm4H2Stq63bCOxkSAsvDRUxVEVCZ3r3S
paqUajXKkaEmLV51QrahXhWgs/B8EWUWIrdDXqikpuru1jz8x41qWKRsdDF9R8t6
li5up1iDMQWKsJuGKl4yMJWw2td9XBTPFs7Dz9hZ5ahTGLF4RcVbgfLaWWrN6kB8
KNCWXRiaETFM4n1zlGmrI0pzHsxitxwbzkZjXzV5jnIkjiiLo0KeqyVjJy3M+2qV
CGsFzNTdRoZjc1MDyCgsrTZ5fe/oPvst+ShfYb3FnUTUh32HkAAAAAAAAAAAAAAA
AAHh+peo/nRfZynG+0veWpka7VF6vkbEAAAAAAAAAAAAAAAAAAAAAI7eJyfMbpxX
2S5ya7euLjABUVu7h/H8dZmWjLAeutUx+RxKdk1xeEa6am3RWNXHNXHAu2lUuHTI
aQoTUa1E1IfWQe212TLUR4cdzs1WYaCWy1PSDCSF6kbgQSxlzzLNT0Sfa/OWJjo5
sT47yrjodrX8PBicDF9bk1/gRum5NkTS2bmnRmYYZq4liXbXcMsRCdBhuzmuXEil
4VwTLRxkmJWJ4O/1q3HT2HwU/JtZFgvhT0ZY7nfRcuK4dpZVg7INsnKtlWLnI31k
iIFWbqmVOeSfV+Cp6iYVGmJOwXQVXBFbhiQ27C6hlhXRXMfncKuK9pyrzLioVroj
Y8F3ARU1uboVewjtLybYjYrYk3NOjNav0VxwLup9PZT2JDhNRrUTQiH0EOvJu2hW
2gcE/Br/AFP9aFYSmTNMQ8GvnXOhov0dOBddCs7DpMBsu1EVqJgvvKhtFk3Pm5l8
zKTLoGeuODcU7j7pjJwgTbISxH50aG5FWJ61JdeFdky2MtDlXuzUh4aepET5Hfsp
Z1LPwGy7VxRqImJEba3PQ7TzsOec/NWHho6iwZWB4O1GcyYEBvJughWvwexeCip+
3TX+BAHZNc65MPD39ri1bGWKfQpNZSLFWKqoqZy69KYHx2GuwZZWI6I12dnKqnuv
Ou5bbmAkB7s3BccTr2cssyjyjJJfSa1ubp9ZUc/kzuSadNSsy6EjlxVqY/IuWzdJ
dSYDYL3Z6tT6S+s6ZCrzLsoVt4PBuwY9NT/WhWsnkzzDFa2JOufDav0dOBb6WLgL
KeBOaiszcF/SVBMZMkaFEc6WnHQ2KuhqY6DrSmTdChuhxnxVdFYqKrvWpPLd2Bba
uCyC52ajFTSdizdCSiQUgtXFETWQuZuaZHqbapn+k1fonRtrdiy08eHMOdmqzDQS
2DIJChcF6s3AglibnmWXnYs81+csTHRzYnw3k3GQ7WROHgxOBi+tyfvEdpuTZEXF
s3NOjMwwRq4/MsO7q7hli4L4EN2LXL2EUqeTxAnFiREfhFeqqj/WhwadkyxEitfN
TborGr9BccFLo8nocKWWVhJmszcEwInYG6Zlko747X5yvx0EctvcdNWimFmIc46G
i/tUxPgoWTjEl4yRJuadGYi/RXFU/EuuRkWSLEhw0waiYIh7I0FIyK1yYoutCjrQ
ZNr5qYfMSky6BnrqbincdCPk4wJpsJ0R+dGhuRVietSUXg3cxbTQGQIMdYOaiJim
Pq6iuUyaZtcEdPvVPWmnSW9Yiw8GykLg4aYuX6TvWpGLx7l4dq3JFgu4GKn7Zuhf
wIS7JsnXfz3v7XFx2Js4+z0u2XiRFiOT9sus7wAAAAAAAAAAAAAABzLUbLG3T+5T
LlyH0Y+8XvL6s36ibS+o/9PVIAAABReVRs8tvk+RcdnNmg7pnch0QAAAAAAAAAAA
AAAAAAAAAAACgsrTZ5fe/oPvst+ShfYTuLOompDvsPIAAAAAAAAAAAAAAAAAPD9S
9R/Oi+zlON9pe8tXI12qL1fI2GAAAAAAAAAAAAAAAAAAAAAR28Tk+Y3Tivslzk12
9cXGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADmWo2WNun
9ymXLkfox94veX3Zz1E1l9R//9TVIAAABReVRs8tvk+RcdnNmhbpnch0QAAAAAAA
AAAAAAAAAAAAAAACgsrTZ5fe/oPvsv8AkoX2E7izqJqQ77DyAAAAAAAAAAAAAAAA
ADw/Up/Oi+zlON9pe8tXI12qL1fI2GAAAAAAAAAAAAAAAAAAAAAR28Tk+Y3Tivsl
zk129cXGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADmWo2
WNun9ymXLkfox94veX3Zz1E1l9R//9XVIAAABRmVRs8tvk+RcVnNmg7pnch0QAAR
i21v4Nk2I6LpVV0NTWdujVNKpCZGamCPTFEU+wAEPtDeXAoky2UiIue7DAlsCMkZ
qOTUqYn7AAAAAAAAAAAAVcCCUe9yXqM26SwVr2rhiupSdgAAFBZWmzy+9/QffZf8
lC+w3uLOomo77DyAAAAAAAAAAAAAAAAADw/UvUfzovs5TjfaXvLVyNdqi9XyNhgA
AAAAAAAAAAAAAAAAAAAEdvE5PmN04r7Jc5NdvXFxgAgl4V7cvY5ERUWK/wBbW6VQ
iFIyoJSdiNhRIT4ecuCK7QncXLKTTZpqPYuKKmKKh7SqL1LdzNBmoMKAuDXYYll0
eYWZhNe7WqaT7AACB3y2ojWbkXx5dcHpqPZc3aaNaOnsmJhcXrjiTgAAAAAAAAAA
/MVc1FX3KVBYi8GaqdQiS8RfQa5UQuE+apTySEN0V2pqKqkLsRfBK2vjOl4CLnNx
x+4noB8VZqSU2C+M7U1qqVLdJbuetPPRuFX9bJjmlzgAAAAAEBvhtVHs5LNiS64O
V2B2bv6zEq8s2LF+kqISUhV4F6kvYlWpMY+lqwJLQK0ytwWzEP6LkxQ6AABDrwbz
pexCNdMY+lqwO5Zm0LLQQGzEL6LtR1SpL/rezVk4UN0quCuciKWHY+oPqMpCjRPp
OYir1nYAAAAI5eDV4lIk4kaF9NrVVCI3A22mLWyr4s0uLkfghaIAB88eow4C5r3I
i8yqiH0NdnaUAAAAAOZajZY26f3KZcuR+jH3i95fdnPUTWX1H//W1SAAAAUZlUbP
Lb5PkXFZzZoW6Z3IdEAAOXN0mdrUT/lJX4cBdMJqpinqNCy8u2XajGpgiJgiHqj1
OFAXB72ovvciH6l56HM/Qc13UqL3ELvZtu6y0vwkJzUfzKqYni6i3i2mlUix3tz8
dWKYlfXqszqvCXqLpkKtBhw2osRiLgmjOT9J02PSImKLinuPxGmGwExeqInvXA+d
lZgPXBIjFX7SfpPszvWel09Damcrm4c+KYHiXnocz+Tc13UqL3HvPD3oxMVXBD4/
HkD2rPib+k+qDHbHTFqoqc6LifiYnWS/03Nb1qid564NUhR1wY9qrzI5F+Z9L3oz
SuhDxDjJE+iqL1aT8xZlsL6TkTrVEPMSO2HpVUTrU9MapwoK4Oe1F97kQ93Dtwzs
Uw58dB8yVmAq4cIzHmzk/SfW1yP0ppQ9Eeow5fQ97W9aoneJeow5nQx7XL7lRe4+
hVwPjdWoDVwWIzH7SfpPfAm2TOljkcnuVF7jPt8sFLOVOXmITcEe5M5U6y/qbOJO
w2xG6lRFPpAABQWVpol5fe/oPtsvNQkhQsYjfoJ6/cWZRp+A1PyrO1DstqsH2jPi
T9J58awfaM+JP0jxrB9oz4k/SPGsH2jPiT9I8awfaM+JP0jxrB9oz4k/SPGsH2jP
iT9I8awfaM+JP0jxrB9oz4k/SPGsH2jPiT9I8awfaM+JP0jxrB9oz4k/SPGsH2jP
iT9I8awfaM+JP0jxrB9oz4k/SPGsH2jPiT9I8awfaM+JP0jxrB9oz4k/SPGsH2jP
iT9I8awfaM+JP0jxrB9oz4k/SPGsH2jPiT9I8awfaM+JP0jxrB9oz4k/SPGsH2jP
iT9I8awfaM+JP0jxrB9oz4k/SPGsH2jPiT9I8awfaM+JP0jxrB9oz4k/SPGsH2jP
iT9I8awfaM+JP0jxrB9oz4k/SPGsH2jPiT9I8awfaM+JP0jxrB9oz4k/SPGsH2jP
iT9J4dVISovpt1fWT9J/PG+p6PqUZUXFM5dXWWtka7VF6vkbDAAAAAAAAAAAAAAA
AAAAAAI7eJyfMbpxX2S5yY7euLjABE5S7aWgTT5xyZ73+pyYonaQbKEslLRZNIiN
axzV0KiIi/gdq4KcfMyCcIqrguCY8xZZRV+So2dgK5cETDSp9sTKOkKC1IL2vcrU
RFVE0FlWOtrL2sgpHl1xRfUus9dsbcwLKw+Ejrj7k1ldwsqanPejFZETFcMVTQW7
Taiyow2xYa4tciKhCLfX1yVi3pCj4uevqbpKzvMvjlLZU6IyCjmuT1O0Fg5PKYUq
F95ZZEq1edKUaMsvGdmvRMSEzmVBTpV/Bua/XhjhoLSoFfhV2E2PBXFrkxODbq8+
VsYiLMKqqvqTWQ6l5TtOn4rYOa9iuXBFcmCFuwI7ZhqOYqKipoVNJ+zj2ptVBs1C
WPHXBqer1laS2VBT470h5kRMVwxVNBa9NqrKhCbGYvoOTHEr21eUBI2dirBej3qn
1dKH2WBvukraRFgwM5r09TtBKLU2tg2ahpFjrg1VwIPaDKIp9HVPpPxTH0dJ3rv7
2JS26Ksuqoqep2s6Fp7fy1m3thzC4K7UvqIPW8pan0p6sVr3YetE0E8sZbiXtdBS
PLroX1LrFr7bQLLQ+Fjr9yayuGZU9OVyNVkRMVwxVNBbMhU2VSCkaEuLXNxTsM8W
atDCs9PR5iMuhrl0etdJNqflN06cjNg5r2q5cMVTBCzp6LCn5dzlXGG5i4qnMVnd
dJUmVm4iSH5XTnfMmdurx5axsPhI6qq/VbpUgkplRSEy5GpDiaV5i26ZUG1GG2K3
U5MUxK1v9tStOlfBmfSi6E5zqXJ2e8TyDM5MHu0qvrPTbS/OSspEWDEznuT1N0nv
sNfRJ2wfwUFHNdzO0EotNaiDZ2EsaMuhPV6yromVPToa4KyJhjhjhoLVs7aGFX4L
ZiCuLXJj7yO1G9ySp8R8KI7BzNac5EoeVBTnREhK16YrhiqaC1pWrw5qFw7FxZm4
/MhM7fjISrHPVyqrVwVqazkUDKSp9YjpLoj2OcuhXJghazY7XNzkVM3DHH1FaWrv
+kbORFgvRz1T6ulD67BX3SVs4iwYOc16ep2g5+UCmMoz7ZH6HfZJ2Pl2QYqOe7NT
6Okn1gL2ZS2yLwCq1yftXaFOLfFTqbMZjql6vokqoNQl6XItiwfyDW4p1Ebqd/dP
kYXC4q7TqTSp67GX/wAhamN4PDzmP/O0FlRY7YTVe5cERMcSqK5lJ0+lRFhK171a
ulWpihJLvr2pS3CL4Oqorf2rtCnNvip9OmWMWpfRTUSawaS7JRngn5LDQRG12UJI
WajrLPznvTXm6Sqb7ryZa2crCfAxauemh2hTQ136YSEDdNOjXa0yiwljxfot1kIr
9+0hR4bYqqr0d6m6VQ82FvzkbYRFhQsWOT1O0YkjtlbqXskxsSZXBrlwRSHVvKIk
KXEZDwc/PwwVulNJMZ63MvIyqTsRcGKmOC6yuYuVTToa4KyJhjhjhoLUs3aSDaGC
2YgORWuTHXpTrOBeBetKWHRFmVVVXUiayu7RX8SVqpONBho5i5i4K7Qmo9+S3ESF
T4r11I9V7yybOXhy1fiOhQVXOauCn0WytrAslB4eYxzfcfZZ20MOvwGzML6DkxTE
gtrr/wCRs1FWC9HPcmvN0nTsVfBKWsRywcWq1MVR2hTPt8N68OZn0WHnojHaffgX
ndrfFLWpRkCE16PRqIqqmjQhZIAAAAOZajZY26f3KZcuR+jH3i95fdnPUTWX1H//
19UgAAAFGZVGzy2+T5FxWc2aFumdyHRAAPnqMTgob3czXdxm+6WK2r1d8X1teveX
deTbVLISjphdLk1IUpZO6+YvNxn5yM+Gx+KtRpzZmVnLk51ma9Y0CK7D0tOgkV/t
iWV2WbUGxXJnNRc31HLuQuTZOwmzax3oqOT0U1d577+YseTnoTZRM6JgiH6ncnyN
Pyvhb5h7Y6tzs1FXBPcSTJ2ttFqKRJGOuKwdGK69BHbcWoj2/n1pkF/BQ2LgrkXB
TzX8nxKFD8Ll5xyvhJnKjnaFw+8n92dvnWrp0V0TQ+G1zVVPci6Si7v5WoWymo0g
6I5JdXri/FcUND3bXWNsSio2K+Jj9YnZS2UPbWPRUhy0PFIcbQ5yeoj9DydIFThN
jJOvXORF0L++W7RKOywkk5Fer0Y1VxXXqKRkJWavomXvV7oUux2GLT5rbXYzN1it
qUlGfEY1Uxa5S05m2TrTUR001c2IrNOHqU9Vws3EmJdViOVy+8hmUjUo0rMyyQ3q
1FemOC4es7GUNUo0lSoESC5Uiejhh61wQjdhLqZm8CBDm6hGfDc3DBG46Tr3pWrj
UVYdElFVXOREzv2x8zMm2I2Ckw2ZieEYIubiuHVrLEptYmLJ05z5tMXQm6F5ypLO
WVi3tRHzczHWFDxXBGrh80P3U7NRLnI7JqDMLFhvdgrXLp7MSxr3LwI1KpjJqWTH
hUTHD1YoV5ZC5CDa2Ck26cej36Vai6l7S5ru7vW2OhqxsV0TH1uIZlFS+bCZFwxz
fX95NLpqh4fT4b/cTAAAGe8shcJCH9sx+y0ExDTBIjkw96ntbaqabqjP+JT9+V83
7aJ8Sjyvm/bRPiUeV837aJ8Sjyvm/bRPiUeV837aJ8Sjyvm/bRPiUeV837aJ8Sjy
vm/bRPiUeV837aJ8Sjyvm/bRPiU8eV037aJ8Snnyvm/bRPiUeV837aJ8Sjyvm/bR
PiUeV837aJ8Sjyvm/bRPiUeV837aJ8Sjyvm/bRPiUeV837aJ8Sjyvm/bRPiU8eV0
37aJ8Snnyvm/bRPiUeV837aJ8Sjyvm/bRPiU8eV837aJ8Snnyvm/bRPiUeV837aJ
8Sjyvm/bRPiUeV837aJ8Sjyvm/bRPiUeV837aJ8Sjyvm/bRPiUeV837aJ8Sjyvm/
bRPiUeV837aJ8Sjyvm/bRPiUeV837aJ8Sjyvm/bRPiU5kxMumVznqqrzqaMyNdqi
9XyNhgAAAAAAAAAAAAAAAAAAAAEdvE5PmN04r7Jc5MdvXFxggVrr6pGyr+DmFcjv
cmJ+rHXyyNrX8HLK5V96YE3mJhsu1XvXBqJiqmb7xa7FvNnW0+TxWEx3pOTV7y/b
K2eZQJdkBiampj1nXM+5RlM8bTMGBjm44aUJ9QLrpKXkEhPhteqs0vVMV7SsLg4z
qfVpiUYv6k3OwT1E/vDkKdRI3h1RermquiHrTsK9t1efQKnLLDgwkR+HoqjETD7y
VZPtce+nRojlVWtRVb9yKQ+6GzzLc1CNNTaI9Ib1wR2lNZIspO7aXjSSzEJEhqz1
NTDHsJfk9OzqTC+8sszPe7Zltoqw2E52amKaU9ZadoLspJtPWHwTMWw8c7BM7HDX
iQDJrq74UKaYqqrYauzU6jkXW0pLfVOPFnVz0hOXBq6U1llXwXaSc7IxIrIbYcSG
zFrmoiLo6jlZNFdizcmsGKquzVXBV1lzGabxpl1q64yQVypCxTR6i6Jq6+SmJdJf
gmJgiekjUx68T3StiWSUq6Ua9UYqa+YrBLYUCx71lo6cLERVxcrUeVtaC2clPVGF
EpTeDxemOCZvrLjv/Z4TTYbV/bYafuQ/Ny91srJSedFa2K56a3Jjh2ldRJNLL2jh
wZb0Yb3Ji1NCayS5SVKSrRoEFVzccNP3k6sxdbJS0gkF8Nr1VmlzkxUq64yI6m1m
PKMX9STOwT1Fi3jU6n0eL4fUHqrfZ607CvLbXoWfqUssODCRH4eiqMRMPvJVk1VR
87KRc5VVqL6OPqTSQWz1h2WkrER8Vy5rX6W+pdJaV7t3cm6nxXw4TGPY3FrkTBTi
XE1iJO0mJCiKrs1HIiqR64qGjanGw/OPzfFRY9FqaVKO3hJPFMW60JXZO8qgV2I2
DChMbEXDWxEwXrLhgNbDaiMwzUTRhqM4WmqLrdVlkFulsB+lOpS6LxKn4ip8V8PQ
rWYJh6tBVOT3Y+HXYbqhNIkVznKiZyY95Z0a62VSYSahIkNyepqYIcy8miycuqTk
/EXg2ftOf7ivLQ3qWdnJZ0JkJMcNHoIi9p9eTFV1nVjNaq8En0U5tJGq3Y1lpa45
HuzUa7SnPpLOvWu8k2U9zmQmNdDZociIi6EORk8VN85SovCLjmq5Ex6lIVddd7Br
dSiR4y4tR6+h6l0kkyjLHy1MlkmpeG2HEaqYK1MCe3fwltBR4bYrlRXMwV3rIR5X
0Cx8RZaOnCxEVcXK1Hlb2htpIz1RhRKU3g8Xpjgmb6y5L+sZimw2rrdhp+5D13L3
XysnKI+M1IrnetyY4dpALfUttjq5AdJ+g1yoqtTQhJ8oxyTEGE9U14EspvoUH+5S
ld3B3awJqI+ajfqmlcGLpRD5soOzsGzkeBMSjUhuc9Mc1MCR332sjSFKl0hqqLEa
1HL69SEququ2lJSSZEiQ2xHxWI5yuRFXT1lUXn2dbYirwIskvBteqKrU0JrJnlCR
PC5OE9U1oh1qHU1pFn1it0KkNcCJ5PNioNda+ozLUiPVyp6SY95w8pu76DT3QpuD
gz009BuhDQNgHZ0jAX+FtOde4v8AA6L1FYXAXZwFY6Yj4RcccGu0onac3KCsxCs3
Hl5qTRITlemKN0Y6T68oaOtXpUsr9CuzcV+5NJMbl7t5WnyLFiMbFcqIuc5MVTtK
8vCjutJW4VNcubAxT0U1F2TN18hGl/BlgswzcMc1MevEpK5KdfZupTEojldCRXIi
epD1UamJb+uxGTHpMhqqo1dKaCxb67spWfp71hsbCVjV0tTBV0atBwsmVuZSYzOZ
XJ+CnpuQhok5Gw+up28p1mdTl60Pgla26iWYbEhrg7MwRUPGT/YaDPS3h8y1sV8R
V+kmd3k/hXWy0vMeEwkzMdbWpghTF91GgQp+GiQ2pi5MdGsv2y9Al5KDDdChtauY
3SiIi6jugAAAA5lqNljbp/cply5H6MfeL3l92c9RNZfUf//Q1SAAAAUXlUbPLb5P
kXHZzZoW6Z3IdEAA+aqQ+EhPTnY7uM23KyiUuqxWLrc9e8n+UvJOj01zmpiiLpOj
cDX4NQpkKHDdi5jcHJ60IJlLVNk/FlpaEudER+lE0+skF6Uu6So0Nr00oxMew62T
1HbEp6YL+2Ineo7Nq8L7i5pl361Vf4X8ihsm/wBKoTnW7vIPN2QdV63GhujLLqrl
wVNGJY8XJmjxmq1Z96tVNOsmliLqmWAk40NkRX50N2Kr1Ff5N8TGZj7xe80YDiWs
stBtHBdBjIi4poVdae8oquXBTFl4bpuBOOwh4uzMVRNHqJJY63Ua3dJj57fTYxW4
8+CHHyWK3CgMjyrlwi8Iq5q6CYZRFZhy1OfBV3pvVME9ZwbH0uJL2ednJgqtxRPW
dLJ8n2RILoaL6SY4oV/lHWjgTc/Ly7FxiNiJin3kryidFMlutnchYl0z1dIQ8fqp
3FMXmM8S1+DMxfyeKafUaK8dwkgpMK5EhqmOJCryqpDrtMjLLrn+iuooO6O6d9p4
TsybdCcirixFUnkfJafOubw8456NXFEXEuORshCgSiScXB7EbhpKerGTZEl1fGlZ
t0NNLkYiqic+B2LiryI9Ye+QjpisFc3P58D95SNTSXl2w1/bEtuXluApsJEJyAAD
P+V7C8IlIMP60TDuKwo+TTCnmMcsX6TUUlkjkcQJhMVjKfb5lkv7dfxHmWS3t1/E
eZZLe3X8R5lkt7dfxHmWS3t1/EeZZLe3X8R5lkt7dfxHmWS3t1/EeZZLe3X8R5lk
t7dfxHmWS3t1/EeZZLe3X8R5lkt7dfxHmWS/t1/EeZZLe3X8R5lkt7dfxHmWS3t1
/EeZZLe3X8R5lkt7dfxHmWS3t1/EeZZLe3X8R5lkt7dfxHmWS3t1/EeZZLe3X8R5
lkt7dfxHmWS3t1/EeZZLe3X8R5lkt7dfxHmWS3t1/EeZZLe3X8R5lkt7dfxHmWS3
t1/EeZZLe3X8R5lkt7dfxHmWS3t1/EeZZLe3X8R5lkt7dfxHmWyyY4x3aveZkt9Z
ptm5t8s1cUaqpiXdka7VF6vkbDAAAAAAAAAAAAAAAAAAAAAI7eJyfMbpxX2S5ya7
euLjBw6tYeSq7s6PBY9edUPNJsVJ0dc6XgsYvOiGfr/L7lSP4shKrWquD3JoO9dr
buhWJgI1IuMVUxc7DFeouCyttpa1LOElXZzerA7xRF+b8J6X0L6i36Yv60T7HyKB
uSfjXZrQv7Y5dvJhabWnPquLpTHQi6UOjeDamiTkoraZBY+NhqRuCohJMmmEs1T4
zHJgq4ph1opD7C2k4rqhGZPorIcRy4Lh7z7b9b3EtJKOhUtFiw/27sNRZ2T0mFJh
feWUZ8ts/CutTBdaFzWkXCSfu/kUjkxwvCvDGLoxVydqnBs3W4l0VUipOtVIEZy4
Ow9WJN7xb8pSsS7pOnu4WJFTN1asSSXEWGiWalMY6YRHrjh1lnGcb4aRFsnU2Vdj
cYSKmKoTKLlH090u18J+dGVE9DD1nvtfVpy0NIfGgtVj1TFMNeBVl1lpaLIQlZV2
osyirnK9uJG7XVOXnalCdIwUbL56YORMMdJd9+zsKfB629yErupXGSZ1IUnax/7J
4OhfpISq/t+E3L6F9XeW5Rl/WjfsfIz/AHOvxtDM6F/bHPvHjup1aWJVMXSeOhF0
odK3dqaHNyispkFj42GhEbgqEgyW3K6UjZyK1cdXMQSStlGsvVokRGKsDPXPdhq0
k1vQvykq7JulJJyvjREwRMDuXN2Ti2fpD1jpg9zXLgRG4p+dU42hf2xZ1tbz6TT3
LKT7kVfW1UxQpu8usUasQUZRmok1nJgrEzVLYo1Yi2WoqRZxf1RGevXpQjGT9ZXO
ixqk7TwqqqFq26oS1yTiwE+k5q4dZQt0940O7qI+m1FVhojlVFwLHpl9cO0E0kvI
JwjfW7ArS+10aUqUOLN4rJ6M5P2p99etbZ+Yk1ZJQmOjq30W5unE/WSs9XPj5zcx
fq/ee2nP/g7E0L9L5lqXsrhTo32F7iusmx2NKj9bu5T1XHvxm4uhfpqdfKedhT/v
Q9MpCjxrNNSVxSJmaMNZAbrbS0anw1ZV2osyirnK9uJHLX1OXnalCdIwUbAz0wci
YY6S7r91VtMhq1MXIjcE+5COXW34waLL8DVMYT0T0dGtCMzc0686tQ5iURVgMVMX
YcxMco9OAhQmoiqiYEqp7v4A4/wpTjZPT86G/R61I7lTPzVl9H87E7zs3uWMjWjo
8B0smc+GxrsPdhifPdnlAScnKtlp93BRYTc3DDXgRuqzUS9mpwosq1eAhKmLsPVi
S3KJhJKSsNiYqiYJ2HZszS1rFAWC1MXOhrgnvK5udvIg3fI+RqSrDVHKqaDhX+3j
vtXwaSjFdKo9PTwNL2ATCRgbtpz72kxp0XqKWubvbSzbXQqinBwtOa7A+S8217bz
ZyBBpuMRrHJnLh7yUZSEv4DT5aHhqVqaPuLOusXGRhfZTuKXvhpExZGqw6uxiugo
qYrrwJ1Gyk6astwjH4xVb9DD1kbuRsbGqU1Gqcw1WsiKqt9+JHYs8+7WtRJmZarY
ERVwdgSW9O+2FW5J8GlYxnq1c7RqQ+nJdhOjUuK1yYOc5cU96opG6Fapt21SfCns
WMe5VzsD0ZQN5/lNKoynIsWDime5E1E8odmltFZxkuxMXKzFE95E7or2IFimuptR
VYaw1XBVQsKzt8TbTzXASTc+Gi6XYYFd5RkN9LmYc25F4NFTFULXu9vRkbSQ4cKX
fi/MRFTD3E6AAAABzLUbLG3T+5TLlyP0Y+8XvL7s56iay+o//9HVIAAABRmVRs8t
vk+RcVnNmg7pnch0QADw9meipzoZym5FbO2iZ6mOXHH1GhJ+nw6nDWHFRHMcmlF1
FFT+ThMysd8WnzSwGOVfRRV0Eku8uN8RRVmJ2J4RE9SriuC/eWJaizcO0EB0vETQ
5FRPcU3ZbJ6nbORs+DNqkLOxzNPYTi011XjuZhzTn4KxEx95OIshnweB/NwIBdpd
D5GTEaYz87hVXRzHsvLugh2swiQVSFGT9umhSAuuBqyph4wd7tKlp2JsbHo0m6Vm
YqxXuRUzl96YHGu0ugSxkWJFz87PcqllAri9C7uctSqeCzCwcOZV+RA25PlTiqiR
Z5XM/bNxXShclkbHQbNwOAhomCp6XvKztzk9rU5nwunxfB3LrwxTT9x6LOZPsdkw
2PUZhY7UX6K4r3l0tpsNsPgUamZhhm+rAo6u5O8ysy+YkJpYKPX6KYofZN5NzJ5s
KJFiZ0xDciufzkyvIuxS2MrDlVfm8Hhp6kRPkSKyFnfJ+XbL445qImJybybuoVs4
CwnYNiftX+tCqZbJ0qLESE6dVYSftcVLosxZKHRZZJbBHJhg73lYWpyf4seO6PTo
/g+culExTuPgkbiKrAiNe6fcqIqKqYrpLEt3YmZr0s2BLx1hPRERXadJWPm/VVyI
iz7sPXpUta727qFZGHgnpRF+k7nKrygP4MT0tLM0pnJndpednqS2kwGQW6mtQ6IA
AKCytNnl97+g++y35KF9hvcWdRNSHfYeQAAAAAAAAAAAAAAAAAeH6l6j+dF9nKcb
7S95auRrtUXq+RsMAAAAAAAAAAAAAAAAAAAAAjt4nJ8xunFfZLnJrt64uMAKmJFK
pdbTqo9YsaA1z11qp8C3IUlf552kjs9ZOWs83MlWIxvMh1zm1KzkCpOR8ViOcmpV
PvZARjc1E0Yajl06yctToqx4UNGxHa3JrU9dobGSlokwmoaP6zl0u6am0t2dCgNR
VJBSaDBpCKkBiMRVxXA51pLBSdpFRZqE16pqxPVSbuJCksdCgwWtY7WnOdqmUqHS
2JDgtRrU1Ih9ZzJizMvMROHcxFifW9Z98WXbGarHJi1UwwOfRbLy9FVyy7EZnLpw
9Z6bR2MlbRoiTUNH4asTlUu6Wm0t6RIMBrXJqUl6JgD4qxRYVYhrCjtR7F1opFpe
5ilS7s9su1FQmEKTZDZwaImaiYYerAiVQuepc+9YkSXarl1qdCXu8kZdrWNgtRG6
vcdWpUSDUmJDjNRzU1Ip75KRZJNzIaYNT1HOj2RlY8ZJl0NFipqd6z31OzsCpuR8
ZiOVupVPuhwEhtzUTRhqOXIWSlpCKsxCho2I7W5Nan5tDY6VtEmbNQ0envOTS7pK
bTHZ8KA1FO/SbPwKSipAYjUdrwPlj2MlI6Oa6E1Uf9L3nGkbnqXIvSLDl2o5FxRS
YPgI9uYqaMMMDm02y0tTHrEgw0a5daocmuXW0+uROFmILXv51PXSrpabSoiRYMBr
XpqUiN+VMmq2jJKAxVhuwzlTUhO7AWcSz0nDl/W1NJIiMV+7SQr7+EmYLXu511nv
s9YGTs8udKwkYvOh9ldsxL15uZMsR7fecCn3P0ynvSJDgNRyeskNLs3ApTldBYjV
drwPyyzEuyIsdGJwi/tvWfbPSDJ5iw4iYtXWh8lIs5ApDFhQGIxi60QU6zcCnOV8
JiNVdaofusUKDWWcHMMR7eZT2yVLhyUNIMNqIxEwRvqItULnqXUHrEiS7VcutToS
93kjLtaxsFqI3V7jrz9GhT7UZFajmpqRTg1i66n1hUdHgNcqajo2csfK2carZWGj
EXmPoq9nYFXwSOxH4asT3NpMJsLgEanB4YZvqPXS6FBpSYQWI1F5j1Vqy8vWsPCG
I/BcUxOhClmwmoxEwaiYYe4iE9c7S556xIku1XKuKqd2z9lZazzVZKsRiL6kPdVq
BBq6ZsdiOROc+iQp7JBiQ4SZrU1IhHq9dhT68/hZmC1719Z9Etd/JS8HwdsFvBou
OB3ZaWbKtRjEwaiYIhEL3lzadFX3IQW6aykraiURJqGkTDViWXZy76Ss45XSsJrF
X1odGtWegVpEbMMR6IuKIp9UnJMkmoyGmDU1IeqrUiFVoawo7UcxdaKROHcrSoa5
yS7cSZScm2TYkOGmDUTBEObaOyEraNqMmoaPRNWJz6JdnT6JnLLwWtzkwU7NIoUG
kNVsBiMRVxVEObaOwElaNUdNQmvVPWp+Kbd1I06EsCFBakN2tDuU+nsp7EhwkzWp
qRCN1q6ynVp6xY8BrnrrX1nQs9YmUs7ssNGY8x9Vds5ArzOCmWI9vMpzbP3dSNn3
Z8tCRjudCSAAAAA5lqNljbp/cply5H6MfeL3l92c9RNZfUf/0tUgAAAFF5VGzy2+
T5Fx2c2aDumdyHRAABAbyrtfKjNiwXZkZqpg4l1AkXyMBkKIuc5rURV5zoAAAAAA
AAAAAAAAAKVTSroYqVB09MxM9udi1vMWsmgAAAoLK02eX3v6D77LfkoX2E7izqJq
Q77DyAAAAAAAAAAAAAAAAADw/UvUfzovs5TjfaXvLVyNdqi9XyNhgAAAAAAAAAAA
AAAAAAAAAEdvE5PmN04r7Jc5NdvXFxgAAAAAAAAAAAAAAAAAAAAADAAAAAAAAAAA
AAAAA+Wp0yHU2LCipi1daHoo1n4NGbmQG5qHRAAAAAAAAAAAABzLUbLG3T+5TLly
P0Y+8XvL6s56ibS+o//T1SAAAAUZlUbPLb5PkXFZzZoO6Z3IdEAAAAAAAAAAAAAA
AAAAAAAAAoLK02eX3v6D77LfkoX2G9xZ1E1Id9h5AAAAAAAAAAAAAAAAAB4fqXqP
50X2cpxvtL3lq5Gu1Rer5GwwAAAAAAAAAAAAAAAAAAAACO3icnzG6cV9kucmu3ri
4wAAAAAAAemanWSqYxHI1PeuB+oEw2YTOYqKnOmk9h885UIcmmMRyNT3rge6FGSM
iOauKLqVD9AAAAA+eLUYcJ2Y5yI7mx0n0IuIAAAAAAAAAAAAPlj1WFAcjHvajl1I
q6T6gAAAAAAAAAAAAAAAAAAAAADmWo2WNun9ymXLkfox94veX1Zv1E2l9R//1NUg
AAAFF5VGzy2+T5Fx2c2aFumdyHRAAAAAAAAAAB8NXrUKksWJGcjURMdK4Fe0DKFp
9cmfBIKqr8cMfUWe12cmJ5AAAAAAAAAABQWVps8vvf0H32W/JQvsN7izqJqQ77Dy
AAAAAAAAAAAAAAAAADw/UvUfzovt5TjfaXvLVyNdqi9XyNhgAAAAAAAAAAAAAAAA
AAAAEdvE5PmN04r7Jc5NdvXFxgAz7e3elU6ZOJKSGGKrgh4gQrWuVqqrc1cFXUXX
ZRJlIKeGflfWdgAAAAqHKLiOZKtzXKnUSG5N6vp0NXKqrzqT0o7KlivhyjFY5W+m
mosi7Byup0uqrivBppJSAAD5apUW02G6K/6LUxUj9j7xZe1TnNgY4s14kqBQV5EZ
7azDRHKiaNHqL2kPybfsoe8AAAAAAAAAAAAzRfDHeyuSyI5UTOTRjo1mlIP0U6kP
2AAAAAAAAAAAAAAAAAAAAADmWo2WNun9ymXLkfox94veX1Zz1E2l9R//1dUgAAAF
GZVGzy2+T5FxWc2aDumdyHRAAAAAAAAAABQ97t2k/bCM/wBNWS7UVdClG3VURtFr
PAIuODsMTc8D6KdSH7AAAAAAAAAABQWVps8vvf0H32X/ACUL7De4s6iakO+w8gAA
AAAAAAAAAAAAAAA8P1L1H86L7OU432l7y1cjXaovV8jYYAAAAAAAAAAAAAAAAAAA
ABHbxOT5jdOK+yXOTXb1xcYAMsXw1tKHVWxojXK1HYqqIWfR8o+mTishIrkcqIml
MExLUl5hsw1HtXFFTFFPYQi8y8mFZCFrxjO+i0qplv7SxGeFJBTgNepMcC3rFW3S
rSvDx/Qc1PTx0FZV29+o12ZdAojEe1q61TQfFSL6qnZybSDXIeZDcuCORC1reW1W
kSPhsv6WOCp1Ke67m1MS0cukaImCqQi8S9yYs7UoMlDaisiORFU/eUSudKMU71zU
wktS2vdoREVV7Cuq/fPVK1OrLUaGj2poxVMSCXw25nosFkpVWZsZXphgmg01di3N
p0BP4WhKCh7VX+xqJORJLMxdjgzR6zh1S9G0VDzY8zBRICriq4eovKxls4VpJVJp
i6MPS92jSVda++ScqEz4JRW8I5NCrhimJxId8NZspMMSswkbAVUxciE3vWtHNVKn
8PTER8J7dK+vAoq56qVqWjP8Bho5VX08UNb2YjR40BqzSYRf2yHVM4X1VxlCqjI0
TToTDDnExeDaNYaTEvBRZfWi4ac0tG6i89ls4Stdojs+mnvI9eXfDEkIqSdMThJj
HBUwxQicxb+0tEc2LOQUSDj6SompC8bI2qhWmgNjwVxRdfuU7RCLw7f+IU4GCium
HfRTDFCqqlba1MkxY6wU4NPdpwLVutvCba2Aiv0Rmp6aEdvRvgdRnpKSCZ8wq4Ya
yJwbwLRUh7Hz0FEguVNSeouGetzAkJTwyKuDc3H348xTLLza/aRzolNhIsFq6FVE
1E/urvBmK1nQZ9uZGb7sEOTeTfDFk4ySdLThI+OCphihFY94NpKE5sSdgokDH0lR
NSF10e20CqSnhrF9BG4u92Gspyo3sVi0kZ3iWGj4LVwVcMSUXfVivzMdG1GEjYXr
XA++9a9RbNqkrLYLMv8AoopBpW0trImCrBbgvuTUXRQ6nFgSqRp7Br0TF/uKgrd7
tSr8w6DRIee1q61Q8WevXqtDmUh1uHmQnLgiomGkuKv2sg0iVWbcvoZuKe/RoKHp
l6lobTve+QhIsFq6FVE1EKrVr4loaxLMjtzYzHJnp78TYsH6KdSH7AAAAAAAAAAA
AAAAAAAAAABzLUbLG3T+5TLlyP0Y+8XvL7s56iay+o//1tUgAAAFGZVGzy2+T5Fx
Wc2aFumdyHRAAAAAAAAAAB8lX/Iv+wvcYysZ/MQO+2vebVg/RTqQ/YAAAAAAAAAA
KCytNnl97+g++y/5KF9hO4s6iakO+w8gAAAAAAAAAAAAAAAAA8P1L1H86L7OU432
l7y1cjXaovV8jYYAAAAAAAAAAAAAAAAAAAABHbxOT5jdOK+yXOTXb1xcYKlvEttW
aVFzZCX4RnPhiey7e2lYq8RWz8vwbefDAsGpWXlaquMaEx6+9MSvL2Lq5KJJPiQo
bIT2NVUciYKczJhr8epSj2RlVyMdgiqXWZovhVZuuS8OL+TxTXqNHS0oxkNIaImZ
momHqwILe/LNp9NjLBRGqrV1aCPZMEoxKdwmCZ6vXFfWevKhk4cSRY9yJnJETBfW
fFPxViWeZncyEyuTT9Zt6kKqvqT+DcrpT6Sd5N8ofY2CzcV0Gzz1Zr4Nxy8luUY+
XiRVROEz10+s9eVTTYT5ZkVWpwiPTT6y0Lr1xp0vu0JSZzkKdCnK49YrUcqO0Y+r
SWte9Ba6mxUVNTFw7CrbmYzodBmVav1vmfZkrSrIkGPFciLE4RdPrJdlEScOPS4i
vRFVFTA4N2MZzqC5F1I1cDn5ODs6NH+/vL8Bny9KShztYhtioit0aF1F6S8BkKXR
qIiMSHq9WGBnC5uKkGqzSQtCZztRFZWtTtOrMd8lCSM/OXQuknNdt1aOrQHy7pJM
HtwxzSX5PNnZ2gy7oc4xWYqq4FwFYXp3gy1nnI2GxsSc/aNVMVK8qt5topqA7Pk0
RiprzfUe3JhjvjRZh8RMHrjih8d3UBtRtDHWYTFUVcMTSc1JsmUzYjUVOZSkMp1V
lZOHDhpgxXpjhqLJutkYcrT4PBImliKuHOd2NTYUFHPa1EdmrpTXqMh0iuT1Oq8d
8lC4Z+cuvT6yc2gtvaOswHy7pLBHphjmkuuPshNScjElJ9itSIi4p1kQi2Xqt2Ew
9KTDWNBcqrgqYk1u8vrfUIvglUYkGYVdDcMD2Xy3WLX1bUJZV8IhImaiesh0he9W
6BmJUJbNgNwRz8PUWNbC1MK0VIizEu7FqsKCuktdV6VCd4BLJETOX0sMVO1bqctB
bdjIMWUzEa5FxRMDv3vJMyFGgwYyYKmailq3QSUOWp0FYaJpYir1lKXt06FKV2Xd
CREcrkxw6zTkH6KdSH7AAAAAAAAAAAAAAAAAAAAABzLUbLG3T+5TLlyP0Y+8XvL7
s56iay+o/9fVIAAABReVRs8tvk+RcdnNmg7pnch0QAAAAAAAAAAUJfDlGrY6K+Ub
CzlwVMTMtHvRWmz61BGYqq45pr65i+hbft9KHmKha4AAAAAAAAAAKCytNnl97+g+
+y35KF9hvcWdRNSHfYeQAAAAAAAAAAAAAAAAAeH6l6j+dF9nKcb7S95auRrtUXq+
RsMAAAAAAAAAAAAAAAAAAAAAjt4nJ8xunFfZLnJrt64uMA/MVmeipzoUDX7SVixs
690KE6YhLjgmlUORXLS1i8lEk3S6y7FX0nYLqLpuysCyxUqku1cVXS5feS4qW/G7
Z9cYk7Lfl4WGCJ6yCSN69cbASUWTdn4YcJgpadmLJxqvIOhT7lV0Vq4ovqKepkGq
3STL4MrCWYl1VVTQuB97pOp3sTDWTsJYEBq44YLgXXWLCw5uQ8Bboa1uCL70Qomz
draxYF75VsqsaHnYNdgvafFUbtqlP1KXqURFVrnIqt+rpLZv0oEeryrGS7c5yeo6
V3dmoi0rwSYTNc5rkX70KflJeqXSzL4cpAWPCcqrqVU/A+C8Cy9XvIhNnXsWHmuT
9S06jR938m+SkYMOImDmsRFQkJRtKsrNQ6w+OrF4NXaFLGvPp8SoSEWHCTF6tXBC
FXB2RjSdNiy04xWq9zkwXmXEr+LZ+pXSzrnSENY8B64q1EXDSfXUp+q3pxGysxAW
XgYpjoXAu+RsOynyHgENdGZhjzqZ7s3Gqt289FZClliwnKunBec0tZipxKnAbFjM
zHrrbzHVM/30XezlpJ5r5XFqNRFzk9xyo959cp8HwFJRXKiZnCYLq1Yk2uLuufZ5
Hzkz+VjaVRfViR+31gpqyU34zpqK9XLi5iIep9+9ZRNFPXscW7d7aSYr8ukaahcE
/wCqScoG+672ZbNsqso1Yj2YejrOdGvLrNpoPgSyawlcmCvwU6+TvYubs5GjJNtX
Tjg5fWfJezYKas9NpVKa1Xvc7FzUPQ+8qtWmVkukq6DpTOfgpZtqbu/KOnpLRnYx
Ebii+/Ap2zFuK1YdrpPwR0ZjVwa7BfuLKuoZP1Zz5iexYi6mL7yJ26sLN2NnFqNN
asTOXFzEQ/D796zhop69ji0bPWumqhIrNRYOZGRPyekrCLfpWWOciSCqiLo0KfPZ
OyU3b6oNqk7CWArP2uGBNLyLyahZmI2FKSqxm8+CkAr94NXtrDWQiSSw2RNCuwXR
2lqWGuxbR6ashEXHPTT7sSrIUGp3VR3slIKx4KquCYLgdWVvyrEV7WrIKiKulcF0
FjXgWPW3dPSE/wBB6ojsOZcNRTVm7cVqxLVkWyixGtXBrsF7Tnx7sanM1OBUYqK5
r3Irm/VNWQkwROpD9AAAAAAAAAAAAAAAAAAAAAA5lqNljbp/cply5H6MfeL3l92c
9RNZfUf/0NUgAAAFGZVGzy2+T5FxWc2aDumdyHRAAAAAAAAAABFbQ3XyFoX8JMwU
e7nU5K3D0hdHg7SQ2asLKWaTCUhoxPcd8AAAAAAAAAAFBZWmzy+9/QffZf8AJQvs
J3FnUTUh32HkAAAAAAAAAAAAAAAAAHh+peo/nRfZynG+0veWrka7VF6vkbDAAAAA
AAAAAAAAAAAAAAAAI7eJyfMbpxX2S5ya7euLjAAwGAAGAGAwAwAAwGAAAGAwAwAA
wAGAAGAAwAwAGAwGAwwGAwAwGAGAAAAAAAAAAAAAAAAAAAAAAABzLUbLG3T+5TLl
yP0Y+8XvL6s36ibS+o//0dUgAAAFF5VGzy2+T5Fx2c2aDumdyHRAAAAAAAAAAAAA
AAAAAAAAAAKCytNnl97+g++y35KF9hO4s6iajvsPIAAAAAAAAAAAAAAAAAPD9S9R
/Oi+zlON9pe8tXI12qL1fI2GAAAAAAAAAAAAAAAAAAAAAR28Tk+Y3Tivslzk129c
XGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADmWo2WNun9y
mXLkfox94veX3Zz1E1l9R//S1SAAAAUZlUbPLb5PkXFZzZoO6Z3IdEAAAAAAAAAA
AAAAAAAAAAAAAoLK02eX3v6D77LfkoX2G9xZ1E1Id9h5AAAAAAAAAAAAAAAAAB4f
qXqP50X2cpxvtL3lq5Gu1Rer5GwwAAAAAAAAAAAAAAAAAAAACO3icnzG6cV9kucm
u3ri4wAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAcy1Gyxt
0/uUy5cj9GPvF7y+7OeomsvqP//T1SAAAAUXlUrhLy2+T5Ft2dqMJJaDi9v5Jn7Z
OZPedDxlC+u34k/SefGUL67fiT9I8ZQvrt+JP0jxlC+u34k/SPGUL67fiT9I8ZQv
rt+JP0jxlC+u34k/SPGUL67fiT9I8ZQvrt+JP0jxlC+u34k/SPGUL67fiT9I8ZQv
rt+JP0jxlC+u34k/SPGUL67fiT9I8ZQvrt+JP0jxlC+u34k/SPGUL67fiT9I8ZQv
rt+JP0jxlC+u34k/SPGUL67fiT9I8ZQvrt+JP0jxlC+u34k/SPGUL67fiT9I8ZQv
rt+JP0jxlC+u34k/SPGUL67fiT9I8ZQvrt+JP0jxlC+u34k/SPGUL67fiT9I8ZQv
rt+JP0jxlC+u34k/SPGUL67fiT9I8ZQvrt+JP0jxlC+u34k/SPGUL67fiT9I8ZQv
rt+JP0jxlC+u34k/SPGUL67fiT9I8ZQvrt+JP0jxlC+u34k/SPGUL67fiT9I8ZQv
rt+JP0jxlC+u34k/SPGUL67fiT9I8ZQvrt+JP0jxlC+u34k/SPGUL67fiT9JQ2Vh
Mtiy8ujXIq8L6lReY6ll0/UoX2E7izaJqQ77DyAAAAAAAAAAAAAAAAADw/UvUfzo
vs5TjfaXvLVyNdqi9XyNhgAAAAAAAAAAAAAAAAAAAAEdvE5PmN04r7Jc5NdvXFxg
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA5lqNljbp/cply
5H6MfeL3l92c9RNZfUf/1NUgAAAEOvNu4h27gJLxXZuC4opT89k3xZJMGzj8E1Ji
pH5i5aYhapt/ap8/E9M9Lf2qOJ6Z6W/tUcT0z0t/ao4npnpb+1RxPTPS39qjieme
lv7VHE9M9Lf2qOJ6Z6W/tUcT0z0t/ao4npnpb+1RxPTPS39qjiemelv7VHE9M9Lf
2qOJ6Z6W/tUcT0z0t/ao4npnpb+1RxPTPS39qjiemelv7VHE9M9Lf2qOJ6Z6W/tU
cT0z0t/ao4npnpb+1RxPTPS39qjiemelv7VHE9M9Lf2qOJ6Z6W/tUcT0z0t/ao4n
pnpb+1RxPTPS39qjiemelv7VHE9M9Lf2qOJ6Z6W/tUcT0z0t/ao4npnpb+1RxPTP
S39qjiemelv7VHE9M9Lf2qOJ6Z6W/tUcT0z0t/ao4npnpb+1RxPTPS39qjiemelv
7VHE9M9Lf2qOJ6Z6W/tUcT0z0t/ao4npnpb+1T9QbmHve10eO6IjVxRFVVLXokks
NGt9SJgWHR4eah3GHkAAAA/Cx2p607UPHhLfrJ2oPCW/WTtQeEt+snag8Jb9ZO1B
4S36ydqDwlv1k7UHhLfrJ2oPCW/WTtQeEt+snag8Jb9ZO1B4S36ydqDwlv1k7UHh
LfrJ2oPCW/WTtQeEt+snag8Jb9ZO1B4S36ydqDwlv1k7UHhLfrJ2oPCW/WTtQeEt
+snag8Jb9ZO1B4S36ydqDwlv1k7UHhLfrJ2oPCW/WTtQ8OmGqi6U1c6H86763I6p
xsPrL3lq5GzkbMxcVRNHr6jYHhLfrJ2oPCW/WTtQeEt+snag8Jb9ZO1B4S36ydqD
wlv1k7UHhLfrJ2oPCW/WTtQeEt+snag8Jb9ZO1B4S36ydqDwlv1k7UHhLfrJ2oPC
W/WTtQeEt+snag8Jb9ZO1B4S36ydqDwlv1k7UHhLfrJ2oPCW/WTtQeEt+snag8Jb
9ZO1B4S36ydqDwlv1k7UHhLfrJ2oPCW/WTtQeEt+snagSYavrTtQ/eceQAAAAAAR
28Tk+Y3TivMl2Ijaa7FU/KuLi4dvOnag4dvOnaOHbzp2jh286do4dvOnag4dvOna
OHbzp2oOHbzp2jh286do4dvOnaOHbzp2jh286do4dvOnaOHbzp2jh286do4dvOna
OHbzp2jh286do4dvOnaOHbzp2jh286do4dvOnaOHbzp2jh286do4dvOnaOHbzp2j
h286do4dvOnaOHbzp2oOHbzp2jh286do4dvOnaOHbzp2oOHbzp2jh286do4dvOna
OHbzp2oOHbzp2jh286do4dvOnaOHbzp2jh286do4dvOnaOHbzp2jh286do4dvOna
OHbzp2jh286do4dvOnaOHbzp2jh286do4dvOnaOHbzp2jh286do4dvOnaOHbzp2j
h286do4dvOnaOHbzp2jh286do4dvOnaOHbzp2jh286do4dvOnaOHbzp2jh286do4
dvOnag4dvOnaOHbzp2jh286do4dvOnaOHbzp2oOHbzp2jh286dqDh286do4dvOna
OHbzp2jh286do4dvOnag4dvOnaOHbzp2oOHbzp2jh286dqDh286dqDh286dqDh28
6do4dvOnaOHbzp2jh286dqDh286do4dvOnaOHbzp2oOHbzp2jh286do4dvOnaOHb
zp2jh286do4dvOnaOHbzp2jh286do4dvOnaOHbzp2jh286do4dvOnacy08VFlY2l
PyT/AF+5TL9yP0Y+8XvL7s56iay+o//V1SAAAAfmImJyJ+Q4U4MegZy6j0eTnuHk
57h5Oe4eTnuHk57h5Oe4eTnuHk57h5Oe4eTnuHk57h5Oe4eTnuHk57h5Oe4eTnuH
k57h5Oe4eTnuHk57h5Oe4eTnuHk57h5Oe4eTnuHk57h5Oe4eTnuHk57h5Oe4eTnu
Hk57h5Oe4eTnuHk57h5Oe4eTnuHk57h5Oe4eTnuHk77h5Oe4eTnuHk57h5Oe4eTn
uPKWd9x90nRODUkMpL5iH3ImAAAABxrZzjpKTjxG6HNhOVOwzXdrdvPXgwHzjp17
P1RURuKks83Ce6e/tUebfPdPf2qPNvnunv7VHm3z3T39qjzb57p7+1R5t8909/ao
82+e6e/tUebfPdPf2qPNvnunv7VHm3z3T39qjzb57p7+1R5t8909/ao83Ce6e/tU
ebfPdPf2qPNvnunv7VHm3z3T39qjzb57p7+1R5t8909/ao82+e6e/tUebfPdPf2q
PNvnunv7VHm3z3T39qjzb57p7+1R5uE909/ao83Ce6e/tUebfPdPf2qEycJ5P573
9qnGmMjVs25XxJlVcutdJ9FOySH0lcZabcxV5sTo+bhPdPf2qPNvnunv7VHm3z3T
39qjzb57p7+1R5t8909/ao82+e6e/tUebfPdPf2qPNvnunv7VHm4T3T39qjzb57p
7+1R5uE909/ao82+e6e/tUebfPdPf2qPNvnunv7VHm3z3T39qjzcJ7p7+1R5t890
9/ao82+e6e/tUebfPdPf2qPNvnunv7VHm3z3T39qjzb57p7+1R5t8909/ao83Ce6
e/tUebfPdPf2qPNvnunv7VHm3z3T39qkVvJuwnrBSyTrZ171R6IrcVL+sHXFnpCB
FeuLnMTEk0GPnnvQAAAAAA+KtU5KnBfAdqe1W9pn2Lk1zdKzvBZtzGKqrmoqocOb
ukqUuuHhju1T4lu1qafz2O7VPHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFt
U+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU
+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+
mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+m
O7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO
7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7
VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7V
HFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VH
FtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHF
tU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFt
U+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU
+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+
mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+m
O7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO
7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VHFtU+mO7VPES7OpREVrpx2autM
VJdYOxnk1DWEi4qq6VLWs9BzcCYQNR//1tUgAAAA/DoeJ+Fl0U/PgqDwVB4Kg8FQ
eCoPBUHgqDwVB4Kg8FQeCoPBUHgqDwVB4Kg8FQeCoPBUHgqDwVB4Kg8FQeCoPBUH
gqDwVB4Kg8FQeCoPBUHgqDwVB4Kg8FQeCoPBUHgqDwVB4Kg8FQeCoPBUHgqDwVB4
Kg8FQ8pKoeUgIh7WtwPIAAABHrwuT5jcu7ivMlrk129cXIAAAAAAAAAAAAAAAAAA
AAAAAAAAACo8p/kl322nxXbVZUkIDfzULNpMznoh22LieQAAAAAeHIc+dluEI7OU
TPU+FbO+48eTvuHk77h5O+4eTvuHk57h5O+4eTvuHk77h5Oe4eTnuHk77h5O+4eT
nuHk57h5O+4eTnuHk57h5Oe4eTvuHk77h5O+4eTvuHk77h5O+4eTnuHk57h5Oe4e
TnuHk57h5Oe4eTvuHk57h5Oe4eTnuHk57h5Oe4eTvuHk57h5Oe4eTg8nPcPJz3Dy
d9w8nfcPJz3Dyc9w8nfcPJz3Dyd9w8nPcPJz3Dyc9w8nPcPJ33Dyd9w8nPcPJz3D
yc9w8nPcPJz3Dyc9w8nPcPJz3Dyc9w8nfcPJz3Dyc9w8nPcPJz3Dyd9w8nPcPJz3
Dyd9w8nPcPJz3Dyc9w8nPcPJz3Dyc9w8nPcPJz3Dyc9w8nPcPJz3Dyc9w8nPcPJz
3Dyc9w8nPcPJz3Dyc9w8nfcPJz3Dyc9w8nfcPJ33Dyc9w8nfcPJz3Dyc9w8nfcPJ
z3Dyc9x74Fn81dRIKdIcEdiG3A//19UgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAj14fJ8xuXFeZLXJrt64uQAAAAAAAAAAAAAAAAAAAAAAAAAAAFR5T/JLvttIxdu
/wDWUD7KFuUJdCElh6j9AAAAAAH5czE9TpdFPysqg8EQeCIPBEHgiDwRB4Ig8EQe
CIPBEHgiDwRB4Ig8EQeCIPBEHgiDwRB4Ig8EQeCIPBEHgiDwRB4Ig8EQeCIPBEHg
iDwVB4Kg8EQeCIPBEHgqDwRB4Ig8EQeCIPBEHgiDwRB4Ig8EQeCIPBEHgiDwRB4I
g8EQeCIPBEHgiDwRB4Ig8EQeCIPBEHgiDwRB4Ig8EQeCIPBEHgiDwRB4Ig8EQeCI
PBEHgiDwRB4Ig8EQeCIPBEHgiDwRB4Ig8EQeCIPBEHgiDwVB4Ig8EQeCoPBEHgiD
wRB4Ig8EQeCIPBEHgiDwRB4Ig8EQeCIPBEHgiDwRB4Ig8EQ8pLIh7WQ8D9n/0NUg
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAj14fJ8xuXFeZLXJrt64uQAAAAAAAAA
AAAAAAAAAAAAAAAAAAFR5T/JLvttItdvsUH7KFu0DUhJoeo/QAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAP/R1SAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAACPXh8nzG5cV5ktcmu3ri5AAAAAAAAAAAAAAAAAAAAAAA
AAAAAVHlP8ku+20i12+xQfsoW7QNSEmh6j9AAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA/9LVIAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAI9eHyfMblxXmS1yY7euLkAAAAAAAAAAAAAAAAAAAAAAAAAAABUeU/yS77
bSLXb7FB+yhbtA1ISaHqP0AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAD/09UgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAj14fJ8
xuXFeZLXJrt64uQAAAAAAAAAAAAAAAAAAAAAAAAAAAFR5T/JLvttItdvsUH7KFu0
DUhJoeo/QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAP/U1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACPXh8nzG5cV5ktcmu3ri
5AAAAAAAAAAAAAAAAAAAAAAAAAAAAVHlP8ku+20i12+xwfsoW7QNSEmhn6AAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAB//9XVIAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAI9eHyfMblxXmS1yY7euLkAAAAAAAAAAAA
AAAAAAAAAAAAAAABUeU/yS77bSLXb7FB+yhbtA1ISaHqP0AAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD/1tUgAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAj14fJ8xuXFeZLXJjt64uQAAAAAAAAAAAAAAAAAAAAAAAAA
AAFR5T/JLvttItdvsUH7KFu0DUhJoeo/QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAP/X1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAACPXh8nzG5cV5ktcmu3ri5AAAAAAAAAAAAAAAAAAAAAAAAAAAAVHlP8ku+20i
t2+xQfsoW9QNSEmh6j9AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAA/9DVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAI9eHyfMbl
xXmS1ya7euLkAAAAPDno3WeUXHUAACL1G8iUp8dJWI7CIq4IhJ2uzkxPIB+YkRIa
Kq6kI1QbxpSuR3ysB2MRn0kJOADk2ltPBs5CWPMLgxNan7s5aODaGCkxLrix2pTp
gAAAHrmZlJZqvdqRMVI9Za8GVtO98OWdnLDXBxI+ETVih+gAAAAAACo8p/kl322k
Wu32KD9lC3aBqQk0M/QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAP/9HVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAI9eHyfMbl
xXmS1yY7euLkAAAAKgyhqpGkILFgvVq+4l9002+ap8J8Rc5y61JhieEdieTwrkQ8
ouJmO8CEi1ti/np3mmJfQ1OpO49gxB88+qLDd9lTOFx0NG1ya/kRpfHA8Z6HkKuB
VeUY1H0x59OT03NpML7yywq4HjPTnOPa2urQ5d0dExVqaiMXVXlOtmj1e1G5i+os
DEDEY4HMtHg6XiJ+YvcUNkwQ0ZNTn2l7z75mzVYdWOFRy+DZ2rHRhiX43UM5Dyi4
hVwPGenOeQAAAAVHlP8AJLvttItdvsUH7KFu0DUhJoeo/QAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAP/0tUgAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAj14fJ8xuXFeZLXJrt64uQAAAApfKS/IM/i9ZILDRVg0TOa
uCpDdgpTVmK5V7dRHSDHuY1HL+qaT21KFU7p5pkWYmFjQXKia1w/Evi0l4TKLT0q
DkxRzUVE96oUtQ7KVW8tXTbZl0CGq4tTT8ifXVylRoEZ0tOKsVnqfpIFeAn8Gmfb
TvLHvurUalSsJ0B2aquTHD7iV3ezr5yUY+IuLlRNJT1TtZNstHDlkiLwSqmLfUSW
/m8OLSWtkZXRGi4YKmtMSGSV1VYp8t4e+bc9yNzlhYrpObkzTkSfqkxEjNzX+lih
Mr0rwpisTXimn4tiY4OeinEqVy1ZpTEmWTrnq1M5zMV9WlU0ln3UXieU0s5YiYPg
pg734esqO0ldqF5dQWWkIqwYbFwVUVcPwOJe1ZmpWGlVhxYqzMOJrXTo7S8Mn5MK
VCLIM93n23mLQz/ieXiLAVF+nqPfTLhqpLPa90+rkRUVUxdpO7fVYqZn5JFhx1bm
N9JOcp+5i6+eq7nPgzSw0aulEVdPYWxexU5mzkOXgw4i44ojnc5Z9l5l0eVa964u
Vuv7ik7I2sm5m0T5Z8RVhJj6PqOhfrb+YdFbS5FVbFcqYuTWR2cuzq9mZVZ1006M
uZ6UPT60PZklzDpqJMxIiYPVdKfedCuWznIVZbLtifqWfhh95YV7t4/khARGpjEi
Jg0q6l3SVi08Lwt046Er9LWYqSC661k1Zqb8TVB3CPVdD1XE9d9N4EZ022kQHLCW
Jh+qatZ8UjcJVUzXrUFVNC63F5Wdpz6dAZCiOz3NTS7nOiAAAAVHlP8AJLvttItd
vsUH7KFu0DUhJoZ+gAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAf/T1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACPXh8nzG5cV5
ktcmO3ri5AAAACl8pH8gw7dj+Ql3bjgZPrvyn2lPgyqV/UIX20PXe3Kvi2fl1bqR
rcSxLlZ+HNU2CkNUxa1Ed1kwZVoT38Gj0z+bHSZxt/y0z7ad5PMoHRKQl9WcnyJd
dhMNfIsVFxRE0r9xRk1UYU/adnAuR2C6cD7b3l8Fr8u+Ivo4tNDTs/DgwFiuVEZm
Y4+rDAzvcLOMna1NPhKitXO0pqItaqjzU/XojJWJwL1VfSXQTuNdFaKO1WLPIrXJ
gvpLqO7d5c/M2Klo3CRc9z2uVcOojuTTNMhzM1Dd9NXrhz6yX5SVXgylOdDiORHO
+ii61Olk+JhSoX3lklaXpXQttT+rSypDmUX6eorKf8dXWK2bnZjh4CKiZuOJatpL
RNtDSFmmpgj244EQyaHo5kbDn+Z78oVc10BV1Y6/vLKslNMSSa/H0UbpX7igbv56
HPWliOguzm6dKHvrMRJK1DVjLoVdGJf9q6jDk5WJEiuRrMxdK6tRRmS7HbMTM29i
4tVy4L958Nf5db9v5nRyrpd8VJfM0LjodzaT5rP3aV+bgsiQZ5EYrUwTOU6Fl7g6
jLzzZ+cmEiORefSWJeZdbDtdCRzcGzLUTNiesqWo0KuXbsScjzPCy8NUxaiqpeV3
ltG2vlWzTUzcU1EmAAAAKjyn+SXfbaRW7fYoP2ULeoGpCTQ9R+gAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAf/9TVIAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAI9eHyfMblxXmS1ya7euLkAAAAK9vdu+i2whNZBciK
h0aBY+JT6asi5cX5ipj1nLusu7i2UzuFci4qp819d2ca3ENjIDkarXIq4kplbHsj
yDJGZTORIaNXr5yloF0Ves1FiJTI6NguVcEVfUT2627mapD3TFRfwkVffihz7U3Q
TFWqLZ1rkRiOxwLEtVZaHaCWWXiJiuboXmXAo6k3WWhoarAl46JLudpTH1HYoOT2
+i1KHUIb+ZX4rrX1kzvZusbbCHwkP0Zhn0HFd0u7C0E1my07HRZbU5EXTgSS6e5B
1g52JHY7GE9FwT16Tp3p3R+UKpMya5kyi452OBCUsfaxqZqTKYImCekhaN2tKqEp
AcyqvSI9fXjjoK7tpclOyc14VRHpDVy4uxXDSc+euHqNsIL/ABvFzoqfQVF0Fu3Y
WUfZWSZKxFxc31kscUxbezVopqYV0jHRsL1JjgcGDdRXLQxGw6tGR8BFxwxxLpZZ
KDDlPAkT9TzcCjKXc1W7MTT30+MjYLnY4Y+rEtm0th3WmkOAmcFjo3Q73lVUO7C0
VPRJVY6eCqulMdOB37A3CusjUlnYbsYappTHTidm9y6JbTqk1KLmTTdTtRDqfdVX
KzhL1SOjpbDDBF0ksuWuffd8+MmdjDevo9p8tVufmJupJPI5MxHY4E+tvYmDaqAs
GMmKonorzKU1L3bWkomMGTmESDjoRVJXd3Z6vyUxnVGMj4PNjiey8iz9enY+dTYy
Mhc2OBEnXZWhrrkg1COjpdV9JMS7rJ2Yh2bgNl4KYI1DsgAAAFR5T/JLvttItdvs
UH7KFu0DUhJoeo/QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAP//V1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACPXh8nzG5cV5
ktcmu3ri5AAAAAAAAAAAAAAAAAAAAAAAAAAAAVHlP8ku+20i12+xwfsoW7QNSEmh
6j9AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
/9bVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAI9eHyfMblxXmS1yY7euLkAAAA
AAAAAAAAAAAAAAAAAAAAAAABUeU/yS77bSLXb7HB+yhbtA1ISaGfoAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAH//19UgAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAj14fJ8xuXFeZLXJjt64uQAAAAAAAAAAAA59ar0
Giw1ix3I1qetSEtygaO92YkdMccCeUyqQ6mxIsFyOaupUIraG+Cm2fesKZio1yeo
5bcoajuXDwhCc0Suwq3DSNAdnMXUp94AAAAAAAAAAABUeU/yS77bSLXb7FB+yhbt
A1ISaGfoAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAH//Q1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACPXh8nzG5cV5ktcmO3ri
5AAAAAAAAAAAADOl8d3dStvPpAhuc2WXWunAra8vJgdY2VWbbGz83WTvJBtbHqLY
kCIqua1NHuK0v7p7JyrrDiOzWudpdzHZpmT7Sp1WoyfRXLhoxTXzGpLu7HtsnKtl
mOzkT1knAAAAAAAAAAAAKjyn+SXfbaRa7fYoP2ULdoOpCTQ9R+gAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAf/9HVIAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAI9eHyfMblxXmS1yY7euLkAAAAAAAAAAAAPxGjJBRX
OXBE1qZZv9vRdamKlKkPTRVwdhpLXuGuuSxMqiuT9UemKkMvSyZYtspl0wyMjUVc
cFKQvLuJm7t2pMJEVyIv0kNH5MtsItekESO7Oe3nLlAAAAAAAAAAAAKjyn+SXfba
Ra7fYoP2ULdoGpCTMP0AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAD/9LVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAI9eHyfMbl
xXmS1yY7euLkAAAAAAAAAAAAMr5S188zTI3gUs7NYqekRG6q9+k2TTho8JXzC6c7
DHSXxYPKLlbZvWDBY5rvViRWr5STrHzsSBPQ3LDT6KoVnfNf1xiw0lZOG5Ex5sVL
ryZLGRKHIo+MmDneoukAAAAAAAAAAAAqPKf5Jd9tpFrt9jg/ZQt2gakJMw/QAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAP//T1SAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACPXh8nzG5cV5ktcmu3ri5AAAAAAAAAAA
ACtbZ3A0610Xh5lFzvccHzTqP9VxIrF3EU+yEThZZFzvefbby5yQtqqOmmaU9aaF
ORZfJ1plnInCwmKrvfpLOhQkhJmtTBE9SH6AAAAAAAAAAAAKjyn+SXfbaRa7fYoP
2ULdoGpCTQ9R+gAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAf/1NUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAj14fJ8xuXFeZLX
Jjt64uQAAAAAAAAAAAAAAAAAAAAAAAAAAAFR5T/JLvttIrdvsUH7KFvUDUhJoeo/
QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAP/V
1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACPXh8nzG5cV5ktcmu3ri5AAAAAAA
AAAAAAAAAAAAAAAAAAAAAVHlP8ku+20i12+xQfsoW7QNSEmh6j9AAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA/9bVIAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAI9eHyfMblxXmS1yY7euLkAAAAAAAAAAAAAAAAAAAA
AAAAAAABUeU/yS77bSLXb7FB+yhbtA1ISaHqP0AAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD/19UgAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAj14fJ8xuXFeZLXJrt64uQAAAAAAAAAAAAAAAAAAAAAAAAAAAFR5T/J
LvttItdvscD7KFu0DUhJoeo/QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAP/Q1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACPXh
8nzG5cV5ktcmO3ri5AAAAAAAAAAAAAAAAAAAAAAAAAAAAVHlP8ku+20i12+xQfso
W7QNSEmh6j9AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAA/9HVIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAI9eHyfMblxXmS1yY7
euLkAAAAAAAAAAAAAAAAAAAAAAAAAAABUeU/yS77bSLXb7HB+yhbtA1ISaHqP0AA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD/0tUg
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAj14fJ8xuXFeZLXJjt64uQAAAAAAAAA
AAAAAAAAAAAAAAAAAAFR5T/JLvttItdvscH7KFu0DUhJoeo/QAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAP/T1SAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAACPXh8nzG5cV5ktcmu3ri5AAAAAAAAAAAAAAAAAAAAAAA
AAAAAVHlP8ku+20i12+xwfsoW7QNSEmh6j9AAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA/9TVIAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAI9eHyfMblxXmS1ya7euLkAAAAAAAAAAAAAAAAAAAAAAAAAAABUeU/yS77
bSLXb7HB+yhbtA1ISaHqP0AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAD/1dUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAj14fJ8
xuXFeZLXJrt64uQAAAAAAAAAAAAAAAAAAAAAAAAAAAFR5T/JLvttItdvsUH7KFu0
DUhJoeo/QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAP/W1SAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACPXh8nzG5cV5ktcmO3ri
5AAAAAAAAAAAAAAAAAAAAAAAAAAAAVHlP8ku+20i12+xQfsoW7QNSEmh6j9AAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA/9fVIAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAObaSm+NJaLATW9it7TOVHu8tHY1r4MnER
ISuVUPxMVG1EvriHyraK06fzsHlFab2g8orTe0HlFab2g8orTe0HlFab2g8orTe0
HlFab2g8orTe0HlFab2g8orTe0HlFab2g8orTe0HlFab2g8orTe0HlHab2g8orT+
0HlFab2g8orTe0HlFab2g8orTe0HlFab2g8orTe0HlHab2g8o7Te0HlFab2g8orT
e0HlFab2g8o7Te0HlHab2g8orT+0HlFab2g8orTe0HlHab2g8orTe0HlFab2g8o7
Te0HlFab2g8orTe0HlHab2g8o7Te0HlFab2g8orTe0HlFab2g8orTe0HlHab2g8o
rTe0HlFab2g8orTe0HlFab2g8orTe0HlFab2g8orTe0HlFab2g8orTe0ObaGXr1q
oaS04/GFiiqWVZGmLT4MOD9VEQs+hMwRCRwz9AAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA//0NUgAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAA8OPgn4avTWRWfpLoinNdQnHjxCp58QqPEKjxCo8QqPEKjxCo8QuHiF
R4hUeIVHiFR4hUeIVHiFR4hU8eIVPPiFR4hUeIVHiJR4hUeIVHiFR4iUeIVHiFR4
hU8eIVPPiFR4hUeIVHiFR4iUeIVHiFR4hUeIVHiFR4hUeIVPHiFTz4hUeIVHiFR4
iUeIVHiFR4hUeIVHiFR4hUeIVHiFQlBU+2SoeYpKadK8Gh1WpgeQAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAf//R1SAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAfh8PE+d8min4WQQeAIPAEHgCDwBB4Ag8AQeAIPA
EHgCDwBB4Ag8AQeAIPAEHgCDwBB4Ag8AQeAIPAEHgCDwBB4Ag8AQeAIPAEHgCDwB
B4Ag8AQeAIPAEHgCDwBB4Ag8AQeAIPAEHgCDwBB4Ag8AQeAIPAEHgCDwBB4Ag8AQ
eAIPAEHgCDwBB4Ag8AQJIIftkmiH0Mh5p+wAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAD/9LVIAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAwAAAAAAAAAAAAAAAAAAAAAAAAAGAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAP/Z">
<p style="top:525.9pt;left:51.0pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Fig. 1  </span></b><span style="font-family:STIX,serif;font-size:8.5pt">Flowchart of the selection process of studies.</span></p>
<p style="top:32.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">1214</span></p>
<p style="top:32.8pt;left:399.6pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">Psychopharmacology (2022) 239:1211&#x2013;1230</span></p>


<p style="top:733.2pt;left:503.7pt;line-height:15.0pt"><span style="font-family:Springnew,serif;font-size:15.0pt">1 3</span></p>
<p style="top:708.8pt;left:48.7pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Table 1  </span></b><span style="font-family:STIX,serif;font-size:8.5pt">Summary of pre-clinical studies with cannabinoids and amphetamine co-administration</span></p>
<p style="top:708.8pt;left:65.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Study</span></p>
<p style="top:611.0pt;left:65.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Sample</span></p>
<p style="top:611.0pt;left:75.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(sample size)</span></p>
<p style="top:536.8pt;left:65.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cannabinoid</span></p>
<p style="top:446.8pt;left:65.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Intervention/design</span></p>
<p style="top:338.8pt;left:65.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Outcome measures</span></p>
<p style="top:258.5pt;left:65.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Pattern of cannabinoid </span></p>
<p style="top:258.5pt;left:75.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">administration</span></p>
<p style="top:153.5pt;left:65.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Main results</span></p>
<p style="top:708.8pt;left:93.7pt;line-height:8.5pt"><b><span style="font-family:STIX,serif;font-size:8.5pt">Non-contingent models of addiction</span></b></p>
<p style="top:708.8pt;left:106.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Yang et&#xa0;al., </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2020</span></p>
<p style="top:611.0pt;left:106.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Rats</span></p>
<p style="top:611.0pt;left:116.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(3&#x2013;10/group)</span></p>
<p style="top:536.8pt;left:106.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">CBD</span></p>
<p style="top:536.8pt;left:116.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">10, 20, 40, and 80&#xa0;mg/</span></p>
<p style="top:530.8pt;left:126.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">kg, i.p</span></p>
<p style="top:446.8pt;left:106.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Effects of CBD exposure on </span></p>
<p style="top:440.8pt;left:116.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH-induced conditioned </span></p>
<p style="top:440.8pt;left:126.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">place preference (vehicle-</span></p>
<p style="top:440.8pt;left:136.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">controlled study)</span></p>
<p style="top:338.8pt;left:106.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH-induced </span></p>
<p style="top:332.8pt;left:116.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">conditioned place </span></p>
<p style="top:332.8pt;left:126.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">preference and </span></p>
<p style="top:332.8pt;left:136.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">brain signalling </span></p>
<p style="top:332.8pt;left:146.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">pathways</span></p>
<p style="top:258.5pt;left:106.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Single CBD administration </span></p>
<p style="top:252.5pt;left:116.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">during METH-induced </span></p>
<p style="top:252.5pt;left:126.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">conditioning place prefer-</span></p>
<p style="top:252.5pt;left:136.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ence, 1&#xa0;h before METH </span></p>
<p style="top:252.5pt;left:146.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">administration</span></p>
<p style="top:153.5pt;left:106.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span><span style="font-family:STIX,serif;font-size:8.5pt"> CBD reduced METH </span></p>
<p style="top:147.5pt;left:116.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">place preference in a </span></p>
<p style="top:147.5pt;left:126.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">dose-dependent manner </span></p>
<p style="top:147.5pt;left:136.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(</span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.05) and decreased </span></p>
<p style="top:147.5pt;left:146.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH-induced pathways </span></p>
<p style="top:147.5pt;left:156.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(e.g. Sigma1 recep-</span></p>
<p style="top:147.5pt;left:166.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tor, p-AKT, p-GSK-3&#x3b2;, </span></p>
<p style="top:147.5pt;left:176.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">p-CREB) levels in the </span></p>
<p style="top:147.5pt;left:186.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">prefrontal cortex, nucleus </span></p>
<p style="top:147.5pt;left:196.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">accumbens, hippocampus, </span></p>
<p style="top:147.5pt;left:206.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and ventral tegmental area </span></p>
<p style="top:147.5pt;left:216.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(</span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.05)</span></p>
<p style="top:708.8pt;left:228.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Karimi-Haghighi et&#xa0;al., </span></p>
<p style="top:702.8pt;left:238.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2020</span></p>
<p style="top:611.0pt;left:228.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Rats</span></p>
<p style="top:611.0pt;left:238.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(4&#x2013;5/group)</span></p>
<p style="top:536.8pt;left:228.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">CBD</span></p>
<p style="top:536.8pt;left:238.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">10&#xa0;&#xb5;g/5&#xa0;&#xb5;l, i.c.v</span></p>
<p style="top:446.8pt;left:228.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Effects of CBD exposure </span></p>
<p style="top:440.8pt;left:238.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">on neuroinflammatory </span></p>
<p style="top:440.8pt;left:248.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">factors during METH- and </span></p>
<p style="top:440.8pt;left:258.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">stress-induced METH-</span></p>
<p style="top:440.8pt;left:268.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">reinstatement</span></p>
<p style="top:338.8pt;left:228.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Neuroinflammatory </span></p>
<p style="top:332.8pt;left:238.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">factors (e.g. IL</span><span style="font-family:Code2000,sans-serif;font-size:8.5pt">&#x2010;</span><span style="font-family:STIX,serif;font-size:8.5pt">1&#x3b2;, </span></p>
<p style="top:332.8pt;left:248.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">IL</span><span style="font-family:Code2000,sans-serif;font-size:8.5pt">&#x2010;</span><span style="font-family:STIX,serif;font-size:8.5pt">6, IL</span><span style="font-family:Code2000,sans-serif;font-size:8.5pt">&#x2010;</span><span style="font-family:STIX,serif;font-size:8.5pt">10, TNF) </span></p>
<p style="top:332.8pt;left:258.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">in the prefrontal </span></p>
<p style="top:332.8pt;left:268.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cortex and hip-</span></p>
<p style="top:332.8pt;left:278.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">pocampus</span></p>
<p style="top:258.6pt;left:228.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">After METH-self admin-</span></p>
<p style="top:252.6pt;left:238.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">istration extinction, </span></p>
<p style="top:252.6pt;left:248.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">single CBD administration </span></p>
<p style="top:252.6pt;left:258.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">60&#xa0;min before METH-</span></p>
<p style="top:252.6pt;left:268.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">induced reinstatement </span></p>
<p style="top:252.6pt;left:278.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">in sleep deprived/non-</span></p>
<p style="top:252.6pt;left:288.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">deprived animals</span></p>
<p style="top:153.6pt;left:228.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> </span><span style="font-family:Code2000,sans-serif;font-size:8.5pt">&#x2194;</span><span style="font-family:STIX,serif;font-size:8.5pt"> CBD reduced neuroin-</span></p>
<p style="top:147.6pt;left:238.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">flammatory factors expres-</span></p>
<p style="top:147.6pt;left:248.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">sion in the prefrontal cortex </span></p>
<p style="top:147.6pt;left:258.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and hippocampus in the </span></p>
<p style="top:147.6pt;left:268.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH-induced reinstate-</span></p>
<p style="top:147.6pt;left:278.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ment group (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.05), but </span></p>
<p style="top:147.6pt;left:288.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">augmented in the hip-</span></p>
<p style="top:147.6pt;left:298.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">pocampus of the sleep-</span></p>
<p style="top:147.6pt;left:308.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">deprived group (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.05)</span></p>
<p style="top:708.8pt;left:321.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Karimi-Haghighi &amp; Hagh-</span></p>
<p style="top:702.8pt;left:331.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">parast, </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2018</span></p>
<p style="top:611.0pt;left:321.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Rats</span></p>
<p style="top:611.0pt;left:331.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(4&#x2013;6/group)</span></p>
<p style="top:536.8pt;left:321.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">CBD</span></p>
<p style="top:536.8pt;left:331.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">10&#xa0;&#xb5;g/5&#xa0;&#xb5;l</span></p>
<p style="top:536.8pt;left:341.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">i.c.v</span></p>
<p style="top:446.8pt;left:321.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Effects of CBD exposure on </span></p>
<p style="top:440.8pt;left:331.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH-reinstatement in </span></p>
<p style="top:440.8pt;left:341.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">sleep deprived rats (vehicle-</span></p>
<p style="top:440.8pt;left:351.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">controlled study)</span></p>
<p style="top:338.8pt;left:321.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH-induced </span></p>
<p style="top:332.8pt;left:331.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">reinstatement</span></p>
<p style="top:258.6pt;left:321.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">After METH-self admin-</span></p>
<p style="top:252.6pt;left:331.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">istration extinction, </span></p>
<p style="top:252.6pt;left:341.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">single CBD administration </span></p>
<p style="top:252.6pt;left:351.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">60&#xa0;min before METH&#x2013;</span></p>
<p style="top:252.6pt;left:361.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">induced reinstatement </span></p>
<p style="top:252.6pt;left:371.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">in sleep deprived/non-</span></p>
<p style="top:252.6pt;left:381.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">deprived animals</span></p>
<p style="top:153.6pt;left:321.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span><span style="font-family:STIX,serif;font-size:8.5pt"> CBD reduced METH-</span></p>
<p style="top:147.6pt;left:331.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">induced reinstatement </span></p>
<p style="top:147.6pt;left:341.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">in sleep and non-sleep </span></p>
<p style="top:147.6pt;left:351.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">deprived animals (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(3, </span></p>
<p style="top:147.6pt;left:361.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">22) = 11.13, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.001; </span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(2, </span></p>
<p style="top:147.6pt;left:371.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">15) = 18.29, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.001)</span></p>
<p style="top:708.8pt;left:393.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Ellgren et&#xa0;al., </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2004</span></p>
<p style="top:611.0pt;left:393.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Rats</span></p>
<p style="top:611.0pt;left:403.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(6&#x2013;8/group)</span></p>
<p style="top:536.8pt;left:393.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">THC</span></p>
<p style="top:536.8pt;left:403.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">0.75, 1.5 and 3.0&#xa0;mg/kg</span></p>
<p style="top:536.8pt;left:413.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">i.p</span></p>
<p style="top:446.8pt;left:393.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Effects of THC exposure on </span></p>
<p style="top:440.8pt;left:403.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">AMPH-sensitization in dif-</span></p>
<p style="top:440.8pt;left:413.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ferent ages</span></p>
<p style="top:446.8pt;left:423.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(vehicle-controlled study)</span></p>
<p style="top:338.8pt;left:393.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">AMPH-sensitization </span></p>
<p style="top:332.8pt;left:403.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">in adolescent and </span></p>
<p style="top:332.8pt;left:413.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">adult rats</span></p>
<p style="top:258.6pt;left:393.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Daily THC administration </span></p>
<p style="top:252.6pt;left:403.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">for five days, 7 or 35&#xa0;days </span></p>
<p style="top:252.6pt;left:413.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">before AMPH administra-</span></p>
<p style="top:252.6pt;left:423.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tion</span></p>
<p style="top:153.6pt;left:393.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> </span><span style="font-family:Code2000,sans-serif;font-size:8.5pt">&#x2194;</span><span style="font-family:STIX,serif;font-size:8.5pt"> THC had no effect on </span></p>
<p style="top:147.6pt;left:403.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">AMPH-sensitization neither </span></p>
<p style="top:147.6pt;left:413.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">in adolescents nor in adults </span></p>
<p style="top:147.6pt;left:423.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(</span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(3, 97) = 31.2, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.001; </span></p>
<p style="top:147.6pt;left:433.5pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(4, 95) = 23.2, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.001)*</span></p>
<p style="top:708.8pt;left:446.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Parker et&#xa0;al., </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2004</span></p>
<p style="top:611.0pt;left:446.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Rats</span></p>
<p style="top:611.0pt;left:456.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(8&#x2013;12/group)</span></p>
<p style="top:536.8pt;left:446.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">CBD</span></p>
<p style="top:536.8pt;left:456.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(5&#xa0;mg/kg) or</span></p>
<p style="top:536.8pt;left:466.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">THC</span></p>
<p style="top:536.8pt;left:476.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(0.5&#xa0;mg/kg), i.p</span></p>
<p style="top:446.8pt;left:446.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Effects of CBD or THC </span></p>
<p style="top:440.8pt;left:456.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">exposure on the extinction </span></p>
<p style="top:440.8pt;left:466.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">of AMPH place preference </span></p>
<p style="top:440.8pt;left:476.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">memory (vehicle-controlled </span></p>
<p style="top:440.8pt;left:486.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">study)</span></p>
<p style="top:338.8pt;left:446.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Extinction of AMPH-</span></p>
<p style="top:332.8pt;left:456.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">induced place </span></p>
<p style="top:332.8pt;left:466.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">preference</span></p>
<p style="top:258.6pt;left:446.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Single CBD or THC admin-</span></p>
<p style="top:252.6pt;left:456.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">istration 30&#xa0;min before </span></p>
<p style="top:252.6pt;left:466.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH-induced place </span></p>
<p style="top:252.6pt;left:476.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">preference training</span></p>
<p style="top:153.6pt;left:446.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span><span style="font-family:STIX,serif;font-size:8.5pt"> CBD and THC potentiated </span></p>
<p style="top:147.6pt;left:456.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">the extinction of AMPH-</span></p>
<p style="top:147.6pt;left:466.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">induced place-preference </span></p>
<p style="top:147.6pt;left:476.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">learning (F(3, 32) = 4.7, </span></p>
<p style="top:147.6pt;left:486.0pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.01)</span></p>
<p style="top:32.8pt;left:528.3pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">1215</span></p>
<p style="top:32.8pt;left:50.4pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">Psychopharmacology (2022) 239:1211&#x2013;1230</span></p>


<p style="top:733.2pt;left:52.5pt;line-height:15.0pt"><span style="font-family:Springnew,serif;font-size:15.0pt">1 3</span></p>
<p style="top:708.8pt;left:48.7pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Table 1  </span></b><span style="font-family:STIX,serif;font-size:8.5pt">(continued)</span></p>
<p style="top:708.8pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Study</span></p>
<p style="top:611.0pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Sample</span></p>
<p style="top:611.0pt;left:75.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(sample size)</span></p>
<p style="top:536.8pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cannabinoid</span></p>
<p style="top:446.8pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Intervention/design</span></p>
<p style="top:338.8pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Outcome measures</span></p>
<p style="top:258.5pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Pattern of cannabinoid </span></p>
<p style="top:258.5pt;left:75.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">administration</span></p>
<p style="top:153.5pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Main results</span></p>
<p style="top:708.8pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lamarque et&#xa0;al., </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2001</span></p>
<p style="top:611.0pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Rats</span></p>
<p style="top:611.0pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(9&#x2013;12/group)</span></p>
<p style="top:536.8pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">THC</span></p>
<p style="top:536.8pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">0.6, 3 and 15&#xa0;mg/kg</span></p>
<p style="top:536.8pt;left:113.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">i.p</span></p>
<p style="top:446.8pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Effects of THC exposure </span></p>
<p style="top:440.8pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">on AMPH-sensitization </span></p>
<p style="top:440.8pt;left:113.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(vehicle-controlled study)</span></p>
<p style="top:338.8pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">AMPH-sensitiza-</span></p>
<p style="top:332.8pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tion in high- or </span></p>
<p style="top:332.8pt;left:113.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">low-locomotion </span></p>
<p style="top:332.8pt;left:123.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">responsive-animals</span></p>
<p style="top:258.5pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Twenty-seven THC adminis-</span></p>
<p style="top:252.5pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">trations in a 3-week period, </span></p>
<p style="top:252.5pt;left:113.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">3 and 55&#xa0;days before </span></p>
<p style="top:252.5pt;left:123.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">AMPH administration</span></p>
<p style="top:153.5pt;left:93.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span><span style="font-family:STIX,serif;font-size:8.5pt"> THC (0.6 and 15&#xa0;mg/kg) </span></p>
<p style="top:147.5pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">increased AMPH-induced </span></p>
<p style="top:147.5pt;left:113.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">hyperlocomotion in high-</span></p>
<p style="top:147.5pt;left:123.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">locomotion-responsive </span></p>
<p style="top:147.5pt;left:133.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">animals shortly after treat-</span></p>
<p style="top:147.5pt;left:143.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ment (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">H</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(3) = 7.27, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.05) </span></p>
<p style="top:147.5pt;left:153.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">but not after longer time </span></p>
<p style="top:147.5pt;left:163.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(</span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &gt; 0.05)</span></p>
<p style="top:708.8pt;left:175.5pt;line-height:8.5pt"><b><span style="font-family:STIX,serif;font-size:8.5pt">Contingent models of addiction</span></b></p>
<p style="top:708.8pt;left:188.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Hay et&#xa0;al., </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2018</span></p>
<p style="top:611.0pt;left:188.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Rats</span></p>
<p style="top:611.0pt;left:198.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(10&#x2013;12/experiment)</span></p>
<p style="top:536.8pt;left:188.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">CBD</span></p>
<p style="top:536.8pt;left:198.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">20, 40 and 80&#xa0;mg/kg, i.p</span></p>
<p style="top:446.8pt;left:188.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Effects of CBD exposure on </span></p>
<p style="top:440.8pt;left:198.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH-seeking and relapse </span></p>
<p style="top:440.8pt;left:208.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(vehicle-controlled study)</span></p>
<p style="top:338.8pt;left:188.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH-seeking, </span></p>
<p style="top:332.8pt;left:198.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">relapse and </span></p>
<p style="top:332.8pt;left:208.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">-induced hyperac-</span></p>
<p style="top:332.8pt;left:218.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tivity</span></p>
<p style="top:258.6pt;left:188.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Single CBD administration </span></p>
<p style="top:252.6pt;left:198.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">30&#xa0;min before METH self-</span></p>
<p style="top:252.6pt;left:208.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">administration test or, after </span></p>
<p style="top:252.6pt;left:218.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">extinction, 30&#xa0;min before </span></p>
<p style="top:252.6pt;left:228.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH administration</span></p>
<p style="top:153.6pt;left:188.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span><span style="font-family:STIX,serif;font-size:8.5pt"> CBD reduced METH-</span></p>
<p style="top:147.6pt;left:198.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">induced hyperactivity in </span></p>
<p style="top:147.6pt;left:208.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">all doses (F(3, 33) = 11.01, </span></p>
<p style="top:147.6pt;left:218.3pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.001); at 80&#xa0;mg/kg </span></p>
<p style="top:147.6pt;left:228.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">attenuated METH-seeking </span></p>
<p style="top:147.6pt;left:238.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and relapse (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(1, 9) = 13.84, </span></p>
<p style="top:147.6pt;left:248.2pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> = 0.005; </span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(1.792, </span></p>
<p style="top:147.6pt;left:258.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">19.707) = 4.96, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> = 0.021)</span></p>
<p style="top:708.8pt;left:270.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cortright et&#xa0;al., </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2011</span></p>
<p style="top:611.0pt;left:270.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Rats</span></p>
<p style="top:611.0pt;left:280.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(6&#x2013;16/group)</span></p>
<p style="top:536.8pt;left:270.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">THC</span></p>
<p style="top:536.8pt;left:280.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">0.4, 0.75, 1.5, 3.0 and </span></p>
<p style="top:530.8pt;left:290.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">6.0&#xa0;mg/kg i.p</span></p>
<p style="top:446.8pt;left:270.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Effects of THC exposure on </span></p>
<p style="top:440.8pt;left:280.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">AMPH-induced hyperloco-</span></p>
<p style="top:440.8pt;left:290.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">motion and self-adminis-</span></p>
<p style="top:440.8pt;left:300.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tration (vehicle-controlled </span></p>
<p style="top:440.8pt;left:310.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">study)</span></p>
<p style="top:338.8pt;left:270.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">AMPH-induced </span></p>
<p style="top:332.8pt;left:280.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">hyperlocomotion, </span></p>
<p style="top:332.8pt;left:290.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">self-administration, </span></p>
<p style="top:332.8pt;left:300.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and nucleus accum-</span></p>
<p style="top:332.8pt;left:310.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">bens dopamine </span></p>
<p style="top:332.8pt;left:320.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">levels</span></p>
<p style="top:258.6pt;left:270.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Five THC administrations </span></p>
<p style="top:252.6pt;left:280.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">in a 15-day period, 2&#xa0;days </span></p>
<p style="top:252.6pt;left:290.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and 2&#xa0;weeks before AMPH </span></p>
<p style="top:252.6pt;left:300.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">administration or 10&#xa0;days </span></p>
<p style="top:252.6pt;left:310.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">before AMPH self-admin-</span></p>
<p style="top:252.6pt;left:320.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">istration training</span></p>
<p style="top:153.6pt;left:270.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> </span><span style="font-family:Code2000,sans-serif;font-size:8.5pt">&#x2194;</span><span style="font-family:STIX,serif;font-size:8.5pt"> THC (0.75, 1.5, and </span></p>
<p style="top:147.6pt;left:280.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">3.0&#xa0;mg/kg) increased </span></p>
<p style="top:147.6pt;left:290.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">AMPH-induced locomotion </span></p>
<p style="top:147.6pt;left:300.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(</span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(5, 30) = 2.80, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.05; </span></p>
<p style="top:147.6pt;left:310.6pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(5, 30) = 2.70, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.05) </span></p>
<p style="top:147.6pt;left:320.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">but did not affect AMPH </span></p>
<p style="top:147.6pt;left:330.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">self-administration and </span></p>
<p style="top:147.6pt;left:340.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">dopamine levels (data not </span></p>
<p style="top:147.6pt;left:350.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">shown)</span></p>
<p style="top:708.8pt;left:363.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Anggadiredja et&#xa0;al., </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2004</span></p>
<p style="top:611.0pt;left:363.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Rats</span></p>
<p style="top:611.0pt;left:373.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(4&#x2013;8/group)</span></p>
<p style="top:536.8pt;left:363.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Delta-8-THC</span></p>
<p style="top:536.8pt;left:373.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">0.32, 1.0 and 3.2&#xa0;mg/kg</span></p>
<p style="top:536.8pt;left:383.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">i.p</span></p>
<p style="top:446.8pt;left:363.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Effect of delta-8-THC expo-</span></p>
<p style="top:440.8pt;left:373.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">sure on METH-seeking and </span></p>
<p style="top:440.8pt;left:383.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">-reinstatement (vehicle-</span></p>
<p style="top:440.8pt;left:393.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">controlled study)</span></p>
<p style="top:338.8pt;left:363.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH- and cue-</span></p>
<p style="top:332.8pt;left:373.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">induced seeking </span></p>
<p style="top:332.8pt;left:383.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and reinstatement</span></p>
<p style="top:258.6pt;left:363.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Repeated (five days) delta-8-</span></p>
<p style="top:252.6pt;left:373.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">THC administration after </span></p>
<p style="top:252.6pt;left:383.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH-extinction session </span></p>
<p style="top:252.6pt;left:393.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and before METH- or </span></p>
<p style="top:252.6pt;left:403.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cue-induced reinstate-</span></p>
<p style="top:252.6pt;left:413.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ment; single delta-8-THC </span></p>
<p style="top:252.6pt;left:423.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">administration 24&#xa0;h before </span></p>
<p style="top:252.6pt;left:433.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH- or cue-induced </span></p>
<p style="top:252.6pt;left:443.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">reinstatement</span></p>
<p style="top:153.6pt;left:363.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span><span style="font-family:STIX,serif;font-size:8.5pt"> Acute delta-8-THC </span></p>
<p style="top:147.6pt;left:373.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">attenuated METH-</span></p>
<p style="top:147.6pt;left:383.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">seeking (0.32&#xa0;mg/kg, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(3, </span></p>
<p style="top:147.6pt;left:393.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">23) = 13.10, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.01), </span></p>
<p style="top:147.6pt;left:403.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">enhanced METH cue-</span></p>
<p style="top:147.6pt;left:413.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">seeking (1&#xa0;mg/kg, </span></p>
<p style="top:147.6pt;left:423.0pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(1,10) = 12.20, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.01) </span></p>
<p style="top:147.6pt;left:433.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and decreased METH- </span></p>
<p style="top:147.6pt;left:443.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and cue-reinstatement </span></p>
<p style="top:147.6pt;left:453.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(3.2&#xa0;mg/kg, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(2,19) = 14.6, </span></p>
<p style="top:147.6pt;left:463.0pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.0001; </span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(1, 10) = 11.4, </span></p>
<p style="top:147.6pt;left:473.0pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.01); at 3.2&#xa0;mg/kg </span></p>
<p style="top:147.6pt;left:483.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(repeatedly) decreased </span></p>
<p style="top:147.6pt;left:493.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH-reinstatement (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(2, </span></p>
<p style="top:147.6pt;left:503.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">20) = 22.08, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.0001)</span></p>
<p style="top:32.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">1216</span></p>
<p style="top:32.8pt;left:399.6pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">Psychopharmacology (2022) 239:1211&#x2013;1230</span></p>


<p style="top:733.2pt;left:503.7pt;line-height:15.0pt"><span style="font-family:Springnew,serif;font-size:15.0pt">1 3</span></p>
<p style="top:708.8pt;left:48.7pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Table 1  </span></b><span style="font-family:STIX,serif;font-size:8.5pt">(continued)</span></p>
<p style="top:708.8pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Study</span></p>
<p style="top:611.0pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Sample</span></p>
<p style="top:611.0pt;left:75.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(sample size)</span></p>
<p style="top:536.8pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cannabinoid</span></p>
<p style="top:446.8pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Intervention/design</span></p>
<p style="top:338.8pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Outcome measures</span></p>
<p style="top:258.5pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Pattern of cannabinoid </span></p>
<p style="top:258.5pt;left:75.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">administration</span></p>
<p style="top:153.5pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Main results</span></p>
<p style="top:708.8pt;left:93.1pt;line-height:8.5pt"><b><span style="font-family:STIX,serif;font-size:8.5pt">Amphetamine-induced mental health model or neurotoxicity</span></b></p>
<p style="top:708.8pt;left:105.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Razavi et&#xa0;al., </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2020</span></p>
<p style="top:611.0pt;left:105.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Rats</span></p>
<p style="top:611.0pt;left:115.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(5&#x2013;7/group)</span></p>
<p style="top:536.8pt;left:105.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">CBD</span></p>
<p style="top:536.8pt;left:115.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">32 and 160&#xa0;nmol i.c.v</span></p>
<p style="top:446.8pt;left:105.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Effects of CBD on METH-</span></p>
<p style="top:440.8pt;left:115.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">induced memory impair-</span></p>
<p style="top:440.8pt;left:125.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ment (vehicle-controlled </span></p>
<p style="top:440.8pt;left:135.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">study)</span></p>
<p style="top:338.8pt;left:105.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Locomotor activity, </span></p>
<p style="top:332.8pt;left:115.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">spatial memory </span></p>
<p style="top:332.8pt;left:125.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(Y-maze), short- </span></p>
<p style="top:332.8pt;left:135.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and long-term </span></p>
<p style="top:332.8pt;left:145.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">memory (novelty </span></p>
<p style="top:332.8pt;left:155.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">object recognition)</span></p>
<p style="top:258.5pt;left:105.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Twice-daily CBD admin-</span></p>
<p style="top:252.5pt;left:115.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">istration for 10&#xa0;days after </span></p>
<p style="top:252.5pt;left:125.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">10&#xa0;days of daily METH </span></p>
<p style="top:252.5pt;left:135.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">administration</span></p>
<p style="top:153.5pt;left:105.8pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span><span style="font-family:STIX,serif;font-size:8.5pt"> CBD had no effect on </span></p>
<p style="top:147.5pt;left:115.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH-induced hyperlo-</span></p>
<p style="top:147.5pt;left:125.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">comotion (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(2, 21) = 0.08; </span></p>
<p style="top:147.5pt;left:135.8pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &gt; 0.05) but reversed </span></p>
<p style="top:147.5pt;left:145.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH-induced spatial </span></p>
<p style="top:147.5pt;left:155.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">memory, short-term </span></p>
<p style="top:147.5pt;left:165.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">memory and long-term </span></p>
<p style="top:147.5pt;left:175.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">memory impairment (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(4, </span></p>
<p style="top:147.5pt;left:185.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">37) = 7.12; </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.001; </span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(4, </span></p>
<p style="top:147.5pt;left:195.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">40) = 3.472; </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.005; </span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(2, </span></p>
<p style="top:147.5pt;left:205.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">22) = 5.36; </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.025)</span></p>
<p style="top:708.8pt;left:218.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Renard et&#xa0;al., </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2016</span></p>
<p style="top:611.0pt;left:218.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Rats</span></p>
<p style="top:611.0pt;left:228.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(8&#x2013;10/group)</span></p>
<p style="top:536.8pt;left:218.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">CBD</span></p>
<p style="top:536.8pt;left:228.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">100&#xa0;ng/0.5 ul</span></p>
<p style="top:536.8pt;left:238.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(per side)</span></p>
<p style="top:536.8pt;left:248.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">i.c</span></p>
<p style="top:446.8pt;left:218.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Effects of CBD on D-AMPH-</span></p>
<p style="top:440.8pt;left:228.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">induced schizophrenia </span></p>
<p style="top:440.8pt;left:238.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">model</span></p>
<p style="top:446.8pt;left:248.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(vehicle-controlled study)</span></p>
<p style="top:338.8pt;left:218.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">D-AMPH-induced </span></p>
<p style="top:332.8pt;left:228.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">neuronal sensitiza-</span></p>
<p style="top:332.8pt;left:238.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tion and hyperlo-</span></p>
<p style="top:332.8pt;left:248.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">comotion; ventral </span></p>
<p style="top:332.8pt;left:258.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tegmental area </span></p>
<p style="top:332.8pt;left:268.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">molecular pathways</span></p>
<p style="top:258.6pt;left:218.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Daily administration for </span></p>
<p style="top:252.6pt;left:228.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">5&#xa0;days, right before and </span></p>
<p style="top:252.6pt;left:238.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">16&#xa0;days before D-AMPH </span></p>
<p style="top:252.6pt;left:248.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">administration</span></p>
<p style="top:153.6pt;left:218.2pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span><span style="font-family:STIX,serif;font-size:8.5pt"> CBD decreased D-METH-</span></p>
<p style="top:147.6pt;left:228.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">induced hyperlocomotion, </span></p>
<p style="top:147.6pt;left:238.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">dopaminergic neuronal </span></p>
<p style="top:147.6pt;left:248.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">sensitization (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(3, </span></p>
<p style="top:147.6pt;left:258.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">36) = 18.711, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.001; </span></p>
<p style="top:147.6pt;left:268.2pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(5, 113) = 4.17, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.01) </span></p>
<p style="top:147.6pt;left:278.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and modified ventral </span></p>
<p style="top:147.6pt;left:288.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tegmental area molecular </span></p>
<p style="top:147.6pt;left:298.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">pathways (e.g. mTOR </span></p>
<p style="top:147.6pt;left:308.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and p70S6K increase </span></p>
<p style="top:147.6pt;left:318.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">t(6) =  &#x2212; 3.60, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.05; </span></p>
<p style="top:147.6pt;left:328.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">t(6) =  &#x2212; 3.70, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.05)</span></p>
<p style="top:708.8pt;left:340.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Pedrazzi et&#xa0;al., </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2015</span></p>
<p style="top:611.0pt;left:340.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Mice</span></p>
<p style="top:611.0pt;left:350.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(8&#x2013;10/group)</span></p>
<p style="top:536.8pt;left:340.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">CBD</span></p>
<p style="top:536.8pt;left:350.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">15, 30 and 60&#xa0;mg/kg, </span></p>
<p style="top:530.8pt;left:360.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">i.p. or 60&#xa0;nmol/0.2&#xa0;&#x3bc;l </span></p>
<p style="top:530.8pt;left:370.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">intra accumbens</span></p>
<p style="top:446.8pt;left:340.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Effects of CBD exposure on </span></p>
<p style="top:440.8pt;left:350.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">AMPH-induced PPI disrup-</span></p>
<p style="top:440.8pt;left:360.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tion (vehicle-controlled </span></p>
<p style="top:440.8pt;left:370.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">study)</span></p>
<p style="top:338.8pt;left:340.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">AMPH-induced PPI </span></p>
<p style="top:332.8pt;left:350.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">disruption</span></p>
<p style="top:258.6pt;left:340.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Single i.p. administration </span></p>
<p style="top:252.6pt;left:350.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">60&#xa0;min before PPI test </span></p>
<p style="top:252.6pt;left:360.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and 30&#xa0;min before AMPH </span></p>
<p style="top:252.6pt;left:370.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">administration; single </span></p>
<p style="top:252.6pt;left:380.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">intra-accumbens admin-</span></p>
<p style="top:252.6pt;left:390.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">istration 10&#xa0;min before </span></p>
<p style="top:252.6pt;left:400.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">PPI test and immediately </span></p>
<p style="top:252.6pt;left:410.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">before AMPH administra-</span></p>
<p style="top:252.6pt;left:420.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tion</span></p>
<p style="top:153.6pt;left:340.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span><span style="font-family:STIX,serif;font-size:8.5pt"> Intra-accumbens CBD </span></p>
<p style="top:147.6pt;left:350.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">attenuated amphetamine-</span></p>
<p style="top:147.6pt;left:360.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">induced PPI impairment </span></p>
<p style="top:147.6pt;left:370.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(</span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(1, 25) = 6.38, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> = 0.018), </span></p>
<p style="top:147.6pt;left:380.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">while intraperitoneal CBD </span></p>
<p style="top:147.6pt;left:390.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(30 and 60&#xa0;mg/kg) was </span></p>
<p style="top:147.6pt;left:400.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">marginally significant (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(3, </span></p>
<p style="top:147.6pt;left:410.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">67) = 4.09, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> = 0.07)</span></p>
<p style="top:708.8pt;left:433.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Castelli et&#xa0;al., </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2014</span></p>
<p style="top:611.0pt;left:433.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Rats</span></p>
<p style="top:611.0pt;left:443.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(109 total)</span></p>
<p style="top:536.8pt;left:433.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">THC</span></p>
<p style="top:536.8pt;left:443.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">1 and 3&#xa0;mg/kg</span></p>
<p style="top:536.8pt;left:453.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">i.p</span></p>
<p style="top:446.8pt;left:433.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Effects of THC exposure on </span></p>
<p style="top:440.8pt;left:443.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH-induced neurotox-</span></p>
<p style="top:440.8pt;left:453.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">icity</span></p>
<p style="top:446.8pt;left:463.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(vehicle-controlled study)</span></p>
<p style="top:338.8pt;left:433.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Body temperature, </span></p>
<p style="top:332.8pt;left:443.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and neurotoxicity </span></p>
<p style="top:332.8pt;left:453.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">markers in caudate-</span></p>
<p style="top:332.8pt;left:463.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">putamen and </span></p>
<p style="top:332.8pt;left:473.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cingulate cortex</span></p>
<p style="top:258.6pt;left:433.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Multiple administration at </span></p>
<p style="top:252.6pt;left:443.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">several time-points, before </span></p>
<p style="top:252.6pt;left:453.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">or after METH administra-</span></p>
<p style="top:252.6pt;left:463.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tion</span></p>
<p style="top:153.6pt;left:433.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span><span style="font-family:STIX,serif;font-size:8.5pt"> THC decreased caudate-</span></p>
<p style="top:147.6pt;left:443.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">putamen GFAP-IR and </span></p>
<p style="top:147.6pt;left:453.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">nNOS (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(2, 32) = 8.12, </span></p>
<p style="top:147.6pt;left:463.0pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> = 0.001; </span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(2, 37) = 20.53, </span></p>
<p style="top:147.6pt;left:473.0pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.001), and cingulate </span></p>
<p style="top:147.6pt;left:483.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cortex GFAP-IR (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(2, </span></p>
<p style="top:147.6pt;left:493.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">32) = 25.49, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.001), </span></p>
<p style="top:147.6pt;left:503.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">but did not affect METH-</span></p>
<p style="top:147.6pt;left:513.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">increased body temperature</span></p>
<p style="top:32.8pt;left:528.3pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">1217</span></p>
<p style="top:32.8pt;left:50.4pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">Psychopharmacology (2022) 239:1211&#x2013;1230</span></p>


<p style="top:733.2pt;left:52.5pt;line-height:15.0pt"><span style="font-family:Springnew,serif;font-size:15.0pt">1 3</span></p>
<p style="top:708.8pt;left:48.7pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Table 1  </span></b><span style="font-family:STIX,serif;font-size:8.5pt">(continued)</span></p>
<p style="top:708.8pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Study</span></p>
<p style="top:611.0pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Sample</span></p>
<p style="top:611.0pt;left:75.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(sample size)</span></p>
<p style="top:536.8pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cannabinoid</span></p>
<p style="top:446.8pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Intervention/design</span></p>
<p style="top:338.8pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Outcome measures</span></p>
<p style="top:258.5pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Pattern of cannabinoid </span></p>
<p style="top:258.5pt;left:75.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">administration</span></p>
<p style="top:153.5pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Main results</span></p>
<p style="top:708.8pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Valvassori et&#xa0;al., </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2011</span></p>
<p style="top:611.0pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Rats</span></p>
<p style="top:611.0pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(5&#x2013;15/group)</span></p>
<p style="top:536.8pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">CBD</span></p>
<p style="top:536.8pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">15, 30 and 60&#xa0;mg/kg i.p</span></p>
<p style="top:446.8pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">CBD effects on a D-AMPH-</span></p>
<p style="top:440.8pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">induced mania model</span></p>
<p style="top:446.8pt;left:113.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(vehicle-controlled study)</span></p>
<p style="top:338.8pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">D-AMPH-induced </span></p>
<p style="top:332.8pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">hyperlocomotion, </span></p>
<p style="top:332.8pt;left:113.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">brain damage, and </span></p>
<p style="top:332.8pt;left:123.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">BDNF levels in the </span></p>
<p style="top:332.8pt;left:133.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">hippocampus</span></p>
<p style="top:258.5pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Twice a day for 6 (mania </span></p>
<p style="top:252.5pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">reversal) or 14 (mania </span></p>
<p style="top:252.5pt;left:113.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">prevention) days, partially </span></p>
<p style="top:252.5pt;left:123.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">concomitant to D-AMPH </span></p>
<p style="top:252.5pt;left:133.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">administration</span></p>
<p style="top:153.5pt;left:93.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span><span style="font-family:STIX,serif;font-size:8.5pt"> CBD did not reverse/</span></p>
<p style="top:147.5pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">prevent D-AMPH-induced </span></p>
<p style="top:147.5pt;left:113.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">hyperlocomotion (data </span></p>
<p style="top:147.5pt;left:123.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">not shown), but protected </span></p>
<p style="top:147.5pt;left:133.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">from D-AMPH-induced </span></p>
<p style="top:147.5pt;left:143.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">brain damage (15&#xa0;mg/kg) </span></p>
<p style="top:147.5pt;left:153.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and increased BDNF levels </span></p>
<p style="top:147.5pt;left:163.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(30&#xa0;mg/kg) (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.05)</span></p>
<p style="top:708.8pt;left:175.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Moreira &amp; Guimar&#xe3;es, </span></p>
<p style="top:702.8pt;left:185.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2005</span></p>
<p style="top:611.0pt;left:175.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Mice</span></p>
<p style="top:611.0pt;left:185.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(7/group)</span></p>
<p style="top:536.8pt;left:175.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">CBD</span></p>
<p style="top:536.8pt;left:185.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">15, 30 and 60&#xa0;mg/kg i.p</span></p>
<p style="top:446.8pt;left:175.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Effects of CBD on D-AMPH-</span></p>
<p style="top:440.8pt;left:185.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">induced hyperlocomotion</span></p>
<p style="top:446.8pt;left:195.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(vehicle-controlled study)</span></p>
<p style="top:338.8pt;left:175.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">D-AMPH-induced </span></p>
<p style="top:332.8pt;left:185.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">hyperlocomo-</span></p>
<p style="top:332.8pt;left:195.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tion and distance </span></p>
<p style="top:332.8pt;left:205.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">travelled</span></p>
<p style="top:258.6pt;left:175.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Single administration 20&#xa0;min </span></p>
<p style="top:252.6pt;left:185.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">before D-AMPH adminis-</span></p>
<p style="top:252.6pt;left:195.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tration</span></p>
<p style="top:153.6pt;left:175.8pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span><span style="font-family:STIX,serif;font-size:8.5pt"> CBD (30 and 60&#xa0;mg/</span></p>
<p style="top:147.6pt;left:185.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">kg) reduced D-AMPH-</span></p>
<p style="top:147.6pt;left:195.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">induced hyperlocomotion </span></p>
<p style="top:147.6pt;left:205.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and distance travelled at </span></p>
<p style="top:147.6pt;left:215.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">selected time points (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(45, </span></p>
<p style="top:147.6pt;left:225.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">132) = 1.49, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> = 0.044)</span></p>
<p style="top:710.8pt;left:243.5pt;line-height:5.9pt"><span style="font-family:STIX,serif;font-size:5.9pt">*</span><span style="font-family:STIX,serif;font-size:8.5pt"> Post hoc </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &gt; 0.05. Legends: Protective (</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span><span style="font-family:STIX,serif;font-size:8.5pt">), counter-protective (</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span><span style="font-family:STIX,serif;font-size:8.5pt">) or no effect ( </span><span style="font-family:Code2000,sans-serif;font-size:8.5pt">&#x2194;</span><span style="font-family:STIX,serif;font-size:8.5pt">) of cannabis/cannabinoid co-exposure with amphetamine on related outcomes. Abbreviation codes can be </span></p>
<p style="top:708.8pt;left:254.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">found at the abbreviation list</span></p>
<p style="top:32.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">1218</span></p>
<p style="top:32.8pt;left:399.6pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">Psychopharmacology (2022) 239:1211&#x2013;1230</span></p>


<p style="top:733.2pt;left:503.7pt;line-height:15.0pt"><span style="font-family:Springnew,serif;font-size:15.0pt">1 3</span></p>
<p style="top:708.6pt;left:48.7pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Table 2  </span></b><span style="font-family:STIX,serif;font-size:8.5pt">Summary of studies in humans with cannabis and amphetamine co-use</span></p>
<p style="top:708.6pt;left:65.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Study</span></p>
<p style="top:614.3pt;left:65.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Sample/groups</span></p>
<p style="top:614.3pt;left:75.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(sample size)</span></p>
<p style="top:528.2pt;left:65.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Participant characteristics</span></p>
<p style="top:428.2pt;left:65.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Intervention/design</span></p>
<p style="top:337.2pt;left:65.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Outcome measures</span></p>
<p style="top:255.2pt;left:65.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Temporality of canna-</span></p>
<p style="top:255.2pt;left:75.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">bis use or measure</span></p>
<p style="top:171.2pt;left:65.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Main results</span></p>
<p style="top:708.6pt;left:93.7pt;line-height:8.5pt"><b><span style="font-family:STIX,serif;font-size:8.5pt">Brain structure/metabolism</span></b></p>
<p style="top:708.6pt;left:106.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Sung et&#xa0;al., </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2013</span></p>
<p style="top:614.3pt;left:106.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH (9)</span></p>
<p style="top:614.3pt;left:116.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH + cannabis (8)</span></p>
<p style="top:614.3pt;left:126.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Controls (10)</span></p>
<p style="top:528.2pt;left:106.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Male/female adolescents </span></p>
<p style="top:522.2pt;left:116.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">with METH and cannabis </span></p>
<p style="top:522.2pt;left:126.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">dependence (criterion not </span></p>
<p style="top:522.2pt;left:136.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">specified), and healthy, </span></p>
<p style="top:522.2pt;left:146.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">non-drug-dependent </span></p>
<p style="top:522.2pt;left:156.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">controls</span></p>
<p style="top:428.2pt;left:106.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Case&#x2013;control study on </span></p>
<p style="top:422.1pt;left:116.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH and cannabis </span></p>
<p style="top:422.1pt;left:126.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">neurochemical toxicity</span></p>
<p style="top:337.1pt;left:106.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">MRS of brain </span></p>
<p style="top:331.1pt;left:116.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">metabolite levels; </span></p>
<p style="top:331.1pt;left:126.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">self-report sub-</span></p>
<p style="top:331.1pt;left:136.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">stance use</span></p>
<p style="top:255.1pt;left:106.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Current cannabis </span></p>
<p style="top:249.1pt;left:116.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">dependence diagnos-</span></p>
<p style="top:249.1pt;left:126.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tic at admission</span></p>
<p style="top:171.2pt;left:106.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span><span style="font-family:STIX,serif;font-size:8.5pt"> METH + cannabis had lower </span></p>
<p style="top:165.2pt;left:116.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tNAA/PCr + Cr ratio than </span></p>
<p style="top:165.2pt;left:126.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">other groups (F(2, 22) = 4.23, </span></p>
<p style="top:165.2pt;left:136.3pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> = 0.03) and it negatively </span></p>
<p style="top:165.2pt;left:146.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">correlated with METH and </span></p>
<p style="top:165.2pt;left:156.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cannabis life-time-doses (F(1, </span></p>
<p style="top:165.2pt;left:166.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">6) = 11.13, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> = 0.02; F(1, </span></p>
<p style="top:165.2pt;left:176.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">6) = 11.44, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> = 0.02)</span></p>
<p style="top:708.5pt;left:188.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Churchwell et&#xa0;al., </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2012</span></p>
<p style="top:614.3pt;left:188.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH (9)</span></p>
<p style="top:614.3pt;left:198.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH + cannabis (9)</span></p>
<p style="top:614.3pt;left:208.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Controls (10)</span></p>
<p style="top:528.1pt;left:188.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Male/female adolescents </span></p>
<p style="top:522.1pt;left:198.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">with METH and cannabis </span></p>
<p style="top:522.1pt;left:208.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">dependence (DSM-IV) </span></p>
<p style="top:522.1pt;left:218.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and healthy, non-drug-</span></p>
<p style="top:522.1pt;left:228.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">dependent controls</span></p>
<p style="top:428.1pt;left:188.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Case&#x2013;control study of </span></p>
<p style="top:422.1pt;left:198.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">striatal morphology on </span></p>
<p style="top:422.1pt;left:208.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH and cannabis </span></p>
<p style="top:422.1pt;left:218.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">dependents</span></p>
<p style="top:337.1pt;left:188.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">MRI of striatum vol-</span></p>
<p style="top:331.1pt;left:198.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ume, novelty-seek-</span></p>
<p style="top:331.1pt;left:208.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ing, and lifetime </span></p>
<p style="top:331.1pt;left:218.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH use</span></p>
<p style="top:255.1pt;left:188.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Current cannabis </span></p>
<p style="top:249.1pt;left:198.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">dependence at </span></p>
<p style="top:249.1pt;left:208.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">admission</span></p>
<p style="top:171.1pt;left:188.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> </span><span style="font-family:Code2000,sans-serif;font-size:8.5pt">&#x2194;</span><span style="font-family:STIX,serif;font-size:8.5pt"> METH + cannabis depend-</span></p>
<p style="top:165.1pt;left:198.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ents had greater left putamen </span></p>
<p style="top:165.1pt;left:208.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">volume and novelty-seeking </span></p>
<p style="top:165.1pt;left:218.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">score than control (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(2, </span></p>
<p style="top:165.1pt;left:228.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">24) = 4.94, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.02; </span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(2, </span></p>
<p style="top:165.1pt;left:238.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">24) = 3.56, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.04); lifetime </span></p>
<p style="top:165.1pt;left:248.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH doses correlated to </span></p>
<p style="top:165.1pt;left:258.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">left putamen volume in drug </span></p>
<p style="top:165.1pt;left:268.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">groups (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">r</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(9) = 0.56, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> = 0.05; </span></p>
<p style="top:165.1pt;left:278.7pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">r</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(8) = 0 .65, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> = 0.04), and </span></p>
<p style="top:165.1pt;left:288.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">with novelty-seeking in </span></p>
<p style="top:165.1pt;left:298.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH-only dependents </span></p>
<p style="top:165.1pt;left:308.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(</span><i><span style="font-family:STIX,serif;font-size:8.5pt">r</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(9) = 0.64, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.03)</span></p>
<p style="top:708.5pt;left:321.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Voytek et&#xa0;al., </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2005</span></p>
<p style="top:614.3pt;left:321.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH (7)</span></p>
<p style="top:614.3pt;left:331.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH + cannabis (7)</span></p>
<p style="top:528.1pt;left:321.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Men/women with METH </span></p>
<p style="top:522.1pt;left:331.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">use with/without current </span></p>
<p style="top:522.1pt;left:341.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cannabis use (&lt; / &gt; 4 </span></p>
<p style="top:522.1pt;left:351.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">joints/month)</span></p>
<p style="top:428.1pt;left:321.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Case&#x2013;control study of </span></p>
<p style="top:422.1pt;left:331.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">brain metabolism on </span></p>
<p style="top:422.1pt;left:341.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH and cannabis </span></p>
<p style="top:422.1pt;left:351.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">users</span></p>
<p style="top:337.1pt;left:321.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">PET of rCMRglc </span></p>
<p style="top:331.1pt;left:331.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">in several brain </span></p>
<p style="top:331.1pt;left:341.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">regions; auditory </span></p>
<p style="top:331.1pt;left:351.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">performance task</span></p>
<p style="top:255.1pt;left:321.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Current cannabis </span></p>
<p style="top:249.1pt;left:331.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">use (self-report) at </span></p>
<p style="top:249.1pt;left:341.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">experiment admis-</span></p>
<p style="top:249.1pt;left:351.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">sion</span></p>
<p style="top:171.1pt;left:321.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> </span><span style="font-family:Code2000,sans-serif;font-size:8.5pt">&#x2194;</span><span style="font-family:STIX,serif;font-size:8.5pt"> METH + cannabis users had </span></p>
<p style="top:165.1pt;left:331.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">lower rCMRglc in several </span></p>
<p style="top:165.1pt;left:341.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">regions, e.g. right orbitofron-</span></p>
<p style="top:165.1pt;left:351.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tal cortex, temporal gyrus, </span></p>
<p style="top:165.1pt;left:361.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">hippocampus (all </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.05) but </span></p>
<p style="top:165.1pt;left:371.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">had no between-group differ-</span></p>
<p style="top:165.1pt;left:381.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ence in auditory accuracy or </span></p>
<p style="top:165.1pt;left:391.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">reaction time (test not shown)</span></p>
<p style="top:708.5pt;left:403.3pt;line-height:8.5pt"><b><span style="font-family:STIX,serif;font-size:8.5pt">Neuropsychological function or psychopathology symptoms</span></b></p>
<p style="top:708.5pt;left:416.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cuzen et&#xa0;al., </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2015</span></p>
<p style="top:614.3pt;left:416.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH (10)</span></p>
<p style="top:614.3pt;left:426.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH + cannabis (10)</span></p>
<p style="top:614.3pt;left:436.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Controls (20)</span></p>
<p style="top:528.1pt;left:416.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Male/female adolescents </span></p>
<p style="top:522.1pt;left:426.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">with METH and cannabis </span></p>
<p style="top:522.1pt;left:436.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">dependence (DSM-IV) </span></p>
<p style="top:522.1pt;left:446.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and use (&gt; 3 use/week </span></p>
<p style="top:522.1pt;left:456.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">prior 6&#xa0;months); healthy, </span></p>
<p style="top:522.1pt;left:466.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">non-drug-dependent </span></p>
<p style="top:522.1pt;left:476.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">controls</span></p>
<p style="top:428.1pt;left:416.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Longitudinal study of </span></p>
<p style="top:422.1pt;left:426.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH and cannabis </span></p>
<p style="top:422.1pt;left:436.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">co-use on neurocogni-</span></p>
<p style="top:422.1pt;left:446.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tive functions</span></p>
<p style="top:337.1pt;left:416.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Neurocognitive </span></p>
<p style="top:331.1pt;left:426.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">performance and </span></p>
<p style="top:331.1pt;left:436.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">psychopathology </span></p>
<p style="top:331.1pt;left:446.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">scores at baseline </span></p>
<p style="top:331.1pt;left:456.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and 12-month </span></p>
<p style="top:331.1pt;left:466.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">follow-up</span></p>
<p style="top:255.1pt;left:416.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Current cannabis </span></p>
<p style="top:249.1pt;left:426.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">dependence and use </span></p>
<p style="top:249.1pt;left:436.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(self-report)</span></p>
<p style="top:171.1pt;left:416.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span><span style="font-family:STIX,serif;font-size:8.5pt"> METH + cannabis dependents </span></p>
<p style="top:165.1pt;left:426.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">had worse neurocognitive per-</span></p>
<p style="top:165.1pt;left:436.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">formance, e.g. verbal memory, </span></p>
<p style="top:165.1pt;left:446.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">planning (all </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.05) than </span></p>
<p style="top:165.1pt;left:456.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">controls, and worse verbal </span></p>
<p style="top:165.1pt;left:466.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">memory (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.001) scores </span></p>
<p style="top:165.1pt;left:476.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">than METH-only at baseline </span></p>
<p style="top:165.1pt;left:486.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">but not at follow-up</span></p>
<p style="top:32.8pt;left:528.3pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">1219</span></p>
<p style="top:32.8pt;left:50.4pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">Psychopharmacology (2022) 239:1211&#x2013;1230</span></p>


<p style="top:733.2pt;left:52.5pt;line-height:15.0pt"><span style="font-family:Springnew,serif;font-size:15.0pt">1 3</span></p>
<p style="top:708.8pt;left:48.7pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Table 2  </span></b><span style="font-family:STIX,serif;font-size:8.5pt">(continued)</span></p>
<p style="top:708.8pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Study</span></p>
<p style="top:614.5pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Sample/groups</span></p>
<p style="top:614.5pt;left:75.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(sample size)</span></p>
<p style="top:528.4pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Participant characteristics</span></p>
<p style="top:428.4pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Intervention/design</span></p>
<p style="top:337.4pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Outcome measures</span></p>
<p style="top:255.4pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Temporality of canna-</span></p>
<p style="top:255.4pt;left:75.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">bis use or measure</span></p>
<p style="top:171.4pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Main results</span></p>
<p style="top:708.8pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">McKetin et&#xa0;al, </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2013</span></p>
<p style="top:614.5pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH (278)</span></p>
<p style="top:528.4pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Male/female METH </span></p>
<p style="top:522.4pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">dependents (DSM-IV) </span></p>
<p style="top:522.4pt;left:113.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">with/without cannabis </span></p>
<p style="top:522.4pt;left:123.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">use in the prior month </span></p>
<p style="top:522.4pt;left:133.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(&#x2265; 16&#xa0;days)</span></p>
<p style="top:428.4pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Longitudinal study of </span></p>
<p style="top:422.4pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">psychotic symptoms </span></p>
<p style="top:422.4pt;left:113.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">on METH dependents</span></p>
<p style="top:337.4pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Psychotic symptoms </span></p>
<p style="top:331.4pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and drug use pattern</span></p>
<p style="top:255.4pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Past month cannabis </span></p>
<p style="top:249.4pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">use (self-report) </span></p>
<p style="top:249.4pt;left:113.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">at baseline and 3 </span></p>
<p style="top:249.4pt;left:123.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">follow-ups</span></p>
<p style="top:171.4pt;left:93.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span><span style="font-family:STIX,serif;font-size:8.5pt"> METH use was associated </span></p>
<p style="top:165.4pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">with increased odds of expe-</span></p>
<p style="top:165.4pt;left:113.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">riencing psychotic symptoms </span></p>
<p style="top:165.4pt;left:123.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(</span><i><span style="font-family:STIX,serif;font-size:8.5pt">OR</span></i><span style="font-family:STIX,serif;font-size:8.5pt">: 5.3, 95% CI[3.4, 8.3]) </span></p>
<p style="top:165.4pt;left:133.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and cannabis use (&#x2265; 16&#xa0;days/</span></p>
<p style="top:165.4pt;left:143.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">last month) further enhanced </span></p>
<p style="top:165.4pt;left:153.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">the risk (95% CI[1.1, 3.5, </span></p>
<p style="top:165.4pt;left:163.3pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> = 0.02)</span></p>
<p style="top:708.8pt;left:175.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Gonzalez et. al., </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2004</span></p>
<p style="top:614.5pt;left:175.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH (26)</span></p>
<p style="top:614.5pt;left:185.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH + cannabis (27)</span></p>
<p style="top:614.5pt;left:195.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Controls (41)</span></p>
<p style="top:528.4pt;left:175.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Men/women with METH </span></p>
<p style="top:522.4pt;left:185.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and/or cannabis depend-</span></p>
<p style="top:522.4pt;left:195.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ence history (DSM-IV) </span></p>
<p style="top:522.4pt;left:205.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and healthy, non-drug-</span></p>
<p style="top:522.4pt;left:215.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">dependent controls</span></p>
<p style="top:428.4pt;left:175.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Case&#x2013;control study on </span></p>
<p style="top:422.4pt;left:185.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">neuropsychological </span></p>
<p style="top:422.4pt;left:195.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">performance of METH </span></p>
<p style="top:422.4pt;left:205.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and cannabis depend-</span></p>
<p style="top:422.4pt;left:215.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ents</span></p>
<p style="top:337.4pt;left:175.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Neuropsychologi-</span></p>
<p style="top:331.4pt;left:185.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cal performance, </span></p>
<p style="top:331.4pt;left:195.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">comorbid disorders </span></p>
<p style="top:331.4pt;left:205.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and drug use</span></p>
<p style="top:255.4pt;left:175.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lifetime cannabis </span></p>
<p style="top:249.4pt;left:185.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">dependence at treat-</span></p>
<p style="top:249.4pt;left:195.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ment admission</span></p>
<p style="top:171.4pt;left:175.8pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span><span style="font-family:STIX,serif;font-size:8.5pt"> Neuropsychological per-</span></p>
<p style="top:165.4pt;left:185.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">formance linear worsening: </span></p>
<p style="top:165.4pt;left:195.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">better scores by controls, </span></p>
<p style="top:165.4pt;left:205.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">followed by METH + can-</span></p>
<p style="top:165.4pt;left:215.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">nabis and METH-only groups </span></p>
<p style="top:165.4pt;left:225.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(</span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(1,92) = 9.75, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">R</span></i><span style="font-family:STIX,serif;font-size:5.9pt">2</span><span style="font-family:STIX,serif;font-size:8.5pt"> = 0.096, </span></p>
<p style="top:165.4pt;left:235.9pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> = 0.002); METH-only </span></p>
<p style="top:165.4pt;left:245.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">had worse scores in learn-</span></p>
<p style="top:165.4pt;left:255.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ing, recall/retention and </span></p>
<p style="top:165.4pt;left:265.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">general neuropsychological </span></p>
<p style="top:165.4pt;left:275.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">performance than controls </span></p>
<p style="top:165.4pt;left:285.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(</span><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(2, 91) = 3.58, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.05); </span></p>
<p style="top:165.4pt;left:295.9pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(2, 91) = 4.09, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.05; </span></p>
<p style="top:165.4pt;left:305.8pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">F</span></i><span style="font-family:STIX,serif;font-size:8.5pt">(2, 91) = 4.92, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.05); </span></p>
<p style="top:165.4pt;left:315.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">no differences in lifetime </span></p>
<p style="top:165.4pt;left:325.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">comorbid disorders (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &gt; 0.05) </span></p>
<p style="top:165.4pt;left:335.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and METH use (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">z</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> =  &#x2212; 0.28, </span></p>
<p style="top:165.4pt;left:345.8pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> = 0.78)</span></p>
<p style="top:708.8pt;left:358.0pt;line-height:8.5pt"><b><span style="font-family:STIX,serif;font-size:8.5pt">Methamphetamine use patterns</span></b></p>
<p style="top:708.8pt;left:370.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Yockey et&#xa0;al., </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2020</span></p>
<p style="top:614.5pt;left:370.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH users with/</span></p>
<p style="top:608.5pt;left:380.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">without cannabis use </span></p>
<p style="top:608.5pt;left:390.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(912)</span></p>
<p style="top:528.4pt;left:370.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Men/women with at least </span></p>
<p style="top:522.4pt;left:380.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">one occasion of past-year </span></p>
<p style="top:522.4pt;left:390.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH and/or cannabis </span></p>
<p style="top:522.4pt;left:400.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">use</span></p>
<p style="top:428.4pt;left:370.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cross-sectional study on </span></p>
<p style="top:422.4pt;left:380.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">factors correlated to </span></p>
<p style="top:422.4pt;left:390.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH use</span></p>
<p style="top:337.4pt;left:370.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Demographics and </span></p>
<p style="top:331.4pt;left:380.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">past-year drug use </span></p>
<p style="top:331.4pt;left:390.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">pattern</span></p>
<p style="top:255.4pt;left:370.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">At least one occur-</span></p>
<p style="top:249.4pt;left:380.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">rence of past-year </span></p>
<p style="top:249.4pt;left:390.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cannabis use (self-</span></p>
<p style="top:249.4pt;left:400.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">report)</span></p>
<p style="top:171.4pt;left:370.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span><span style="font-family:STIX,serif;font-size:8.5pt"> Past-year cannabis strongly </span></p>
<p style="top:165.4pt;left:380.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">increased the risk of past-year </span></p>
<p style="top:165.4pt;left:390.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH use (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">aOR</span></i><span style="font-family:STIX,serif;font-size:8.5pt">: 5.51, 95% </span></p>
<p style="top:165.4pt;left:400.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">CI[4.22, 7.19])</span></p>
<p style="top:708.8pt;left:413.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Paul et&#xa0;al., </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2020</span></p>
<p style="top:614.5pt;left:413.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Street-living people </span></p>
<p style="top:608.5pt;left:423.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(56)</span></p>
<p style="top:614.5pt;left:433.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Youth-focused care </span></p>
<p style="top:608.5pt;left:443.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">providers (13)</span></p>
<p style="top:528.4pt;left:413.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Men/women street-</span></p>
<p style="top:522.4pt;left:423.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">involved drug users</span></p>
<p style="top:428.4pt;left:413.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Descriptive qualitative </span></p>
<p style="top:422.4pt;left:423.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">interviews on drug use </span></p>
<p style="top:422.4pt;left:433.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">among street-involved </span></p>
<p style="top:422.4pt;left:443.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">youths</span></p>
<p style="top:337.4pt;left:413.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cannabis use in the </span></p>
<p style="top:331.4pt;left:423.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">context of street </span></p>
<p style="top:331.4pt;left:433.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">entrenchment and </span></p>
<p style="top:331.4pt;left:443.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">drug use trajectories</span></p>
<p style="top:255.4pt;left:413.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Natural history</span></p>
<p style="top:171.4pt;left:413.2pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span><span style="font-family:STIX,serif;font-size:8.5pt"> Several participants framed </span></p>
<p style="top:165.4pt;left:423.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cannabis use as a form to alle-</span></p>
<p style="top:165.4pt;left:433.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">viate harms from other drugs, </span></p>
<p style="top:165.4pt;left:443.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and as being more effective </span></p>
<p style="top:165.4pt;left:453.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">than psychopharmaceutical-</span></p>
<p style="top:165.4pt;left:463.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">assisted treatments for mental </span></p>
<p style="top:165.4pt;left:473.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">health and substance use </span></p>
<p style="top:165.4pt;left:483.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">treatment</span></p>
<p style="top:32.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">1220</span></p>
<p style="top:32.8pt;left:399.6pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">Psychopharmacology (2022) 239:1211&#x2013;1230</span></p>


<p style="top:733.2pt;left:503.7pt;line-height:15.0pt"><span style="font-family:Springnew,serif;font-size:15.0pt">1 3</span></p>
<p style="top:708.8pt;left:48.7pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Table 2  </span></b><span style="font-family:STIX,serif;font-size:8.5pt">(continued)</span></p>
<p style="top:708.8pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Study</span></p>
<p style="top:614.5pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Sample/groups</span></p>
<p style="top:614.5pt;left:75.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(sample size)</span></p>
<p style="top:528.4pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Participant characteristics</span></p>
<p style="top:428.4pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Intervention/design</span></p>
<p style="top:337.4pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Outcome measures</span></p>
<p style="top:255.4pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Temporality of canna-</span></p>
<p style="top:255.4pt;left:75.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">bis use or measure</span></p>
<p style="top:171.4pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Main results</span></p>
<p style="top:708.8pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lucas et&#xa0;al., </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2013</span></p>
<p style="top:614.5pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Medical cannabis dis-</span></p>
<p style="top:608.5pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">pensary users (404)</span></p>
<p style="top:528.4pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Men/women medical can-</span></p>
<p style="top:522.4pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">nabis dispensary users</span></p>
<p style="top:428.4pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Descriptive survey study </span></p>
<p style="top:422.4pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">on cannabis use as a </span></p>
<p style="top:422.4pt;left:113.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">substitute for other </span></p>
<p style="top:422.4pt;left:123.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">drugs</span></p>
<p style="top:337.4pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cannabis use as a </span></p>
<p style="top:331.4pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">substitution for </span></p>
<p style="top:331.4pt;left:113.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">other drugs use</span></p>
<p style="top:255.4pt;left:93.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cannabis use (self-</span></p>
<p style="top:249.4pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">report) at the time of </span></p>
<p style="top:249.4pt;left:113.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">survey</span></p>
<p style="top:171.4pt;left:93.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span><span style="font-family:STIX,serif;font-size:8.5pt"> Cannabis use was reported as </span></p>
<p style="top:165.4pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">a substitute for illicit drugs, </span></p>
<p style="top:165.4pt;left:113.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">including METH (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">n</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> = 7) due </span></p>
<p style="top:165.4pt;left:123.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">to lesser withdrawal, fewer </span></p>
<p style="top:165.4pt;left:133.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">side effects, and better symp-</span></p>
<p style="top:165.4pt;left:143.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tom management</span></p>
<p style="top:708.8pt;left:155.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simons et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2008</span></p>
<p style="top:614.5pt;left:155.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Sample (2,270) con-</span></p>
<p style="top:608.5pt;left:165.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">taining METH (112) </span></p>
<p style="top:608.5pt;left:175.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and cannabis (1,087) </span></p>
<p style="top:608.5pt;left:185.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">users</span></p>
<p style="top:528.4pt;left:155.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Male/female college stu-</span></p>
<p style="top:522.4pt;left:165.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">dents with lifetime (&gt; 1 </span></p>
<p style="top:522.4pt;left:175.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">occasion) and/or current </span></p>
<p style="top:522.4pt;left:185.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(last 6&#xa0;month) METH use </span></p>
<p style="top:522.4pt;left:195.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and lifetime cannabis use</span></p>
<p style="top:428.4pt;left:155.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Prospective study on </span></p>
<p style="top:422.4pt;left:165.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">factors associated with </span></p>
<p style="top:422.4pt;left:175.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">METH use</span></p>
<p style="top:337.4pt;left:155.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Demographic and </span></p>
<p style="top:331.4pt;left:165.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">drug use pattern </span></p>
<p style="top:331.4pt;left:175.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">at baseline and </span></p>
<p style="top:331.4pt;left:185.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">6-month follow-up</span></p>
<p style="top:255.4pt;left:155.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lifetime cannabis use </span></p>
<p style="top:249.4pt;left:165.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">at baseline (self-</span></p>
<p style="top:249.4pt;left:175.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">report)</span></p>
<p style="top:171.4pt;left:155.8pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span><span style="font-family:STIX,serif;font-size:8.5pt"> Multivariate path-analysis </span></p>
<p style="top:165.4pt;left:165.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">model found METH-lifetime </span></p>
<p style="top:165.4pt;left:175.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">use at baseline and METH use </span></p>
<p style="top:165.4pt;left:185.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">at follow-up to be positively </span></p>
<p style="top:165.4pt;left:195.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">associated with lifetime can-</span></p>
<p style="top:165.4pt;left:205.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">nabis use (</span><i><span style="font-family:STIX,serif;font-size:8.5pt">b</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> = 1.03, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.001; </span></p>
<p style="top:165.4pt;left:215.8pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">b</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> = 0.60, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">p</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> &lt; 0.001)</span></p>
<p style="top:708.8pt;left:234.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Legends: Protective (</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span><span style="font-family:STIX,serif;font-size:8.5pt">), counter-protective (</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span><span style="font-family:STIX,serif;font-size:8.5pt">) or no effect ( </span><span style="font-family:Code2000,sans-serif;font-size:8.5pt">&#x2194;</span><span style="font-family:STIX,serif;font-size:8.5pt">) of cannabis/cannabinoid co-use with amphetamines on related outcomes. Abbreviation codes can be found at the abbreviation </span></p>
<p style="top:708.8pt;left:244.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">list</span></p>
<p style="top:32.8pt;left:528.3pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">1221</span></p>
<p style="top:32.8pt;left:50.4pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">Psychopharmacology (2022) 239:1211&#x2013;1230</span></p>


<p style="top:733.2pt;left:52.5pt;line-height:15.0pt"><span style="font-family:Springnew,serif;font-size:15.0pt">1 3</span></p>
<p style="top:56.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">of amphetamine-induced place-preference (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(3, 32) = 4.7, </span></p>
<p style="top:68.9pt;left:51.0pt;line-height:10.0pt"><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.01, post hoc </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05) (Parker et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2004</span><span style="font-family:STIX,serif;font-size:10.0pt">). CBD (10, </span></p>
<p style="top:81.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">20, 40 and 80&#xa0;mg/kg, i.p.) administrated 1&#xa0;h before metham-</span></p>
<p style="top:93.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">phetamine (2&#xa0;mg/kg, i.p.) administration (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 3&#x2013;10/group) </span></p>
<p style="top:106.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">reduced methamphetamine-induced place preference in a </span></p>
<p style="top:118.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">dose-dependent manner (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05) and decreased several </span></p>
<p style="top:131.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">methamphetamine-induced signalling pathways (e.g. Sigma1 </span></p>
<p style="top:143.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">receptor, p-AKT, p-GSK-3&#x3b2;, p-CREB) levels in the prefron-</span></p>
<p style="top:156.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tal cortex, nucleus accumbens, hippocampus, and ventral </span></p>
<p style="top:168.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tegmental area (all </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05) (Yang et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">). Single intrac-</span></p>
<p style="top:181.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">erebral ventricular CBD (10&#xa0;&#xb5;g/5&#xa0;&#xb5;l) administration 60&#xa0;min </span></p>
<p style="top:193.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">before methamphetamine (0.25 and 0.5&#xa0;mg/kg, s.c.) admin-</span></p>
<p style="top:206.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">istration in animals with/without sleep deprivation stress and </span></p>
<p style="top:218.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">methamphetamine-induced conditioned place preference </span></p>
<p style="top:231.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 4&#x2013;6/group) impaired methamphetamine-reinstatement </span></p>
<p style="top:243.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">response in both sleep and non-sleep deprived animals (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(3, </span></p>
<p style="top:256.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">22) = 11.13, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.001; </span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(2, 15) = 18.29, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.001, both post </span></p>
<p style="top:268.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">hoc </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05) (Karimi-Haghighi and Haghparast </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2018</span><span style="font-family:STIX,serif;font-size:10.0pt">). In </span></p>
<p style="top:281.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">a sequencing study with the same experimental conditions </span></p>
<p style="top:293.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 4&#x2013;5/group), IL</span><span style="font-family:Code2000,sans-serif;font-size:10.0pt">&#x2010;</span><span style="font-family:STIX,serif;font-size:10.0pt">1&#x3b2;, IL</span><span style="font-family:Code2000,sans-serif;font-size:10.0pt">&#x2010;</span><span style="font-family:STIX,serif;font-size:10.0pt">6 and IL</span><span style="font-family:Code2000,sans-serif;font-size:10.0pt">&#x2010;</span><span style="font-family:STIX,serif;font-size:10.0pt">10 mRNA expression </span></p>
<p style="top:306.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">in the prefrontal cortex, and TNF</span><span style="font-family:Code2000,sans-serif;font-size:10.0pt">&#x2010;</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x3b1;, IL</span><span style="font-family:Code2000,sans-serif;font-size:10.0pt">&#x2010;</span><span style="font-family:STIX,serif;font-size:10.0pt">1&#x3b2; and IL</span><span style="font-family:Code2000,sans-serif;font-size:10.0pt">&#x2010;</span><span style="font-family:STIX,serif;font-size:10.0pt">6 in the </span></p>
<p style="top:318.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">hippocampus were reduced in methamphetamine-induced </span></p>
<p style="top:331.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">reinstatement animals (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05). TNF</span><span style="font-family:Code2000,sans-serif;font-size:10.0pt">&#x2010;</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x3b1;, IL</span><span style="font-family:Code2000,sans-serif;font-size:10.0pt">&#x2010;</span><span style="font-family:STIX,serif;font-size:10.0pt">1&#x3b2;, IL</span><span style="font-family:Code2000,sans-serif;font-size:10.0pt">&#x2010;</span><span style="font-family:STIX,serif;font-size:10.0pt">6 and </span></p>
<p style="top:343.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">IL</span><span style="font-family:Code2000,sans-serif;font-size:10.0pt">&#x2010;</span><span style="font-family:STIX,serif;font-size:10.0pt">10 mRNA expression levels were augmented in the hip-</span></p>
<p style="top:356.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">pocampus, but IL</span><span style="font-family:Code2000,sans-serif;font-size:10.0pt">&#x2010;</span><span style="font-family:STIX,serif;font-size:10.0pt">10 was reduced in the prefrontal cortex of </span></p>
<p style="top:368.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">sleep-deprivation-induced reinstatement animals (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05) </span></p>
<p style="top:381.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(Karimi-Haghighi et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">).</span></p>
<p style="top:393.9pt;left:62.3pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Two vehicle-controlled studies in rats assessed the effects </span></p>
<p style="top:406.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">of repeated THC administration on amphetamine-induced </span></p>
<p style="top:418.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">sensitization (i.e. a drug-dependent increase of locomo-</span></p>
<p style="top:431.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tor activity). Repeated THC (0.75, 1.5 and 3.0&#xa0;mg/kg, i.p.) </span></p>
<p style="top:443.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">administration for 5&#xa0;days (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 6&#x2013;8/group) had no effect on </span></p>
<p style="top:456.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amphetamine-induced sensitization (0.5 and 2.0&#xa0;mg/kg, i.p.) </span></p>
<p style="top:468.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">in adolescent or adult rats (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(3, 97) = 0.38, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.001; </span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(4, </span></p>
<p style="top:481.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">95) = 23.2, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.001, post hoc </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &gt; 0.05) (Ellgren et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2004</span><span style="font-family:STIX,serif;font-size:10.0pt">); </span></p>
<p style="top:493.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">however, 27 THC (0.6, 3 and 15&#xa0;mg/kg, i.p.) administrations </span></p>
<p style="top:506.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">in a 3-week period (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 9&#x2013;12/group), 3 and 55&#xa0;days before </span></p>
<p style="top:518.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amphetamine (1&#xa0;mg/kg, i.p.) administration, increased </span></p>
<p style="top:531.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amphetamine sensitization in previously high-locomotion-</span></p>
<p style="top:543.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">responsive animals shortly after treatment (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">H</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(3) = 7.27, </span></p>
<p style="top:556.4pt;left:51.0pt;line-height:10.0pt"><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05, post hoc </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05), but not after longer time </span></p>
<p style="top:568.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(</span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &gt; 0.05) (Lamarque et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2001</span><span style="font-family:STIX,serif;font-size:10.0pt">).</span></p>
<p style="top:581.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Overall, studies with non-contingent models of amphet-</span></p>
<p style="top:593.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amine/methamphetamine exposure showed a protective </span></p>
<p style="top:606.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">potential of CBD by reducing amphetamine reward and risk </span></p>
<p style="top:618.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">of relapse and facilitating related memory extinction. CBD </span></p>
<p style="top:631.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">was also shown to reduce neuroinflammatory factors in the </span></p>
<p style="top:643.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">brain, though it also enhanced the same factors in one spe-</span></p>
<p style="top:656.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cific (sleep-deprivation stress) condition. While THC was </span></p>
<p style="top:668.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">found to potentiate the extinction of amphetamine-related </span></p>
<p style="top:681.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">memory, it also showed no or counter-protective effects, spe-</span></p>
<p style="top:693.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cifically in vulnerable drug animals, as measured by meth-</span></p>
<p style="top:706.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amphetamine sensitization.</span></p>
<p style="top:56.5pt;left:306.1pt;line-height:10.0pt"><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">Contingent models of&#xa0;addiction (n = 3)</span></b></p>
<p style="top:81.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Three vehicle-controlled studies assessed the effects of sin-</span></p>
<p style="top:94.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">gle or repeated CBD or THC administration in rats trained </span></p>
<p style="top:106.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">to self-administer amphetamine or methamphetamine on </span></p>
<p style="top:119.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cue- or amphetamine/methamphetamine-seeking (response </span></p>
<p style="top:131.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">to acquire drug), relapse (drug-seeking after drug self-</span></p>
<p style="top:144.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">administration extinction) or reinstatement. Single CBD (20, </span></p>
<p style="top:156.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">40 and 80&#xa0;mg/kg, i.p.) administration in animals trained to </span></p>
<p style="top:169.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">self-administer methamphetamine (0.05&#xa0;ml/infusion, i.v.) </span></p>
<p style="top:181.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">30&#xa0;min before methamphetamine-seeking and relapse trials </span></p>
<p style="top:194.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 10&#x2013;12/experiment) attenuated, at 80&#xa0;mg/kg, metham-</span></p>
<p style="top:206.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">phetamine-seeking and relapse responses (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(1, 9) = 13.84, </span></p>
<p style="top:219.0pt;left:306.1pt;line-height:10.0pt"><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 0.005; </span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(1.792, 19.707) = 45.96, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 0.021 both post </span></p>
<p style="top:231.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">hoc </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05), and at all doses reduced methamphetamine-</span></p>
<p style="top:244.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">induced hyperactivity (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(3, 33) = 11.01, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.001, all post </span></p>
<p style="top:256.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">hoc </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0 0.05) (Hay et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2018</span><span style="font-family:STIX,serif;font-size:10.0pt">). Acute delta-8-THC (0.32, </span></p>
<p style="top:269.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">1.0 and 3.2&#xa0;mg/kg, i.p.) administration before metham-</span></p>
<p style="top:281.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">phetamine self-administration extinction sessions (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 4&#x2013;8/</span></p>
<p style="top:294.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">group) attenuated, at 0.32&#xa0;mg/kg, methamphetamine-seeking </span></p>
<p style="top:306.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(3, 23) = 13.10, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.01, post hoc </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.001), at 1&#xa0;mg/kg </span></p>
<p style="top:319.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">enhanced methamphetamine cue-seeking (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(1, 10) = 12.20, </span></p>
<p style="top:331.5pt;left:306.1pt;line-height:10.0pt"><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.01, post hoc </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.001) and at 3.2&#xa0;mg/kg decreased </span></p>
<p style="top:344.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">methamphetamine- and cue-reinstatement (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(2, 19) = 14.6, </span></p>
<p style="top:356.5pt;left:306.1pt;line-height:10.0pt"><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.0001; </span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(1, 10) = 11.4, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.01, both post hoc </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.01), </span></p>
<p style="top:369.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">while repeated delta-8-THC (5&#xa0;days, 3.2&#xa0;mg/kg, i.p.) admin-</span></p>
<p style="top:381.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">istration decreased methamphetamine-reinstatement (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(2, </span></p>
<p style="top:394.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">20) = 22.08, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.0001, post hoc </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.001) (Anggadiredja </span></p>
<p style="top:406.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2004</span><span style="font-family:STIX,serif;font-size:10.0pt">). However, five administrations of THC (0.4, </span></p>
<p style="top:419.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">0.75, 1.5, 3.0 and 6.0&#xa0;mg/kg i.p.) in a 15-day period before </span></p>
<p style="top:431.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amphetamine administration (0.75&#xa0;mg/kg, i.p.) in animals </span></p>
<p style="top:444.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">with amphetamine self-administration history (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 6&#x2013;12/</span></p>
<p style="top:456.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">group) had no effect on dopamine levels and amphetamine </span></p>
<p style="top:469.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">self-administration (data not shown), but increased ampheta-</span></p>
<p style="top:481.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">mine-sensitization (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(5, 30) = 2.80, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05; </span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(5, 30) = 2.70, </span></p>
<p style="top:494.0pt;left:306.1pt;line-height:10.0pt"><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05, both post hoc </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05) (Cortright et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2011</span><span style="font-family:STIX,serif;font-size:10.0pt">).</span></p>
<p style="top:506.5pt;left:317.4pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Overall, contingent models of amphetamine/methamphet-</span></p>
<p style="top:519.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amine addiction studies generally showed a relapse-preven-</span></p>
<p style="top:531.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tive potential of CBD and THC by reducing the motivation </span></p>
<p style="top:544.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">to seek and consume methamphetamine, while one study </span></p>
<p style="top:556.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">showed THC to increase amphetamine-induced hyperloco-</span></p>
<p style="top:569.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">motion but without affecting its self-administration.</span></p>
<p style="top:593.2pt;left:306.1pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">Amphetamine&#x2011;induced mental health model </span></b></p>
<p style="top:605.7pt;left:306.1pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">or&#xa0;neurotoxicity (n = 6)</span></b></p>
<p style="top:631.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Four vehicle-controlled studies assessed the effects of sin-</span></p>
<p style="top:644.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">gle or repeated CBD administration, either by intraperi-</span></p>
<p style="top:656.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">toneal or intra-nucleus accumbens injections, before (D-) </span></p>
<p style="top:669.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amphetamine administration in a model of human psycho-</span></p>
<p style="top:681.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ses/mental health (e.g. schizophrenia, bipolar disorder) on </span></p>
<p style="top:694.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">behavioural and neurobiological outcomes. Single CBD </span></p>
<p style="top:706.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(15, 30 and 60&#xa0;mg/kg, i.p.) administration in mice (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 7/</span></p>
<p style="top:32.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">1222</span></p>
<p style="top:32.8pt;left:399.6pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">Psychopharmacology (2022) 239:1211&#x2013;1230</span></p>


<p style="top:733.2pt;left:503.7pt;line-height:15.0pt"><span style="font-family:Springnew,serif;font-size:15.0pt">1 3</span></p>
<p style="top:56.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">group) 20&#xa0; min before D-amphetamine administration </span></p>
<p style="top:68.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(5&#xa0;mg/kg, i.p.), at 30 and 60&#xa0;mg/kg, reduced D-ampheta-</span></p>
<p style="top:81.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">mine-induced hyperlocomotion and total distance travelled </span></p>
<p style="top:93.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">at selected time-points (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(45, 132) = 1.49, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 0.044, post </span></p>
<p style="top:106.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">hoc </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05) (Moreira and Guimar&#xe3;es </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2005</span><span style="font-family:STIX,serif;font-size:10.0pt">). Single CBD </span></p>
<p style="top:118.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(60&#xa0;nmol/0.2&#xa0;&#x3bc;l, intra-accumbens) administration in mice </span></p>
<p style="top:131.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 8&#x2013;10/group) immediately before amphetamine (10, 30 </span></p>
<p style="top:143.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and 60&#xa0;mg/kg, i.p.) administration and 10&#x2013;30&#xa0;min before </span></p>
<p style="top:156.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">pre-pulse inhibition test (i.e. reflex response inhibition by </span></p>
<p style="top:168.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">a weak sensory event) attenuated amphetamine-induced </span></p>
<p style="top:181.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">pre-pulse impairment (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(1, 25) = 6.38, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 0.018, post hoc </span></p>
<p style="top:193.9pt;left:51.0pt;line-height:10.0pt"><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05), but this effect was only marginally significant at </span></p>
<p style="top:206.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">30 and 60&#xa0;mg/kg doses (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(3, 67) = 4.09, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 0.07, post hoc </span></p>
<p style="top:218.9pt;left:51.0pt;line-height:10.0pt"><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05) (Pedrazzi et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015</span><span style="font-family:STIX,serif;font-size:10.0pt">). Repeated CBD (100&#xa0;ng/0.5 </span></p>
<p style="top:231.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ul, intra-accumbens) for five or 16 days and (in another </span></p>
<p style="top:243.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">group) immediately before a D-amphetamine-induced </span></p>
<p style="top:256.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(100&#xa0;ng/0.5 ul, intra-accumbens) model of schizophrenia in </span></p>
<p style="top:268.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">rats (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 8&#x2013;10/group) decreased D-amphetamine-induced </span></p>
<p style="top:281.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">hyperlocomotion, dopaminergic neuronal sensitization </span></p>
<p style="top:293.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(3, 36) = 18.711, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.001; </span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(5, 113) = 4.17, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.01, </span></p>
<p style="top:306.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">both post hoc </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05) and modified ventral tegmental </span></p>
<p style="top:318.9pt;left:50.9pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">area molecular pathways (e.g. mTOR and p70S6K increase </span></p>
<p style="top:331.4pt;left:50.9pt;line-height:10.0pt"><i><span style="font-family:STIX,serif;font-size:10.0pt">t</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(6) =  &#x2212; 3.60, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05; t(6) =  &#x2212; 3.70, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05) (Renard </span></p>
<p style="top:343.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2016</span><span style="font-family:STIX,serif;font-size:10.0pt">). However, twice-daily CBD (15, 30 and 60&#xa0;mg/</span></p>
<p style="top:356.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">kg, i.p.) administration for 6 or 14&#xa0;days (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 5/group), par-</span></p>
<p style="top:368.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tially concomitant to repeated D-amphetamine (2&#xa0;mg/kg, </span></p>
<p style="top:381.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">i.p.) administration, did not reverse or prevent a bipolar </span></p>
<p style="top:393.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">manic model (i.e. D-amphetamine-induced hyperlocomo-</span></p>
<p style="top:406.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tion) (data not shown), but at 15&#xa0;mg/kg protected from </span></p>
<p style="top:418.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the D-amphetamine-induced brain damage and at 30&#xa0;mg/</span></p>
<p style="top:431.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">kg increased BDNF levels in the hippocampus (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05) </span></p>
<p style="top:443.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(Valvassori et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2011</span><span style="font-family:STIX,serif;font-size:10.0pt">).</span></p>
<p style="top:456.4pt;left:62.3pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Two studies investigated the effect of THC or CBD </span></p>
<p style="top:468.9pt;left:50.9pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">administration on methamphetamine-induced neurotoxic-</span></p>
<p style="top:481.4pt;left:50.9pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ity on behavioural or biological outcomes of rats. Single </span></p>
<p style="top:493.9pt;left:50.9pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">THC (1 and 3&#xa0;mg/kg, i.p.) administration before or after </span></p>
<p style="top:506.4pt;left:50.9pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">methamphetamine-induced (10&#xa0;mg/kg, s.c.) neurotoxicity </span></p>
<p style="top:518.9pt;left:50.9pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(total </span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 109) decreased caudate-putamen GFAP-IR and </span></p>
<p style="top:531.4pt;left:50.9pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">nNOS-positive neurons in selected doses (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(2, 32) = 8.12, </span></p>
<p style="top:543.9pt;left:50.9pt;line-height:10.0pt"><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 0.001; </span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(2, 37) = 20.53, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.001, both post hoc </span></p>
<p style="top:556.4pt;left:50.9pt;line-height:10.0pt"><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.01) and in all doses decreased cingulate cortex GFAP-</span></p>
<p style="top:568.9pt;left:50.9pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">IR (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(2, 32) = 25.49, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.001, post hoc </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.001) but did </span></p>
<p style="top:581.4pt;left:50.9pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">not affect METH-increased body temperature (Castelli et&#xa0;al. </span></p>
<p style="top:593.9pt;left:50.9pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2014</span><span style="font-family:STIX,serif;font-size:10.0pt">). Repeated CBD administration (32 and 160&#xa0;nmol </span></p>
<p style="top:606.4pt;left:50.9pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">i.c.v./day) during a 10-day methamphetamine-abstinence </span></p>
<p style="top:618.9pt;left:50.9pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">period did not affect methamphetamine-induced hyperloco-</span></p>
<p style="top:631.4pt;left:50.9pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">motion (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(2, 21) = 0.08; </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &gt; 0.05), but both doses reversed </span></p>
<p style="top:643.9pt;left:50.9pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">methamphetamine-induced spatial memory impairment </span></p>
<p style="top:656.4pt;left:50.9pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(4, 37) = 7.12; </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.001, post hoc </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05), short-term </span></p>
<p style="top:668.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">memory impairment (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(4, 40) = 3.472; </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.005; post hoc </span></p>
<p style="top:681.4pt;left:51.0pt;line-height:10.0pt"><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05) and at 160&#xa0;nmol, long-term memory impairment </span></p>
<p style="top:693.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(2, 22) = 5 0.36; </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.025, post hoc </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05) (Razavi et&#xa0;al. </span></p>
<p style="top:706.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">).</span></p>
<p style="top:56.4pt;left:317.4pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Overall, for amphetamine-induced mental health, there </span></p>
<p style="top:68.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">was a CBD-related protective effect for amphetamine/</span></p>
<p style="top:81.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">methamphetamine-induced animal models of psychosis but </span></p>
<p style="top:93.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">not mania, suggesting antipsychotic-like action. Also, CBD </span></p>
<p style="top:106.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and THC protected against amphetamine/methamphetamine-</span></p>
<p style="top:118.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">induced brain damage.</span></p>
<p style="top:154.8pt;left:306.1pt;line-height:12.0pt"><b><span style="font-family:MyriadPro,serif;font-size:12.0pt">Studies in&#xa0;humans</span></b></p>
<p style="top:180.6pt;left:306.1pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">Brain structure/metabolism (n = 3)</span></b></p>
<p style="top:206.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Two case&#x2013;control studies compared adolescents with </span></p>
<p style="top:218.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">methamphetamine dependence, methamphetamine and </span></p>
<p style="top:231.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cannabis dependence and healthy controls on their brain </span></p>
<p style="top:243.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">structure or metabolism. Using proton magnetic resonance </span></p>
<p style="top:256.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">spectroscopy (MRS) to investigate neurochemical toxicity </span></p>
<p style="top:268.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">in the cingulate brain area in South African adolescents </span></p>
<p style="top:281.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 8&#x2013;10/group), Sung et&#xa0;al. (</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2013</span><span style="font-family:STIX,serif;font-size:10.0pt">) found no between-</span></p>
<p style="top:293.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">group differences in mI/PCr + Cr, GPC + PC/PCr + Cr and </span></p>
<p style="top:306.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Glu + Gln/PCr + Cr metabolite (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &gt; 0.05), but metham-</span></p>
<p style="top:318.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">phetamine and cannabis dependents (criteria not specified) </span></p>
<p style="top:331.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">had lower tNAA/PCr + Cr ratio than methamphetamine-</span></p>
<p style="top:343.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">only dependent subjects and healthy, non-drug-depend-</span></p>
<p style="top:356.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ent controls (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(2, 22) = 4.23, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 0.03, post hoc </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05). </span></p>
<p style="top:368.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Also, tNAA/PCr + Cr ratio correlated with several drug </span></p>
<p style="top:381.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">use patterns, e.g. a negative correlation with metham-</span></p>
<p style="top:393.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">phetamine and cannabis life-time-doses (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(1, 6) = 11.13, </span></p>
<p style="top:406.4pt;left:306.2pt;line-height:10.0pt"><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 0.02; </span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(1, 6) = 11.44, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 0.02). Churchwell et&#xa0;al. </span></p>
<p style="top:418.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2012</span><span style="font-family:STIX,serif;font-size:10.0pt">) used structural magnetic resonance images (MRI) </span></p>
<p style="top:431.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and found methamphetamine- and cannabis-dependent </span></p>
<p style="top:443.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(DSM-IV) US-based adolescents (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 9&#x2013;10/group) to have </span></p>
<p style="top:456.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">greater left putamen volume and higher novelty-seeking </span></p>
<p style="top:468.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">scores than healthy, non-drug-dependent controls (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(2, </span></p>
<p style="top:481.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">24) = 4.94, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.02; </span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(2, 24) = 3.56, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.04, both post </span></p>
<p style="top:493.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">hoc </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05); also, lifetime methamphetamine doses </span></p>
<p style="top:506.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">positively correlated to left putamen volume in metham-</span></p>
<p style="top:518.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">phetamine and methamphetamine + cannabis dependents </span></p>
<p style="top:531.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(</span><i><span style="font-family:STIX,serif;font-size:10.0pt">r</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(9) = 0.56, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 0.05; </span><i><span style="font-family:STIX,serif;font-size:10.0pt">r</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(8) = 0.65, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 0.04), and with </span></p>
<p style="top:543.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">novelty-seeking in methamphetamine-only dependents </span></p>
<p style="top:556.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(</span><i><span style="font-family:STIX,serif;font-size:10.0pt">r</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(9) = 0.64, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.03).</span></p>
<p style="top:568.9pt;left:317.5pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Another study, using positron emission tomographic </span></p>
<p style="top:581.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(PET) in US-based methamphetamine users with/without </span></p>
<p style="top:593.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cannabis co-use (&gt; 4 joints/month, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 7/group) during an </span></p>
<p style="top:606.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">auditory performance task (i.e. discrimination of high-</span></p>
<p style="top:618.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">pitched tone among lower-pitched tone distracters) found </span></p>
<p style="top:631.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">methamphetamine + cannabis users to have lower cerebral </span></p>
<p style="top:643.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">glucose metabolism (rCMRglc) in several brain regions, e.g. </span></p>
<p style="top:656.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">right orbitofrontal cortex, temporal gyrus, hippocampus (all </span></p>
<p style="top:668.9pt;left:306.2pt;line-height:10.0pt"><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05) but no difference in auditory performance accuracy </span></p>
<p style="top:681.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(</span><i><span style="font-family:STIX,serif;font-size:10.0pt">mean</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &#xb1; </span><i><span style="font-family:STIX,serif;font-size:10.0pt">SEM</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> [log 1 + % errors]): 0.69 &#xb1; 0.16; 0.80 &#xb1; 0.10) or </span></p>
<p style="top:693.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">reaction time (0.65 &#xb1; 0.06; 0.75 &#xb1; 0.07) was found (Voytek </span></p>
<p style="top:706.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2005</span><span style="font-family:STIX,serif;font-size:10.0pt">).</span></p>
<p style="top:32.8pt;left:528.3pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">1223</span></p>
<p style="top:32.8pt;left:50.4pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">Psychopharmacology (2022) 239:1211&#x2013;1230</span></p>


<p style="top:733.2pt;left:52.5pt;line-height:15.0pt"><span style="font-family:Springnew,serif;font-size:15.0pt">1 3</span></p>
<p style="top:56.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Overall, brain structure and metabolism studies showed </span></p>
<p style="top:68.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">that cannabinoids co-use with methamphetamines is associ-</span></p>
<p style="top:81.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ated with neurotoxicity and abnormal brain function.</span></p>
<p style="top:105.6pt;left:51.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">Neuropsychological function or&#xa0;psychopathology </span></b></p>
<p style="top:118.1pt;left:51.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">symptoms (n = 3)</span></b></p>
<p style="top:143.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Two case&#x2013;control studies assessed neuropsychological per-</span></p>
<p style="top:156.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">formance in adolescents or adults with methamphetamine </span></p>
<p style="top:168.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">dependence, methamphetamine + cannabis dependence and </span></p>
<p style="top:181.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">healthy controls. One study among South African adoles-</span></p>
<p style="top:193.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cents with methamphetamine + cannabis dependence (DSM-</span></p>
<p style="top:206.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">IV) (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 10) found their performance to be impaired in sev-</span></p>
<p style="top:218.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">eral neuropsychological tasks (e.g. verbal memory, planning, </span></p>
<p style="top:231.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">all </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05) compared to healthy, non-drug-dependent con-</span></p>
<p style="top:243.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">trols (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 20), and worse verbal memory (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.001) com-</span></p>
<p style="top:256.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">pared to methamphetamine-only dependents (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 10) (Cuzen </span></p>
<p style="top:268.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015</span><span style="font-family:STIX,serif;font-size:10.0pt">). Conversely, Gonzalez et&#xa0;al. (</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2004</span><span style="font-family:STIX,serif;font-size:10.0pt">) reported a </span></p>
<p style="top:281.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">linear worsening of neuropsychological performance in a </span></p>
<p style="top:293.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">US-based adult sample when considering lifetime canna-</span></p>
<p style="top:306.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">bis/methamphetamine dependence (DSM-IV), with better </span></p>
<p style="top:318.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">scores in the control (i.e. healthy, non-drug dependents) </span></p>
<p style="top:331.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">group (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 41), followed by methamphetamine + cannabis </span></p>
<p style="top:343.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 27) and methamphetamine-only dependents (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 26) </span></p>
<p style="top:356.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">groups (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(1, 92) = 9.75, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">R</span></i><sup><span style="font-family:STIX,serif;font-size:7.0pt">2</span></sup><span style="font-family:STIX,serif;font-size:10.0pt"> = 0.096, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 0.002). Moreo-</span></p>
<p style="top:368.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ver, methamphetamine-only dependents had worse learn-</span></p>
<p style="top:381.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ing, recall/retention and general neuropsychological per-</span></p>
<p style="top:393.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">formance scores than controls (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(2, 91) = 3.58, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05); </span></p>
<p style="top:406.4pt;left:51.0pt;line-height:10.0pt"><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(2, 91) = 4.09, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05; </span><i><span style="font-family:STIX,serif;font-size:10.0pt">F</span></i><span style="font-family:STIX,serif;font-size:10.0pt">(2, 91) = 4.92, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05, all post </span></p>
<p style="top:418.9pt;left:51.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">hoc </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.05). This same study also did not find between-</span></p>
<p style="top:431.4pt;left:51.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">group differences in lifetime psychiatric comorbid disor-</span></p>
<p style="top:443.9pt;left:51.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ders (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &gt; 0.05) and methamphetamine use among groups </span></p>
<p style="top:456.4pt;left:51.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(</span><i><span style="font-family:STIX,serif;font-size:10.0pt">z</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> =  &#x2212; 0.28, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 0.78).</span></p>
<p style="top:468.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">In regard to psychopathology, an Australian-based </span></p>
<p style="top:481.4pt;left:51.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">longitudinal prospective cohort with methamphetamine </span></p>
<p style="top:493.9pt;left:51.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">dependents (DSM-IV, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 278) found prior-month meth-</span></p>
<p style="top:506.4pt;left:51.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amphetamine use to be associated with increased odds of </span></p>
<p style="top:518.9pt;left:51.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">experiencing psychotic symptoms (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">OR</span></i><span style="font-family:STIX,serif;font-size:10.0pt">: 5.3, 95% CI [3.4, </span></p>
<p style="top:531.4pt;left:51.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">8.3]) and prior-month cannabis use (&#x2265; 16&#xa0;days) to further </span></p>
<p style="top:543.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">increase the odds of experiencing psychotic symptoms (95% </span></p>
<p style="top:556.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">CI [1.1, 3.5], </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 0.02), even when controlling for alcohol </span></p>
<p style="top:568.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">use (McKetin et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2013</span><span style="font-family:STIX,serif;font-size:10.0pt">).</span></p>
<p style="top:581.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Overall, two studies suggested that cannabis co-use was </span></p>
<p style="top:593.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">associated with increased methamphetamine-related harm by </span></p>
<p style="top:606.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">increasing neurocognitive impairment and psychotic symp-</span></p>
<p style="top:618.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">toms, while one found no exacerbation of cannabis exposure </span></p>
<p style="top:631.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">on methamphetamine-related neurotoxicity measures.</span></p>
<p style="top:655.6pt;left:51.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">Methamphetamine use patterns (n = 4)</span></b></p>
<p style="top:681.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Two US-based studies assessed different factors associated </span></p>
<p style="top:693.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">with methamphetamine use, including cannabis use. A cross-</span></p>
<p style="top:706.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">sectional study with 18&#x2013;34-year-old methamphetamine-users </span></p>
<p style="top:56.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(at least 1 prior-year use instance) using data from the pop-</span></p>
<p style="top:68.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ulation-representative National Survey of Drug Use and </span></p>
<p style="top:81.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Health (NSDUH, 2015/18) found that self-reported past-year </span></p>
<p style="top:93.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cannabis use strongly increased the risk of past-year meth-</span></p>
<p style="top:106.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amphetamine use (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 912) (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">aOR</span></i><span style="font-family:STIX,serif;font-size:10.0pt">: 5.51, 95% CI [4.22, 7.19]) </span></p>
<p style="top:118.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(Yockey et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">). A prospective study among a conveni-</span></p>
<p style="top:131.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ence sample of rural area college students (18&#x2013;25&#xa0;years </span></p>
<p style="top:143.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">old), based on a self-report electronic questionnaire con-</span></p>
<p style="top:156.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">taining methamphetamine (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 112) and cannabis (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 1,087) </span></p>
<p style="top:168.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">users, found methamphetamine-lifetime use at baseline and </span></p>
<p style="top:181.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">methamphetamine-use at 6-month follow-up (controlled by </span></p>
<p style="top:193.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">lifetime-methamphetamine use) to be positively associated </span></p>
<p style="top:206.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">with lifetime cannabis use (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">b</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 1.03, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.001; </span><i><span style="font-family:STIX,serif;font-size:10.0pt">b</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 0.60, </span></p>
<p style="top:218.9pt;left:306.1pt;line-height:10.0pt"><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> &lt; 0.001), although 89% of cannabis users reported having </span></p>
<p style="top:231.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">never used methamphetamine at 6-month follow-up (Simons </span></p>
<p style="top:243.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2008</span><span style="font-family:STIX,serif;font-size:10.0pt">).</span></p>
<p style="top:256.4pt;left:317.5pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Two Canada-based descriptive studies explored the influ-</span></p>
<p style="top:268.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ence of cannabis use on the use of other drugs (including </span></p>
<p style="top:281.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">methamphetamine) from the participants&#x2019; perspectives. A </span></p>
<p style="top:293.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">study with anonymous self-reported survey-data from a sam-</span></p>
<p style="top:306.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ple of medical cannabis dispensary users (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 404) reported </span></p>
<p style="top:318.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cannabis use as a substitute for illicit drugs (36.1%), includ-</span></p>
<p style="top:331.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ing methamphetamine (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 7), due to perceived lesser with-</span></p>
<p style="top:343.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">drawal, fewer side effects and better symptom management </span></p>
<p style="top:356.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">characteristics ascribed to cannabis use (Lucas et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2013</span><span style="font-family:STIX,serif;font-size:10.0pt">). </span></p>
<p style="top:368.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">In-depth qualitative interviews with street-involved young </span></p>
<p style="top:381.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">people (16&#x2013;26&#xa0;years old, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 56) and youth-focused care </span></p>
<p style="top:393.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">providers (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">n</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 13) reported that most drug users engaged </span></p>
<p style="top:406.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">in daily cannabis use at the same time as they used other </span></p>
<p style="top:418.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">substances (including methamphetamine), and several par-</span></p>
<p style="top:431.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ticipants described cannabis use as a form to alleviate harms </span></p>
<p style="top:443.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">from other drugs&#x2019; use. Respondents also perceived canna-</span></p>
<p style="top:456.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">bis use as being more effective than psychopharmaceuti-</span></p>
<p style="top:468.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cal-assisted treatments for mental health and substance use </span></p>
<p style="top:481.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">treatment, and few participants reported harms related to the </span></p>
<p style="top:493.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">intensive-cannabis use (Paul et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">).</span></p>
<p style="top:506.4pt;left:317.5pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Overall, two studies on methamphetamine use patterns </span></p>
<p style="top:518.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">showed cannabis use to be associated with increased meth-</span></p>
<p style="top:531.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amphetamine use; conversely, two self-reports suggested </span></p>
<p style="top:543.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cannabis use to alleviate harms from, or to substitute for, </span></p>
<p style="top:556.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">methamphetamine use.</span></p>
<p style="top:592.3pt;left:306.1pt;line-height:12.0pt"><b><span style="font-family:MyriadPro,serif;font-size:12.0pt">Discussion</span></b></p>
<p style="top:618.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Animal studies retrieved in this review showed mostly pro-</span></p>
<p style="top:631.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tective effects of both CBD and THC upon amphetamine </span></p>
<p style="top:643.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">exposure in models used to investigate several phases of </span></p>
<p style="top:656.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amphetamine addiction (e.g. drug-seeking, relapse, extinc-</span></p>
<p style="top:668.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tion) (Kuhn et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2019</span><span style="font-family:STIX,serif;font-size:10.0pt">; Spanagel </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2017</span><span style="font-family:STIX,serif;font-size:10.0pt">), and neurobiological </span></p>
<p style="top:681.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">markers (e.g. neurotoxicity, brain damage). While almost </span></p>
<p style="top:693.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">all CBD-based studies disclosed protective results, includ-</span></p>
<p style="top:706.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ing for alleviating amphetamine-induced psychosis, some </span></p>
<p style="top:32.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">1224</span></p>
<p style="top:32.8pt;left:399.6pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">Psychopharmacology (2022) 239:1211&#x2013;1230</span></p>


<p style="top:733.2pt;left:503.7pt;line-height:15.0pt"><span style="font-family:Springnew,serif;font-size:15.0pt">1 3</span></p>
<p style="top:56.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">studies with THC-agents reported no effect and one showed </span></p>
<p style="top:68.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">a counter-protective effect, suggesting a facilitated progres-</span></p>
<p style="top:81.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">sion of THC towards amphetamine use in vulnerable indi-</span></p>
<p style="top:93.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">viduals (i.e. prior high-locomotion responsive animals).</span></p>
<p style="top:106.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">The endocannabinoid system has been a topic of growing </span></p>
<p style="top:118.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">interest as a possible target for treating craving and addiction </span></p>
<p style="top:131.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">given its relationship to reward pathways, and substances </span></p>
<p style="top:143.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">acting on this system have been suggested as possible candi-</span></p>
<p style="top:156.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">dates for the pharmacotherapeutic treatment of substance use </span></p>
<p style="top:168.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">disorders (Batalla et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2019</span><span style="font-family:STIX,serif;font-size:10.0pt">; Chye et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2019</span><span style="font-family:STIX,serif;font-size:10.0pt">; Manzanares </span></p>
<p style="top:181.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2018</span><span style="font-family:STIX,serif;font-size:10.0pt">; Parsons and Hurd </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015</span><span style="font-family:STIX,serif;font-size:10.0pt">; Prud&apos;homme et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015</span><span style="font-family:STIX,serif;font-size:10.0pt">; </span></p>
<p style="top:193.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Spanagel </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">). Although the full mechanisms of action of </span></p>
<p style="top:206.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">CBD are yet to be determined, CBD has been reported to </span></p>
<p style="top:218.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">act as a negative allosteric modulator of the  CB</span><span style="font-family:STIX,serif;font-size:7.0pt">1</span><span style="font-family:STIX,serif;font-size:10.0pt"> receptor </span></p>
<p style="top:231.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and is unlikely to produce a rewarding effect (e.g. voluntary </span></p>
<p style="top:243.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">self-administration) (Ibeas Bih et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015</span><span style="font-family:STIX,serif;font-size:10.0pt">; Laprairie et&#xa0;al. </span></p>
<p style="top:256.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015</span><span style="font-family:STIX,serif;font-size:10.0pt">; Spanagel </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">). CBD also exerts its actions through </span></p>
<p style="top:268.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">other circuitry relevant to addictive disorder (e.g. 5HT1a, </span></p>
<p style="top:281.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">&#x3b1;7-nicotinic receptors), and some of its pharmacological </span></p>
<p style="top:293.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">effects such as reversing amphetamine-induced neuroinflam-</span></p>
<p style="top:306.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">mation and cognitive deficits, as well as alleviating men-</span></p>
<p style="top:318.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tal disorder comorbidities (e.g. anxiety, depression) can be </span></p>
<p style="top:331.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">implied as a therapeutic benefit for amphetamine addiction </span></p>
<p style="top:343.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(Calpe-L&#xf3;pez et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2019</span><span style="font-family:STIX,serif;font-size:10.0pt">; Manzanares et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2018</span><span style="font-family:STIX,serif;font-size:10.0pt">). In con-</span></p>
<p style="top:356.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">trast, THC features substantial differences in its pharmaco-</span></p>
<p style="top:368.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">logical actions that may account for the more heterogeneous </span></p>
<p style="top:381.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">results. By acting as an agonist of the  CB</span><span style="font-family:STIX,serif;font-size:7.0pt">1</span><span style="font-family:STIX,serif;font-size:10.0pt"> receptor, THC </span></p>
<p style="top:393.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">produces a dose-sensitive rewarding effect, with increasing </span></p>
<p style="top:406.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">doses shifting to negative, instead of positive, reinforce-</span></p>
<p style="top:418.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ment (Spanagel </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">). Moreover, the differences in results </span></p>
<p style="top:431.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">observed in THC studies, ranging from protective to counter-</span></p>
<p style="top:443.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">protective effects, indicate a possible benefit from THC to </span></p>
<p style="top:456.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amphetamine addiction that may depend on experimental </span></p>
<p style="top:468.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">factors (e.g. dose, length and timing of administration).</span></p>
<p style="top:481.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Overall, pre-clinical studies identified in this review </span></p>
<p style="top:493.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">aggregate evidence that phyto-cannabinoids, especially </span></p>
<p style="top:506.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">CBD, may have protective potential both for amphetamine </span></p>
<p style="top:518.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">addiction in several phases (e.g. relapse, abstinence) and for </span></p>
<p style="top:531.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">other amphetamine-related consequences (e.g. neurotoxic-</span></p>
<p style="top:543.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ity). Also, CBD showed some protective effects for amphet-</span></p>
<p style="top:556.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amine-induced models of psychosis. Amphetamine-induced </span></p>
<p style="top:568.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">sensitization is a useful animal model for assessing human </span></p>
<p style="top:581.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">mental health conditions (e.g. schizophrenia, mania) that </span></p>
<p style="top:593.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">relies on the behavioural and neurochemical, including toxic, </span></p>
<p style="top:606.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">effects of amphetamine (Featherstone et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2007</span><span style="font-family:STIX,serif;font-size:10.0pt">; Young </span></p>
<p style="top:618.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2011</span><span style="font-family:STIX,serif;font-size:10.0pt">). Moreover, investigating CBD&#x2019;s potential on </span></p>
<p style="top:631.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the amphetamine-induced model of mental health can pro-</span></p>
<p style="top:643.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">vide insights  &#xa0;into behavioural and neuroprotective factors </span></p>
<p style="top:656.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">that may be used translationally not only for specific men-</span></p>
<p style="top:668.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tal illness populations, but also to amphetamine users. For </span></p>
<p style="top:681.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">instance, some of the known psychiatric (e.g. acute mania or </span></p>
<p style="top:693.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">psychotic) symptoms of amphetamine exposure observed in </span></p>
<p style="top:706.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">different populations (Anand et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2000</span><span style="font-family:STIX,serif;font-size:10.0pt">; Curran et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2004</span><span style="font-family:STIX,serif;font-size:10.0pt">; </span></p>
<p style="top:56.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">McKetin et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2013</span><span style="font-family:STIX,serif;font-size:10.0pt">; Strakowski and Sax </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">1998</span><span style="font-family:STIX,serif;font-size:10.0pt">) could be </span></p>
<p style="top:68.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">reduced by CBD-related actions.</span></p>
<p style="top:81.4pt;left:317.5pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">In contrast, studies in human mostly showed counter-pro-</span></p>
<p style="top:93.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tective effects or no effect on the co-use of cannabis with </span></p>
<p style="top:106.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amphetamine for several outcomes, including brain (e.g. </span></p>
<p style="top:118.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">MRS, MRI), mental health, cognition (e.g. neuropsycho-</span></p>
<p style="top:131.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">logical performance, psychotic symptoms) and amphetamine </span></p>
<p style="top:143.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">use. Several factors may account for the observed discrepan-</span></p>
<p style="top:156.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cies with the human-based results and the growing body of </span></p>
<p style="top:168.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">literature suggesting a therapeutic potential of cannabinoids </span></p>
<p style="top:181.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">for addictive, including psychostimulant- and amphetamine-</span></p>
<p style="top:193.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">related behaviours (Abrams </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2018</span><span style="font-family:STIX,serif;font-size:10.0pt">; Prud&apos;homme et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015</span><span style="font-family:STIX,serif;font-size:10.0pt">). </span></p>
<p style="top:206.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">First, these studies are highly heterogeneous, with funda-</span></p>
<p style="top:218.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">mental differences in design (e.g. case&#x2013;control, longitudinal, </span></p>
<p style="top:231.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">prospective), cannabis use pattern (e.g. use or dependence), </span></p>
<p style="top:243.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">outcomes measured and population studied (e.g. college </span></p>
<p style="top:256.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">students, drug dependents). One major difference between </span></p>
<p style="top:268.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the pre-clinical and human studies that may account to the </span></p>
<p style="top:281.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">discrepant results is the cannabinoid/cannabis exposure </span></p>
<p style="top:293.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">pattern. While all human studies assessed cannabis and </span></p>
<p style="top:306.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amphetamines co-used within a naturalistic form of use and/</span></p>
<p style="top:318.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">or dependence, with no studies assessing the direct admin-</span></p>
<p style="top:331.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">istration (e.g. experimental setting) of cannabis or cannabis </span></p>
<p style="top:343.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">products (e.g. CBD, THC, Sativex&#xae;) on amphetamine users, </span></p>
<p style="top:356.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">pre-clinical studies did not evaluate cannabinoids within an </span></p>
<p style="top:368.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">abuse model (e.g. THC self-administration learning, condi-</span></p>
<p style="top:381.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tioned place preference).</span></p>
<p style="top:393.9pt;left:317.5pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Given the non-clinical nature, the human studies included </span></p>
<p style="top:406.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">did not control other relevant factors on addiction, such as </span></p>
<p style="top:418.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">drug (cannabinoid)-related conditioned response (e.g. elicit-</span></p>
<p style="top:431.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ing drug desire, triggering relapse) and social interactions </span></p>
<p style="top:443.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(Bardo et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2013</span><span style="font-family:STIX,serif;font-size:10.0pt">; Kenny et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2003</span><span style="font-family:STIX,serif;font-size:10.0pt">; O&apos;Brien et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">1998</span><span style="font-family:STIX,serif;font-size:10.0pt">; </span></p>
<p style="top:456.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Pelloux et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2019</span><span style="font-family:STIX,serif;font-size:10.0pt">). In addition to the common pathway (i.e. </span></p>
<p style="top:468.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">inhalation) that cannabis and amphetamine use may share, </span></p>
<p style="top:481.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the ongoing, naturalistic use of cannabis by participants, </span></p>
<p style="top:493.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">often taken as co-dependence, may entail a poly-substance </span></p>
<p style="top:506.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">use scenario, which is commonly associated with more co-</span></p>
<p style="top:518.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">occurring and/or severe problems (e.g. psychological dis-</span></p>
<p style="top:531.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tress, anxiety, depression) among users (Connor et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2013</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:543.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2014</span><span style="font-family:STIX,serif;font-size:10.0pt">). Also, it could be possible that amphetamine users </span></p>
<p style="top:556.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">with co-morbid conditions use cannabis in an attempt to </span></p>
<p style="top:568.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">self-regulate or self-treat comorbid mental health or cogni-</span></p>
<p style="top:581.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tive problems experienced. Some qualitative reports, mostly </span></p>
<p style="top:593.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">focusing on crack cocaine but also methamphetamine use, </span></p>
<p style="top:606.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">highlight intentional cannabis use patterns towards allevia-</span></p>
<p style="top:618.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tion of psychostimulant-related problems (Andrade et&#xa0;al. </span></p>
<p style="top:631.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2011</span><span style="font-family:STIX,serif;font-size:10.0pt">; Gon&#xe7;alves and Nappo </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015</span><span style="font-family:STIX,serif;font-size:10.0pt">; Paul et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">).</span></p>
<p style="top:643.9pt;left:317.5pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">On this basis, the absence of more controlled studies (e.g. </span></p>
<p style="top:656.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">clinical trials) for psychostimulants, and for amphetamines </span></p>
<p style="top:668.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">specifically, still represents a major gap in the field; con-</span></p>
<p style="top:681.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ducting such studies would allow for a better translation of </span></p>
<p style="top:693.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the pre-clinical findings into human/clinical setting. Despite </span></p>
<p style="top:706.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">these translational limitations, some of the human studies </span></p>
<p style="top:32.8pt;left:528.3pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">1225</span></p>
<p style="top:32.8pt;left:50.4pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">Psychopharmacology (2022) 239:1211&#x2013;1230</span></p>


<p style="top:733.2pt;left:52.5pt;line-height:15.0pt"><span style="font-family:Springnew,serif;font-size:15.0pt">1 3</span></p>
<p style="top:56.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">in this review suggest that cannabis use, especially when </span></p>
<p style="top:68.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">involving subjects with substance use disorder/dependence, </span></p>
<p style="top:81.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">may entail increased risks for adverse outcomes or co-mor-</span></p>
<p style="top:93.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">bidities among users, which highlights the importance of </span></p>
<p style="top:106.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">considering potential cannabis use-related risks as much as </span></p>
<p style="top:118.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">its therapeutic potential among amphetamine users.</span></p>
<p style="top:131.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Two descriptive studies in human samples reported can-</span></p>
<p style="top:143.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">nabis use reducing amphetamine use-related harms and </span></p>
<p style="top:156.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">detrimental effects, including one qualitative in-depth self-</span></p>
<p style="top:168.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">report study. Similar results have been reported more fre-</span></p>
<p style="top:181.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">quently for the co-use of cannabis with crack cocaine, and </span></p>
<p style="top:193.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">some observers have already proposed for cannabis applica-</span></p>
<p style="top:206.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tion use a pragmatic, substitutive or therapeutic option for </span></p>
<p style="top:218.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">other harmful drug use to be further investigated (Andrade </span></p>
<p style="top:231.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2011</span><span style="font-family:STIX,serif;font-size:10.0pt">; Gon&#xe7;alves and Nappo </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015</span><span style="font-family:STIX,serif;font-size:10.0pt">; Lau et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015</span><span style="font-family:STIX,serif;font-size:10.0pt">; </span></p>
<p style="top:243.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Soc&#xed;as et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2017</span><span style="font-family:STIX,serif;font-size:10.0pt">). Different dynamics in the context of </span></p>
<p style="top:256.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">drug use, motivational aspects or subpopulation specifi-</span></p>
<p style="top:268.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cities could be involved in these contrasting, protective </span></p>
<p style="top:281.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">results. However, while descriptive designs with qualitative </span></p>
<p style="top:293.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">approaches are relevant to investigate specific populations </span></p>
<p style="top:306.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(Patton </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015</span><span style="font-family:STIX,serif;font-size:10.0pt">), the identified studies are limited in nature </span></p>
<p style="top:318.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">since they rely on participants&#x2019; (or others&#x2019;) subjective per-</span></p>
<p style="top:331.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ception/beliefs and lack control measures for generalization </span></p>
<p style="top:343.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(e.g. control group, standardized measures, biased sample), </span></p>
<p style="top:356.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and, as such, conclusions are limited. At best, these results, </span></p>
<p style="top:368.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">together with the mostly enhanced harm outcomes in human </span></p>
<p style="top:381.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">study populations described, suggest that any possible ben-</span></p>
<p style="top:393.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">efits from cannabis use regarding amphetamines addiction </span></p>
<p style="top:406.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">is likely strongly dependent on patterns of cannabis use (e.g. </span></p>
<p style="top:418.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">timing, motivation, dependence).</span></p>
<p style="top:431.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Although the limitations of the studies in humans show-</span></p>
<p style="top:443.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ing some protective effects related to cannabinoids use (i.e. </span></p>
<p style="top:456.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">less frequently and/or less controlled than studies finding </span></p>
<p style="top:468.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">counter-protective effects), they reinforce, together with </span></p>
<p style="top:481.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the pre-clinical studies&#x2019; results, the necessity to conduct </span></p>
<p style="top:493.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">controlled studies on cannabinoids and their potential to </span></p>
<p style="top:506.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">alleviate amphetamine addiction or amphetamine-related </span></p>
<p style="top:518.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">deficits. Overall, in addition (or due) to the non-specific </span></p>
<p style="top:531.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cannabinoid&#x2019;s, especially CBD, mechanisms, the therapeu-</span></p>
<p style="top:543.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tic potential for substance use disorder may crucially vary </span></p>
<p style="top:556.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">according to the substance. For example, when considering </span></p>
<p style="top:568.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">other types of psychostimulants, two randomized controlled </span></p>
<p style="top:581.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">trials with repeated CBD administration on cocaine or crack </span></p>
<p style="top:593.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cocaine users found no differences in cue-induced craving or </span></p>
<p style="top:606.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">relapse risk (Meneses-Gaya et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">; Mongeau-P&#xe9;russe </span></p>
<p style="top:618.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2021</span><span style="font-family:STIX,serif;font-size:10.0pt">); conversely, controlled trials found a protective </span></p>
<p style="top:631.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">action of CBD for other drug classes (e.g. cannabinoids, </span></p>
<p style="top:643.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">opioids), either by reducing cue-induced craving or drug </span></p>
<p style="top:656.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">consumption (Freeman et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">; Hurd et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2019</span><span style="font-family:STIX,serif;font-size:10.0pt">; Morgan </span></p>
<p style="top:668.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2013</span><span style="font-family:STIX,serif;font-size:10.0pt">). For the specific case of amphetamines, there </span></p>
<p style="top:681.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">are different pathways in which CBD may have therapeutic </span></p>
<p style="top:693.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">effects for addiction-related outcomes. CBD agonist actions </span></p>
<p style="top:706.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">on serotoninergic and dopaminergic receptors could play </span></p>
<p style="top:56.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">a relevant role, given that the agonist action on 5-HT1a </span></p>
<p style="top:68.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">receptors can inhibit behaviours related to addiction, and </span></p>
<p style="top:81.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">partial dopaminergic agonists have been shown to attenuate </span></p>
<p style="top:93.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">stimulants self-administration in pre-clinical models (Calpe-</span></p>
<p style="top:106.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">L&#xf3;pez et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2019</span><span style="font-family:STIX,serif;font-size:10.0pt">; M&#xfc;ller and Homberg </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015</span><span style="font-family:STIX,serif;font-size:10.0pt">). Nevertheless, </span></p>
<p style="top:118.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">while much emphasis has been given on whether cannabi-</span></p>
<p style="top:131.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">noids may help with problematic substance use-related crav-</span></p>
<p style="top:143.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ing and relapse, a main role for cannabinoid products may </span></p>
<p style="top:156.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">also be able to decrease deleterious biological impact (e.g. </span></p>
<p style="top:168.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">neuronal toxicity, psychiatric symptoms) of amphetamines </span></p>
<p style="top:181.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and other drugs, as has been demonstrated by several of the </span></p>
<p style="top:193.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">pre-clinical studies included in this review (Castelli et&#xa0;al. </span></p>
<p style="top:206.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2014</span><span style="font-family:STIX,serif;font-size:10.0pt">; Karimi-Haghighi et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">; Prud&apos;homme et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015</span><span style="font-family:STIX,serif;font-size:10.0pt">; </span></p>
<p style="top:218.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Razavi et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2020</span><span style="font-family:STIX,serif;font-size:10.0pt">; Valvassori et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2011</span><span style="font-family:STIX,serif;font-size:10.0pt">).</span></p>
<p style="top:231.4pt;left:317.5pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">The present review&#x2019;s limited search and selection </span></p>
<p style="top:243.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">approach, including English-language studies only, number </span></p>
<p style="top:256.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">of databases, exclusive reliance on peer-reviewed (i.e. no </span></p>
<p style="top:268.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">grey literature) studies, may imply limitations of the pre-</span></p>
<p style="top:281.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">sent work. Furthermore, no meta-analyses of the study data </span></p>
<p style="top:293.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">were done given the heterogeneous approach and designs. In </span></p>
<p style="top:306.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">conclusion, data from pre-clinical studies suggest potentially </span></p>
<p style="top:318.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">protective effect of THC and CBD regarding amphetamine </span></p>
<p style="top:331.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(or methamphetamine)-related addiction behaviour and </span></p>
<p style="top:343.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">impairments, while human studies, despite some prelimi-</span></p>
<p style="top:356.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">nary protective results limited to specific populations, sug-</span></p>
<p style="top:368.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">gest greater morbidity between the co-use of cannabis and </span></p>
<p style="top:381.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">amphetamines in a range of (e.g. brain, cognitive, health) </span></p>
<p style="top:393.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">outcomes but mostly assessing natural cannabis use or </span></p>
<p style="top:406.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">abuse. Given recent evidence of increasing psychostimulant </span></p>
<p style="top:418.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">use and harms (e.g. in North America and elsewhere (Farrell </span></p>
<p style="top:431.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2019</span><span style="font-family:STIX,serif;font-size:10.0pt">; Fischer et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2021</span><span style="font-family:STIX,serif;font-size:10.0pt">; Strickland et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2019</span><span style="font-family:STIX,serif;font-size:10.0pt">)) and </span></p>
<p style="top:443.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">substantive pre-clinical evidence of cannabinoids therapeu-</span></p>
<p style="top:456.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tic potential for addiction (Chye et&#xa0;al. </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2019</span><span style="font-family:STIX,serif;font-size:10.0pt">; Parsons and </span></p>
<p style="top:468.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Hurd </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2015</span><span style="font-family:STIX,serif;font-size:10.0pt">), the dearth of systematic, rigorous (e.g. con-</span></p>
<p style="top:481.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">trolled clinical) studies assessing the potentially beneficial </span></p>
<p style="top:493.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">effects of cannabinoids on amphetamine-related health or </span></p>
<p style="top:506.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">behavioural outcomes should urgently be addressed.</span></p>
<p style="top:530.0pt;left:306.1pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Abbreviations</span></b><span style="font-family:STIX,serif;font-size:8.5pt"> AMPH:&#xa0;Amphetamine; aOR:&#xa0;Adjusted odds ratio; </span></p>
<p style="top:540.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">BDNF:&#xa0; Brain-derived neurotrophic factor; CBD:&#xa0; Cannabidiol; </span></p>
<p style="top:550.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">CB1:&#xa0; Cannabinoid receptor 1; CB2:&#xa0; Cannabinoid receptor 2; </span></p>
<p style="top:560.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">CI:&#xa0;Confidence interval; delta-8-THC:&#xa0;Delta-8-tetrahydrocannabinol; </span></p>
<p style="top:570.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ECS:&#xa0;Endocannabinoid system; GFAP:&#xa0;Glial fibrillary acidic pro-</span></p>
<p style="top:580.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tein; Glu + Gln/PCr + Cr:&#xa0;Glutamate plus glutamine/phosphocreatine </span></p>
<p style="top:590.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">plus creatine ratio; GPC + PC/PCr + Cr:&#xa0;Glycerophosphocholine plus </span></p>
<p style="top:600.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">phosphocholine/phosphocreatine plus creatine ratio; i.c.:&#xa0;Intracerebral; </span></p>
<p style="top:610.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">i.c.v.:&#xa0;Intracerebral ventricular; IL-1&#x3b2;:&#xa0;Interleukin 1&#x3b2;; IL-6:&#xa0;Interleukin </span></p>
<p style="top:620.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">6; IL-10:&#xa0;Interleukin 10; i.p.:&#xa0;Intraperitoneal; METH:&#xa0;Methampheta-</span></p>
<p style="top:630.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">mine; mI/PCr + Cr:&#xa0;Myo-inositol/phosphocreatine plus creatine ratio; </span></p>
<p style="top:640.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">MRS:&#xa0;Proton magnetic resonance spectroscopy; mRNA:&#xa0;Messenger </span></p>
<p style="top:650.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">RNA; mTOR:&#xa0;Mammalian target of rapamycin; NSDUH:&#xa0;National Sur-</span></p>
<p style="top:660.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">vey of Drug Use and Health; OR:&#xa0;Odds ratio; p-AKT:&#xa0;Phosphorylated </span></p>
<p style="top:670.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">protein kinase B; p-CREB:&#xa0;Phosphorylated cAMP-response element </span></p>
<p style="top:680.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">binding protein; PET:&#xa0;Positron emission tomography; p-GSK-3&#x3b2;:&#xa0;Phos-</span></p>
<p style="top:690.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">phorylated glycogen synthase kinase 3&#x3b2;; PPI:&#xa0;Prepulse inhibition; </span></p>
<p style="top:700.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">PRESS:&#xa0;Peer Review Electronic Search Strategies; p70S6K:&#xa0;P70S6 </span></p>
<p style="top:32.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">1226</span></p>
<p style="top:32.8pt;left:399.6pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">Psychopharmacology (2022) 239:1211&#x2013;1230</span></p>


<p style="top:733.2pt;left:503.7pt;line-height:15.0pt"><span style="font-family:Springnew,serif;font-size:15.0pt">1 3</span></p>
<p style="top:56.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">kinase; rCMRglc:&#xa0;Lower cerebral glucose metabolism; s.c.:&#xa0;Subcutane-</span></p>
<p style="top:66.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ous; SEM:&#xa0;Standard error of the mean; THC:&#xa0;Tetrahydrocannabinol; </span></p>
<p style="top:76.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tNAA/PCr + Cr:&#xa0;N-acetylaspartate plus N-acetylaspartyl glutamate/</span></p>
<p style="top:86.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">phosphocreatine plus creatine ratio; TNF-&#x3b1;:&#xa0;Tumor necrosis factor &#x3b1;; </span></p>
<p style="top:96.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">US:&#xa0;United States; 5-HT:&#xa0;5-Hydroxytryptamine (serotonin</span></p>
<p style="top:119.0pt;left:51.0pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Supplementary Information</span></b><span style="font-family:STIX,serif;font-size:8.5pt"> The online version contains supplemen-</span></p>
<p style="top:129.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tary material available at </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ s00213- 021- 05960-2</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:151.5pt;left:51.0pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Author contribution</span></b><span style="font-family:STIX,serif;font-size:8.5pt"> BF developed the concept for the study. DDB </span></p>
<p style="top:161.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">developed the review strategy and led the data collection and writing </span></p>
<p style="top:171.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">for the paper. DDB and LOM extracted, collated and analysed the data. </span></p>
<p style="top:181.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">All co-authors contributed to data/results interpretation and provided </span></p>
<p style="top:191.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">substantial intellectual content towards iterative drafts and revisions of </span></p>
<p style="top:201.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">the paper. All authors approved the final version of the paper submitted.</span></p>
<p style="top:224.0pt;left:51.0pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Funding</span></b><span style="font-family:STIX,serif;font-size:8.5pt"> Prof. Fischer acknowledges support from the endowed Hugh </span></p>
<p style="top:234.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Green Foundation Chair in Addiction Research, Faculty of Medical </span></p>
<p style="top:244.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and Health Sciences, University of Auckland; he furthermore reports </span></p>
<p style="top:254.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">research grants and contract funding from public only (e.g. public fund-</span></p>
<p style="top:263.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ing, government) agencies. Didier Jutras-Aswad holds a scholar award </span></p>
<p style="top:273.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">from the Fonds de recherche du Qu&#xe9;bec en Sant&#xe9; and has received </span></p>
<p style="top:283.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">investigational product from Insys Therapeutics for a clinical trial </span></p>
<p style="top:293.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">funded by the Canadian Institutes of Health Research; he furthermore </span></p>
<p style="top:303.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">reports research grants and contract funding from public (e.g. public </span></p>
<p style="top:313.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">funding, government) agencies.</span></p>
<p style="top:337.0pt;left:51.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">Declarations </span></b></p>
<p style="top:361.5pt;left:51.0pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Ethics aproval</span></b><span style="font-family:STIX,serif;font-size:8.5pt"> This article is based on previously conducted studies </span></p>
<p style="top:371.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and published data and does not involve any studies with human par-</span></p>
<p style="top:381.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ticipants or animals performed by any of the authors.</span></p>
<p style="top:406.5pt;left:51.0pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Conflict of interest</span></b><span style="font-family:STIX,serif;font-size:8.5pt"> The authors declare no competing interest.</span></p>
<p style="top:429.0pt;left:51.0pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Open Access</span></b><span style="font-family:STIX,serif;font-size:8.5pt"> This article is licensed under a Creative Commons Attri-</span></p>
<p style="top:438.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">bution 4.0 International License, which permits use, sharing, adapta-</span></p>
<p style="top:448.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tion, distribution and reproduction in any medium or format, as long </span></p>
<p style="top:458.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">as you give appropriate credit to the original author(s) and the source, </span></p>
<p style="top:468.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">provide a link to the Creative Commons licence, and indicate if changes </span></p>
<p style="top:478.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">were made. The images or other third party material in this article are </span></p>
<p style="top:488.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">included in the article&apos;s Creative Commons licence, unless indicated </span></p>
<p style="top:498.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">otherwise in a credit line to the material. If material is not included in </span></p>
<p style="top:508.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">the article&apos;s Creative Commons licence and your intended use is not </span></p>
<p style="top:518.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">permitted by statutory regulation or exceeds the permitted use, you will </span></p>
<p style="top:528.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">need to obtain permission directly from the copyright holder. To view a </span></p>
<p style="top:538.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">copy of this licence, visit </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">http:// creat iveco mmons. org/ licen ses/ by/4. 0/</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:573.7pt;left:51.0pt;line-height:12.0pt"><b><span style="font-family:MyriadPro,serif;font-size:12.0pt">References</span></b></p>
<p style="top:599.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Abrams DI (2018) The therapeutic effects of cannabis and cannabi-</span></p>
<p style="top:609.0pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">noids: an update from the National Academies of Sciences, Engi-</span></p>
<p style="top:619.0pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">neering and Medicine report. Eur J Intern Med 49:7&#x2013;11. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// </span></p>
<p style="top:628.9pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">doi. org/ 10. 1016/j. ejim. 2018. 01. 003</span></p>
<p style="top:638.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Anand A, Verhoeff P, Seneca N, Zoghbi SS, Seibyl JP, Charney DS, </span></p>
<p style="top:648.9pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Innis RB (2000) Brain SPECT imaging of amphetamine-induced </span></p>
<p style="top:658.9pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">dopamine release in euthymic bipolar disorder patients. Am J </span></p>
<p style="top:668.9pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Psychiatry 157:1108&#x2013;1114. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1176/ appi. ajp. </span></p>
<p style="top:678.9pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">157.7. 1108</span></p>
<p style="top:688.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Andrade T, Santiago L, Amari E, Fischer B (2011) &#x2018;What a pity!&#x2019; &#x2013; </span></p>
<p style="top:698.9pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">exploring the use of &#x2018;pitilho&#x2019; as harm reduction among crack </span></p>
<p style="top:56.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">users in Salvador Brazil. Drugs Ed Prev Policy 18:382&#x2013;386. </span></p>
<p style="top:66.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 3109/ 09687 637. 2010. 506898</span></p>
<p style="top:76.5pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Anggadiredja K, Nakamichi M, Hiranita T, Tanaka H, Shoyama Y, </span></p>
<p style="top:86.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Watanabe S, Yamamoto T (2004) Endocannabinoid system mod-</span></p>
<p style="top:96.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ulates relapse to methamphetamine seeking: possible mediation </span></p>
<p style="top:106.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">by the arachidonic acid cascade. Neuropsychopharmacology </span></p>
<p style="top:116.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">29:1470&#x2013;1478. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1038/ sj. npp. 13004 54</span></p>
<p style="top:126.5pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Arksey H, O&#x2019;Malley L (2005) Scoping studies: towards a methodologi-</span></p>
<p style="top:136.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cal framework. Int J Soc Res Methodol 8:19&#x2013;32. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ </span></p>
<p style="top:146.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">10. 1080/ 13645 57032 00011 9616</span></p>
<p style="top:156.5pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Bardo MT, Neisewander JL, Kelly TH (2013) Individual differences </span></p>
<p style="top:166.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and social influences on the neurobehavioral pharmacology of </span></p>
<p style="top:176.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">abused drugs. Pharmacol Rev 65:255&#x2013;290. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. </span></p>
<p style="top:186.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">1124/ pr. 111. 005124</span></p>
<p style="top:196.5pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Batalla A, Janssen H, Gangadin SS, Bossong MG (2019) The potential </span></p>
<p style="top:206.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">of cannabidiol as a treatment for psychosis and addiction: who </span></p>
<p style="top:216.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">benefits most? A systematic review. J Clin Med 8. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ </span></p>
<p style="top:226.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">10. 3390/ jcm80 71058</span></p>
<p style="top:236.5pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Brandt L, Chao T, Comer SD, Levin FR (2020) Pharmacotherapeutic </span></p>
<p style="top:246.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">strategies for treating cocaine use disorder - what do we have to </span></p>
<p style="top:256.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">offer? Addiction. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1111/ add. 15242</span></p>
<p style="top:266.5pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cabral GA, Ferreira GA, Jamerson MJ (2015) Endocannabinoids and </span></p>
<p style="top:276.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">the immune system in health and disease. Handb Exp Pharmacol </span></p>
<p style="top:286.4pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">231:185&#x2013;211. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ 978-3- 319- 20825-1_6</span></p>
<p style="top:296.4pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Calpe-L&#xf3;pez C, Garc&#xed;a-Pardo MP, Aguilar MA (2019) Cannabidiol </span></p>
<p style="top:306.4pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">treatment might promote resilience to cocaine and methampheta-</span></p>
<p style="top:316.4pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">mine use disorders: a review of possible mechanisms. Molecules </span></p>
<p style="top:326.4pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">24. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 3390/ molec ules2 41425 83</span></p>
<p style="top:336.4pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Castelli MP et&#xa0;al (2014) &#x394;9-tetrahydrocannabinol prevents metham-</span></p>
<p style="top:346.4pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">phetamine-induced neurotoxicity. PloS one 9:e98079. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. </span></p>
<p style="top:356.4pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">org/ 10. 1371/ journ al. pone. 00980 79</span></p>
<p style="top:366.4pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Castells X, Cunill R, P&#xe9;rez-Ma&#xf1;&#xe1; C, Vidal X, Capell&#xe0; D (2016) Psy-</span></p>
<p style="top:376.4pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">chostimulant drugs for cocaine dependence. Cochrane Database </span></p>
<p style="top:386.4pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Syst Rev. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1002/ 14651 858. CD007 380. pub4</span></p>
<p style="top:396.4pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Churchwell JC, Carey PD, Ferrett HL, Stein DJ, Yurgelun-Todd DA </span></p>
<p style="top:406.4pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(2012) Abnormal striatal circuitry and intensified novelty seek-</span></p>
<p style="top:416.4pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ing among adolescents who abuse methamphetamine and can-</span></p>
<p style="top:426.4pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">nabis. Dev Neurosci 34:310&#x2013;317. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1159/ 00033 </span></p>
<p style="top:436.4pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">7724</span></p>
<p style="top:446.4pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Chye Y, Christensen E, Solowij N, Y&#xfc;cel M (2019) The endocannabi-</span></p>
<p style="top:456.4pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">noid system and cannabidiol&apos;s promise for the treatment of sub-</span></p>
<p style="top:466.4pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">stance use disorder. Frontiers in Psychiatry 10. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ </span></p>
<p style="top:476.4pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">10. 3389/ fpsyt. 2019. 00063</span></p>
<p style="top:486.4pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Connor J, Gullo M, Chan G, Young R, Hall W, Feeney G (2013) Poly-</span></p>
<p style="top:496.4pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">substance use in cannabis users referred for treatment: drug use </span></p>
<p style="top:506.4pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">profiles, psychiatric comorbidity and cannabis-related beliefs. </span></p>
<p style="top:516.4pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Frontiers in Psychiatry 4. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 3389/ fpsyt. 2013. </span></p>
<p style="top:526.4pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">00079</span></p>
<p style="top:536.3pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Connor JP, Gullo MJ, White A, Kelly AB (2014) Polysubstance use: </span></p>
<p style="top:546.3pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">diagnostic challenges, patterns of use and health. Curr Opin Psy-</span></p>
<p style="top:556.3pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">chiatry 27:269&#x2013;275. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1097/ yco. 00000 00000 </span></p>
<p style="top:566.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">000069</span></p>
<p style="top:576.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cortright JJ, Lorrain DS, Beeler JA, Tang WJ, Vezina P (2011) Previ-</span></p>
<p style="top:586.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ous exposure to delta9-tetrahydrocannibinol enhances locomo-</span></p>
<p style="top:596.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tor responding to but not self-administration of amphetamine. J </span></p>
<p style="top:606.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Pharmacol Exp Ther 337:724&#x2013;733. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1124/ jpet. </span></p>
<p style="top:616.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">111. 180208</span></p>
<p style="top:626.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Crippa JA, Guimar&#xe3;es FS, Campos AC, Zuardi AW (2018) Transla-</span></p>
<p style="top:636.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tional investigation of the therapeutic potential of cannabidiol </span></p>
<p style="top:646.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(CBD): toward a new age. Front Immunol 9:2009. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. </span></p>
<p style="top:656.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">org/ 10. 3389/ fimmu. 2018. 02009</span></p>
<p style="top:666.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cumming C, Kinner SA, McKetin R, Li I, Preen D (2020) Metham-</span></p>
<p style="top:676.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">phetamine use, health and criminal justice system outcomes: a </span></p>
<p style="top:686.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">systematic review. Drug Alcohol Rev 39:505&#x2013;518. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. </span></p>
<p style="top:696.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">org/ 10. 1111/ dar. 13062</span></p>
<p style="top:32.8pt;left:528.3pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">1227</span></p>
<p style="top:32.8pt;left:50.4pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">Psychopharmacology (2022) 239:1211&#x2013;1230</span></p>


<p style="top:733.2pt;left:52.5pt;line-height:15.0pt"><span style="font-family:Springnew,serif;font-size:15.0pt">1 3</span></p>
<p style="top:56.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cumming C, Troeung L, Young JT, Kelty E, Preen DB (2016) Barriers </span></p>
<p style="top:66.6pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">to accessing methamphetamine treatment: a systematic review </span></p>
<p style="top:76.6pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and meta-analysis. Drug Alcohol Depend 168:263&#x2013;273. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// </span></p>
<p style="top:86.6pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">doi. org/ 10. 1016/j. druga lcdep. 2016. 10. 001</span></p>
<p style="top:96.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Curran C, Byrappa N, McBride A (2004) Stimulant psychosis: sys-</span></p>
<p style="top:106.6pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tematic review. Br J Psychiatry 185:196&#x2013;204. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. </span></p>
<p style="top:116.6pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">1192/ bjp. 185.3. 196</span></p>
<p style="top:126.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cuzen NL, Koopowitz S-M, Ferrett HL, Stein DJ, Yurgelun-Todd D </span></p>
<p style="top:136.6pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(2015) Methamphetamine and cannabis abuse in adolescence: a </span></p>
<p style="top:146.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">quasi-experimental study on specific and long-term neurocogni-</span></p>
<p style="top:156.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tive effects. BMJ Open 5:e005833. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1136/ bmjop </span></p>
<p style="top:166.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">en- 2014- 005833</span></p>
<p style="top:176.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Degenhardt L et&#xa0;al (2013) Global burden of disease attributable to </span></p>
<p style="top:186.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">illicit drug use and dependence: findings from the global burden </span></p>
<p style="top:196.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">of disease study 2010. Lancet (london, England) 382:1564&#x2013;1574. </span></p>
<p style="top:206.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/ s0140- 6736(13) 61530-5</span></p>
<p style="top:216.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Ellgren M, Hurd YL, Franck J (2004) Amphetamine effects on dopa-</span></p>
<p style="top:226.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">mine levels and behavior following cannabinoid exposure during </span></p>
<p style="top:236.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">adolescence. Eur J Pharmacol 497:205&#x2013;213. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. </span></p>
<p style="top:246.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">1016/j. ejphar. 2004. 06. 048</span></p>
<p style="top:256.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Farrell M et&#xa0;al (2019) Responding to global stimulant use: challenges </span></p>
<p style="top:266.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and opportunities. Lancet (london, England) 394:1652&#x2013;1667. </span></p>
<p style="top:276.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/ S0140- 6736(19) 32230-5</span></p>
<p style="top:286.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Featherstone RE, Kapur S, Fletcher PJ (2007) The amphetamine-</span></p>
<p style="top:296.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">induced sensitized state as a model of schizophrenia. Prog Neu-</span></p>
<p style="top:306.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ropsychopharmacol Biol Psychiatry 31:1556&#x2013;1571. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. </span></p>
<p style="top:316.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">org/ 10. 1016/j. pnpbp. 2007. 08. 025</span></p>
<p style="top:326.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Fischer B et&#xa0;al (2015a) Effectiveness of secondary prevention and treat-</span></p>
<p style="top:336.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ment interventions for crack-cocaine abuse: a comprehensive nar-</span></p>
<p style="top:346.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">rative overview of English-language studies. Int J Drug Policy </span></p>
<p style="top:356.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">26:352&#x2013;363. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/j. drugpo. 2015. 01. 002</span></p>
<p style="top:366.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Fischer B, Kuganesan S, Gallassi A, Malcher-Lopes R, van den Brink </span></p>
<p style="top:376.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">W, Wood E (2015b) Addressing the stimulant treatment gap: a </span></p>
<p style="top:386.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">call to investigate the therapeutic benefits potential of cannabi-</span></p>
<p style="top:396.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">noids for crack-cocaine use. Int J Drug Policy 26:1177&#x2013;1182. </span></p>
<p style="top:406.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/j. drugpo. 2015. 09. 005</span></p>
<p style="top:416.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Fischer B, O&#x2019;Keefe-Markman C, Lee A, Daldegan-Bueno D (2021) </span></p>
<p style="top:426.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">&#x2018;Resurgent&#x2019;, &#x2018;twin&#x2019; or &#x2018;silent&#x2019; epidemic? A select data overview </span></p>
<p style="top:436.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and observations on increasing psychostimulant use and harms in </span></p>
<p style="top:446.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">North America. Subt Abuse Treat Prevent Policy 16(17). </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// </span></p>
<p style="top:456.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">doi. org/ 10. 1186/ s13011- 021- 00350-5</span></p>
<p style="top:466.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Freeman TP et&#xa0;al (2020) Cannabidiol for the treatment of cannabis </span></p>
<p style="top:476.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">use disorder: a phase 2a, double-blind, placebo-controlled, ran-</span></p>
<p style="top:486.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">domised, adaptive Bayesian trial. Lancet Psychiat 7:865&#x2013;874. </span></p>
<p style="top:496.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/ S2215- 0366(20) 30290-X</span></p>
<p style="top:506.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">GlobeNewswire (2020) GW Pharmaceuticals plc and Its U.S. Subsidi-</span></p>
<p style="top:516.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ary Greenwich Biosciences, Inc. Announce That EPIDIOLEX&#xae; </span></p>
<p style="top:526.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(cannabidiol) oral solution has been descheduled and is no longer </span></p>
<p style="top:536.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">a controlled substance. GW Pharmaceuticals plc. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// www. </span></p>
<p style="top:546.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">globe newsw ire. com/ news- relea se/ 2020/ 04/ 06/ 20121 60/0/ en/ </span></p>
<p style="top:556.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">GW- Pharm aceut icals- plc- and- Its-U- S- Subsi diary- Green wich- </span></p>
<p style="top:566.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">Biosc iences- Inc- Annou nce- That- EPIDI OLEX- canna bidiol- Oral- </span></p>
<p style="top:576.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">Solut ion- Has- Been- Desch eduled- And- Is- No- Longer- A- Contr </span></p>
<p style="top:586.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">olled- Subst an. html</span><span style="font-family:STIX,serif;font-size:8.5pt">. Accessed June 17 2021</span></p>
<p style="top:596.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">GlobeNewswire (2021) GW Pharmaceuticals receives European com-</span></p>
<p style="top:606.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">mission approval for EPIDYOLEX&#xae; (cannabidiol) for the treat-</span></p>
<p style="top:616.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ment of seizures associated with tuberous sclerosis complex. </span></p>
<p style="top:626.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">GW Pharmaceuticals plc. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// www. globe newsw ire. com/ en/ </span></p>
<p style="top:636.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">news- relea se/ 2021/ 04/ 20/ 22130 53/ 26153/ en/ GW- Pharm aceut </span></p>
<p style="top:646.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">icals- recei ves- Europ ean- Commi ssion- appro val- for- EPIDY </span></p>
<p style="top:656.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">OLEX- canna bidiol- for- the- treat ment- of- seizu res- assoc iated- </span></p>
<p style="top:666.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">with- tuber ous- scler osis- compl ex. html</span><span style="font-family:STIX,serif;font-size:8.5pt">. Accessed June 17 2021</span></p>
<p style="top:676.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Gon&#xe7;alves JR, Nappo SA (2015) Factors that lead to the use of crack </span></p>
<p style="top:686.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cocaine in combination with marijuana in Brazil: a qualitative </span></p>
<p style="top:696.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">study. BMC Public Health 15:706. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1186/ </span></p>
<p style="top:706.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">s12889- 015- 2063-0</span></p>
<p style="top:56.3pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Gonzalez R et&#xa0;al (2004) Neurocognitive performance of methampheta-</span></p>
<p style="top:66.3pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">mine users discordant for history of marijuana exposure. Drug </span></p>
<p style="top:76.3pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Alcohol Depend 76:181&#x2013;190. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/j. druga </span></p>
<p style="top:86.3pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">lcdep. 2004. 04. 014</span></p>
<p style="top:96.3pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Hay GL et&#xa0;al (2018) Cannabidiol treatment reduces the motivation to </span></p>
<p style="top:106.3pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">self-administer methamphetamine and methamphetamine-primed </span></p>
<p style="top:116.3pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">relapse in rats. J Psychopharmacol 32:1369&#x2013;1378. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ </span></p>
<p style="top:126.3pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">10. 1177/ 02698 81118 799954</span></p>
<p style="top:136.3pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Hurd YL et&#xa0;al (2019) Cannabidiol for the reduction of cue-induced </span></p>
<p style="top:146.3pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">craving and anxiety in drug-abstinent individuals with heroin </span></p>
<p style="top:156.3pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">use disorder: a double-blind randomized placebo-controlled trial. </span></p>
<p style="top:166.3pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Am J Psychiatry 176:911&#x2013;922. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1176/ appi. ajp. </span></p>
<p style="top:176.3pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2019. 18101 191</span></p>
<p style="top:186.3pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ </span></p>
<p style="top:196.3pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(2015) Molecular targets of cannabidiol in neurological disor-</span></p>
<p style="top:206.3pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ders. Neurotherapeutics 12:699&#x2013;730. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ </span></p>
<p style="top:216.3pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">s13311- 015- 0377-3</span></p>
<p style="top:226.3pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Jutras-Aswad D, Le Foll B, Bruneau J, Wild TC, Wood E, Fischer </span></p>
<p style="top:236.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">B (2019) Thinking beyond legalization: the case for expanding </span></p>
<p style="top:246.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">evidence-based options for cannabis use disorder treatment in </span></p>
<p style="top:256.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Canada. Can J Psychiat 64:82&#x2013;87. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1177/ 07067 </span></p>
<p style="top:266.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">43718 790955</span></p>
<p style="top:276.2pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Karimi-Haghighi S, Dargahi L, Haghparast A (2020) Cannabidiol mod-</span></p>
<p style="top:286.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ulates the expression of neuroinflammatory factors in stress- and </span></p>
<p style="top:296.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">drug-induced reinstatement of methamphetamine in extinguished </span></p>
<p style="top:306.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">rats. Addict Biol 25:e12740. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1111/ adb. 12740</span></p>
<p style="top:316.2pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Karimi-Haghighi S, Haghparast A (2018) Cannabidiol inhibits prim-</span></p>
<p style="top:326.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ing-induced reinstatement of methamphetamine in REM sleep </span></p>
<p style="top:336.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">deprived rats. Prog Neuropsychopharmacol Biol Psychiatry </span></p>
<p style="top:346.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">82:307&#x2013;313. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/j. pnpbp. 2017. 08. 022</span></p>
<p style="top:356.2pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Kenny PJ, Koob GF, Markou A (2003) Conditioned facilitation of brain </span></p>
<p style="top:366.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">reward function after repeated cocaine administration. Behav </span></p>
<p style="top:376.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Neurosci 117:1103&#x2013;1107. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1037/ 0735- 7044. </span></p>
<p style="top:386.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">117.5. 1103</span></p>
<p style="top:396.2pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Knapp WP, Soares B, Farrell M, Silva de Lima M (2007) Psychoso-</span></p>
<p style="top:406.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cial interventions for cocaine and psychostimulant amphetamines </span></p>
<p style="top:416.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">related disorders. Cochrane Database Syst Rev. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ </span></p>
<p style="top:426.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">10. 1002/ 14651 858. CD003 023. pub2</span></p>
<p style="top:436.2pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Kogan NM, Mechoulam R (2007) Cannabinoids in health and disease. </span></p>
<p style="top:446.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Dialogues Clin Neurosci 9:413&#x2013;430. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 31887/ </span></p>
<p style="top:456.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">DCNS. 2007.9. 4/ nkogan</span></p>
<p style="top:466.2pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Kruk-Slomka M, Dzik A, Budzynska B, Biala G (2017) Endocannabi-</span></p>
<p style="top:476.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">noid system: the direct and indirect involvement in the memory </span></p>
<p style="top:486.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and learning processes - A short review. Mol Neurobiol 54:8332&#x2013;</span></p>
<p style="top:496.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">8347. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ s12035- 016- 0313-5</span></p>
<p style="top:506.1pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Kuhn BN, Kalivas PW, Bobadilla A-C (2019) Understanding addiction </span></p>
<p style="top:516.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">using animal models. Frontiers in Behavioral Neuroscience 13. </span></p>
<p style="top:526.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 3389/ fnbeh. 2019. 00262</span></p>
<p style="top:536.1pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lake CR, Quirk RS (1984) CNS stimulants and the look-alike drugs. </span></p>
<p style="top:546.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Psychiatr Clin North Am 7:689&#x2013;701</span></p>
<p style="top:556.1pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lamarque S, Taghzouti K, Simon H (2001) Chronic treatment with </span></p>
<p style="top:566.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">&#x394;</span><sup><span style="font-family:STIX,serif;font-size:5.9pt">9</span></sup><span style="font-family:STIX,serif;font-size:8.5pt">-tretrahydrocannabinol enhances the locomotor response to </span></p>
<p style="top:576.6pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">amphetamine and heroin. Implications for vulnerability to drug </span></p>
<p style="top:586.6pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">addiction. Neuropharmacology 41:118-129. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. </span></p>
<p style="top:596.6pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">1016/ S0028- 3908(01) 00039-9</span></p>
<p style="top:606.6pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM (2015) </span></p>
<p style="top:616.6pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cannabidiol is a negative allosteric modulator of the cannabinoid </span></p>
<p style="top:626.6pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">CB1 receptor. Br J Pharmacol 172:4790&#x2013;4805. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ </span></p>
<p style="top:636.6pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">10. 1111/ bph. 13250</span></p>
<p style="top:646.6pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lau N, Sales P, Averill S, Murphy F, Sato S-O, Murphy S (2015) A </span></p>
<p style="top:656.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">safer alternative: cannabis substitution as harm reduction. Drug </span></p>
<p style="top:666.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Alcohol Rev 34:654&#x2013;659. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1111/ dar. 12275</span></p>
<p style="top:676.5pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lee NK, Rawson RA (2008) A systematic review of cognitive and </span></p>
<p style="top:686.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">behavioural therapies for methamphetamine dependence. Drug </span></p>
<p style="top:696.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Alcohol Rev 27:309&#x2013;317. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1080/ 09595 23080 </span></p>
<p style="top:706.5pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">19194 94</span></p>
<p style="top:32.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">1228</span></p>
<p style="top:32.8pt;left:399.6pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">Psychopharmacology (2022) 239:1211&#x2013;1230</span></p>


<p style="top:733.2pt;left:503.7pt;line-height:15.0pt"><span style="font-family:Springnew,serif;font-size:15.0pt">1 3</span></p>
<p style="top:56.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lu H-C, Mackie K (2021) Review of the endocannabinoid system. Biol </span></p>
<p style="top:66.6pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Psychiat Cogn Neurosci Neuroimag 6:607&#x2013;615. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ </span></p>
<p style="top:76.6pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">10. 1016/j. bpsc. 2020. 07. 016</span></p>
<p style="top:86.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lucas P, Reiman A, Earleywine M, McGowan SK, Oleson M, Coward </span></p>
<p style="top:96.6pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">MP, Thomas B (2013) Cannabis as a substitute for alcohol and </span></p>
<p style="top:106.6pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">other drugs: a dispensary-based survey of substitution effect in </span></p>
<p style="top:116.6pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Canadian medical cannabis patients. Addict Res Theory 21:435&#x2013;</span></p>
<p style="top:126.6pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">442. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 3109/ 16066 359. 2012. 733465</span></p>
<p style="top:136.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Maldonado R, Valverde O, Berrendero F (2006) Involvement of the </span></p>
<p style="top:146.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">endocannabinoid system in drug addiction. Trends Neurosci </span></p>
<p style="top:156.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">29:225&#x2013;232. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/j. tins. 2006. 01. 008</span></p>
<p style="top:166.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Manzanares J, Caba&#xf1;ero D, Puente N, Garc&#xed;a-Guti&#xe9;rrez MS, Grandes </span></p>
<p style="top:176.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">P, Maldonado R (2018) Role of the endocannabinoid system in </span></p>
<p style="top:186.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">drug addiction. Biochem Pharmacol 157:108&#x2013;121. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. </span></p>
<p style="top:196.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">org/ 10. 1016/j. bcp. 2018. 09. 013</span></p>
<p style="top:206.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Marcu J (2020) The legalization of cannabinoid products and standard-</span></p>
<p style="top:216.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">izing cannabis-drug development in the United States: a brief </span></p>
<p style="top:226.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">report. Dialogues Clin Neurosci 22:289&#x2013;293. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. </span></p>
<p style="top:236.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">31887/ DCNS. 2020. 22.3/ jmarcu</span></p>
<p style="top:246.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Marshall BD, Werb D (2010) Health outcomes associated with meth-</span></p>
<p style="top:256.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">amphetamine use among young people: a systematic review. </span></p>
<p style="top:266.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Addiction 105:991&#x2013;1002. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1111/j. 1360- 0443. </span></p>
<p style="top:276.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2010. 02932.x</span></p>
<p style="top:286.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Marshall BDL, Galea S, Wood E, Kerr T (2011) Injection metham-</span></p>
<p style="top:296.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">phetamine use is associated with an increased risk of attempted </span></p>
<p style="top:306.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">suicide: a prospective cohort study. Drug Alcohol Depend </span></p>
<p style="top:316.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">119:134&#x2013;137. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/j. druga lcdep. 2011. 05. 012</span></p>
<p style="top:326.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre </span></p>
<p style="top:336.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">C (2016) PRESS Peer Review of Electronic Search Strategies: </span></p>
<p style="top:346.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2015 guideline statement. J Clin Epidemiol 75:40&#x2013;46. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// </span></p>
<p style="top:356.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">doi. org/ 10. 1016/j. jclin epi. 2016. 01. 021</span></p>
<p style="top:366.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">McKetin R et&#xa0;al (2019) Mental health outcomes associated with the </span></p>
<p style="top:376.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">use of amphetamines: A systematic review and meta-analysis. </span></p>
<p style="top:386.5pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">E Clinical Medicine 16:81&#x2013;97. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/j. eclinm. </span></p>
<p style="top:396.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2019. 09. 014</span></p>
<p style="top:406.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">McKetin R, Lubman DI, Baker AL, Dawe S, Ali RL (2013) Dose-</span></p>
<p style="top:416.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">related psychotic symptoms in chronic methamphetamine users: </span></p>
<p style="top:426.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">evidence from a prospective longitudinal study. JAMA Psychiat </span></p>
<p style="top:436.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">70:319&#x2013;324. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1001/ jamap sychi atry. 2013. 283</span></p>
<p style="top:446.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Mechoulam R, Parker LA (2013) The endocannabinoid system and </span></p>
<p style="top:456.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">the brain. Annu Rev Psychol 64:21&#x2013;47. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1146/ </span></p>
<p style="top:466.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">annur ev- psych- 113011- 143739</span></p>
<p style="top:476.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Meneses-Gaya CD et&#xa0;al (2020) Cannabidiol for the treatment of crack-</span></p>
<p style="top:486.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cocaine craving: An exploratory double-blind study. Brazil J </span></p>
<p style="top:496.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Psychiat. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1590/ 1516- 4446- 2020- 1416</span></p>
<p style="top:506.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Minozzi S, Saulle R, De Crescenzo F, Amato L (2016) Psychosocial </span></p>
<p style="top:516.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">interventions for psychostimulant misuse. Cochrane Datab Syst </span></p>
<p style="top:526.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Rev 9:Cd011866. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1002/ 14651 858. CD011 866. </span></p>
<p style="top:536.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">pub2</span></p>
<p style="top:546.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Mongeau-P&#xe9;russe V et&#xa0;al (2021) Cannabidiol as a treatment for crav-</span></p>
<p style="top:556.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ing and relapse in individuals with cocaine use disorder: a ran-</span></p>
<p style="top:566.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">domized placebo-controlled trial. Addiction. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. </span></p>
<p style="top:576.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">1111/ add. 15417</span></p>
<p style="top:586.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Moreira FA, Guimar&#xe3;es FS (2005) Cannabidiol inhibits the hyper-</span></p>
<p style="top:596.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">locomotion induced by psychotomimetic drugs in mice. Eur J </span></p>
<p style="top:606.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Pharmacol 512:199&#x2013;205. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/j. ejphar. 2005. </span></p>
<p style="top:616.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">02. 040</span></p>
<p style="top:626.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Morgan CJA, Das RK, Joye A, Curran HV, Kamboj SK (2013) Can-</span></p>
<p style="top:636.4pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">nabidiol reduces cigarette consumption in tobacco smokers: pre-</span></p>
<p style="top:646.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">liminary findings. Addict Behav 38:2433&#x2013;2436. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ </span></p>
<p style="top:656.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">10. 1016/j. addbeh. 2013. 03. 011</span></p>
<p style="top:666.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Morley KC, Cornish JL, Faingold A, Wood K, Haber PS (2017) Phar-</span></p>
<p style="top:676.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">macotherapeutic agents in the treatment of methamphetamine </span></p>
<p style="top:686.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">dependence. Expert Opin Investig Drugs 26:563&#x2013;578. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// </span></p>
<p style="top:696.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">doi. org/ 10. 1080/ 13543 784. 2017. 13132 29</span></p>
<p style="top:56.3pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">M&#xfc;ller CP, Homberg JR (2015) The role of serotonin in drug use and </span></p>
<p style="top:66.3pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">addiction. Behav Brain Res 277:146&#x2013;192. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. </span></p>
<p style="top:76.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">1016/j. bbr. 2014. 04. 007</span></p>
<p style="top:86.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">NASEM (2017) The health effects of cannabis and cannabinoids: the </span></p>
<p style="top:96.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">current state of evidence and recommendations for research. The </span></p>
<p style="top:106.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">National Academies Press, Washington, DC. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. </span></p>
<p style="top:116.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">17226/ 24625</span></p>
<p style="top:126.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">O&#x2019;Brien CP, Childress AR, Ehrman R, Robbins SJ (1998) Conditioning </span></p>
<p style="top:136.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">factors in drug abuse: Can they explain compulsion? J Psychop-</span></p>
<p style="top:146.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">harmacol 12:15&#x2013;22. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1177/ 02698 81198 01200 </span></p>
<p style="top:156.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">103</span></p>
<p style="top:166.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Parker LA, Burton P, Sorge RE, Yakiwchuk C, Mechoulam R (2004) </span></p>
<p style="top:176.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Effect of low doses of delta9-tetrahydrocannabinol and can-</span></p>
<p style="top:186.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">nabidiol on the extinction of cocaine-induced and ampheta-</span></p>
<p style="top:196.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">mine-induced conditioned place preference learning in rats. </span></p>
<p style="top:206.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Psychopharmacology 175:360&#x2013;366. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ </span></p>
<p style="top:216.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">s00213- 004- 1825-7</span></p>
<p style="top:226.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Parsons LH, Hurd YL (2015) Endocannabinoid signalling in reward </span></p>
<p style="top:236.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and addiction. Nat Rev Neurosci 16:579&#x2013;594. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. </span></p>
<p style="top:246.3pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">1038/ nrn40 04</span></p>
<p style="top:256.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Patton MQ (2015) Qualitative research &amp; evaluation methods: integrat-</span></p>
<p style="top:266.2pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ing theory and practice. 4 edn. Sage/Learning Matters, Thousand </span></p>
<p style="top:276.2pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Oaks</span></p>
<p style="top:286.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Paul B, Thulien M, Knight R, Milloy MJ, Howard B, Nelson S, Fast </span></p>
<p style="top:296.2pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">D (2020) &#x201c;Something that actually works&#x201d;: cannabis use among </span></p>
<p style="top:306.2pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">young people in the context of street entrenchment. PloS one </span></p>
<p style="top:316.2pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">15:e0236243. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1371/ journ al. pone. 02362 43</span></p>
<p style="top:326.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Peacock A et&#xa0;al (2018) Global statistics on alcohol, tobacco and illicit </span></p>
<p style="top:336.2pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">drug use: 2017 status report. Addiction 113:1905&#x2013;1926. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// </span></p>
<p style="top:346.2pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">doi. org/ 10. 1111/ add. 14234</span></p>
<p style="top:356.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Pedrazzi JF, Issy AC, Gomes FV, Guimar&#xe3;es FS, Del-Bel EA (2015) </span></p>
<p style="top:366.2pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cannabidiol effects in the prepulse inhibition disruption induced </span></p>
<p style="top:376.2pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">by amphetamine. Psychopharmacology 232:3057&#x2013;3065. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// </span></p>
<p style="top:386.2pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">doi. org/ 10. 1007/ s00213- 015- 3945-7</span></p>
<p style="top:396.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Pelloux Y, Giorla E, Montanari C, Baunez C (2019) Social modu-</span></p>
<p style="top:406.2pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">lation of drug use and drug addiction. Neuropharmacology </span></p>
<p style="top:416.2pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">159:107545. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/j. neuro pharm. 2019. 02. 027</span></p>
<p style="top:426.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">P&#xe9;rez-Ma&#xf1;&#xe1; C, Castells X, Torrens M, Capell&#xe0; D, Farre M (2013) </span></p>
<p style="top:436.2pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Efficacy of psychostimulant drugs for amphetamine abuse or </span></p>
<p style="top:446.2pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">dependence. Cochrane Database Syst Rev. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. </span></p>
<p style="top:456.2pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">1002/ 14651 858. CD009 695. pub2</span></p>
<p style="top:466.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Prud&#x2019;homme M, Cata R, Jutras-Aswad D (2015) Cannabidiol as an </span></p>
<p style="top:476.2pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">intervention for addictive behaviors: A systematic review of the </span></p>
<p style="top:486.2pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">evidence. Subst Abuse 9:33&#x2013;38. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 4137/ sart. </span></p>
<p style="top:496.2pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">S25081</span></p>
<p style="top:506.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Rathbone J, Carter M, Hoffmann T, Glasziou P (2015) Better dupli-</span></p>
<p style="top:516.1pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cate detection for systematic reviewers: evaluation of systematic </span></p>
<p style="top:526.1pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">review assistant-deduplication Module. Syst Rev 4:6. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. </span></p>
<p style="top:536.1pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">org/ 10. 1186/ 2046- 4053-4-6</span></p>
<p style="top:546.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Razavi Y, Shabani R, Mehdizadeh M, Haghparast A (2020) Neuropro-</span></p>
<p style="top:556.1pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tective effect of chronic administration of cannabidiol during the </span></p>
<p style="top:566.1pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">abstinence period on methamphetamine-induced impairment of </span></p>
<p style="top:576.1pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">recognition memory in the rats. Behav Pharmacol 31:385&#x2013;396. </span></p>
<p style="top:586.1pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1097/ fbp. 00000 00000 000544</span></p>
<p style="top:596.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Renard J et&#xa0;al (2016) Cannabidiol counteracts amphetamine-induced </span></p>
<p style="top:606.1pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">neuronal and behavioral sensitization of the mesolimbic dopa-</span></p>
<p style="top:616.1pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">mine pathway through a novel mTOR/p70S6 kinase signaling </span></p>
<p style="top:626.1pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">pathway. J Neurosci 36:5160&#x2013;5169. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1523/ jneur </span></p>
<p style="top:636.1pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">osci. 3387- 15. 2016</span></p>
<p style="top:646.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Ronsley C et&#xa0;al (2020) Treatment of stimulant use disorder: a system-</span></p>
<p style="top:656.1pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">atic review of reviews. PloS one 15:e0234809. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. </span></p>
<p style="top:666.1pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">1371/ journ al. pone. 02348 09</span></p>
<p style="top:676.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Shearer J (2007) Psychosocial approaches to psychostimulant depend-</span></p>
<p style="top:686.1pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ence: a systematic review. J Subst Abuse Treat 32:41&#x2013;52. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// </span></p>
<p style="top:696.1pt;left:326.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">doi. org/ 10. 1016/j. jsat. 2006. 06. 012</span></p>
<p style="top:32.8pt;left:528.3pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">1229</span></p>
<p style="top:32.8pt;left:50.4pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">Psychopharmacology (2022) 239:1211&#x2013;1230</span></p>


<p style="top:733.2pt;left:52.5pt;line-height:15.0pt"><span style="font-family:Springnew,serif;font-size:15.0pt">1 3</span></p>
<p style="top:468.7pt;left:51.0pt;line-height:12.0pt"><b><span style="font-family:MyriadPro,serif;font-size:12.0pt">Authors and Affiliations</span></b></p>
<p style="top:495.3pt;left:51.0pt;line-height:10.0pt"><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">Dimitri&#xa0;Daldegan&#x2011;Bueno</span></b><sup><b><span style="font-family:MyriadPro,serif;font-size:7.0pt">1</span></b></sup><b><span style="font-family:MyriadPro,serif;font-size:10.0pt"> &#xa0;&#xb7; Lucas&#xa0;O.&#xa0;Maia</span></b><sup><b><span style="font-family:MyriadPro,serif;font-size:7.0pt">2</span></b></sup><b><span style="font-family:MyriadPro,serif;font-size:10.0pt"> &#xa0;&#xb7; Michelle&#xa0;Glass</span></b><sup><b><span style="font-family:MyriadPro,serif;font-size:7.0pt">3</span></b></sup><b><span style="font-family:MyriadPro,serif;font-size:10.0pt"> &#xa0;&#xb7; Didier&#xa0;Jutras&#x2011;Aswad</span></b><sup><b><span style="font-family:MyriadPro,serif;font-size:7.0pt">4,5</span></b></sup><b><span style="font-family:MyriadPro,serif;font-size:10.0pt"> &#xa0;&#xb7; Benedikt&#xa0;Fischer</span></b><sup><b><span style="font-family:MyriadPro,serif;font-size:7.0pt">1,2,6,7</span></b></sup><b><span style="font-family:MyriadPro,serif;font-size:10.0pt"> </span></b></p>
<p style="top:520.2pt;left:51.0pt;line-height:5.9pt"><span style="font-family:STIX,serif;font-size:5.9pt">1</span><span style="font-family:STIX,serif;font-size:8.5pt"> </span></p>
<p style="top:521.5pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Schools of&#xa0;Population Health and&#xa0;Pharmacy, Faculty </span></p>
<p style="top:531.5pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">of&#xa0;Medical and&#xa0;Health Sciences, University of&#xa0;Auckland, 85 </span></p>
<p style="top:541.5pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Park Rd, Grafton, Auckland&#xa0;1023, New&#xa0;Zealand</span></p>
<p style="top:555.2pt;left:51.0pt;line-height:5.9pt"><span style="font-family:STIX,serif;font-size:5.9pt">2</span><span style="font-family:STIX,serif;font-size:8.5pt"> </span></p>
<p style="top:556.5pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Centre for&#xa0;Applied Research in&#xa0;Mental Health &amp; Addiction, </span></p>
<p style="top:566.5pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simon Fraser University, 515 W. Hastings Street,, Vancouver, </span></p>
<p style="top:576.5pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">BC&#xa0;V6B&#xa0;5K3, Canada</span></p>
<p style="top:590.2pt;left:51.0pt;line-height:5.9pt"><span style="font-family:STIX,serif;font-size:5.9pt">3</span><span style="font-family:STIX,serif;font-size:8.5pt"> </span></p>
<p style="top:591.6pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Department of&#xa0;Pharmacology and&#xa0;Toxicology, University </span></p>
<p style="top:601.6pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">of&#xa0;Otago, PO Box&#xa0;56, Dunedin&#xa0;9054, Otago, New&#xa0;Zealand</span></p>
<p style="top:615.2pt;left:51.0pt;line-height:5.9pt"><span style="font-family:STIX,serif;font-size:5.9pt">4</span><span style="font-family:STIX,serif;font-size:8.5pt"> </span></p>
<p style="top:616.6pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Centre de Recherche, Centre Hospitalier Universitaire de </span></p>
<p style="top:626.6pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Universite de Montreal (CHUM), 1051 Rue Sanguinet, </span></p>
<p style="top:636.6pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Montr&#xe9;al, QC&#xa0;H2X&#xa0;3E4, Canada</span></p>
<p style="top:520.2pt;left:306.1pt;line-height:5.9pt"><span style="font-family:STIX,serif;font-size:5.9pt">5</span><span style="font-family:STIX,serif;font-size:8.5pt"> </span></p>
<p style="top:521.5pt;left:320.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Department of&#xa0;Psychiatry and&#xa0;Addiction, Faculty </span></p>
<p style="top:531.5pt;left:320.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">of&#xa0;Medicine, Universit&#xe9; de Montr&#xe9;al, Pavillon Roger-Gaudry, </span></p>
<p style="top:541.5pt;left:320.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2900 Edouard Montpetit Blvd, Montreal, QC&#xa0;H3T&#xa0;1J4, </span></p>
<p style="top:551.5pt;left:320.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Canada</span></p>
<p style="top:565.2pt;left:306.1pt;line-height:5.9pt"><span style="font-family:STIX,serif;font-size:5.9pt">6</span><span style="font-family:STIX,serif;font-size:8.5pt"> </span></p>
<p style="top:566.5pt;left:320.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Department of&#xa0;Psychiatry, University of&#xa0;Toronto, 250 </span></p>
<p style="top:576.5pt;left:320.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">College Street, 8Th Floor, Toronto, ON&#xa0;M5T&#xa0;1R8, Canada</span></p>
<p style="top:590.2pt;left:306.1pt;line-height:5.9pt"><span style="font-family:STIX,serif;font-size:5.9pt">7</span><span style="font-family:STIX,serif;font-size:8.5pt"> </span></p>
<p style="top:591.6pt;left:320.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Department of&#xa0;Psychiatry, Federal University of&#xa0;Sao </span></p>
<p style="top:601.6pt;left:320.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Paulo (UNIFESP), R. Dr. Ov&#xed;dio Pires de Campos, </span></p>
<p style="top:611.6pt;left:320.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Sao&#xa0;Paulo&#xa0;785&#xa0;05403-903, Brazil</span></p>
<p style="top:57.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Shorter D, Domingo CB, Kosten TR (2015) Emerging drugs for the </span></p>
<p style="top:67.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">treatment of cocaine use disorder: a review of neurobiological </span></p>
<p style="top:77.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">targets and pharmacotherapy. Expert Opin Emerg Drugs 20:15&#x2013;</span></p>
<p style="top:87.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">29. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1517/ 14728 214. 2015. 985203</span></p>
<p style="top:97.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Siefried KJ, Acheson LS, Lintzeris N, Ezard N (2020) Pharmacologi-</span></p>
<p style="top:107.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cal treatment of methamphetamine/amphetamine dependence: a </span></p>
<p style="top:117.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">systematic review. CNS Drugs 34:337&#x2013;365. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. </span></p>
<p style="top:127.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">1007/ s40263- 020- 00711-x</span></p>
<p style="top:137.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simons JS, Dvorak RD, Batien BD (2008) Methamphetamine use </span></p>
<p style="top:147.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">in a rural college population: associations with marijuana use, </span></p>
<p style="top:157.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">sensitivity to punishment, and sensitivity to reward. Psychol </span></p>
<p style="top:167.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Addict Behav 22:444&#x2013;449. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1037/ 0893- 164x. </span></p>
<p style="top:177.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">22.3. 444</span></p>
<p style="top:187.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Soc&#xed;as ME et&#xa0;al (2017) Intentional cannabis use to reduce crack cocaine </span></p>
<p style="top:197.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">use in a Canadian setting: a longitudinal analysis. Addict Behav </span></p>
<p style="top:207.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">72:138&#x2013;143. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/j. addbeh. 2017. 04. 006</span></p>
<p style="top:217.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Spanagel R (2017) Animal models of addiction. Dialogues Clin Neu-</span></p>
<p style="top:227.3pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">rosci 19:247&#x2013;258. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 31887/ DCNS. 2017. 19.3/ </span></p>
<p style="top:237.2pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">rspan agel</span></p>
<p style="top:247.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Spanagel R (2020) Cannabinoids and the endocannabinoid system in </span></p>
<p style="top:257.2pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">reward processing and addiction: from mechanisms to interven-</span></p>
<p style="top:267.2pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tions. Dialogues Clin Neurosci 22:241&#x2013;250. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. </span></p>
<p style="top:277.2pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">31887/ DCNS. 2020. 22.3/ rspan agel</span></p>
<p style="top:287.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Strakowski SM, Sax KW (1998) Progressive behavioral response to </span></p>
<p style="top:297.2pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">repeated d-amphetamine challenge: further evidence for sensiti-</span></p>
<p style="top:307.2pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">zation in humans. Biol Psychiat 44:1171&#x2013;1177. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ </span></p>
<p style="top:317.2pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">10. 1016/ s0006- 3223(97) 00454-x</span></p>
<p style="top:327.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Strickland JC, Havens JR, Stoops WW (2019) A nationally representa-</span></p>
<p style="top:337.2pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tive analysis of &#x201c;twin epidemics&#x201d;: rising rates of methampheta-</span></p>
<p style="top:347.2pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">mine use among persons who use opioids. Drug Alcohol Depend </span></p>
<p style="top:357.2pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">204:107592. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/j. druga lcdep. 2019. 107592</span></p>
<p style="top:367.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Sung YH, Carey PD, Stein DJ, Ferrett HL, Spottiswoode BS, Renshaw </span></p>
<p style="top:377.2pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">PF, Yurgelun-Todd DA (2013) Decreased frontal N-acetylaspar-</span></p>
<p style="top:387.2pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tate levels in adolescents concurrently using both methampheta-</span></p>
<p style="top:397.2pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">mine and marijuana. Behav Brain Res 246:154&#x2013;161. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. </span></p>
<p style="top:407.2pt;left:71.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">org/ 10. 1016/j. bbr. 2013. 02. 028</span></p>
<p style="top:57.2pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Tardelli VS, Bisaga A, Arcadepani FB, Gerra G, Levin FR, Fidalgo </span></p>
<p style="top:67.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">TM (2020) Prescription psychostimulants for the treatment of </span></p>
<p style="top:77.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">stimulant use disorder: A systematic review and meta-analysis. </span></p>
<p style="top:87.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Psychopharmacology 237:2233&#x2013;2255. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ </span></p>
<p style="top:97.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">s00213- 020- 05563-3</span></p>
<p style="top:107.2pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Turna J, Syan SK, Frey BN, Rush B, Costello MJ, Weiss M, MacKillop J </span></p>
<p style="top:117.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(2019) Cannabidiol as a novel candidate alcohol use disorder phar-</span></p>
<p style="top:127.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">macotherapy: a systematic review. Alcoholism: Clinical and Experi-</span></p>
<p style="top:137.2pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">mental Research 43:550&#x2013;563 doi:</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1111/ acer. 13964</span></p>
<p style="top:147.1pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">UNODC (2020) World Drug Report 2020. United Nations Publication.</span></p>
<p style="top:157.1pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Valvassori SS et&#xa0;al (2011) Effects of cannabidiol on amphetamine-</span></p>
<p style="top:167.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">induced oxidative stress generation in an animal model of mania. </span></p>
<p style="top:177.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">J Psychopharmacol 25:274&#x2013;280. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1177/ 02698 </span></p>
<p style="top:187.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">81109 106925</span></p>
<p style="top:197.1pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Voytek B et&#xa0;al (2005) Differences in regional brain metabolism associ-</span></p>
<p style="top:207.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ated with marijuana abuse in methamphetamine abusers. Synapse </span></p>
<p style="top:217.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">57:113&#x2013;115. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1002/ syn. 20155</span></p>
<p style="top:227.1pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Wood E, Stoltz J-A, Montaner JSG, Kerr T (2006) Evaluating meth-</span></p>
<p style="top:237.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">amphetamine use and risks of injection initiation among street </span></p>
<p style="top:247.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">youth: The ARYS study. Harm Reduct J 3:18. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. </span></p>
<p style="top:257.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">1186/ 1477- 7517-3- 18</span></p>
<p style="top:267.1pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Yang G et&#xa0;al (2020) Cannabidiol attenuates methamphetamine-induced </span></p>
<p style="top:277.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">conditioned place preference via the Sigma1R/AKT/GSK-3&#x3b2;/</span></p>
<p style="top:287.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">CREB signaling pathway in rats. Toxicology Research 9:202&#x2013;</span></p>
<p style="top:297.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">211. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1093/ toxres/ tfaa0 21</span></p>
<p style="top:307.1pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Yockey RA, King KA, Vidourek RA (2020) Past-year methampheta-</span></p>
<p style="top:317.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">mine use among US young adults: 2015&#x2013;2018. Journal of Sub-</span></p>
<p style="top:327.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">stance Use 25:677&#x2013;682. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1080/ 14659 891. 2020. </span></p>
<p style="top:337.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">17603 80</span></p>
<p style="top:347.1pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Young JW, Henry BL, Geyer MA (2011) Predictive animal models </span></p>
<p style="top:357.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">of mania: Hits, misses and future directions. Br J Pharmacol </span></p>
<p style="top:367.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">164:1263&#x2013;1284. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1111/j. 1476- 5381. 2011. </span></p>
<p style="top:377.1pt;left:326.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">01318.x</span></p>
<p style="top:397.6pt;left:306.2pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Publisher&#x2019;s note</span></b><span style="font-family:STIX,serif;font-size:8.5pt"> Springer Nature remains neutral with regard to </span></p>
<p style="top:407.6pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">jurisdictional claims in published maps and institutional affiliations.</span></p>
<p style="top:32.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">1230</span></p>
<p style="top:32.8pt;left:399.6pt;line-height:8.5pt"><span style="font-family:MyriadProUnicSemiCondens,serif;font-size:8.5pt">Psychopharmacology (2022) 239:1211&#x2013;1230</span></p>

</div>
